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ABSTRACT 
New biologically active β-lactams were designed and synthesized, developing novel antibiotics and 
enzymatic inhibitors directed toward specific targets. 
Within a work directed to the synthesis of mimetics for RGD (Arg-Gly-Asp) sequence able to interact 
with αvβ3 and α5β1-type integrins, new activators were developed and their Structure-Activity 
Relationships (SAR) analysis deepened, enhancing their activity range towards the α4β1 isoform. 
Moreover, to synthesize novel compounds active both against bacterial infections and pulmonary 
conditions of cystic fibrosis patients, new β-lactam candidates were studied. Among the abundant library 
of β-lactams prepared, mainly with antioxidant and antibacterial double activities, it was identified a 
single lead to be pharmacologically tested in vivo. Its synthesis was optimized up to the gram-scale, and 
pretreatment method and HPLC-MS/MS analytical protocol for sub-nanomolar quantifications were 
developed. Furthermore, replacement of acetoxy group in 4-acetoxy-azetidinone derivatives was studied 
with different nucleophiles and in aqueous media. A phosphate group was introduced and the reactivity 
exploited using different hydroxyapatites, obtaining biomaterials with multiple biological activities. 
Following the same kind of reactivity, a small series of molecules with a β-lactam and retinoic hybrid 
structure was synthesized as epigenetic regulators. Interacting with HDACs, two compounds were 
respectively identified as an inhibitor of cell proliferation and a differentiating agent on steam cells. 
Additionally, in collaboration with Professor L. De Cola at ISIS, University of Strasbourg, some new 
photochemically active β-lactam Pt (II) complexes were designed and synthesized to be used as bioprobes 
or theranostics. 
Finally, it was set up and optimized the preparation of new chiral proline-derived α-aminonitriles through 
an enantioselective Strecker reaction, and it was developed a chemo-enzymatic oxidative method for 
converting alcohols to aldehydes or acid in a selective manner, and amines to relative aldehydes, amides 
or imines. Moreover, enzymes and other green chemistry methodologies were used to prepare Active 
Pharmaceutical Ingredients (APIs). 
2 
3 
1. INTRODUCTION 
1.1 β-Lactams 
1.1.1 Definition 
In organic chemistry, cyclic amides are defined lactams. They are formally produced from an 
intramolecular condensation of species characterized by the presence of both an acid and an amino 
function. Their structures have therefore a cyclic system of 1-azacycloalcan-2-one. Among the 
compounds belonging to this family the number of carbon atoms and consequently the amplitude of the 
ring can vary. Moreover, unsaturations, heteroatoms, substitutions or derivatizations of various types 
could be present.
1
 
To indicate the size of the ring are used in alphabetical order Greek letters as prefixes. Thus, β-lactams 
have two atoms in addition to the amide function and an overall tetra-atomic cycle, γ-lactams are cycles 
with five atoms, δ-lactams are six-membered and ε-lactams seven-membered rings. Concerning the 
IUPAC nomenclature, β-lactams would be considered azacyclobutan-2-ones, as well as γ-lactams 
areazacyclopentan-2-ones, while δ-lactams and ε-lactams are azacycloesan-2-ones and azacycloeptan-2-
ones, respectively.
2
 
The importance of these heterocycles is related to their industrial and pharmaceutical applications: nylon 
production uses ε-caprolactam (cyclic amide with 7 terms, Figure 1.1.1), some natural products such as 
polycyclic alkaloids are five or six membered amides and, above all, β-lactam antibiotics are important in 
pharmaceutical field. As a matter of facts, the four membered amide (-lactam) occurs in widely used 
antibiotics such as penicillins, cephalosporins, carbapenems and monobactams. 
 
Figure 1.1.1 Some lactam compounds 
 
1.1.2 Chemical characteristics and reactivity 
Analyzing in details the chemical characteristics of β-lactams, we can notice a remarkable reactivity of 
the amide group. This is mainly due to an higher Bayer strength, caused by the deformation of the 
4 
effective bond angles than those of the hybridized orbitals involved, and an high Pfizer strength, due to 
bond eclipsations and increasingly important with the increase of the substituent size. 
Although β-lactams are amides, the resonance that involves the lone-pair of the nitrogen atom and the 
next carboxy group is hampered by the cyclic structure. In fact, in the charge separation resonance 
structure, the presence of two sp
2
 hybridized atoms on the four membered ring would have a strong 
destabilizing effect (Scheme 1.1.1). The carbonyl group of the β-lactam amide thus maintains the 
electrophilicity determined by inductive effects of the next nitrogen atom, so that the electrophilicity and 
therefore the reactivity of this amide increase. 
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Scheme 1.1.1 Amide resonance 
The major reactivity of these molecules is therefore due to the electrophilicity of the amidic C=O. 
Reactions with nucleophiles were favored with  the consequent opening of the cyclic system, following a 
classic mechanism of the nucleophilic acyl substitution. It consists in an initial addition to the C=O and 
the subsequent ring opening (Scheme 1.1.2).  
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Scheme 1.1.2 β-Lactam system opening 
This mechanism is particularly important because it is involved in the action of β-lactam as antibiotics 
and in other biological activities that these compounds showed. 
However, the chemical characteristics described necessarily involve some difficulties at the experimental 
level; it is necessary, for instance, to make use of mild reaction conditions, inert atmosphere and low 
temperatures. Acidic or basic conditions, by means of Lewis or Brønsted-Lowry acids or bases, are not 
tollerated. Nucleophiles, such as water or primary alcohols, poses problems especially under acid/base 
conditions, or even with dipolar aprotic solvents, known to be excellent for SN2 reactions. Finally, rather 
less attention can be paid to oxidative phenomena, at least avoiding overheating’s (40 to 50)°C, except for 
short periods or under a inert atmosphere,  
1.1.3 Synthesis 
The first synthesis of a β-lactam derivative was realized in 1907 by Hermann Staudinger, who exploited a 
[2+2] cycloaddition between the Schiff base of benzaldehyde with aniline,
3
 and diphenylketene (Scheme 
1.1.3).
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Scheme 1.1.3 Staudinger synthesis 
A [2+2] reaction can be also conducted between an alkene and an isocyanate, as in the case of large-scale 
synthesis of the 3-(1-tbutyldimethylsilyloxy-ethyl)-4-acetoxy azetidin-2-one (an important commercially 
available β-lactam) and of other industrial applications.5 
Of the many routes explored, the use of acyl chlorides or related species in the presence of tertiary amines 
is considered worthy of note, but also the photochemical route from metalcarbenes or the thermal way are 
relevant. Other intermolecular solutions require cycloaddition reactions between imines and oxygen-
protected hydroxyacetylchlorides or, in few cases, corresponding carboxylic acids (Scheme 1.1.4). 
Moreover, the same reaction has applications, although in specific and therefore not general conditions, 
even if the acid chloride do not have heteroatoms as substituens or halides in α position. 
 
Scheme 1.1.4 
Although the applicability of these synthesis presents limits, the relief consists in the existence of 
stereoselective and enantioselectives variants. Some of them were recently introduced where ionic proline 
derivatives or chiral ferrocene complexes were used as catalysts.
6
 
Classical preparations for the formation of two bonds with the nitrogen atom exists, as well as 
intramolecular reactions for the construction of each of the four bonds of the ring. In general, the more 
supported way provides for the formation of the amide bond and requires precursors such as β-amino 
acids or their activated derivatives, for example by the use of carbodiimides method or by amine 
deprotonation (Scheme 1.1.5), whereas less interesting is concerning the C2-C3 bond  
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Scheme 1.1.5 
The formation of the C3-C4 carbon-carbon bond requires by electronwithdrawing groups in the α position 
respect to N, while the C-N bond could be formed by a bimolecular nucleophilic substitution reactions of 
the nitrogen on halides (Scheme 1.1.6). 
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Scheme 1.1.6 
The existence of a significant number of synthetic strategies for the preparation of bicyclic β-lactams 
compounds deserves at least a hint, due to their great importance in the pharmaceutical field, in particular 
as antibiotics. 
To conclude on synthetic aspects it is finally necessary to mention the β-Lactam Synthon Method, 
developed by Prof. Ojima as a technique for the preparation of oligopeptides and obviously optically 
active α and β-amino acids starting from chiral β-lactams. Recently, the use of enantiopure azetidin-2-
onic scaffolds as versatile intermediates underwent a considerable boost, especially to meet the needs of 
structural variability and innovation of the pharmaceutical β-lactam based antibiotic class. 
Moreover, easy ring opening reactions together with new methodologies to exploit their chirality via 
asymmetric induction, even in more subsequent functionalization steps, allowed a fair development both 
in the chemistry of natural compounds and in peptide synthesis, especially in the field of 
peptidomimetics.
7
 
 
 
1.2 Enzyme inhibitors 
1.2.1 Enzymes and enzymatic activity regulation 
Enzymes are defined as biological catalysts of chemical reactions. The term was introduced in 1878 by 
the physiologist Wilhelm Kühne: the etymology is Greek and it means “in yeast”.8 Considering only 
protein enzymes, we can define the active site as that portion, very small compared to the entire enzyme, 
which consists of the catalytic site, where the biochemical reaction actually takes place, and of the 
positioning site, to which are essentially delegated recognition functions usually based on hydrophobic 
and no covalent interactions.
9
 
To present a model for rationalizing the interactions between an enzyme and its substrate, the first model 
introduced was the “key-lock”. It was characterized by a perfect complementarity of the two partners, 
explaining the specificity that distinguishes enzymes, and was proposed in 1894 by Hermann Emil 
Fischer.
10
 The evolution of this first idea was made in 1958 by Daniel Koshland, who accepted the 
existence of some flexibility for the enzymatic structures proposed. Today it is known as the “induced 
adaptation model” of Koshland. According to it, ligands and targets are usually not exactly 
complementary, thus takes place a reciprocal arrangement that maximizes the interactions.
11
 Although 
7 
directed at first to enzymes, such considerations established an applicability also in the pharmaceutical 
field. Current models indeed consider their general lines and can therefore be considered an evolution of 
this model. In this regard, the current theory of constitutively activated receptors always considering 
conformational changes, but also describes the existence of equilibria between different conformers. It 
introduces definitions for different ligands, examined in more details in the next section. However, the 
catalytic activity is the main function of enzymes but not the only one. Indeed, active sites generally 
occupied small portions of the whole protein. In addition to the action of the active site and the ability to 
ensure the positioning of themselves, for example on cell membranes if they are trans-membrane, 
enzymes also take part in recognition functions, always describable with the models introduced above, at 
least articulated on three levels: 
- recognition of small molecules, called ligands; 
- recognition of other proteins; 
- recognition of the DNA; 
which we must refer in the attempt of rationalizing the regulation mechanisms of their activities.
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The enzymatic efficiency can be regulated by the temperature, the acidity in term of pH and, for the sake 
of completeness despite irrelevant for our purposes, by phenomena of activation related to the protection 
from degradation of essentially an oxidative nature. Turning then to a more biochemical level, cells seem 
to be able to control and hence to regulate the enzymatic activities according to at least five main ways, 
starting from the production stage. Transcription and protein synthesis implemented are effectively 
managed through the classic biochemical mechanisms that govern the regulation of gene expression, 
including extracellular stimuli. A second control system is associated to the partitioning of enzymes, in 
some cases adopted to allow completely selective metabolic pathways, different and potentially all 
available for the same substrate. Another regulatory mechanism is based on the biosynthesis of enzymes 
characterized by the request of drastically different conditions (for example of pH) from those of the 
environment of production to become active, thus providing a certain analogy with those species defined 
as zymogens, biosynthesized in inactive forms. Some similarities can be highlighted even with the 
regulatory mechanism which provides the realization of post-transduction modifications, such as 
phosphorylation and glycosylation, or even the cutting of entire protein sections, typical for the zymogen 
activation. The last adjustment way, at least among those considerable as the mains, is related to the 
negative feedback action exerted by the products themselves of an enzymatic transformation or by the 
activity of a whole enzyme complex.
13
 
It remains to be considered the so-called effectors, molecules not necessarily always endogenous but able 
to act on enzymatic efficiencies as activators or orthosteric inhibitors, or as allosteric modulators, thus 
targeting sites defined allosteric, if any. In these cases it is mandatory that there is a correlation between 
the subunit, or the domain, with the active site and the one, or ones, on which the allosteric interaction 
occurs. Depending on whether or not the allosteric effector is the same endogenous substrate, it can be 
labeled as homotropic or heterotropic, and the resulting modulation generally consists in conformational 
8 
deformations such as re-orientations the of enzyme-composing domains, making more or less accessible 
the active site or other regulatory areas. Although the allosteric sites may be the target of a drug 
treatment, with some advantages over classical orthosteric ligands, most of the cases concerns today the 
G-Protein Coupled Receptors (GPCRs), however here of less importance. 
To introduce now orthosteric effectors, it must first be noticed that the differences between activators and 
inhibitors are not always so sharp. At the biological level, the same ligand can have both behaviors 
depending on various boundary conditions. Effects such as the concentration of the ligand itself or of 
other species, the possible interactions of the enzyme with other molecules, or even its phosphorylation 
state should be remembered. However, because the main interest is usually in inhibitors, at least in 
pharmaceutical fields, the discussion will be now limited to them. We define inhibitors those compounds 
able to decrease, so to modulate or even to cancel, the catalytic action of an enzyme, in a reversible or 
irreversible way, that is by binding covalently or non-covalently to the enzyme. As subsequently 
deepened, reversible inhibitors are usually considered to be of greater pharmaceutical importance. They 
are in turn further classified into:  
- competitive: it is set in a competition between the inhibitor and the substrate for the same catalytic site, 
with the only difference that in the case where there is interaction with the effector this does not lead to 
the formation of the product. Usually characterized by structural similarity, the inhibition is highly 
dependent on the concentrations and the relative affinities of the species contenders against the active site 
of the enzyme; 
- not competitive: forming a complex with the enzyme, binary or ternary based on the absence or the 
presence of the substrate, the site of interest is now different. The action may therefore be rationalized 
thinking to a decrease of the enzyme amount available for conversion of the endogenous substrate, which 
concentration has therefore no influence on the inhibition; 
- acompetitive: also known as inhibitors of the ternary complex, they acting at the enzyme-substrate 
complex level. It intervenes in the mechanism by which enzymes catalyze biochemical reactions, bonding 
and blocking the complex in this condition.
14
 
However, irreversible inhibitors have a certain prestige and the entire class of β-lactam antibiotics is 
indeed one of the best known examples. Other members of this family, famous in their own way, are the 
nerve gases, irreversible inhibitors of acetylcholine esterase, which is involved in the process that 
ultimately leads to muscle movement. Even the so-called suicide inhibitors, transformed into irreversible 
inhibitors from chemical reactions in the active site, are irreversible inhibitors. 
 
1.2.2 Enzyme inhibitors  
Drugs are defined as any compound that by interaction with biological systems produces an effect, such 
as in the case of enzyme inhibitors. Ideally, drugs should be easy to take and of course should ensure the 
9 
expected action without presenting side effects. It is not accidental that the term derives from the Greek 
word pharmakon, that means remedy and poison at the same time. 
A first classification of drugs concern the targets and subdivides them depending if are nucleic acids, 
lipids (and particularly membrane phospholipids), carbohydrates or proteins. The latter are the target of 
most of the now available drugs, but being able to treat enzymatic or receptorial proteins, are in turn 
distinguished in intracellular and membrane, on the basis of the biological localization sector. Accessible 
not only to ligands able of entering in cells, membrane receptors basically transduce informations and are 
further divided into six families: 
- channel; 
- G-protein coupled, i.e. the before mentioned GPCRs against which is directed the action of about 70% 
of drugs active against to receptors; 
- with intrinsic tyrosine-kinase activity; 
- with intrinsic guanylate-cyclase activity; 
- adhesion; 
- cytokine; 
where the first two alone account for about the 90% of the targets which drugs active on receptors are 
directed.
15
 
Still limiting to the compounds having proteins as targets of their pharmacological actions, it is initially 
possible to put them together in a single treatment without distinguishing between those directed at 
enzymes and those at receptors. Molecules active on proteins, either receptors or enzymes, can act as 
agonists or antagonists depending if they reduce or potentiate proteins’ activity. 
In the case of receptor proteins, the drug can activate them by binding to the active site and mimicking the 
natural ligand, or preventing their binding with the messenger, the endogenous transmitter, interacting 
with the same site but without initiate their cascades of biological events, thus behaving as antagonist. 
With reference to the theory of constitutively activated receptors, agonists are seen as those compounds 
capable of binding to the active conformer, stabilizing it and shifting the equilibrium towards it, while 
inverse agonists are capable of binding to the inactive form, depressing the receptor action. In this same 
discussion, antagonists are species able to bind to both the forms, still inhibiting the activity. 
As regards enzymes, the inhibition can occur in a similar manner but obviously preventing the bond with 
the natural substrate, while for the activation is necessary to consider allosteric sites. In fact, as examples 
of allosteric agonism also existing in relation to receptor proteins, enzymatic orthosteric agonists should 
be different from the natural substrate, consequently leading not to reinforcing the desired action but to 
biological conversion products different from those obtained under normal physiological conditions. 
Finally, there are for both protein targets examples of allosteric antagonism, often due to conformational 
deformations such as to disadvantage interactions with the endogenous ligand, but in some cases are also 
based on the so-called “umbrella effect”, hindering the access simply providing a spatial hindrance. 
10 
Thus, compounds with an inhibitory action tend to benefit of the most relevance, at least in the 
pharmaceutical field. Their activities are currently expressed by the inhibitory concentration (IC50), 
defined as that drug concentration capable of inhibit 50% of its target. 
Therefore, when enzymes are involved, drugs are usually inhibitors, and with regard to their action 
method enzyme inhibitors are still generally rationalized into three main categories: 
- competitive reversible: establish with the enzyme non-covalent interactions, so as to prevent access from 
the endogenous substrate only temporarily. To a rising concentration of the ligand, the drug is therefore 
likely to be displaced; 
- non-competitive irreversible: forming a covalent-nature bond with the enzyme active sites, any increase 
in the concentration of endogenous substrate is irrelevant; 
- non-competitive allosteric reversible: the contradiction in terms is explained by the existence of an 
accessory site, allosteric, where the drug can reversibly bind the enzyme, inducing conformational 
changes such as rendering the active site no longer suitable or at least less inclined to accept the usual 
substrate; 
which can be reinforced with other mechanisms of action, somewhat intermediate. 
Among the advantages of reversible inhibition as medical cure must surely count the best controllability, 
management and security of the treatment. As a matter of facts, if with the target enzymes are involved 
more substrates, for example under certain boundary conditions such as the location or the concentration 
of other biological effectors, the disturbance caused to the biochemical processes related to those of no 
interest will be only partial and potentially modulated by playing on the relative affinities of the ligands. 
As a further detriment of irreversible inhibitors, the phenomena of tolerance and addiction are here more 
evident and rapid in the establishment. They lead to a gradual increase in the administered dose of 
medication to obtain the same effect, due to a reduction in efficacy caused by the prolonged repetition of 
assumptions. Finally, reversible inhibitors are also easily removable for simple dilution or dialysis, when 
it should be necessary, while irreversible inhibition is not neutralizable. This is instead a considerable 
advantage for β-lactam antibiotics, because they are directed to bacterial enzymes not present in humans, 
with the declared intent to exterminate them.
16
 
To conclude on the design of enzyme inhibitors, or more generally of drugs, the pharmacophore is 
defined as the portion of a drug characterized by the ability to interact with its target and which removal 
therefore results in the loss of the biological activity. Isosteres are chemical groups structurally similar 
and potentially interchangeable even if components of the pharmacophore. Peptidomimetics is the 
intermediate branch between chemistry and pharmacology interested in peptidomimetic compounds, 
molecules that due to structural similarities can mimick natural peptides and thus endogenous ligands. 
These exogenous peptides are delicate because of the usually rapid biological degradation by proteases 
that they may experience. Thus, the isostere often regards the amide bonds. Peptidomimetics precisely 
modified on the peptide bond are called pseudopeptides. In depsipeptides the isostere is an ester bond, 
while if the substitution is related to the lateral chains compounds are peptidoanalogues. All those 
11 
compounds that mimick or inhibit, but without being structurally related, the biological effect of a peptide 
are known as non-peptidomimetics. Finally, drugs, as commonly defined, are different from the 
endogenous species due to the need of performing different tasks, for example in terms of bioavailability, 
stability and ease of administration. A better specificity and thus a less number of possible interaction 
partners, potentially cause of side effects, is also an aspect not to be overlooked in designing drugs.
17
 
 
1.2.3 β-Lactam based enzyme inhibitors  
β-Lactam compounds are often potent irreversible inhibitors of enzymes based on a mechanism of 
covalent modification of the target enzyme and in particular on the selective acylation on the OH of the 
serine which is part of the active site. Obviously, they do not act only for the reactivity of the ring but also 
thanks to appropriate geometries for the site on which they must interact and to the structure subsequently 
adopted from the enzyme-inhibitor adduct, which became no longer divisible. Also other inhibitors, 
specific for β-lactamase and often administered in combination with azetidin-2-onic antibiotics to avoid 
their inactivation, work with the same mechanism of acylation. β-Lactamase are enzymes that can destroy 
β-lactams with a rate close to the limit of diffusion control. The formation of covalent bonds can therefore 
be a successful strategy for the identification of new enzyme inhibitors, and typically the β-lactam 
scaffold constitute a rather versatile starting point, although nothing prohibits the use of γ-lactams duly 
activated, in order to compensate, in terms of reactivity, the lower Bayer and Pfizer strengths that 
characterize them.
18
 Indeed, since the 80s, following the discovery of the first monobactam antibiotic, 
studies relating to the inhibitory activity of β-lactams have risen sharply, so that countless structural 
variants of the first natural compounds are today directed to the antimicrobial action, so antibacterial, 
antifungal and antiviral too. However, azetidin-2-ones have subsequently demonstrated biological 
activities as irreversible inhibitors with different pharmaceutical effects, not exclusively related to the 
antibacterial properties, and have been therefore exploited as acylating agents for the covalent inhibition 
of a wide variety of targets. Among them, we can list elastases, trombines, cathepsin K, calpain, prostate 
specific antigen, low-density lipoproteo-phospholipases, transacylases, cholesterol-acyltransferases and 
proteases of cytomegalovirus. Moreover, are today known compounds with anti-cancer and anti-
tuberculosis properties, anti-HFAAH, HDACs, proteasomes, cathepsins and vasopressin, and even 
cholesterol absorption inhibitors, analgesics and anti-inflammatories compounds. Furthermore, are known 
molecules processed by enzymes themselves in irreversible inhibitors due to reactions that take place in 
the active sites, defined for this mechanism of action suicide inhibitors. In addition to the antimicrobial 
activity was possible to associate an antioxidant effects by introducing of polyphenolic moieties, and are 
finally worth of mentioning the compounds active in DNA cleavage.
19
 The biological activity, however, 
is always related to the type of derivatization present on the β-lactam structures, but the great relevance in 
the pharmaceutical field is also due to the aspect of being often well tolerated by the organism. In fact, 
allergies related to β-lactam antibiotics are almost the unique side reaction associated to them. Therefore 
12 
taken here as a reference, these molecules offer a therapeutic index (TI) always very high. TI is defined in 
animals as the ratio between the lethal dose (toxic, for studies on humans) on 50% of the treated subjects 
(LD50) and that effective on the same percentage (ED50), but it now disused for ethical and economical 
problems. When taken in appropriate cases and in compliance with the correct dosages, the only 
noteworthy side effect is the possibility to affect the intestinal flora. Thus, they can cause a consequent 
change in the bowel habit, however easily compensated by taking lactic acid bacteria.
20
 
 
 
1.3 Organic chemistry and pharmacology  
1.3.1 Drug design 
The design of biologically active molecules is a transverse aspect ranging from molecular biology to 
microbiology, organic chemistry and the synthesis of molecules. The identification of biological targets 
on which designing the synthesis of a new molecule (lead) is only the beginning of the path that leads to 
the “drug”. Some basic steps must be rationally followed: 
- identification and selection of the drug target; 
- study of the active receptorial site through direct or indirect methods, of the interactions and of the 
molecular scaffold which better fit; 
- synthesis of the molecule. 
At first, you need to identify the biological target, usually an enzyme or a protein, and build a molecule 
able to interact with it in order to block, inhibit or more generally alter its activity. The interaction 
between a molecule and an enzyme was first hypothesized by Hermann Emil Fischer in 1894, and 
according to it enzyme and substrate possess forms that allow a perfect complementary interlock.
21
 This 
interaction was defined as the “key-lock” model and suggested that a molecule, and/or classes of related 
compounds, have the unique ability to “open” the enzyme, thus interacting in a very specific way with the 
protein, exerting a particular function. 
However, the interpretation of interaction between enzymes and substrates has evolved over time. 
Enzymes does not behave in a so rigid manner towards their substrates, and their own active sites were 
modified by binding molecules. Thus, was defined a new model called “hand-glove” or even “adaptation 
induced” model.22 Enzymes were not more treated as rigid structures, but rather with a certain grade of 
flexibility, a feature that allowed them to be modelled according to the presence of substrates or not. Then 
substrates binds to the active site on an enzyme, induceing changes due to the adaptation of the enzyme 
itself. 
The active site of an enzyme is the part that binds the substrate and which induces the enzyme to exert its 
activity. From a theoretical point of view, an enzyme is divided into the binding site (where binding takes 
place with the substrate) and the catalytic site (where really occurs the catalytic function). Some enzymes 
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also possess allosteric sites, which interact with molecules called allosteric effectors. In general, these 
molecules can modify the activity of enzymes by inducing changes in their structures. 
Active and/or allosteric sites must be identified in order to understand the structure of the molecule able 
to interact. A direct methodology is surely the use of X-rays on the target protein bounded to its substrate. 
If is not known the receptor structure, is possible to use computational techniques, among which one of 
the more important is QSAR (Quantitative Structure-Activity Relationship). This method establishes a 
relationship between an overall molecular structure and the biological activities of a series of compounds 
active against the target protein. It predicts the activity and the affinity of not yet known compounds from 
the analysis of their structural similarities and differences, providing information about the structural 
requirements of the active receptorial site. Thus, when the structural requirements of the molecule, or of 
the class of molecules, with a biological activity were identified, it is possible to reach a synthetic 
approach. The synthesis of biologically active molecules, when the pharmacophore model was identified, 
can be oriented towards different approaches: 
- Target Oriented Synthesis (TOS); 
- construction of combinatorial library; 
- Diversity Oriented Synthesis (DOS). 
TOS is a methodology that leads to the production of a single molecule, with a set of substituents and 
usually with a very specific synthetic pathway. This methodology was one of the first to be used, but in 
general is chosen when the molecular target has a strong and demonstrated biological activity or a 
considerable complexity.
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 However, this approach severely limits the possibility to vary the molecular 
scaffold, due to the nature of the mentioned specific synthetic pathway (which usually has a retrosynthetic 
strategy). 
The combinatorial synthesis, which has become very popular especially thanks to the solid-phase peptide 
synthesis of Merrifield in the ‘70s,24 allows to obtain a series of scaffolds in a single synthetic process, 
thus reaching a great substrates diversity. From the synthetic and the operating points of view, the 
combinatorial approach allows to expand and enrich the number of similar molecules by random varying 
the substituents, therefore obtaining different combinations. Through this scheme, starting from a unique 
molecule recognized as the founder compound, can be achieved an high number of new compounds 
generated by combinations of different substituents. Combinatorial chemistry has been particularly 
widespread and has led to techniques such as the so-called “split and mix” and many others. The huge 
number of molecules obtained through combinatorial chemistry can extend what is known as “chemical 
space”. It is a virtual zone of n dimensions where the dimensions are descriptors of structural features or 
chemical-physical properties (e.g. empirical formula, table of molecular connections, polarity in terms of 
logP, molar volume, numbers of bonds free to rotate, etc.). The chemical space gives an idea of the 
molecules diversity. It is estimated that the number of possible molecules is 10
200
, among which 10
60 
may 
be active from the biological point of view. However, from the literature, over the year have been 
synthesized only 10
7
 different compounds. Comparing the chemical space of a target oriented and a 
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combinatorial synthesis, is immediately clear how the second method leads to a greater variability and 
therefore to a greater success rate in identifying new active molecules (Figure 1.3.1). 
.  
Figure 1.3.1 TO (left) and combinatorial (right) Synthesis chemical spaces 
The advantage of the combinatorial synthesis is remarkable if considering that a target molecule can often 
be able to exert its biological activity, but also results toxic at the same time, or leading to other problems 
(in terms of absorption, excretion, simultaneously interaction with other proteins, ..). The possibility of 
having the other n-1 structures similar but slightly different can lead to the discovery of molecules with 
probably the same biological activity, although maybe slightly decreased, but not toxic. 
In 2004 Professor Schreiber proposed a synthetic approach that leads to a further expansion of the 
chemical space: the “diversity oriented synthesis”.25 This methodology goes beyond the combinatorial 
approach and aims to develop strategies to synthesize very different molecules starting from similar 
molecules. 
.  
Figure 1.3.2 Diversity Oriented Synthesis chemical space 
In the chemical space, this strategy results in the obtainment of a larger number of potential lead 
compounds, with more n variables than what offered by combinatorial chemistry (Figure 1.3.2). If we 
consider that the increasing of the chemical space is related to the success of a particular lead, then the 
diversity oriented synthesis, also called divergent synthesis, probably will offer great benefits. The 
divergent synthesis opens the door to the concept of “forward analysis”, the opposite of the retrosynthetic 
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analysis. If in retrosynthesis you wonder how a complex molecule can be synthesized from simple 
elements, in a forward analysis you must wonder how a collection of simple molecules and other similar 
compounds can be turned into a library of complex products. 
 
1.3.2 Multi-Target Directed Ligands (MTDL) 
However, many diseases do not allow to focus on a single biological target for the development of 
specifically designed drugs: multifactorial diseases depend on multiple genetic factors, and sometimes 
also on environmental aspects. The multifactorial character may be: 
- continuous: different phenotypes of the same chromosomal character cannot be perfectly distinguished 
and should be measured. They are more similar between relatives, because they have had similar 
environmental influences and have the same genotype; 
- discontinuous: i.e. phenotypes clearly distinguishable from each other without transmission according to 
Mendel's laws. They are also called character with threshold, and indeed the phenotype occurs when 
genetic and environmental factors exceed a threshold. 
The most common multifactorial diseases fall into Alzheimer's and Cystic Fibrosis diseases. In these 
cases, it became necessary to take more drugs simultaneously. With the development of chemical, 
pharmaceutical and medical sciences, the assumption that until now has characterized the pharmaceutical 
research “one drug, one target” is now giving way to a new approach called Multi Target Directed 
Ligands (MTDL). MTDLs design has its roots on the new hire “one drug, more targets”. In fact, in 
diseases with different biological processes altered, the modulation of only one of them may not be 
sufficient to put under control the clinical situation. The MTDL approach is here particularly suitable for 
the design and development of new bioactive molecules able to more efficiently treat these diseases, but 
philosophy of such drugs is so recent that commercially available examples can not yet be cited. 
However, the number of research projects in progress realizes the very high confidence placed in this new 
perspective of modern pharmacology. Of course, there are pros and cons,
26
 and among the advantages can 
be considered that: 
- these drugs allow a single metabolic pathway, reducing the number of drugs and derived species 
circulating in the patient’s body and thus decreasing the side effects related to treatments with more 
compounds; 
- through the unification of two activities in one molecule the risk of potentially harmful interactions 
between drugs is prevented; 
- being an only molecule, will also be sufficient a single route of administration for the treatment of 
multiple symptoms, making the drug more easily in its intake; 
- the presence of a drug with a structure different from the ones of its two individual components 
disadvantages the occurrence of the bacterial resistance phenomena, for compounds having antibiotic 
activity. 
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However, there are some complications: 
- the drug specifically designed and synthesized will be used only for specific symptoms, as opposed to a 
relatively non-specific classic compound, usable in a plurality of similar situations; 
- the molecule will be more difficult to design, as it will be necessary to optimize the structure relating to 
the modulation of all its activities; 
- for the same reasons, the synthesis will be as well more difficult. 
 
1.3.3 Green chemistry and biocatalysis 
In recent years, the world trend of organic synthesis and chemistry in general was strongly directed to 
reinvent itself through a new philosophy called “Green Chemistry”, which consist in the research of a 
sustainable development. This means also to begin the replacement of polluting and high environmental 
impact methods with more environmentally friendly processes. Professor Anastas, in 1991, set out the 
basis of sustainable chemistry listing 12 principles:
 
 
1. It is better to prevent waste than to treat or clean up waste after it is formed. 
2. Synthetic methods should be designed to maximize the incorporation of all materials used in the 
process into the final product. 
3. Wherever practicable, synthetic methodologies should be designed to use and generate substances that 
possess little or no toxicity to human health and the environment. 
4. Chemical products should be designed to preserve efficacy of function while reducing toxicity. 
5. The use of auxiliary substances (e.g. solvents, separation agents, etc.) should be made unnecessary 
wherever possible and innocuous when used. 
6. Energy requirements should be recognized for their environmental and economic impacts and should 
be minimized. Synthetic methods should be conducted at ambient temperature and pressure. 
7. A raw material or feedstock should be renewable rather than depleting wherever technically and 
economically practicable. 
8. Reduce derivatives - Unnecessary derivatization (blocking group, temporary modification, protection 
and deprotection) should be avoided whenever possible. 
9. Catalytic reagents (as selective as possible) are superior to stoichiometric reagents. 
10. Chemical products should be designed so that at the end of their function they do not persist in the 
environment and break down into innocuous degradation products. 
11. Analytical methodologies need to be further developed to allow for real-time, in-process monitoring 
and control prior to the formation of hazardous substances. 
12. Substances and the form of a substance used in a chemical process should be chosen to minimize 
potential for chemical accidents, including releases, explosions, and fires.
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All these principles summarize the sense of green chemisty: it looks for the development of processes that 
use less material and energy as possible and therefore that produce less pollution, all in compliance with 
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the safety of operators. In general, the application of the principles  is based on the acquisition of ethics 
by chemists and humanity, based on awareness of the environment as a limited resource that needs 
protection and security. In this sense, green chemistry become a discipline which is transversal respect to 
chemistry. 
In organic synthesis, it takes more specific meanings: 
- limit of solvents use; develop reactions in solid state or without solvent, or use solvents with lower 
environmental impact, such as water; 
- development of more efficient catalysts; exploit simple catalysts that may be recoverable, or biocatalytic 
methods; 
- limit the number of synthetic steps; if possible avoid the use of protecting groups and try to incorporate 
the greater number of reagents used into the final product; 
- if possible, favor reactions that take place at room temperature; if you cannot, take advantage of 
alternative energy sources; 
Therefore, in recent years have been developed several innovative methodologies which are necessarily 
part of a new vision of organic synthesis. Overall, the introduction of these methodologies is gradually 
revolutionizing the approach to organic synthesis, giving access to molecules with remarkable complexity 
for various uses but in respect of environment health. In particular, two aspects have been recognized as 
crucial for the development of processes more adherent to the green chemistry principles: the reaction 
medium choice and the use of catalytic processes in opposition to stoichiometric processes. As regards 
the problem of using solvents, are known processes that occur even without dissolution in organic 
solvent, and sometimes even two solids are able to react, with high yields and selectivities. Obviously, a 
process without solvent lowers the cost, if you can transfer it to an industrial level. An alternative to 
organic solvents that is gradually increase its spreading is the ability to carry out the reaction in water. 
Water has never attracted much attention, because of the difficulty of dissolving lipophilic compounds. 
However, the possibility of using mixtures of water and organic solvents is often enough for overcoming 
insolubility problems. 
In addition, if reagents can be only partially solubilized, the reaction can still proceed shifting the 
equilibrium towards the products. 
However, precisely the difficult solubility of the reactants in water can sometimes lead to “melt into one 
another” by forcing them in reverse micelles, for hydrophobic effect. This has the result of accelerating 
the reactions and it is therefore a significant and important kinetic advantage. 
The use of water and/or the optimization of a process operating in these conditions has many advantages: 
- water is cheap, much more than any other organic solvent; 
- water is safe, it is not flammable, and it is neither toxic nor carcinogenic; 
- water allows you to carry out the reaction without an inert atmosphere; 
- water allows a better control of the temperature because of its high thermal capacity; 
- water in some cases facilitates reactions for organic hydrophobic effect. 
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The research for always best catalytic methods is closely related to the principles of Green Chemistry. 
The best results in terms of environmental sustainability can be achieved by using catalysts able to work 
in water and/or in salt solutions: this is the case of enzymes, biocatalysts fundamental and ubiquitous 
which are gradually replacing chemical catalysts and innovating organic chemistry. 
Biocatalysis
28
 is known to men for a long time, and its applications were already found in ancient 
Mesopotamia, in China and Japan, in the production of food and beverage. A more scientific approach to 
biocatalysis only began in ‘800; in 1814 Kirchoff observed that the wheat gluten could convert starch into 
sugar. Subsequently, Payen and Persoz observed that the extracts of barley seeds were able to hydrolyze 
the starch furnishing dextrin’s and other sugars.29 These extracts were called “diastase” and were nothing 
else then mixtures of amylases; in 1935 Berzelius recognized the catalytic power of these extracts and 
from those years dextrin began to be produced very easily and commonly.
30
 It is only from 1894 that first 
theories of catalysis of these extracts began to be interpreted and explained by Emil Fisher. The scientist 
was convinced that enzymes were proteins (their true nature was certainly elucidated only after 20 years) 
able to work with a “key-lock” mechanism. A further step on enzymology was made by Buchner, who 
said that the enzyme catalysis does not necessarily require the presence and action of living cells.
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Nowadays, “biocatalysis” means all the chemical processes that are mediated by enzymes or whole cells; 
it is therefore to indicate the use of techniques for the biocatalytic synthesis of “fine chemicals”, and the 
fermentations for “bulk” production of molecules such as ethanol and acetic acid. Inside the biocatalysis 
are also present biotechnology and genetic engineering, i.e. those sciences that aim to build enzymes 
and/or microorganisms ad hoc designed to perform specific functions. 
Between advantages, the first and positive aspect of biocatalysis is certainly linked to the nature of 
enzymes. Enzymes are regioselective, chemoselective and stereoselective catalysts particularly efficient. 
This means that polyfunctional molecules can be transformed in a very selective manner and without the 
use of protecting groups, which is usually impossible the normal organic synthesis. This means a smaller 
number of synthetic steps, with money and time gains, and the possibility of carrying out the synthesis in 
aqueous medium avoiding, or reducing, the use of organic solvents must also be added. Moreover, was 
intensively studied the use of enzymatic catalyst in organic solvents. The chirality of the molecules can 
thus be introduced without the use of chiral catalysts, expensive and often very specific, and/or chiral 
auxiliaries via kinetic resolutions, kinetic dynamics, desymmetryzations and other processes. The use of 
biocatalytic systems allows compliance with many “rules” related to the principles of “green chemistry” 
enunciated by Anastas. 
The disadvantages associated with the biocatalysis are generally due to the nature of the enzyme and/or of 
the whole cell. Enzymes can be very expensive, because they have to be produced, extracted and purified 
from bacterial cells progenitor. They often need to be designed ex-novo, with developments very long and 
expensive. They can be easily re-used only if supported, but up to date a general technique doesn’t exist 
and each enzyme immobilization should be treated as a special case. 
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The immobilization in some cases may be even impossible, especially very complex for enzymes such as 
dehydrogenases. Therefore, the structure of the protein must often be changed to fit immobilization. If the 
cost of the enzyme is not a problem, you have to keep in mind that many of them work with cofactors 
such as NADH and FADH. Their costs must be considered, as well as the possibility to overcome the 
problem by building a system for recycling the cofactor. In some cases, the enzymes may also not be 
stable, preventing a long-term storage and decreasing the availability. 
If using enzymes can often be far from easy, it is not the case of working with whole cells; 
microorganisms in fact are generally very resistant, cheaper and can be cultivated in order to never 
exhausting them. A further advantage is related to the fact that cells do not need cofactors to operate. 
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2. INTEGRIN LIGANDS 
2.1 β-Lactams as integrin ligands 
2.1.1 Cell Adhesion Molecules 
Cell Adhesion Molecules (CAMs) are trans-membrane proteins located on cell surfaces. CAMs are 
composed of an intracellular, an extracellular and a trans-membrane domain. They take part in the so-
called process of cellular adhesion, essential in ensuring the maintenance of a multicellular structure both 
from the point of view of the three-dimensional shape and as far as concerning the arrangement and the 
different tissues organization. This mechanism can obviously affect the adhesion with other cells, through 
junctions therefore called direct, or even with a surface or with the extracellular matrix. Thus, it is so 
involved in the connection between cells, between cells and the cytoplasm, or even in signal transduction. 
Clearly, the importance of cell adhesion varies from a tissue to the other, or from a species to another. 
Adhesion molecules involved in the just considered mechanisms are divided into at least four different 
families, and as regards human cells, in addition to integrins also selectins, cadherins and molecules 
belonging to the so-called immuneglobulin superfamily of adhesion (IgSF CAMs) exist. CAMs are 
always described according to their nature and to the links that can establish, homophilic if directed to 
proteins of the same type or heterophilic if directed to the extracellular matrix or to adhesion molecules 
belonging to a different family. IgSF CAMs are an adhesion molecules family known since a long time 
and characterized by structural similarities with immunoglobulins. IgSF CAMs are able to make both 
homophilic and heterophilic bonds; they contain immuneglobulin-like extracellular domains, which 
perform important roles also for the immune system. Some members of this family worthy of 
consideration are Intercellular CAMs (ICAMs), Vascular CAMs (VCAMs) and Neural CAMs (NCAMs), 
frequently expressed from different cell types and involved in the fine adjustment of development and 
regeneration the processes. 
Cadherins are often expressed with them from the same cells and are characterized by a much stronger 
mediated adhesion, mainly maintaining the cells together and isolated in discrete tissues, and preserving 
the integrity of these tissues. Cadherins are trans-membrane omophilic glycoproteins involved in adhesion 
between cells and appear to be the most common adhesion molecules. Their name results from the 
contraction of “calcium” and “adhesion”, thus already defining their Ca2+ ions mediated mechanism of 
action. As a matter of facts, extracellular domains usually have flexibility points stiffened by interactions 
with calcium ions. Conformations can then match with that of cadherins, equal or of a closely related 
subtype, expressed by adjacent cells. The frequently poor affinity of these interactions has to be 
associated with a weakness of the adhesion itself. However, this limit is solved by the formation of the so-
called anchored junctions, consisting in a relatively high number of parallel formed bonds, always 
characterized by a mutual recognition of the partners. 
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Selectins are calcium dependent glycoproteins all made by a single protein chain and often considered to 
be a type of lectin, proteins specifically interacting with carbohydrates. Even selectins bind 
oligosaccharide portions, ensuring adhesion functions essentially between cells in the bloodstream, 
therefore transients and characterized by mild interactions. 
The management of white blood cells, in addition to an implication in the inflammatory phenomen, is 
among the main roles of these molecules. However, selectins does not work alone but often in 
collaboration with integrins, as regards both the inflammation and the passage of white blood cells from 
blood to tissues. Selectins, thus obviously heterophilic, in this process act from endothelial cells of blood 
vessel walls causing the rolling of these white blood cells, which may eventually activate an integrin. 
Finally, thanks to a conformational variation induced on integrins, which commonly allow the interaction 
of cells with the matrix, white blood cells can reach tissues.
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2.1.2 Integrins 
Integrins are glycoproteic membrane receptors involved both in the mechanisms of adhesion between 
cells and the extracellular matrix (ECM), and in the signals transduction from ECM to cells. ECM is 
formed, organized and decomposed by cells. It act on them through cell adhesion proteins like, mainly, 
integrins, at least in animal cells. Integrins are characterized by a surprising ability to transmit signals 
across cell membranes in both the directions. Interaction with molecules present in the matrix allows the 
transport of a message inside as well as an internal condition can control interactions with the matrix. In 
cases such as for the interaction of white blood cells with the endothelium and a few others, internal 
conditions can even act on surface molecules expressed on different cells. Moreover, in addition to 
molecular or mechanical signals transmission, it has been recently discovered the way by which integrins 
can convert a signal type into another. Among the functions of integrins, are present also biological 
activities related to cellular migration and immune system, and the mechanism that prevents certain virus 
to bind to cells. 
Nowadays are known twenty-four human integrins. These integrins are all formed by two glycoproteic 
subunits non-covalently linked and usually indicated by the Greek letters α and β. These subunits both 
cross the cell membrane, and while the outer portions bind specific aminoacid sequences of proteins, or in 
some cases even to molecules on surfaces of other cells, the inner ones are connected to a protein 
complex attached to the cytoskeleton. From suh a connection derivied the not yet cited control function 
on shape and cell mobility (Figure 2.1.1). 
A remarkable property of integrins is given by the possibility of assuming an active or inactive 
conformation in response to a specific interaction. It can happen by replicating to the action of certain 
ligands on allosteric sites. The activation consists, with regard to the outer portion, in an extension 
reflected in a mutual eversion of the subunits α and β, both in the trans-membrane area and in intracellular 
domains. 
23 
 
Figure 2.1.1 
The “outside-in activation” process ends with the establishment of a strong interaction between the β 
subunit and an anchor protein, which seems to be the key component of the connection between the 
internal regions and ECM. The protein is known as Talin and is thus in competition with the protein chain 
α (Figure 2.1.2). It follows the possibility of a reverse mechanism, an “inside-out activation” already 
observed and intracellular regulated by molecules whose signal is thus transferred to the matrix. 
 
Figure 2.1.2 
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At different dimerizations, associable with one of the eighteen subunits α and one of the eight β chains 
nowadays identified, can be correlated both properties and various functions, as well as different 
specificities in respect of the ligands involved. The concentrations of Ca
2+
 and Mg
2+
 also affect these 
interactions, in terms of specificity and affinity, and obviously overlaps exist. However, activities of 
integrins have high variability depending on the protein chains. Just to list a few examples, mutations may 
be involved in bleeding, favored by lack of platelet aggregation, severe vesicular cutaneous 
manifestations, some forms of muscular dystrophy and even in embryos death. 
As previously mentioned for other CAMs, integrins as well exert additional actions to the simple 
adhesion. For example, in vitro studies showed how a lot of cell types tend not to grow or proliferate, 
albeit with wide availability of nutrients, if the expression of integrins that determine their membership 
with the ECM was inhibited. Moreover, but only for certain types of cells, the loss of contact with the 
ECM induces apoptosis, the process of programmed cell death. A mutation involving integrins can 
determines the loss of cell dependence from the control system of growth and proliferation, and thus 
easily degenerate into cancerous diseases. Furthermore, in vitro and in vivo studies demonstrated that the 
molecular signals associated with integrin systems are crucial for proliferation and cell survival.
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Signals managed by integrins and received from cells are therefore related survival, growth, division, 
differentiation and apoptosis of themselves. Furthermore, were highlighted involvements in the migration 
of embryonic cells, in maintaining the integrity of tissues and in the process of blood coagulation. Finally, 
some integrins has an important role even in the angiogenesis mechanism. It consists in the construction 
of new blood vessels from existing ones, and also endothelial cells are involved. 
Concerning this, worthy of attention is the αvβ3 type integrin, the first crystallized and characterized 
among the αv and the first shown to be active in regulating the angiogenesis process. On one hand, 
angiogenesis is biologically essential for embryonic growth and tissue survival and repair. On the other 
hand is involved in inflammatory processes becoming chronic, in tumor growth and in metastatic 
developments. While in normal physiological conditions it is strictly controlled and finely adjusted, in 
cases of hyperactivity the transition of a latent tumor to an evil one is favored.
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 The development of 
angiogenesis inhibitors has so begun, studying proteins such as fibronectin, fibrinogen, vibronectin and 
osteopontin, ECM components which interact with integrins. Obviously, the aim was to identify the 
pharmacophore and develop inhibitor drugs. 
Moreover, also α4β1-type integrin has been shown to play important roles in many diseases such as 
embryogenesis and pathogenesis, which involve both cell adhesion and cell migration. Integrin α4β1 can 
mediate cell-cell and cell-extracellular matrix adhesion by binding to either fibronectin or Vascular Cell 
Adhesion Molecule 1 (VCAM-1). Both interactions are important for extravasation of leukocytes from 
blood. Thus, rationally designed inhibitors of α4β1 function may be useful for treating a various 
inflammatory conditions.
35
 Ligand-binding sites are contained within the HepII/IIICS domain of 
fibronectin and within the homologous immunoglobulin domains 1 and 4 of VCAM-1. Previous studies 
have shown that the binding of each ligand to α4β1 is mutually exclusive, suggesting that they may 
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employ similar mechanisms to bind receptor. Fibronectin contains at least three distinct peptide sequences 
that are active sites for α4β1 binding, two homologous sequences Leu-Asp-Val-Pro (LDVP) and Ile-Asp-
Ala-Pro (IDAP), and a third related to Arg-Gly-Asp (RGD).
36
 Small peptide and non-peptide α4β1 
antagonists have already shown efficacy in disease models of inflammation (BIO12118
37
 and TR-
140359
38
). 
 
2.1.3 Integrin inhibitors 
Fibrinogen is a plasmatic glycoprotein essential in the process of blood coagulation and perhaps the best 
known integrin inhibitor. Studies on it and on other related proteins have led to identificate the RGD 
peptide sequence (Arg-Gly-Asp) like the key portion for the recognition of ligands operated by integrins 
(Figure 2.1.3). 
 
 Figure 2.1.3 RGD peptide sequence 
Studies conducted by x-rays on αvβ3 type integrins have shown that interactions established with their 
ligands were mainly electrostatic. A positive charge was seen to be delocalized by the guanidine group of 
the arginine, while an opposite sign charge is carried by the aspartic acid residue, at physiological pH. 
These charges interact with integrins on two other aspartic units in α chains and on a metal cation of the β 
parts, respectively. These observations has also been extended to α5β1 and, recently, α4β1 type integrins. 
Thus, integrins become a promising target for the development of angiogenesis treating agents. Nowadays 
many ligands, also with significantly different scaffolds, are able to mimic the RGD sequence showing 
affinities in some cases very high. Structures of these compounds varied during the time, from cyclic 
oligopeptides therefore conformationally rigid to derivatives partially and completely retro-inverse, i.e. 
made in part or in whole by amino acids of the non-natural (D) series. 
New peptidomimetics of the RGD sequence have recently been proposed. They are always cyclic, but 
contains a β-lactam ring as a further reduction of the molecular flexibility. Results furnished are 
comparable to the one of Cilengitide, a ciclopentapeptide endowed of an high activity against the αvβ3 
type integrin, so with a very low concentration able to inhibit the activity of the 50% of targets (IC50). 
The key role of the cationic and anionic dual functionality, originally due to an arginine and an aspartic 
residues and left unscathed in first peptide analogues and pseudopeptides developed, always remained, 
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albeit if in very diverse structures. Acidity and basicity of the two functions, as well as the relative 
distances, immediately appeared to be irreplaceable. First peptidomimetic inhibitors with high activity 
and therefore with a certain therapeutic potential presented however bioavailability problems. These 
necessities prompted the science researchers towards non-peptidomimetic inhibitors (some examples in 
Figure 2.1.4). 
 
 
Figure 2.1.4 Specific integrin inhibitors with high activities 
However, among these antagonists no one has an actual use, and none is still entered into clinical trials, 
not because of an affinity lack or a low target selectivity but for times and costs of the discovery process 
itself.
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It is evident that also remarkable structural variations compared to the RGD sequence are possible. In 
particular, as common in the design of new compounds for potential pharmacological uses and as already 
seen in the cyclic compounds shown, scaffolds exploited introduce a conformational rigidity which is 
often an added value for similar applications. Reduction of molecular weights, increase of metabolic 
stabilities and bioavailabilities, and reduction of the number of potential interaction partners, avoiding the 
consequent side effects, are always the main advantages. 
 
27 
2.1.4 β-Lactam αvβ3 and α5β1-type integrin agonists 
As previously mentioned, among the integrin superfamily αvβ3 and α5β1 type integrins play a pivotal role 
in the formation of new blood vessels and are overexpressed on activated endothelial cells in 
physiological and pathological angiogenesis.
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 The αvβ3 integrin is extensively expressed on tumor cells. 
There are some evidences that this receptor is present in late stage glioblastomas, ovarian carcinoma, 
melanomas; it also is an endothelial cell marker in breast cancer and regulates melanoma cell 
proliferation, survival and metastases.
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 The involvement of integrin αvβ3 in highly important pathologies 
induced the development of potential candidates able to inhibit the functions of this receptor, but the 
mode of action of these molecules has not been elucidated. This means that they could be full or partial 
agonists, inverse agonists or antagonists; they probably engage the integrin altering its conformation as 
response, preventing intramolecular shape change or dragging a conformational equilibrium towards the 
inactive form of the receptor.
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The activation of integrin-mediated cell adhesion by antibodies or small molecules has been recently 
reported: Vanderslice et al. demonstrated that agonists enhanced the effects of stem cell-based therapies 
by improving cell retention and engraftment; Yea et al. found that a single agonist antibody against the 
alpha chains of integrins can induce human stem cells to become dendritic cells.
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 It was thus recognized 
that integrin agonists could open up novel opportunities for therapeutics which gain benefits to increase 
rather than decrease integrin-dependent adhesion. For instance, a significant factor in chemoresistance in 
melanoma is a loss of integrin-mediated adhesion; in this case, stimulation of integrin signaling by 
agonists significantly improved the response to chemotherapy. Gupta et al. have reported that small 
molecule mediated activation of integrins, rather than inhibition, reduced leukocyte migration, tissue 
accumulation and inflammatory injury.
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Up to now, a large number of peptide and non-peptide ligands for the αvβ3 receptor have been developed, 
which are all related to the minimal recognition RGD motif present on αvβ3 integrin ligands of the ECM 
such as fibronectin and vitronectin. As an example, Cilengitide is a small RGD-containing cyclic 
pentapeptide currently in clinical phase III for glioblastoma multiform and in phase II for other types of 
cancers due to its capability to antagonize αvβ3, αvβ5, and α5β1 integrins (Figure 2.1.5).
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 Recent research 
efforts have focused on improving the pharmacological parameters mainly by altering the polarity and 
rigidity of the scaffold and the nature of the basic moiety. Among several heterocyclic structures able to 
antagonize integrins, lactam derivatives found their own niche. In Figure 2.1.5 are reported some lactam 
derivatives active as integrin ligands and some of the ligands include the RGD tripeptide framework. 
Lactams D and E demonstrated that a phenylamine portion could successfully replace the arginine 
residue.
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 In previous papers, some of us have identified a series of αvβ3/α5β1 integrin ligands with 
unsaturated β-amino acid fragment: was known that incorporating a distinct β-amino acid into a RGD-
containing peptide resulted in the stabilization of specific conformations of the ligand.
47
 It was argued that 
a restricted conformation introduced by unsaturated β-amino acid and of a cyclic structure could give a 
28 
favorable alignment of both the basic and carboxylate moieties on the ligand, thus meeting the crucial 
requirements for integrin affinity and selectivity. The β-lactam ring constitutes by itself a site of 
conformational restriction with a β-amino acid moiety in a cyclic structure and constrained features. 
 
Figure 2.1.5 Cilengitide and other integrin ligands, with in red the RGD sequence 
As a part of our studies on design and synthesis of new β-lactam derivatives and of an on-going 
interdisciplinary project,
48
 we would like to evaluate the ability of azetidinones, not inserted into 
cyclopeptides, to target integrins. We report the synthesis and the preliminary biological results on K562 
(human erythroleukemia expressing α5β1 integrin), SK-MEL-24 (human malignant melanoma expressing 
αvβ3 integrin), and Jurkat E6.1 human T cells (expressing α4β1 and αLβ2 integrins) cells of some new β-
lactam derivatives. The approach for the design of the new molecules was based on rationalization of 
known ligands structures: we set out to explore molecules containing the azetidinone as a rigid cyclic 
framework, armed with carboxylic acid and amine terminus spaced from 9 to 14 atoms to activate a 
conceivable recognition by integrins (Figure 2.1.6). 
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Figure 2.1.6 β-Lactams synthesized and tested as trifluoroacetic acid (TFA) salts 
A 4-amidobenzylamine residue was chosen as the basic terminus directly linked to the β-lactam nitrogen 
atom thus resulting as imido function. The carboxylic acid was on the C-4 side chain of the azetidinone 
and differently spaced from the ring: in compound 1 the β-lactam ring together with the C-4 side chain 
could be considered a sort of β-glutamic acid derivative, which was elongated with a glycine residue in 
compound 2, while in the azetidinone 3 the carboxylic acid is directly linked to the β-lactam ring thus 
resembling an aspartic cyclic amide. The C-3 position was not substituted in order to mimic the 
methylene residue of glycine in the RGD peptide. Herein I report our discovery of azetidinones as new 
cell adhesion ligands and their characterization as αvβ3 and α5β1 agonists. 
 
Figure 2.1.7 Synthetic strategies for compounds 1, 2 and 3 
Compounds 1 and 2 were both obtained starting from the commercially available 4-acetoxy-azetidin-2-
one. The introduction of the carboxylic function in the C-4 side chain was achieved through a 
Reformatsky reaction followed by N-acylation of the β-lactam ring to give compound 1. The C-4 side 
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chain was eventually converted into a longer peptide chain through insertion of a glycine unit to give 2, 
while 3 was prepared from 4-carboxylic-azetidin-2-one, easily obtained in enantiomerically pure form by 
ring-closure of an L-aspartic acid diester (Figure 2.1.7). A careful protecting group strategy for the C-4 
and N-1 side chains of azetidinones was developed to preserve the β-lactam ring throughout the synthesis 
and to enable specific combination of temporary or permanent protecting groups to achieve a full or 
partial deprotection depending on the synthetic strategy requirements. 
In Schemes 2.1.1-3, the synthetic steps are described in details. As outlined, t-butylbromoacetate and 
benzylbromoacetate were treated with an excess of metallic Zn in THF to furnish the corresponding 
Reformatsky reagents, which were then coupled with 4-acetoxyazetidin-2-one 4 to give 4-acetate-
azetidin-2-one esters 5 and 6 in good overall yields after purification by flash column chromatography. 
The N-1 side chain was constructed starting from 4-aminobenzylamine 7 selectively protected with a Boc 
group on the benzyl amine and then transformed into the corresponding isocyanate 8 with triphosgene. 
Treatment of azetidinones 5 and 6 with NaHMDSA (Sodium bis-trimethylsilyl-amide) followed by 
addition of isocyanate 8 furnished compound 9 and 10 in good yields after purification by flash column 
chromatography. Compound 9 was then deprotected by treatment with trifluoroacetic acid both on the C-
4 and the N-1 side chains to give compound 1 as trifluoroacetate salt (Scheme 2.1.1). 
 
Scheme 2.1.1 Synthesis of compound 1 
The benzyl ester of compound 10 was in turn selectively deprotected to give acid 11 so that a DCC 
mediated coupling with benzylglycine 12 could be accomplished to deliver compound 13. Compound 13 
was subsequently deprotected in a two steps procedure furnishing 14 by hydrogenolysis and then 
azetidinone 2 as trifluoroacetate salt treating with TFA (Scheme 2.1.2). 
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Scheme 2.1.2 Synthesis of compound 2 
As to the synthesis of 3, the starting 4-carboxylic-azetidin-2-one 16 was obtained by a Grignard mediated 
cyclization of L-aspartic acid dibenzylester 15 Enantiomerically pure 16 was then N-acylated to give 17 
and deprotected in two steps with the same procedures exploited above furnishing 18 and, finally, 3, 
isolated as trifluoroacetate salt (Scheme 2.1.3). 
 
Scheme 2.1.3 Synthesis of compound 3 
 
Pharmacology 
The ability of 1, 2 and 3 to modulate the adhesion of K562 (expressing α5β1 integrin) or SK-MEL-24 
(expressing αvβ3 integrin) cells to immobilized fibronectin (10mg/mL) was evaluated. These cell models 
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are widely used to investigate potential ligands capable of influencing cell adhesion mediated by the 
above mentioned integrins. Interestingly, β-lactams 1, 2 and 3 showed a concentration dependent 
enhancement in fibronectin-mediated adhesion of K562 and SK-MEL-24 cells (in Figure 2.1.8, the 
concentration response curves showing the effects of 1, 2 and 3 on cell adhesion; cells were incubated for 
30min at room temperature with each compound or with the vehicle as described in the experimental 
section). 
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Figure 2.1.8 1, 2 and 3 enhancement of fibronectin-mediated adhesion  
With regards to α5β1 integrin expressing cells, 1 was the most potent in enhancing cell adhesion with an 
EC50 of 12nM; it was more or less five times less potent toward αvβ3 integrin. β-Lactam 2 was the most 
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effective toward αvβ3 integrin (EC50 = 11nM) and 3 was 1000 less effective. These cell models were 
validated demonstrating that the αvβ3 and α5β1 agonist fibronectin produces a concentration-dependent 
elevation of cell adhesion in SK-MEL-24 and K562 cells (data not shown). 
Reference antagonists were capable to displace cell adhesion in SK-MEL-24 cell line (Ac-Asp-Arg-Leu-
Asp-Ser-OH, IC50 = 25nM) and in K562 cell line (cyclo-Arg-Gly-Asp-D-Phe-Val, IC50 = 34.7mM). In 
another set of cell adhesion assays, 1 and 2 were ineffective to modify Jurkat E6.1 cell adhesion mediated 
by α4β1 - (toward vascular cell adhesion molecule-1, abbreviated in VCAM-1) and αLβ2 - (toward 
intercellular adhesion molecule-1, ICAM-1) integrin (IC50 ≥ 10 mM, data not shown), thus demonstrating 
selective interactions by the new β-lactam ligands. The ability of the new β-lactams to increase cell 
adhesion was then tested in the absence of fibronectin. In a second set of experiments, adhesion of K562 
and SK-MEL-24 cells to wells previously coated by passive adsorption with the most active β-lactams 1 
and 2, fibronectin as comparison, and BSA as a control, were tested (in Figure 2.1.9, K562 and SK-MEL-
24 cell adhesions to wells coated with 10μg/mL of fibronectin FN, compound 1 and 2. Controls were cells 
plated in wells coated with 10μg/mL of bovine serum albumin BSA. Each value is the mean ± S.E.M. 
from four separate experiments carried out in duplicate). 
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Figure 2.1.9 K562 and SK-MEL-24 cell adhesions 
Both β-lactams 1 and 2 produced a significant adhesion, comparable to fibronectin, of K562 and SK-
MEL-24 cells, while on the contrary both cell lines did not adhere to wells coated with bovine serum 
albumin alone. Neutralizing antibodies to the β1 or αv integrin subunit (10mg/mL), added to the cells 10 
min in advance, blocked the adhesion mediated by compounds 1 and 2 (10mg/mL) to K562 and SK-
MEL- 24 cells, respectively (data not shown). This result strengthened the evidence that the cell adhesion 
was effectively and specifically mediated on αvβ3 and α5β1 integrins by the new β-lactam ligands. 
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Wandzik et al. have reported that the protein kinase C (PKC) activator PMA (Phorbol Myristate Acetate) 
induces megakaryocytic differentiation of K562 cells upregulating αIIbβ3 integrin expression, which may 
represent a target of the assayed β-lactams.49 We ascertained, by flow cytometry analysis, that K562 cells 
exposed to PMA (25 /mL for 40h) express this integrin subtype, in addition 
to α5β1. Interestingly, cell adhesion of K562 cells mediated by compounds 1 and 2 was partially blocked 
by the selective αIIbβ3 antagonist tirofiban (in Figure 2.1.10, integrin αIIbβ3 partially mediates K562 cells 
adhesion to compound 1 and 2. A: PMA, 25ng/mL for 40h, induces upregulation of αIIbβ3 integrin 
expression on K562 cell surface in comparison to untreated cells. A representative experiment repeated 
three times with the same result is shown. B: the selective αIIbβ3 antagonist tirofiban TF at 5, 10 or 50mM 
partially blocks K562 cell adhesion to wells coated with 1 or 2. Each value is the mean ±S.E.M. from four 
separate experiments carried out in duplicate).
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Figure 2.1.10 cytometry analysis of αIIbβ3 integrin expression on K562 
These data seem to be indicative that both α5β1 and αIIbβ3 integrins may contribute to mediate cell 
adhesion induced by 1 and 2 in K562 cells. These data support the hypothesis that the novel β -lactam 
derivatives 1 and 2 possess an interesting activity as αvβ3 and α5β1 integrin agonists. Compound 1 displays 
an higher affinity toward α5β1 integrin whereas 2 is more selective for integrin αvβ3. Both integrins are 
targeted by the RGD sequence and it is conceivable to presume that these novel compounds could mimic 
the sequence. Interestingly, Aizpurua et al. have already described cyclic peptides bearing a β-lactam 
moiety (as already shown in Figure 2.1.5) that bind to αvβ3 integrin: the cyclic tetrapeptide with a deleted 
glycine residue behaves as an agonist and displays opposite angiogenic gene-regulation activity of the 
peptidomimetic RGD parent.
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Agonists have also been described for the β2 family of integrins and for αMβ2.
52
 These latter compounds 
are thought to stabilize the high affinity conformation of αMβ2 integrin and may function as anti-
inflammatory drugs through a novel mechanism of action (perturbation of integrin de-adhesion). 
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Recently, Vanderslice et al. have reported that a small molecule agonist of α4β1 integrin induces 
progenitor cell adhesion and may be an adjunct to cell-based therapy. 
Until now, small molecules acting as integrin antagonists have been developed and proposed as novel 
drugs. However, it would be advisable to develop novel small molecules that behave as integrin agonists 
and increase rather than decrease integrin dependent cell adhesion. Further studies will better address the 
mechanism of agonism of these ligands and how they may influence cell signaling. 
 
 
2.2 Other integrin ligands 
2.2.1 Developing β-lactam αvβ3 and α5β1-type integrin antagonists 
The activating effect shown by compounds 1, 2 and 3 is particularly of interest when compared with other 
mimetics of the RGD sequence which carry the same p-aminobenzylamine moiety. There are abundant 
examples that showing how this portion, as mimetic for the basic group of arginine, determines an 
inhibitory activity against the same αvβ3 and α5β1 type integrins.From a first Structure-Activity 
Relationship analysis, this inconsistency seemed to depend only from the connectivity of the 
aminobenzylamine portion of the molecule.  
 
Figure 2.2.1 β-Lactams synthesized and tested as TFA salts 19, 20 and 21 
Notwithstanding the need for a separation between the two functions of 9-14 carbon atoms, we therefore 
designed three new compounds to be tested as inhibitors for the same αvβ3 and α5β1 type integrins. 
Therefore, these structures are very similar to those of compounds 1, 2 and 3, although only 1 and 2 have 
proven to be interestingly active as agonists in the assays conducted by us. The only difference was the 
aminobenzylamine connectivity, as shown in Figure 2.2.1. 
Regarding the retrosynthetic analysis of these three new β-lactam based molecules, we designed a 
synthesis based on the previously shown strategy in Figure 2.1.7. The chain on the C-4 of β-lactam ring 
can follow the same synthetic sequence, with or without the elongation steps previously shown, as well as 
also the Reformatsky reaction can be maintained.  
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Figure 2.2.2 Synthetic strategies for compounds 19, 20 and 21 
The amine used for the formation of its corresponding isocyanate and the subsequent β-lactam acylation 
can as well be prepared from the 4-aminobenzylamine, but it must be instead protected on the aniline 
group (Scheme 2.2.1). 
 
Scheme 2.2.1 Synthesis of 4-(Boc-amino)-benzylamine 24 and of its isocyanate 25 
The protecting groups strategy was kept unchanged as well. Moreover, we chose the more efficient 
vstrategy with two orthogonal protecting groups for the acid and the amine, to be removed at the end in 
two steps, an hydrogenolysis and a subsequent trifluoroacetic acid treatment.It allowed to obtain the two 
targets as their trifluoroacetic acid salts (Scheme 2.2.2). 
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Scheme 2.2.2 Synthesis of compounds 19 and 20 
Compound 21 was prepared starting from the already shown intermediate 16. It requires an acylation of 
the β-lactam nitrogen and then the two steps deprotection (Scheme 2.2.3). 
 
Scheme 2.2.3 Synthesis of compound 21 
β-Lactams 19 and 21 showed interestingly and opposite results in fibronectin-mediated adhesion on K562 
cells (in Figure 2.2.3, the concentration response curves showing effects of 19 and 21 on cell adhesion; 
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cells were incubated for 30min at room temperature with each compound or with the vehicle, as described 
in the experimental section). 
 
Figure 2.2.3 19 and 21 influence on fibronectin-mediated adhesion  
With regards to α5β1 integrin expressing cells, 19 was quite potent in enhancing cell adhesion with an IC50 
of 44.5nM. Indeed, β-lactam 21 was an antagonist toward the same α5β1 integrins (IC50 = 525nM). These 
cell models were validated demonstrating that the α5β1 agonist fibronectin produces a concentration-
dependent variation of cell adhesion in K562 cells (data not shown). 
 
2.2.2 α4β1-type integrin inhibitors 
As mentioned before, α4β1-type integrin are involved in many diseases such as embryogenesis and 
pathogenesis. Antagonism of α4β1 represents a well validated target for the treatment of inflammatory 
disorders, and the o-tolyl-ureido moiety seems to be fundamental for interactions between ligands and 
these integrins. Comparing to the already developed compounds, we designed new β-lactam molecules 
that must present the same acid function, and an o-tolyl-moiety in place of the amine group. 
 
Figure 2.2.4 β-Lactams synthesized and tested 32, 33 and 34 
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The distance between these two functionality must be fixed, as before considered, from nine to fourteen 
atoms. Thus, we started a new study with three β-lactam molecules specifically designed for interacting 
with α4β1-type integrins, in order to initiate a preliminary SAR evaluation (Figure 2.2.4). 
For the synthesis, we thought to work on the chain in position 4 of the ring by introducing it with the 
same Reformatsky reaction previously optimized, elongating it where necessary by peptide coupling 
between the deprotected acid group and the O-benzyl protected glycine (Figure 2.2.5). 
 
Figure 2.2.5 Synthetic strategies for compounds 29, 30 and 31 
Preparations of compounds 32 and 33 differ only in the length of the C-4 chain. Therefore, reaching 33 
from 32 requires two additional synthetic steps (Scheme 2.2.4). 
As regards the portion in 1, even in this case we conducted the acylation reactions of the nitrogen with 
appropriate isocyanates. Indeed, a good comfort about that was provided by the commercial availability 
of the o-tolylisocyanate. Furthermore, to lengthen this portion of the molecule, we evaluated two different 
synthetic pathways, both however converging on the benzyl ester 6 obtained by Reformatsky reaction 
(Figure 2.2.5). 
To lengthen the chain on the β-lactam nitrogen atom we exploited the protecting groups orthogonality on 
compound 10, already shown, selectively removing the Boc moiety by treatment with trifluoroacetic acid.  
The corresponding free amine in the corresponding TFA salt form was so obtained. After a desalting 
treatment with triethylamine, conducted under nitrogen athmosphere, we acylated the N-chain with the 
same o-tolylisocyanate. The reaction was carried out under basic conditions and without any metalation. 
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Scheme 2.2.4 Synthesis of compounds 32 and 33 
Target compound 34 was finally obtained liberating the acid functionality by removal of the benzyl 
protecting group, via Pd-catalyzed hydrogenolysis (Scheme 2.2.5). 
 
Scheme 2.2.5 Synthesis of compound 34 
Preliminary biological results, obtained in collaboration with prof. S. Spampinato of the University of 
Bologna, showed for the last derivative an activity roughly nothing, or at least with a scarce relevance. 
Compounds 32 and 33 appeared to be much more encouraging. The first one has mainly shown an agonist 
activity against α4β1 type integrin, whereas the latter appeared to have an antagonist behavior. 
Although these data derived from essays that still being completed and fully investigated, we decided to 
continue the study exacerbating the structural characteristics of these two compounds. We shortened the 
portion bringing the acid in one case, designing compound 39, and we lengthened the same chain while 
designing compound 40 (Figure 2.2.6). 
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Figure 2.2.6 β-Lactams synthesized and tested as TFA salts 39 and 40 
These modifications took account of past experiencse in the synthesis of related compounds and were by 
a formal removal, in the case of compound 39, and an introduction, for 37, of only one methylene residue. 
Such a small modification should theoretically be able to provide sufficient indications on the conjectured 
SAR considerations. 
For the synthesis of compound 39 we followed the acylation pathway. It was conducted using the 
commercially available o-tolylisocyanate on the benzyl ester 16, then deprotecting the acid functionality 
by hydrogenolysis (Scheme 2.2.6). 
 
Scheme 2.2.6 Synthesis of compound 39 
For the preparation of compound 40 we followed the synthesis of intermediate 36, but for the peptide 
coupling was employed the corresponding protected amino acid with one more methylene, i.e. the benzyl 
ester of β-alanine. It was obtained by treating, in the presence of p-toluenesulfonic acid, β-alanine with 
benzyl alcohol (Scheme 2.2.7). At the end, the acid functionality was at the end obtained by 
hydrogenolysis, reaching the desired target 40. 
 
Scheme 2.2.7 Synthesis of compound 40 
Preliminary results showed what we expected. Shortening the chain on C-3 of the β-lactam ring, 
antagonist activity resulting accentuated, as shown by the data for compound 39, while lengthening it, as 
in 40, a sharp increase in adhesion and thus in agonism was observed (in Figure 2.2.7, the concentration 
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response curves showing the effects of 39 and 40 on cell adhesion; cells were incubated for 30min at 
room temperature with each compound or with the vehicle as described in the experimental section). 
 
Figure 2.2.7 39 and 40 influence on fibronectin-mediated adhesion 
With regards to α4β1 integrin expressing cells, 39 was very potent in reducing adhesion with an IC50 of 
1.39nM. Indeed, 40 was an agonist toward the same α4β1 integrins (IC50 = 49.0nM). These cell models 
were validated demonstrating a concentration-dependent variation of cell adhesion in K562 cells (data not 
shown). 
 
 
2.3 Experimental section 
2.3.1 General informations 
Commercial reagents were used as received without additional purification. 
1
H, 
13
C, and 
31
P NMR spectra 
were recorded with an INOVA 400 or a GEMINI 200 instrument with a 5mm probe. All chemical shifts 
are quoted relative to deuterated solvent signals (δ in ppm and J in Hz). Polarimetric Analyses were 
conducted on Unipol L 1000 “Shcmidt&Haensch” Polarimeter at 598nm. FTIR spectra: Thermo Nicolet 
380 instrument, measured as films between NaCl plates; wave numbers are reported in cm
-1
. TLC: Merck 
60 F254plates. Column chromatography: Merck silica gel 200-300mesh. HPLC-MS: Agilent 
Technologies HP1100 instrument, equipped with a ZOBRAX-Eclipse XDΒ-C8 Agilent Technologies 
column, mobile phase: H2O/CH3CN, 0.4 mL/min, gradient from 30 to 80% of CH3CN in 8min, 80% of 
CH3CN until 25min, coupled with an Agilent Technologies MSD1100 single-quadrupole mass 
spectrometer: full scan mode from m/z = 50 to 2600, scan time 0.1s in positive ion mode, ESI spray 
voltage 4500V, nitrogen gas 35psi, drying gas flow 11.5mL/min, fragmentor voltage 20V. Elemental 
analysis were performed on a Thermo Flash 2000 CHNS/O Analyzer. A Shimadzu UV-1601 PC 
spectrophotometer was used for spectrophotometric measurements. 
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2.3.2 Synthesis 
Azetidinone 4 is commercial, compounds 7
53
, 12
54
, and 15
55
 were synthesized following already reported 
procedures, while for 42 was followed the same procedure indicated for 12. 
 
tButyl 2-(4-oxo-azetidin-2-yl) acetate (5) 
In a 50mL 3-neck flask under nitrogen, Zn powder (2.0g, 31mmol) and THF (10mL) 
were introduced followed by TMSCl (200mL, 1.55mmol). After 30 min of stirring the 
temperature was raised to 30÷35°C and a solution of tbutylbromoacetate (1.43mL, 
15.5mmol) in THF (20mL) was slowly added in 30min. After 30min of stirring the 
mixture was cooled to rt and decanted, providing a limpid grey supernatant that was slowly added 
dropwise to a 100mL flask under nitrogen containing a solution of 4 (500mg, 3.88mmol) in anhydrous 
THF (22mL) at 0°C. The mixture was stirred at rt for 3h, quenched with ice and a saturated Seignette salt 
solution and extracted with EtOAc. The organic layers were dried on Na2SO4, filtered and concentrated in 
vacuum. Flash-chromatography (cyclohexane/EtOAc, 6/4) gave 5 (545mg) as a white solid in 76% yield. 
M.p. 83-84°C; Rf 0.34 (cyclohexane/EtOAc, 1/4) 
1
H NMR (400MHz, CDCl3): δ = 1.49 (s, 9H, tBu), 2.50 (dd, J = 8.8, 16.0Hz, 1H, CHHCO2tBu), 2.67 (dd, 
J = 4.8, 16.0Hz, 1H, CHHCO2tBu), 2.69 (ddd, J = 1.2, 2.4, 14.8Hz, 1H, CHHCHCH2CO2tBu), 3.19 (ddd, 
J = 2.4, 4.8, 14.8Hz, 1H, CHHCHCH2CO2tBu), 3.95 (dddd, J = 2.4, 4.8, 4.8, 8.8Hz, 1H, 
CHHCHCH2CO2tBu), 6.40 (bs, 1H, NH) ppm 
13
C NMR (100MHz, CDCl3): δ = 28.0, 41.0, 43.3, 43.9, 81.4, 167.2, 170.1 ppm 
IR: ṽ = 3238, 2964, 1763, 1735, 1398, 1261 cm-1 
GC-MS: Rt = 13.5min, m/z (%) = 170 (7), 129 (13), 112 (13), 101 (10), 86 (12), 70 (36), 57 (100) 
 
Benzyl 2-(4-oxoazetidin-2-yl) acetate (6) 
In a 50mL 3-neck flask under nitrogen, Zn powder (2.0g, 31mmol) and THF (10mL) 
were introduced followed by TMSCl (200mL, 1.55mmol). After 30min of stirring the 
temperature was raised to 30÷35°C and a solution of benzylbromoacetate (2.46mL, 
15.52mmol) in THF (19.4mL) was slowly added in 30min. After 30min of stirring the 
mixture was cooled to rt and decanted, providing a limpid grey supernatant that was slowly added 
dropwise to a 100mL flask under nitrogen containing a solution of 4 (500mg, 3.88mmol) in anhydrous 
THF (22mL) at 0°C. The mixture was stirred at rt for 3h, quenched with ice and a saturated Seignette salt 
(potassium sodium tartrate) solution and extracted with EtOAc. The organic layers were dried on Na2SO4, 
filtered and concentrated in vacuum. FC (cyclohexane/EtOAc, 1/1) gave 6 (552mg) as a white solid in 
65% yield. 
M.p. 92-95°C; Rf 0.42 (cyclohexane/EtOAc, 1/4) 
1
H NMR (400MHz, CDCl3): δ = 2.64 (dd, J = 9.2, 16.8Hz, 1H, CHHCO2Bn), 2.66 (ddd, J = 1.2, 2.4, 
15.2Hz, 1H, CHHCHCH2CO2Bn), 2.78 (dd, J = 4.8, 16.8Hz, 1H, CHHCO2Bn), 3.15 (ddd, J = 2.4, 4.8, 
15.2Hz, 1H, CHHCHCH2CO2Bn), 3.96 (dddd, J = 2.4, 4.8, 4.8, 9.2Hz, 1H, CHHCHCH2CO2Bn), 5.15 (s, 
2H, CH2Ph), 6.22 (bs, 1H, NH), 7.34-7.39 (m, 5H, Ph) ppm 
13
C NMR (100MHz, CDCl3): δ = 39.8, 43.4, 43.8, 66.8, 128.3, 128.5, 128.7, 135.3, 166.9, 170.7 ppm 
IR: ṽ = 3238, 2961, 1738, 1460, 1372, 1262 cm-1 
HPLC-MS: Rt = 4.82min, m/z = 220 [M+H]
+
, 237 [M+H2O]
+
, 439 [2M+H]
+
 
 
tButyl 4-isocyanatobenzylcarbamate (8) 
In a 50mL 2-neck flask with a reflux condenser under nitrogen atmosphere, a 
solution of (7) (149mg, 0.67mmol) and TEA (188mL, 1.34mmol) in anhydrous 
DCM (7.0mL) was cooled to 0°C and after was added with bis(trichloromethyl)-
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carbonate (398mg, 1.34mmol) in one portion. The mixture was warmed to rt and then refluxed for 3-4h. 
The reaction was monitored through the increase of isocyanate IR signal (found at 2274cm
-1
). The solvent 
was evaporated under vacuum avoiding any air exposure. The crude was extracted five times with 
anhydrous Et2O under nitrogen, concentrated in vacuum, stored under nitrogen atmosphere and 
immediately used. 
 
tButyl 2-(4-Boc-aminomethyl-phenylcarbamoyl)-4-oxoazetidin-2-yl acetate (9) 
In a 25mL 2-neck flask under nitrogen at -78°C, a solution of NaHMSA (Sodium 
bis(trimethylsilyl)amide) 1.0M in THF (500μL, 0.5mmol) was added dropwise to 
a solution of 5 (83mg, 0.45mmol) in anhydrous THF (4mL). After 15min of 
stirring, a solution of isocyanate 8 (166mg, 0.67mmol) in THF (2mL) was added 
dropwise. After completion (TLC monitoring, 30min) the mixture was quenched 
with a saturated solution of NH4Cl and extracted with EtOAc and then DCM. 
The combined organic extracts were dried over Na2SO4, concentrated in vacuum 
and purified by flash-chromatography (DCM/Et2O, 95/5) affording 9 (162mg) as a white solid in 83% 
yield. 
Rf 0.67 (cyclohexane/EtOAc, 2/3) 
1
H NMR (400MHz, CDCl3): δ = 1.45 (s, 9H, tBu), 1.46 (s, 9H, tBu), 2.68 (dd, J = 8.8, 16.0Hz, 1H, 
CHCHHCO2tBu), 2.96 (dd, J = 2.8, 16.0Hz, 1H, CHCHHCO2tBu), 3.24 (dd, J = 4.0, 16.4Hz, 1H, 
CHHCHCHHCO2tBu), 3.35 (dd, J = 5.6, 16.4Hz, 1H, CHHCHCHHCO2tBu), 4.28 (d, J = 5.6 Hz, 2H, 
CH2NHCO2tBu), 4.39 (m, 1H, CHHCHCHHCO2tBu), 4.80 (bs, 1H, NH), 7.25 (d, J = 8.8Hz, 2H, arom), 
7.43 (d, J = 8.8Hz, 2H, arom), 8.47 (bs, 1H, NH) ppm 
13
C NMR (100MHz, CDCl3): δ = 28.0, 28.3, 37.9, 42.6, 44.2, 47.7, 81.7 (2 C), 119.8, 128.2, 134.9, 136.1, 
140.3, 147.7, 166.9, 169.0 ppm 
IR: ṽ = 3337, 2976, 2926, 2852, 1769, 1712, 1603, 1543, 1367, 1162 cm-1 
HPLC-MS: Rt = 9.71min, m/z = 456 [M+Na]
+
, 472 [M+K]
+
 
 
Benzyl 2-(4-Boc-aminomethyl-phenylcarbamoyl)-4-oxoazetidin-2-yl acetate (10) 
In a 2 mL 2-neck flask under nitrogen at -78°C, a solution of NaHMSA (Sodium 
bis(trimethylsilyl)amide) 1.0M in THF (500μL, 0.5mmol) was added dropwise to 
a solution of 6 (100mg, 0.45mmol) in anhydrous THF (4mL). After 15 min of 
stirring at room temperature, a solution of 8 (166mg, 0.67mmol) in THF (2mL) 
was added dropwise. After completion (TLC monitoring, 30min) the mixture was 
quenched with a saturated solution of NH4Cl and extracted with EtOAc and then 
DCM. The combined organic extracts were dried over Na2SO4, filtered, 
concentrated in vacuum and purified by flash-chromatography (FC, with DCM/Et2O 95/5) affording 10 
(187mg) in 89% yield as a colorless oil. 
Rf 0.73 (cyclohexane/EtOAc, 2/3) 
1
H NMR (400MHz, CDCl3): δ = 1.47 (s, 9H, tBu), 2.80 (dd, J = 8.8, 16.4 Hz, 1H, CHCHHCO2Bn), 2.94 
(dd, J = 3.2, 16.4 Hz, 1H, CHCHHCO2Bn), 3.34 (dd, J = 2.8, 16.4Hz, 1H, CHHCHCH2CO2Bn), 3.35 (dd, 
J = 4.0, 16.4Hz, 1H, CHHCHCH2CO2Bn), 4.27 (d, J = 5.2Hz, 2H, CH2NHCO2tBu), 4.44 (dddd, J = 2.8, 
3.2, 4.0, 8.8Hz, 1H, CH2CHCH2CO2Bn), 4.88 (bs, 1H, NHCO2tBu), 5.14 (d, JAB = 12.4Hz, 1H, PhCHH), 
5.18 (d, JAB = 12.4Hz, 1H, PhCHH), 7.23e7.43 (m, 9H, arom), 8.42 (s, 1H, NCONH) ppm 
13
C NMR (100MHz, CDCl3): δ = 28.3, 36.8, 42.5, 44.0, 47.4, 66.7, 79.3, 119.7, 128.1, 128.2, 128.3, 
128.5, 134.9, 135.2, 135.9, 147.6, 155.8, 166.5, 169.6 ppm 
IR: ṽ = 3337, 2976, 1769, 1732, 1709, 1603, 1543, 1244, 1168 cm-1 
HPLC-MS: Rt = 9.84 min, m/z = 412 [M-tBu+2H]
+
, 485 [M+H2O]
+ 
 
 
45 
4-(2-Carboxymethyl-4-oxoazetidine-carboxamido) phenylmethanaminium trifluoroacetate (1) 
In a 10mL 2-neck flask under nitrogen at 0°C, TFA (34μL, 457μmol) was 
added dropwise to a solution of 9 (33mg, 76μmol) in anhydrous DCM (1.4mL). 
The mixture was stirred at rt for 21h, cooled at 0°C and then treated with 
another aliquot of TFA (68μL, 910μmol). At starting material disappearing, the 
mixture was evaporated under vacuum yielding 1 (29mg) in 97% yield as a 
light yellow waxy oil. 
1
H NMR (400MHz, CD3OD): δ = 2.85 (dd, J = 8.8, 16.4Hz, 1H, CHCHHCO2H), 3.05 (dd, J = 3.2, 
16.4Hz, 1H, CHCHHCO2H), 3.22 (dd, J = 3.2, 16.4Hz, 1H, CHHCHCHHCO2H), 3.40 (dd, J = 5.6, 
16.4Hz, 1H, CHHCHCHHCO2H), 4.12 (s, 2H, CH2N), 4.45 (m, 1H, CHHCHCHHCO2H), 7.45 (d, J = 
8.8Hz, 2H, arom), 7.63 (d, J = 8.8Hz, 2H, arom) ppm 
13
C NMR (50MHz, D2O): δ = 35.9, 41.4, 42.2, 47.4, 115.9 (q, J1CF = 290Hz), 121.7, 129.0, 129.4, 136.3, 
149.1, 162.5 (q, J2CF = 35Hz), 168.4, 174.0 ppm 
IR: ṽ = 3334, 2958, 2921, 1769, 1677, 1610, 1544, 1422, 1335, 1203 cm-1 
HPLC-MS: Rt = 1.10min, m/z = 261 [M-TFA-NH3+H]
+
, 296 [M-TFA+H2O+H]
+
, 555 [2M-2TFA+H]
+
, 
577 [2M-2TFA+Na]
+
 
Found C, 46.32; H, 4.21; N, 10.43%; C15H16F3N3O6 requires C, 46.04; H, 4.12; N, 10.74% 
 
2-(4-Boc-aminomethyl-phenylcarbamoyl)-4-oxoazetidin-2-yl acetic acid (11) 
In a 25mL 2-neck flask a mixture of 10 (100mg, 0.214mmol), anhydrous THF 
(2.5mL), MeOH (2.5mL) and Pd/C 10%w/w (10mg) was stirred under H2 
atmosphere (1atm) at room temperature. At starting material consumption (2h) 
the mixture was filtered and concentrated in vacuum. The desired product 11 was 
obtained as a light yellow solid (76mg) in 94% yield after titration with DCM. 
M.p. 162-164°C, dec.; Rf 0.69 (DCM/MeOH/NH4OH, 30/10/1) 
1
H NMR (400MHz, CDCl3): δ = 1.47 (s, 9H, tBu), 2.81 (dd, J = 8.4, 16.8Hz, 1H, 
CHCHHCO2H), 2.98 (dd, J = 3.2, 16.8Hz, 1H, CHCHHCO2H), 3.33e3.42 (m, 2H, CH2CHCH2CO2H), 
4.28 (m, 2H, CH2N), 4.46 (m, 1H, CH2CHCH2CO2H), 4.83 (bs, 1H, NHCO2tBu), 7.25 (d, J = 8.4Hz, 2H, 
arom), 7.43 (d, J = 8.8Hz, 2H, arom), 8.46 (s, 1H, NH) ppm 
13
C NMR (50MHz, CD3OD): δ = 29.6, 38.6, 44.2, 45.4, 46.9, 81.0, 122.0, 129.7, 137.8, 138.3, 150.7, 
159.4, 169.5, 179.7 ppm 
IR: ṽ = 3338, 2977, 2929, 1767, 1699, 1650, 1539, 1333, 1246, 1168 cm-1 
HPLC-MS: Rt = 4.77min, m/z = 395 [M+H2O]
+
, 400 [M+Na]
+
 
 
Benzyl 2-(2-(1-(4-Boc-aminomethyl-phenylcarbamoyl)-4-oxoazetidin-2-yl)acetamido) acetate (13) 
In a 25mL 2-neck flask, dicyclohexylcarbodiimide (DCC) (45.4mg, 0.22mmol) 
was added to a solution of 11 (51mg, 0.135mmol) in anhydrous DCM (2.5mL) 
and CH3CN (0.5mL) at 0°C. Then a previously prepared solution of 12 (106.6 
mg, 0.3mmol) and stoichiometric TEA in DCM (2mL) was immediately added 
dropwise, followed by DMAP (4.9mg, 0.04mmol). The solution was warmed to 
rt and after complete consumption of the starting material (16h) the mixture was 
quenched with H2O (10mL) and extract with DCM (3x10mL). The organic layers 
were dried on Na2SO4 and filtered. The crude was suspended in EtOAc, the 
residual urea by-product of DCC remained solid and was eliminated by filtration, the organic layer was 
concentrated in vacuum and purified by FC (DCM/CH3CN, 90/10) to afford 13 (45mg) in 63% yield. 
Light yellow waxy solid. Rf 0.75 (EtOAc), 0.79 (DCM/CH3CN, 1/1) 
1
H NMR (400 MHz, CDCl3): δ = 1.46 (s, 9H, tBu), 2.74 (dd, J = 8.4, 15.2Hz, 1H, CHCHHCONH), 3.16 
(m, 2H, CHCHHCONH, CHHCHCHHCONH), 3.32 (dd, J = 5.6, 16.4Hz, 1H, CHHCHCHHCONH), 
4.02 (dd, J = 5.2, 18.0Hz, 1H, NCHHCO2), 4.10 (dd, J = 5.6, 18.4Hz, 1H, NCHHCO2), 4.27 (d, J = 
46 
5.6Hz, 2H, tBuOCOCH2N), 4.42 (m, 1H, CHHCHCHHCONH), 4.85 (bs, 1H, NHCO2tBu), 5.16 (s, 2H, 
CH2Ph), 6.50 (t, J = 5.2 Hz, CONH), 7.22-7.42 (m, 9H, arom), 8.51 (s, 1H, NCONH) ppm 
13
C NMR (50MHz, CD3OD): δ = 28.3, 38.1, 41.2, 42.6, 44.1, 48.3, 67.1, 79.5, 120.0, 128.1, 128.2, 128.3, 
128.5, 128.6, 135.0, 135.9, 148.2, 155.9, 167.0, 169.2, 169.4 ppm 
IR: ṽ = 3326, 2978, 2921, 1761, 1741, 1708, 1687, 1663, 1601, 1548, 1413, 1319, 1246, 1164, 1050 cm-1 
HPLC-MS: Rt = 10.51min, m/z = 525 [M+H]
+
, 542 [M+H2O]
+
, 547 [M+Na]
+
 
 
2-(2-(4-Boc-aminomethyl-phenylcarbamoyl)-4-oxoazetidin-2-yl acetamido) acetic acid (14) 
In a 10mL 2-neck flask, Pd on C (10%w/w) (3mg) was added to a solution of 13 
(31mg, 59mmol) in anhydrous THF (350mL) and MeOH (350mL). The mixture 
was stirred under H2 atmosphere at rt (1atm) and after complete SM consumption 
(2h) it was filtered and concentrated. The crude was then titrated with chloroform 
to afford 14 after evaporation as a white solid (25mg) in 98% yield. 
Rf 0.12 (CH3CN/MeOH, 4/1) 
1
H NMR (400MHz, CD3OD): δ = 1.48 (s, 9H, tBu), 2.75 (dd, J = 8.4, 14.8 Hz; 
1H, CHCHHCONH), 3.10 (dd, J = 3.2, 16.0Hz, 1H, CHHCHCHHCONH), 3.17 
(dd, J = 4.4, 14.8Hz, 1H, CHCHHCONH), 3.34 (dd, J = 5.6, 16.0Hz, 1H, CHHCHCHHCONH), 3.91 (d, J 
= 17.6Hz, 1H, NCHHCO2), 3.97 (d, J = 17.6 Hz, 1H, NCHHCO2), 4.21 (s, 2H, CH2NHCO2tBu), 4.45 (m, 
1H, CHHCHCHHCONH), 7.26 (d, J = 8.4Hz, 2H, arom), 7.46 (d, J = 8.4 Hz, 2H, arom), 8.39 (bs, 1H, 
NH), 8.77 (s, 1H, NH) ppm 
13
C NMR (100MHz, CD3OD): δ = 29.6, 39.7, 42.6, 43.9, 45.4, 50.5, 81.0, 122.0, 129.7, 137.8, 138.3, 
150.6, 159.4, 169.4, 173.2,173.7 ppm 
IR: ṽ = 3314, 2974, 2925, 1757, 1712, 1683, 1638, 1609, 1556, 1422, 1319, 1172 cm-1 
HPLC-MS: Rt = 2.16min, m/z = 457 [M+Na]
+
, 473 [M+K]
+
 
 
4-(2-(2-(Carboxymethylamino)-2-oxoethyl)-4-oxoazetidine-1-carboxamido) phenylmethanaminium 
trifluoroacetate (2) 
In a 10 mL 2-neck flask under nitrogen at 0°C, TFA (12μL, 165μmol) was 
added dropwise to a solution of 14 (24mg, 55μmol) in anhydrous DCM 
(1.4mL). The mixture was stirred at rt for 21h, cooled at 0°C and then treated 
with another aliquot of TFA (16μL, 220μmol). At starting material 
disappearing, the mixture was evaporated under vacuum, the crude was 
triturated with a drop of MeOH and pentane to provide 2 as a white solid 
(16mg) in 65% yield. 
1
H NMR (400MHz, CD3OD): δ = 2.78 (dd, J = 8.4, 14.8Hz, 1H, 
CHCHHCONH), 3.13 (m, 2H, CHCHHCONH + CHHCHCH2CONH), 3.35 (m, 1H, 
CHHCHCH2CONH), 3.90-3.98 (m, 2H, NHCH2COOH), 4.11 (s, 2H, CH2NH3
+
), 4.46 (m, 1H, 
CH2CHCH2CONH), 7.44 (d, J = 8.8Hz, 2H, arom), 7.61 (d, J = 8.8Hz, 2H, arom), 8.90 (s, 1H, NH) ppm 
13
C NMR (100MHz, CD3OD): δ = 39.6, 42.6, 43.9, 44.7, 50.5, 116.8 (q, J1CF = 286Hz), 122.2, 130.8, 
131.7, 140.5, 150.5, 162.3 (q), 169.4, 173.2, 173.7 ppm 
IR: ṽ = 3387, 2949, 2921, 2839, 1772, 1707, 1678, 1654, 1621, 1560, 1458, 1417, 1020 cm-1 
HPLC-MS: Rt = 1.13min, m/z = 318 [M-TFA-NH3+H]
+
, 357 [M-TFA+Na]
+
, 373 [M-TFA+K]
+
, 669 
[2M-2TFA+H]
+
, 691 [2M-2TFA+Na]
+
 
Found C, 45.86; H, 4.34; N, 12.38%; C17H19F3N4O7 requires C, 45.54; H, 4.27; N, 12.50% 
 
(S)-Benzyl 4-oxoazetidine-2-carboxylate (16) 
Commercially available, it has also been prepared starting from dibenzylester of L-aspartic 
acid 15 according to the procedure reported in literature.
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M.p. 137-140°C; Rf 0.6 (cyclohexane/EtOAc, 1/4) 
1
H NMR (400MHz, CDCl3): δ = 3.05-3.11 (m, 1H, CHCHH), 3.33 (dd, J = 6.0, 14.8Hz, 1H, CHCHH), 
4.22 (dd, J = 2.8, 6.0Hz, 1H, CHCHH), 5.21 (s, 2H, CH2Ph), 6.32 (bs, NH), 7.36e7.38 (m, 5H, Ph) ppm 
13
C NMR (100MHz, CDCl3): δ = 43.5, 47.3, 67.4, 128.5, 128.6, 128.7, 134.8, 166.3, 170.8 ppm 
HPLC-MS: Rt = 4.29min, m/z = 206 [M+H]
+
, 223 [M+H2O]
+
, 228 [M+Na]
+
, 433 [2M+Na]
+
 
 
(S)-Benzyl (4-Boc-aminomethyl-phenylcarbamoyl)-4-oxoazetidine-2-carboxylate (17) 
In a 10mL 2-neck flask under inert atmosphere at -78°C, NaHMSA (Sodium 
bis(trimethylsilyl)amide) 1.0M in THF (190μL, 0.190mmol) was added dropwise 
to a solution of 16 (35mg, 0.17mmol) in anhydrous THF (1.5mL) followed after 
30 min by a solution of isocyanate 8 (64mg, 0.26mmol) in THF (1mL); after 
starting material disappearing (30min), the mixture was quenched with a 
saturated solution of NH4Cl and extracted with EtOAc and DCM. The organic 
extracts were dried over Na2SO4, concentrated in vacuum and purified by flash-
chromatography (DCM to DCM/Et2O 95/5) to afford 17 as a colorless viscous oil (69 mg) in 90% yield. 
Rf 0.6 (cyclohexane/EtOAc, 4/1) 
[α]D = -64.1° (c = 0.7, DCM) 
1
H NMR (400MHz, CDCl3): δ = 1.47 (s, 9H, tBu), 3.10 (dd, J = 2.8, 16.0Hz, 1H, CHHCH), 3.40 (dd, J = 
6.0, 16.0Hz, 1H, CHHCH), 4.28 (d, J = 5.2Hz, 2H, CH2NH), 4.60 (dd, J = 2.8, 6.4Hz, 1H, CHHCH), 4.85 
(bs, 1H, NHCO2tBu), 5.24 (d, JAB = 12.4Hz, 1H, PhCHH), 5.29 (d, JAB = 12.4Hz, 1H, PhCHH), 7.25 (d, J 
= 8.4Hz, 2H, arom), 7.35-7.38 (m, 5H, arom), 7.43 (d, J = 8.4Hz, 2H, arom), 8.28 (s, 1H, NH) ppm 
13
C NMR (100MHz, CDCl3): δ = 28.3, 41.2, 44.1, 48.9, 67.8, 79.4, 119.9, 128.2, 128.3, 128.6, 128.7, 
134.7, 135.1, 135.8, 146.6, 155.8, 165.0, 168.8 ppm 
IR: ṽ = 3424, 3342, 3060, 2974, 2921, 1777, 1744, 1708, 1683, 1601 cm-1 
HPLC-MS: Rt = 11.14min, m/z = 471 [M+H2O]
+
, 476 [M+Na]
+
 
 
(S)-1-(4-Boc-aminomethyl-phenylcarbamoyl)-4- oxoazetidine-2-carboxylic acid (18) 
In a 10mL 2-neck flask, Pd/C (10%w/w) (3mg) was added to a solution of 17 
(33mg, 73μmol) in anhydrous THF (400mL) and MeOH (400mL). The mixture 
was stirred under H2 atmosphere (1atm) at room temperature and after starting 
material complete consumption (2h), it was filtered and concentrated in vacuum. 
The crude was then triturated with a few drops of DCM and pentane to afford the 
desired product as a white lumpy solid (25mg) in 95% yield. 
Rf 0.03 (cyclohexane/EtOAc, 1/4) 
[α]D = -51.5° (c = 0.4, CH3OH) 
1
H NMR (200MHz, CD3OD): δ = 1,48 (s, 9H, tBu), 3.13 (dd, J = 3.2, 16. Hz, 1H CHHCH), 3.52 (dd, J = 
6.2, 16.0Hz, 1H, CHHCH), 4.21 (s, 2H, CH2N), 4.56 (dd, J = 3.2, 6.2Hz, 1H, CHHCH), 7.27 (d, J = 
8.4Hz, 2H, arom), 7.47 (d, J = 8.4Hz, 2H, arom), 8.69 (bs, 1H, NH) ppm 
13
C NMR (50MHz, CD3OD): δ = 29.6, 42.9, 45.4, 51.1, 81.1, 122.2, 129.7, 138.0, 138.1, 149.8, 159.4, 
167.9, 173.6 ppm 
IR: ṽ = 3342, 2978, 2929, 1773,1704,1667, 1605,1540,1417,1319,1242,1164 cm-1 
HPLC-MS: Rt = 2.03min, m/z = 280 [M-CO2tBu+H2O]
+
 
 
(S) - (2-carboxy-4-oxoazetidine-1-carboxamido) phenylmethanaminium trifluoroacetate (3) 
In a 10mL 2-neck flask under nitrogen at 0°C a, TFA (13μL, 165μmol) was 
added dropwise to a solution of 18 (24μg, 66μmol) in anhydrous DCM 
(1.2mL). After stirring at rt for 15h, the mixture was again cooled to 0°C and 
treated with another aliquot of TFA (20mL, 265mmol). After starting 
material complete disappearing (24h), the crude was evaporated under 
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vacuum and triturated with a drop of DCM and pentane to provide 3 as a white solid (22mg) in 88% 
yield. 
[α]D = -41.8° (c = 0.25, DCM) 
1
H NMR (200MHz, CD3OD): δ = 3.15 (dd, J = 3.0, 16.2Hz, 1H, CHHCH), 3.54 (dd, J = 6.4, 16.2Hz, 1H, 
CHHCH), 4.11 (s, 2H, CH2NH3
+
), 4.58 (dd, J = 3.0, 6.4Hz, 1H, CHHCH), 7.45 (d, J = 8.4Hz, 2H, arom), 
7.63 (d, J = 8.4Hz, 2H, arom) ppm 
13
C NMR (100MHz, CD3OD): δ = 43.0, 44.7, 51.3, 116.8 (q), 122.4, 131.0, 131.7, 140.3, 149.7, 163.7 
(q), 167.9, 173.6 ppm 
IR: ṽ = 3411, 2954, 2921, 2851, 1777, 1691, 1625, 1552, 1462, 1323, 1204 cm-1 
HPLC-MS: Rt = 1.07min, m/z = 247 [M-TFA-NH3+H]
+
, 527 [2M-2TFA+H]
+
, 549 [2M-2TFA+Na]
+
 
Found C, 44.78; H, 3.95; N, 10.88%; C14H14F3N3O6 requires C, 44.57; H, 3.74; N, 11.14% 
 
Benzyl 4-aminobenzylcarbamate (22) 
In a 25mL 2-neck flask under nitrogen, in 3.25mL of anhydrous DCM were dissolved 
244mg (2.0mmol) of 4-amino-benzylamine and, at 0°C, were added 253μL (1.8mmol) 
of TEA and, dropwise, 257μL (1.8mmol) of CbzCl. The mixture was stirred at rt and 
follow by TLC (cyclohexane/EtOAc 4/6), then filtered on cotton at, and concentrated 
under vacuum. The slurry was then treated with water, checking pH ˂ 7, extracted with EtOAc (3 times), 
dried over Na2SO4, concentrated in vacuum and purified by flash-chromatography (EtOAc/cyclohexane 
25/75, then 40/60). Yield: 49%. 
 
Benzyl 4-Boc-aminobenzylcarbamate (23) 
In a 25mL 2-neck flask under nitrogen, 243mg (0.95mmol) of amine 22 were 
dissolved  in 3.75mL of anhydrous THF and, at 0°C, were slowly added 229mg 
(1.05mmol) of Boc2O. The reaction was stirred at rt for 40h, following by TLC 
(cyclohexane/EtOAc 4/6) the starting material disappearance, and then directly 
concentrated under vacuum and finally purified by flash-chromatography (EtOAc/cyclohexane 25/75, 
then 40/60). Yield: 96%. 
M.p. 134-135°C; Rf 0.78 (cyclohexane/EtOAc, 4/6) 
1
H NMR (400MHz, CDCl3): δ = 1.52 (s, 9H, tBu), 4.33 (d, J = 5.6Hz, 2H, CH2N), 5.01 (bs, 1H, NH), 
5.14 (s, 1H, CH2O), 6.47 (bs, 1H, NH), 7.21 (d, J = 8.0Hz, 2H, Ar), 7.32 (d, J = 8.4Hz, 2H, Ar) 7.34-7.37 
(m, 5H, Bn) ppm. 
13
C NMR (100MHz, CDCl3): δ = 28.2, 44.5, 66.7, 80.4, 118.7, 128.0, 128.1, 128.3 128.4, 132.8, 136.4, 
137.7, 152.7, 156.4 ppm 
IR: ṽ = 3331, 2978, 2932, 2851, 1702, 1698, 1526, 1242, 1160 cm-1 
HPLC-MS: Rt = 9.88min, m/z = 374 (100) [M+H2O]
+
, 379 (89) [M+Na]
+
, 395 (10) [M+K]
+
 
 
tButyl (4-(aminomethyl)phenyl)carbamate (24) 
In a 10mL 2-neck flask, Pd/C (10%w/w) (34mg) was added to a solution of 23 (325mg, 
0.91mmol) in anhydrous THF (11mL) and MeOH (11mL). The mixture was stirred 
under H2 atmosphere (1atm) at room temperature and after starting material complete 
consumption (2h), it was filtered and concentrated in vacuum. The crude was then 
triturated with a few drops of DCM to afford the desired product as a white lumpy solid (202mg) in 100% 
yield. 
M.p. waxy solid; Rf 0.01 (cyclohexane/EtOAc, 40/60) 
1
H NMR (400MHz, CD3OD): δ = 1.51 (s, 9H, tBu), 3.78 (s, 2H, CH2NH2), 7.24 (d, J = 8.4Hz, 2H, Ar), 
7.37 (d, J = 8.0Hz, 2H, Ar) ppm 
13
C NMR (100MHz, CD3OD): δ = 28.7, 45.5, 80.8, 119.9, 129.4, 130.3, 140.0, 155.2 ppm 
IR: ṽ = 3309, 2980, 2932, 1715, 1599, 1524, 1316, 1244, 1163, 738 cm-1 
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HPLC-MS: Rt = 1.28min, m/z = 206 (100) [M-NH3+H]
+
, 245 (8) [M+ Na]
+
, 445 (54) [2M+H]
+ 
 
tbutyl (4-isocyanatomethylphenyl)carbamate (25) 
In a 50mL 2-neck flask with a reflux condenser under nitrogen atmosphere, a solution 
of (24) (87mg, 0.39mmol) and TEA (109μL, 0.78mmol) in anhydrous DCM (3.76mL) 
was cooled to 0°C; was then added in one portion with 231.5mg (0.78mmol) of 
bis(trichloromethyl)-carbonate. The mixture was warmed to rt and monitored through 
the increase of isocyanate IR signal (2274cm
-1
). After 1hthe solvent was evaporated under vacuum 
avoiding any air exposure. The crude was extracted five times with anhydrous Et2O (5x4mL) under 
nitrogen, concentrated in vacuum, stored under nitrogen atmosphere and immediately used. 
 
benzyl 2-(1-(4-tbutoxycarbonylaminobenzylcarbamoyl)-4-oxoazetidin-2-yl acetate (26) 
In a 25mL 2-neck flask under nitrogen at -78°C, a solution of NaHMSA 
(Sodium bis(trimethylsilyl)amide) 1.0M in THF (325μL, 0.325mmol) was 
added dropwise to a solution of 6 (57mg, 0.26mmol) in anhydrous THF 
(2.2mL). After 15min of stirring, a solution of isocyanate 25 (157mg, 
0.39mmol) in THF (1.15mL) was added dropwise. After completion (TLC 
monitoring, 30min) the mixture was quenched with a saturated solution of NH4Cl and extracted with 
EtOAc and then DCM. The combined organic extracts were dried over Na2SO4, concentrated in vacuum 
and purified by flash-chromatography (DCM/Et2O, from 95/5 to 80/20) affording 26 (70mg) as a 
colorless oil in 62% yield. 
Rf 0.88 (cyclohexane/EtOAc, 20/80) 
1
H NMR (400MHz, CDCl3): δ = 1.52 (s, 9H, tBu), 2.72 (dd, J = 9.2, 16.4Hz, 1H), 2.85 (dd, J = 2.4, 
16.0Hz, 1H), 3.27 (dd, J = 5.6, 16.4Hz, 1H), 3.35 (dd, J = 3.6, 16.4Hz, 1H), 4.33-4.40 (m, 1H), 4.34 (dd, J 
= 6.0, 9.6Hz, 1H, CHHN), 4.41 (dd, J = 6.0, 14.8Hz, 1H, CHHN), 5.15 (d, JAB = 12.0Hz, 1H, CHHO), 
5.17 (d, JAB = 12.4Hz, 1H, CHHO), 6.47 (bs, 1H, BocNH), 6.78 (t, J = 6.0Hz, NH) 7.21 (d, J = 8.4Hz, 2H, 
Ar), 7.32 (d, J = 8.8Hz, 2H, Ar), 7.31-7.40 (m, 5H, Bn) ppm 
13
C NMR (100MHz, CDCl3): δ = 28.2, 37.0, 42.5, 43.0, 47.0, 66.6, 80.4, 118.7, 128.2, 128.3, 128.4, 
128.5, 132.2, 135.3, 137.8, 150.2, 152.7, 166.1, 169.7 ppm 
IR: ṽ = 3365, 2979, 2930, 1769, 1730, 1703, 1697, 1530, 1315, 1161 cm-1 
HPLC-MS: Rt = 10.18min, m/z = 468 (16) [M+H]
+
, 485 (85) [M+H2O]
+
, 490 (100) [M+Na]
+
, 506 
[M+K]
+
 
 
2-(1-(4-tbutoxycarbonylaminobenzylcarbamoyl)-4-oxoazetidin-2-yl acetic acid (27) 
In a 25mL 2-neck flask a mixture of 26 (70mg, 0.15mmol), anhydrous THF 
(1.74mL), MeOH (1.74mL) and Pd/C 10%w/w (7mg) was stirred under H2 
atmosphere (1atm) at room temperature. At starting material consumption 
(2h) the mixture was filtered and concentrated in vacuum. The desired 
product 27 was obtained as a white solid (76mg) in 84% yield after trituration 
with DCM. 
M.p. 78-81°C; Rf 0.69 (cyclohexane/EtOAc, 40/60) 
1
H NMR (400MHz, CD3OD): δ = 1.51 (s, 9H, tBu), 2.73 (dd, J = 8.8, 16.4Hz, 1H),  2.91 (dd, J = 2.8, 
16.0Hz, 1H), 3.13 (dd, J = 4.0, 16.8Hz, 1H), 3.27 (dd, J = 5.2, 16.0Hz, 1H), 4.27- 4.32 (m, 1H), 4.35 (s, 
2H, CH2NH), 7.20 (d, J = 8.4Hz; 2H, Ar), 7.35 (d, J = 8.8Hz; 2H, Ar), 8.85 (bs, 1H, ArNH) ppm 
13
C NMR (50MHz, CD3OD): δ = 28.7, 37.3, 43.2, 43.7, 43.8, 80.8, 119.9, 128.9, 133.9, 139.7, 152.4, 
155.2, 168.1, 173.5 ppm 
IR: ṽ = 3355, 2977, 2927, 1769, 1731, 1707, 1527, 1318, 1160 cm-1 
HPLC-MS: Rt = 1.92min, m/z = 412 (95) [M-tBu+2H]
+
, 485 (100) [M+Na]
+ 
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4-(2-(carboxymethyl)-4-oxoazetidine-1-carboxamidomethyl) benzenaminium trifluoroacetate (19) 
In a 10mL 2-neck flask under nitrogen at 0°C, TFA (8.3μL, 111μmol) was 
added dropwise to a solution of 27 (14mg, 37μmol) in anhydrous DCM 
(0.68mL). The mixture was stirred at rt for 21h, cooled at 0°C and treated 
with other TFA (11μL, 148μmol). At SM disappearing, the mixture was 
evaporated and the crude triturated with MeOH and pentane to provide 2 
as a yellow oil in 99% yield. 
Rf = 0.01 (EtOAc); 
1
H NMR (400MHz, CD3OD): δ = 2.75 (dd, J = 8.8, 16.4Hz, 1H), 2.94 (dd, J = 2.8, 16Hz, 1H), 3.11 (dd, J 
= 3.6, 16.4Hz, 1H), 3.29 (dd, J = 5.6, 16.0Hz, 1H), 4.31 (m, 1H), 4.47 (s, 2H, CH2NH), 7.35 (d, J = 
8.4Hz, 2H, Ar), 7.49 (d, J = 8.8Hz; 2H, Ar) ppm 
13
C NMR (100MHz): δ = 30.7, 37.3, 43.2, 43.5, 124.0, 130.1, 131.5, 141.2, 152.6, 168.1, 173.5 ppm 
19
F NMR (400MHz, CD3OD): -77.0 ppm 
IR: ṽ = 3365, 2924, 2854, 2626, 1771, 1703, 1679, 1539, 1201 cm-1 
HPLC-MS: Rt = 4.21min, m/z = 278 (100) [M-TFA+H]
+
 
 
Benzyl 2-(2-(4-tbutoxycarbonylaminobenzylcarbamoyl)-4-oxoazetidin-2-yl acetamido) acetate (28) 
In a 25mL 2-neck flask, dicyclohexylcarbodiimide (DCC) (45.4mg, 
0.22mmol) was added to a solution of 27 (27mg, 72μmol) in anhydrous DCM 
(0.85mL) and CH3CN (0.5mL) at 0°C. Then a previously prepared solution of 
12 (38mg, 0.11mmol) and stoichiometric TEA in DCM (0.91mL) was 
immediately added dropwise, followed by DMAP (4.9mg, 0.04mmol). The 
solution was warmed to rt and after complete consumption of the starting 
material (16h) the mixture was quenched with H2O (10mL) and extract with DCM (3x10mL). The 
organic layers were dried on Na2SO4 and filtered. The crude was suspended in EtOAc, the residual urea 
by-product of DCC remained solid and was eliminated by filtration, the organic layer was concentrated in 
vacuum and purified by FC (DCM/CH3CN, from 95/5to 80/20) to afford 28 as a light yellow waxy solid 
in 72% yield. 
M.p. 64-66°C; Rf 0.68 (EtOAc) 
1
H NMR (400 MHz, CDCl3): δ = 1.51 (s, 9H, tBu), 2.70 (dd, J = 8.0, 14.8Hz, 1H), 3.06 (dd, J = 2.8, 
16.0Hz, 1H), 3.11 (dd, J = 4.0, 14.8Hz, 1H), 3.23 (dd, J = 5.6, 16.0Hz, 1H), 4.00 (dd, J = 4.8, 18.0Hz, 1H, 
NHCHHCOO), 4.06 (dd, J = 5.6Hz, 18.0Hz; 1H, NHCHHCOO), 4.31-4.33 (m, 1H), 4.33-4.38 (m, 2H, 
CH2N), 5.17 (s, 2H, CH2Bn), 6.55 (bs, 1H, BocNH), 6.67 (bs, 1H, NH), 6.91 (t, J = 6.8Hz, 1H, 
NHCH2Ar), 7.20 (d, J = 8.0Hz, 2H, Ar), 7.28 (d, J = 8.4Hz, 2H, Ar), 7.30-7.37 (m, 5H, Bn) ppm 
13
C NMR (50MHz, CDCl3): δ = 28.3, 38.4, 41.3, 42.5, 43.1, 48.0, 67.2, 80.6, 118.8, 128.3, 128.4, 128.5, 
128.6, 132.2, 135.1, 137.8, 150.9, 152.7, 166.6, 169.3, 169.5 ppm 
IR: ṽ = 3355, 2976, 1766, 1724, 1707, 1691, 1671, 1598, 1161 cm-1 
HPLC-MS: Rt = 8.98min, m/z = 525 (55) [M+H]
+
, 542 (40) [M+H2O]
+
, 547 (100) [M+Na]
+
, 563 [M+K]
+
 
 
2-(2-(1-(4-tbutoxycarbonylaminobenzylcarbamoyl)-4-oxoazetidin-2-yl) acetamido) acetic acid (29) 
In a 10mL 2-neck flask a mixture of 28 (22mg, 42μmol), anhydrous THF 
(0.49mL), MeOH (0.49mL) and Pd/C 10%w/w (3mg) was stirred under H2 
atmosphere (1atm) at room temperature. At starting material consumption 
(2h) the mixture was filtered and concentrated in vacuum. TM 27 was 
obtained as a white solid in 86% yield after trituration with DCM. 
M.p. 100-103°C; Rf 0.01 (cyclohexane/EtOAc, 40/60) 
1
H NMR (400MHz, CD3OD): δ = 1.51 (s, 9H, tBu), 2.65 (dd, J = 8.4, 14.4Hz, 1H), 2.99 (d, J = 16.0Hz, 
1H), 3.10 (d, J = 14.4Hz, 1H), 3.24 (dd, J = 5.2, 16.0Hz, 1H), 3.86 (d, J = 20.0Hz, 1H, NHCHHCOOH), 
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3.91 (d, J = 20.0Hz, 1H, NHCHHCOOH), 4.35 (m, 3H, NHCH2Ar + NCHCH2), 7.21 (d, J = 7.6Hz, 2H, 
Ar), 7.35 (d, J = 8.0Hz, 2H, Ar), 8.87 (bs, 1H, ArCH2NH) ppm 
13
C NMR (100MHz, CDCl3): δ = 28.7, 30.7, 39.1, 43.0, 43.8, 49.3, 80.8, 119.9, 129.0, 129.0, 134.0, 
139.8, 152.5, 155.3, 168.1, 172.4 ppm 
IR: ṽ = 3350, 2927, 2855, 1768, 1717, 1694, 1682, 1530, 1317, 1239, 1162, 1056 cm-1 
HPLC-MS: Rt = 2.50min, m/z = 412 (95) [M-tBu+2H]
 +
, 485 (100) [M+Na]
+ 
 
4-(2-(1-carboxymethyl-amidomethyl)-4-oxoazetidine-1-carboxamidomethyl) benzenaminium 2,2,2-
trifluoroacetate (20) 
In a 10mL 2-neck flask under nitrogen at 0°C, TFA (9.7μL, 131μmol) was 
added dropwise to a solution of 29 (19mg, 44μmol) in anhydrous DCM 
(0.81mL). The mixture was stirred at rt for 24h, cooled at 0°C and then 
treated with another aliquot of TFA (13μL, 175μmol). At starting material 
disappearing, monitored by TLC (MeCN/MeOH 80/20) and by HPLC-MS 
(sample preparation in MeCN and pH = 7.5 phosphate buffer 1/1), the 
mixture was evaporated under vacuum, and the crude was triturated with a 
drop of MeOH and pentane to provide 20 as a yellow oil in 95% yield. 
Rf = 0.01 (cyclohexane/EtOAc 40/60); 
1
H NMR (400MHz, CD3OD): δ = 2.68 (dd, J = 8.4, 15.2Hz, 1H), 3.01 (dd, J = 3.2, 16.4Hz, 1H), 3.05 (dd, 
J = 4.0Hz, 14.8Hz, 1H), 3.25 (dd, J = 6.0, 16.4Hz, 1H), 3.89 (t, J =10.0Hz, 2H), 4.36-4.31 (m, 1H), 4.47 
(t, J = 15.2Hz, 2H), 7.35 (d, J = 8.8Hz, 2H, Ar), 7.49 (d, J = 8.4Hz, 2H, Ar), 2.75 (dd, J = 8.8, 16.4Hz, 
1H), 2.94 (dd, J = 2.8, 16Hz, 1H), 3.11 (dd, J = 3.6, 16.4Hz, 1H), 3.29 (dd, J = 5.6, 16.0Hz, 1H), 4.31 (m, 
1H), 4.47 (s, 2H, CH2NH), 7.35 (d, J = 8.4Hz, 2H, Ar), 7.49 (d, J = 8.8Hz, 2H, Ar) ppm 
13
C NMR (100MHz, CD3OD): δ = 30.7, 38.9, 41.7, 42.9, 43.5, 123.9, 130.1, 131.7, 141.0, 152.6, 168.1, 
172.4, 172.8 ppm 
19
F NMR (400MHz, CD3OD): -77.0 ppm 
IR: ṽ = 3356, 2925, 2854, 1793, 1782, 1736, 1712, 1698, 1465, 1286, 1170 cm-1 
HPLC-MS: Rt = 4.57min, m/z = 334 [M-TFA+H]
+
, 485 [M+Na]
+
 
 
(S)-benzyl 1-(4-tbutoxycarbonylaminobenzylcarbamoyl)-4-oxoazetidine-2-carboxylate (30) 
In a 10mL 2-neck flask under inert atmosphere at -78°C, NaHMSA (Sodium 
bis(trimethylsilyl)amide) 1.0M in THF (375μL, 0.375mmol) was added 
dropwise to a solution of 16 (61.5mg, 0.3mmol) in anhydrous THF (2.5mL) 
followed after 30min by a solution of isocyanate 25 (106mg, 0.45mmol) in 
THF (1.3mL); after starting material disappearing (30min), the mixture was 
quenched with a saturated solution of NH4Cl and extracted with EtOAc and DCM. The organic extracts 
were dried over Na2SO4, concentrated in vacuum and purified by flash-chromatography (DCM, then 
DCM/Et2O 99/1 to 80/20) to afford 30 as a colorless oil (51mg) in 37% yield. 
Rf 0.92 (cyclohexane/EtOAc, 20/80), 0.45 (DCM/cyclohexane/Et2O, 60/20/20) 
[α]D = -37.77° (c = 9.27, DCM) 
1
H NMR (400MHz, CDCl3): δ = 1.52 (s, 9H, tBu), 3.01 (dd, J = 2.8, 16.0Hz, 1H, CHHCH), 3.31 (dd, J = 
6.0, 15.6Hz, 1H, CHHCH), 4.38 (dd, J = 6.0, 15.2Hz, 1H, CHHNH), 4.46 (dd, J = 5.6, 14.8Hz, 1H, 
CHHNH), 4.54 (dd, J = 2.4, 6.4Hz, 1H, CHHCH), 5.23 (d, JAB = 17.2Hz, 1H, PhCHH), 5.27 (d, JAB = 
17.2Hz, 1H, PhCHH), 6.57 (s, 1H, NHCO2tBu), 6.67 (bt, J = 5.2Hz, 1H, NHCH2), 7.21 (d, J = 8.0Hz, 2H, 
arom), 7.28-7.39 (m, 7H, arom + Ph) ppm 
13
C NMR (100MHz, CDCl3): δ = 28.2, 41.0, 43.3, 48.7, 67.6, 80.4, 118.7, 128.2, 128.3, 128.5, 129.9, 
132.0, 134.7, 137.8, 149.3, 152.6, 164.5, 169.0 ppm 
IR: ṽ = 3358, 2976, 2927, 1780, 1744, 1731, 1709, 1700, 1527, 1159 cm-1 
HPLC-MS: Rt = 10.01min, m/z = 471 [M+H2O]
+
, 476 [M+Na]
+
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(S)-1-(4-tbutoxycarbonylaminobenzylcarbamoyl)-4-oxoazetidine-2-carboxylic acid (31) 
In a 25mL 2-neck flask a mixture of 30 (51mg, 110μmol), anhydrous THF 
(1.3mL), MeOH (1.3mL) and Pd/C 10%w/w (5mg) was stirred under H2 
atmosphere (1atm) at room temperature. At starting material complete 
consumption (2h, as by TLC monitoring) the mixture was directly filtered 
and concentrated in vacuum. The desired product 31 was obtained as a waxy 
white solid in 88% yield after flash-chromatography purification (MeCN, then MeCN/MeOH 90/10) and 
repetead DCM titration and evaporation. 
Rf 0.01 (cyclohexane/EtOAc, 40/60) 
[α]D = -46.57° (c = 6.36, MeOH) 
1
H NMR (400MHz, CD3OD): δ = 1.50 (s, 9H, tBu), 2.90 (dd, J = 2.8, 15.6Hz, 1H, CHHCHCOOH), 3.27 
(dd, J = 6.0, 15.6Hz, 1H, CHHCHCOOH), 4.30-4.41 (m, 3H, NHCH2Ar + NCHCOOH), 7.22 (d, J = 
8.4Hz, 2H, Ar), 7.32 (d, J = 8.8Hz, 2H, Ar) ppm 
13
C NMR (100MHz, CD3OD): δ = 28.7, 30.7, 42.0, 43.8, 80.8, 119.8, 129.0, 133.9, 139.7, 152.4, 155.2, 
168.5, 176.8 ppm 
IR: ṽ = 3363, 2979, 2931, 1770, 1699, 1694, 1692, 1600, 1327, 1162, 1068 cm-1 
HPLC-MS: Rt = 6.50min, m/z = 362 [M-H]
-
 
 
(S)-4-(2-carboxy-4-oxoazetidine-1-carboxamidomethyl) benzenaminium 2,2,2-trifluoroacetate (21) 
In a 25mL 2-neck flask under nitrogen at 0°C, TFA (21μL, 288μmol) was 
added dropwise to a solution of 31 (35mg, 96μmol) in anhydrous DCM 
(1.8mL). The mixture was stirred at rt for 24h, cooled at 0°C and then 
treated with other aliquots of TFA (116μL, overall). At starting material 
disappearing, monitored by TLC (MeCN/MeOH 90/10) and by HPLC-MS 
(sample preparation in MeCN and pH = 7.5 aqueous phosphate buffer 
1/1), the mixture was directly evaporated under vacuum. The resulting crude was triturated with a drop of 
MeCN and pentane to provide 21 as a sticky solid in 99% yield. 
Rf = 0.04 (MeCN/MeOH 90/10) 
[α]D = -28.22° (c = 8.545, MeOH) 
1
H NMR (400MHz, CD3OD): δ = 3.04 (dd, J = 2.8, 15.6Hz, 1H), 3.44 (dd, J = 6.0, 15.6Hz, 1H), 4.45-
4.48 (m, 3H, CHCOOH + CH2NH), 7.35 (d, J = 7.2Hz; 2H, Ar) 7.49 (d, J = 8.4Hz, 2H, Ar), ppm 
13
C NMR (100MHz, CD3OD): δ = 42.0, 43.6, 50.2, 124.2, 129.8 (q, J = 21.2Hz), 130.1, 131.1, 141.2, 
151.8, 162.4 (q, J = 35.6Hz), 166.6, 172.9 ppm 
19
F NMR (400MHz, CD3OD): -77.1 ppm 
IR: ṽ = 3362, 2924, 1780, 1698, 1677, 1543, 1202, 1139, 800 cm-1 
HPLC-MS: Rt = 1.52min, m/z = 264 [M-TFA+H]
+
, 281 [M-TFA+H2O]
+
 
 
Benzyl 2-(4-oxo-(o-tolylcarbamoyl)azetidin-2-yl) acetate (35) 
In a 10mL 2-neck flask under inert atmosphere at -78°C, NaHMSA (Sodium 
bis(trimethylsilyl)amide) 1.0M in THF (360μL, 0.36mmol) was added dropwise to a 
solution of 6 (88mg, 0.4mmol) in anhydrous THF (3.51mL). After 30 minutes stirring at 
-78°C a solution of o-tolyl-isocyanate (59.2μL, 0.48mmol) in THF (1.43mL) was added 
dropwise.At starting material disappearing (30min), the mixture was quenched with a 
saturated solution of NH4Cl and extracted with EtOAc and DCM. The organic extracts 
were dried over Na2SO4, filtered and concentrated in vacuum. The crude was purified by flash-
chromatography (cyclohexane/EtOAc 80/20) to finally afford 35 as a white solid in 77% yield. 
M.p. 74-76°C; Rf 0.81 (cyclohexane/EtOAc, 40/60) 
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1
H NMR (400MHz, CD3OD): δ = 2,30 (s, 3H, Me), 2.82 (dd, J = 8.8, 16.8Hz, 1H), 2.96 (dd, J = 2.8, 
16.4Hz, 1H), 3.37 (m, 2H), 4.48 (m, 1H, CHNH), 7.06 (t, J = 7.2Hz, 1H), 7.19 (d, J = 6.8Hz, 1H), 7.22 (t, 
J = 7.6Hz, 1H),  7.30-7.40 (m, 5H, Bn), 7.93 (d, J = 8.4Hz, 1H), 8.43 (s, 1H, NH) ppm 
13
C NMR (100MHz, CDCl3): δ = 17.6, 36.9, 42.6, 47.5, 66.8, 120.9,  124.4, 126.8, 127.5, 128.3, 128.4, 
128.6, 130.4, 135.2, 135.3, 147.8, 166.7, 169.7 ppm 
IR: ṽ = 3338, 1767, 1733, 1713, 1614, 1593, 1549, 1459, 1334, 1307, 1253, 1171, 755, 698 cm-1 
HPLC-MS: Rt = 10.35min, m/z = 353 [M+H]
 +
, 375 [M+Na]
+
, 727 [2M+Na]
+ 
 
2-(4-oxo-(o-tolylcarbamoyl)azetidin-2-yl) acetic acid (32) 
In a 25mL 2-neck flask 35 (103mg, 292μmol) was dissolved in a mixture of anhydrous 
THF (3.5mL) and MeOH (3.5mL), then Pd/C 10%w/w (10mg) was added and the reaction 
was stirred under H2 atmosphere (1atm) at room temperature. At starting material 
complete consumption (2h, as by TLC monitoring) the mixture was directly filtered with 
celite, washed with MeOH and concentrated in vacuum. The desired product 27 was 
finally obtained as a white solid in 91% yield after repeated titration with MeOH and 
DCM. 
M.p. 114-117°C; Rf 0.19 (cyclohexane/EtOAc, 40/60) 
1
H NMR (400MHz, CD3OD): δ = 2.27 (s, 3H, Me), 2.90 (dd, J = 9,2, 16.8Hz,1H), 3.08 (dd, J = 2.8, 
16.0Hz, 1H), 3.26 (dd, J = 3.6, 16.8Hz, 1H), 3.42 (dd, J = 5.6, 16.0Hz, 1H), 4.45 (ddt, J = 3.2, 6.0, 8.8Hz, 
1H), 7.02 (t, J = 7.6Hz, 1H), 7.17 (t, J = 8.0Hz, 1H), 7.22 (d, J = 7.6Hz, 1H), 7.99 (d, J = 8.4Hz, 1H, NH), 
8.55 (s,1H, NH), 10.98 (bs, 1H, COOH) ppm 
13
C NMR (100MHz, CDCl3): δ = 17.6, 36.6, 43.3, 48.4, 121.2, 124.7, 127.4, 127.7, 131.2, 136.9, 148.8, 
168.4, 171.7 ppm 
IR: ṽ = 3344, 2922, 1766, 1708, 1614, 1593, 1552, 1460, 1331, 1307, 1253, 1124 cm-1 
HPLC-MS: Rt = 5.06min, m/z = 263 [M+H]
 +
, 285 (100) [M+Na]
+
, 547 [2M+Na]
+ 
 
 
Benzyl 2-(2-(4-oxo-(o-tolylcarbamoyl)azetidin-2-yl) acetamido) acetate (36) 
In a 25mL 2-neck flask, to a solution of 32 (98mg, 374μmol) in anhydrous DCM 
(5.4mL) was added dropwise a previously prepared solution of 12 (189mg, 
0.56mmol) and stoichiometric TEA in DCM (4.7mL). Then was immediately 
introduced 45.0mg (374μmol) of  DMAP and, at 0°C, 72mg  (374μmol) of 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). The solution was warmed 
to rt and after complete consumption of the starting material (16h) the mixture 
was quenched with H2O (10mL) and extracted with DCM (3x10mL). The organic 
layers were dried on Na2SO4, filtered, concentrated in vacuum and purified by flash-chromatography 
(DCM/MeCN, from 95/5to 80/20) to afford 36 as a light yellow waxy solid in 56% yield.  
M.p. 174-176°C; Rf 0.61 (DCM/MeCN 80/20) 
1
H NMR (400MHz, CDCl3): δ = 2.31 (s, 3H, Me), 2.79 (dd, J = 8.0, 14.8Hz, 1H), 3.17 (dd, J = 2.8, 
15.2Hz, 1H), 3.19 (dd, J = 2.4, 16.4Hz, 1H), 3.35 (dd, J = 5.2, 16.4Hz, 1H), 4.03 (dd, J = 5.2, 18.0Hz, 1H, 
CHHNH), 4.12 (dd, J = 5.6, 18.4Hz, 1H, CHHNH), 4.47 (m, 1H), 5.17 (s, 2H, Bn), 6.44 (bs, 1H,NH), 
7.06 (t, J = 7.6Hz, 1H, Tol), 7.20 (d, J = 7.6Hz, 1H, Tol), 7.22 (t, J = 7.6Hz, 1H, Tol), 7.32-7.39 (m, 5H, 
Bn), 7.90 (d, J = 7.6Hz, 1H, Tol), 8.52 (s, 1H, NH) ppm 
13
C NMR (100MHz, CDCl3): δ = 38.2, 41.3, 42.6, 48.3, 67.2, 121.2, 124.6, 126.7, 127.8, 128.4, 128.5, 
128.6, 130.5, 135.0, 135.1, 148.5, 167.2, 169.2, 169.4 ppm 
IR: ṽ = 3321, 2923, 1767, 1708, 1645, 1614, 1593, 1550, 1458, 1308 cm-1 
HPLC-MS: Rt = 8.49min, m/z = 410 (100) [M+H]
+
, 432 (44) [M+Na]
+
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2-(2-(4-oxo-(o-tolylcarbamoyl)azetidin-2-yl) acetamido) acetic acid (33) 
In a 25mL 2-neck flask a mixture of 36 (85mg, 207μmol), anhydrous THF 
(2.4mL), MeOH (2.4mL) and Pd/C 10%w/w (9mg) was stirred under H2 atmosphere 
(1atm) at room temperature. At starting material consumption (2h) the mixture 
was filtered and concentrated in vacuum. The desired product 27 was obtained as a 
white solid in 99% yield after trituration with DCM. 
M.p. 182-185°C; Rf 0.03 (DCM/MeCN 80/20) 
1
H NMR (400MHz, CD3CN): δ = 2.27 (s, 3H, Me), 2.70 (dd, J = 8.0, 15.2Hz, 1H), 
3.01 (dd, J = 4.0, 6.0Hz, 1H), 3.05 (dd, J = 3.6, 6.4Hz, 1H),  3.25 (dd, J = 6.0, 16.4Hz ,1H), 3.86 (d, J  = 
5.6Hz, 2H, CH2COOH), 4.35 (m, 1H), 6.86 (bs, 1H, NH), 7.05 (t, J = 7.6Hz, 1H), 7.18-7.24 (m, 2H), 7.86 
(d, J = 8.0Hz, 1H), 8.47 (bs, 1H, NH) ppm 
13
C NMR (100MHz, CD3OD): δ = 18.6, 39.7, 42.6, 43.9, 55.7, 123.7, 126.7, 128.5, 130.7, 132.3, 137.5, 
150.9, 169.8, 173.1, 173.7 ppm 
IR: ṽ = 3300, 2924, 2853, 2464, 1764, 1720, 1649, 1617, 1595, 1556, 1458, 1390, 1367, 1345, 1308, 
1284, 1256, 1209 cm
-1 
HPLC-MS: Rt = 2.51min, m/z = 318 [M-H]
-
, 637 [2M-H]
- 
 
4-(2-(2-(benzyloxy)-2-oxoethyl)-4-oxoazetidine-carboxamido)phenyl methanaminium 
2,2,2-trifluoroacetate (37) 
In a 25mL 2-neck flask under nitrogen at 0°C, TFA (160μL, 2.16mmol) was 
added dropwise to a solution of 10 (133mg, 284μmol) in anhydrous DCM 
(3.98mL). The mixture was stirred at rt for 24h, cooled at 0°C and then 
treated with another aliquot of TFA (160μL, 2.16mmol). At SM 
disappearing (as by TLC cyclohexane/EtOAc 40/60) the mixture was 
evaporated under vacuum, and the crude was triturated with a drop of MeOH 
and pentane to provide 37 as a waxy white solid in 99% yield.   
Rf = 0.01 (cyclohexane/EtOAc 40/60) 
1
H NMR (400MHz, CD3OD): δ = 2.72 (dd, J = 7.6, 16.0Hz, 1H), 2.88 (d, J = 16.0Hz, 1H), 3.20 (d, J = 
12.8Hz, 1H), 3.29 (d, J =10.4Hz, 1H), 3.90 (bs, 2H, CH2NH3), 4.36 (m, 1H, CHCH2COOBn), 5.12 (s, 2H, 
Bn), 7.21-7.35 (9H, Ar), 7.97(bs, 3H, NH3), 8.39 (s, 1H,NH) ppm 
13
C NMR (100MHz, CD3OD): δ = 36.7, 42.5, 43.0, 47.6, 66.8, 120.4, 127.9, 128.2, 128.4, 128.5, 129.8, 
135.2, 137.3, 147.9, 166.8, 169.9 ppm 
19
F NMR (400MHz, CD3OD): -75.8 ppm 
IR: ṽ = 3336, 3037, 2957, 2923, 1771, 1680, 1605, 1546, 1422, 1385, 1319, 1298, 1246, 1203, 1139, 723, 
700 cm
-1
 
HPLC-MS: Rt = 1.43min, m/z = 351 (100) [M-TFA-NH3+H]
+
, 735 (52) [2M-2TFA+H]
+
 
 
Benzyl 2-(4-oxo-(4-(3-o-tolylureidomethyl)phenylcarbamoyl)azetidin-2-yl) acetate (38) 
In a 25mL 2-neck flask under inert atmosphere, to a solution of 37 
(136mg, 0.28mmol) in dry THF (1.6mL) were added dropwise 69μL 
(0,49mmol) of TEA. The conversion was followed the by TLC 
(cyclohexane/EtOAc 20/80), and after 30min the mixture was cooled at 
0°C and a solution of o-tolyl-isocyanate (43μL, 0.35mmol) in THF 
(0.8mL) was introduced. After starting material disappearing (1h30min), 
the mixture was concentrated under vacuum and the resulting crude 
purified by flash-chromatography (DCM/EtOAc, from 90/10 to 70/30) to afford 38 as a white solid in 
56% yield. 
M.p. 184-187°C; Rf 0.70 (cyclohexane/EtOAc 20/80) 
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1
H NMR (400MHz, CDCl3): δ = 2.25 (s, 3H, Me), 2.79 (dd, J = 9.2, 16.8Hz, 1H), 2.95 (dd, J = 2.8, 
16.4Hz, 1H), 3.35 (m, 2H), 4.40 (s, 2H), 4.46 (m, 1H), 5.15 (d, J = 12.8Hz, 1H), 5.18 (d, J = 12.8Hz, 1H),  
6.19 (bs, 1H, NH), 7.12-7.41 (m, 14H, Ar+NH), 8.41 (s, 1H, NH) ppm 
13
C NMR (50MHz, CDCl3): δ = 17.8, 36.9, 42.6, 43.7, 47.5, 66.8, 119.9, 125.2, 125.8, 127.0, 128.1, 
128.3, 128.4, 128.5, 128.6, 130.9, 132.3, 135.1, 135.3, 136.0, 147.7, 157.5, 166.5, 169.6 ppm 
IR: ṽ = 3319, 2924, 2362, 1771 1712, 1631, 1604, 1588, 1545, 1457, 1418, 1308, 1242, 1193, 1120, 750 
cm
-1
 
HPLC-MS: Rt = 9.20 min, m/z = 501 [M+H]
+
, 523 [M+Na]
+
, 1001 [2M+H]
+ 
 
2-(4-oxo-(4-(3-o-tolylureidomethyl)phenylcarbamoyl)azetidin-2-yl) acetic acid (34) 
In a 25mL 2-neck flask a mixture of 38 (79mg, 157μmol), anhydrous 
THF (1.8mL), MeOH (1.8mL) and Pd/C 10%w/w (8mg) was stirred under 
H2 atmosphere (1atm) at room temperature. At starting material 
consumption (2h) the mixture was filtered and concentrated in vacuum. 
The desired product 34 was obtained as a white solid in 99% yield after 
trituration with DCM. 
M.p. 160-162°C; Rf 0.06 (cyclohexane/EtOAc 20/80)  
1
H NMR (400MHz, CD3CN): δ = 2,21 (s, 3H, Me), 2.76 (dd, J = 8.0, 
16.4Hz, 1H), 2.93 (d, J = 16.0Hz, 1H), 3.13 (d, J = 16.4Hz, 1H), 3.26 (d, J = 16.0Hz, 1H), 4.32 (m, 3H, 
CH2NH, CHCH2COOH), 5.75 (bs, 1H, NH), 6.68 (bs, 1H, NH), 6.98 (m, 1H, Tol), 7.14 (m, 2H, Tol), 
7.28 (d, J = 7.2Hz, 2H, Ar), 7.43 (d, J = 7.6Hz, 2H, Ar), 7.67 (d, J = 8.0Hz, 1H, Tol), 8.45(s, 1H, NH), 
9.36 (bs, 1H, COOH) ppm 
13
C NMR (100MHz, CD3OD): δ = 18.9, 38.1, 44.2, 45.0, 49.9, 122.0, 125.7, 126.3, 128.3, 129.9,  132.3, 
132.6, 137.9, 138.4, 139.0, 150.6, 159.7, 169.4, 174.5ppm 
IR: ṽ = 3319, 3054, 2926, 1774, 1707, 1629, 1603, 1545, 1440, 1420, 1332, 
1264, 737, 702 cm
-1 
HPLC-MS: Rt = 13.61min, m/z = 411 [M+H]
+
, 433 [M+Na]
+
, 821.6 [2M+H]
+ 
 
(S)-benzyl 4-oxo-(o-tolylcarbamoyl)azetidine-2-carboxylate (41) 
In a 25mL 2-neck flask under inert atmosphere at -78°C, NaHMSA (Sodium 
bis(trimethylsilyl)amide) 1.0M in THF (600μL, 0.6mmol) was added dropwise to a 
solution of 16 (103mg, 05) in anhydrous THF (4.3mL) followed after 30min by a 
solution of o-tolyl-isocyanate (74μL, 0.6mmol) in THF (1.79mL); after starting material 
disappearing (30min), the mixture was quenched with a saturated solution of NH4Cl and 
extracted with EtOAc and DCM. The organic extracts were dried over Na2SO4, 
concentrated in vacuum and purified by flash-chromatography (cyclohexane/EtOAc 80/20) to afford 41 
as a slightly brown oil solid in 75% yield. 
Rf 0.85 (cyclohexane/EtOAc, 40/60) 
[α]D = -86.15° (c = 11.49, DCM) 
1
H NMR (400MHz, CDCl3): δ = 2,31 (s, 3H, Me), 3.12 (dd, J = 2.8, 15.6Hz, 1H), 3.42 (dd, J = 6.0, 
15.6Hz, 1H), 4.63 (dd, J = 2.8, 6.4Hz, 1H, CHCOOBn), 5.25 (d, JAB = 12.0Hz, 1H, Bn), 5.30 (d, JAB = 
12.0Hz, 1H, Bn), 7.07 (t, J = 7.6Hz, 1H, Ar), 7.20 (d, J = 6.8Hz, 1H, Ar), 7.22 (t, J = 8.0Hz, 1H, Ar),  
7.34-7.39 (m, 5H, Bn), 7.93 (d, J = 8.4Hz, 1H, Ar), 8.29 (s, 1H, NH) ppm 
13
C NMR (100MHz, CDCl3): δ = 17.3, 41.0, 48.7, 67.6, 120.9,  124.4, 126.6, 127.4, 128.1, 128.4, 128.4, 
130.2, 134.6, 134.9, 146.6, 165.1, 168.7 ppm 
IR: ṽ = 3348, 3064, 3033, 2964, 1776, 1751, 1718, 1594, 1459, 1549, 1307, 1253, 1188, 755 cm-1 
HPLC-MS: Rt = 9.96min, m/z = 339 [M+H]
 +
, 361 [M+Na]
+
, 699 [2M+Na]
+ 
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(S)-4-oxo-(o-tolylcarbamoyl)azetidine-2-carboxylic acid (39) 
In a 25mL 2-neck flask a mixture of 41 (115mg, 0.34mmol), anhydrous THF (1.88mL), 
MeOH (1.88mL) and Pd/C 10%w/w (12mg) was stirred under H2 atmosphere (1atm) at 
room temperature. At starting material consumption (2h) the mixture was filtered and 
concentrated in vacuum. The desired product 39 was obtained as a white solid in 99% 
yield. 
M.p. 121-124°C; Rf 0.01 (cyclohexane/EtOAc 40/60) 
[α]D = -151.04° (c = 10.0, DCM) 
1
H NMR (400MHz, CDCl3): δ = 2,33 (s, 3H, Me), 3.34-3.41 (m, 1H), 3.45-3.51 (m, 1H), 4.32 (m, 1H, 
CHCOOH), 7.11 (t, J = 7.6Hz, 2H, Ar),  7.22 (d, J = 8.4Hz, 1H, Tol),  7.23 (t, J = 8.4Hz, 2H, Ar), 7.87 (d, 
J = 8.0Hz, 1H, Tol), 8.38 (s, 1H, NH) ppm 
13
C NMR (100MHz, CDCl3): δ = 17.5, 41.2, 49.3, 121.5, 125.0, 126.8, 128.1, 130.5,  134.5, 147.7, 165.6, 
171.8 ppm 
IR: ṽ = 3338, 1787, 1755, 173, 1690, 1590, 1461, 1327, 1311, 1250, 1136, 1061, 759 cm-1 
HPLC-MS: Rt = 1.61min, m/z = 247 [M-H]
- 
 
Benzyl 3-(2-(4-oxo-(o-tolylcarbamoyl)azetidin-2-yl)acetamido) propanoate (43) 
In a 25mL 2-neck flask, to a solution of 32 (63mg, 240μmol) in anhydrous 
DCM (3.47mL) was added dropwise a previously prepared solution of 42 
(127mg, 0.36mmol) and stoichiometric TEA in DCM (3.0mL). Then was 
immediately introduced 29.3mg (240μmol) of  DMAP and, at 0°C, 46mg  
(240μmol) of 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). The 
solution was warmed to rt and after complete consumption of the starting 
material (18h) the mixture was quenched with H2O (10mL) and extracted with DCM (3x10mL). The 
organic layers were dried on Na2SO4, filtered, concentrated in vacuum and purified by flash-
chromatography (DCM/EtOAc 80/20, then 70/30) to afford 61mg (yield = 60%) of 43 as a white waxy 
solid. 
Rf 0.74 (EtOAc) 
1
H NMR (400MHz, CDCl3): δ = 2.30 (s, 3H, Me), 2.58 (t, J = 6.0Hz, 2H, NHCH2CH2), 2.63 (dd, J = 5.6, 
16.0Hz, 1H), 3.08 (dd, J = 4.0, 15.2Hz, 1H), 3.13 (dd, J = 3.2, 16.8Hz, 1H), 3.33 (dd, J = 5.6, 16.4Hz, 
1H), 3.53 (ddd, J = 2.0, 6.8, 12.8Hz, 2H, NHCH2CH2), 4.40 (m, 1H), 5.07 (d, JAB = 12.0Hz, 1H, CHHPh), 
5.10 (d, JAB = 12.4Hz, 1H, CHHPh), 6.45 (bs, 1H, NH) 7.05 (t, J = 7.6Hz, 1H, Tol), 7.18-7.23 (m, 2H, 
Tol), 7.32-7.40 (m, 5H, Ph), 7.93 (d, J = 8.0Hz, 1H, Tol), 8.51 (s, 1H, NH) ppm 
13
C NMR (100MHz, CDCl3): δ = 17.5, 33.8, 34.8, 38.4, 42.6, 48.3, 66.4, 120.9,124.4, 126.7, 127.5, 128.1, 
128.3, 128.5, 130.4, 135.1, 135.5, 148.1, 167.2, 168.8, 172.0 ppm 
IR: ṽ = 3334, 3065, 2951, 1765, 1732, 1712, 1656, 1594, 1549, 1382, 1173, 1065, 755 cm-1 
HPLC-MS: Rt = 8.73 min, m/z = 423 (85) [M+H]
+
, 446 (100) [M+Na]
+
 
 
3-(2-(4-oxo-(o-tolylcarbamoyl)azetidin-2-yl)acetamido) propanoic acid (40) 
In a 25mL 2-neck flask a mixture of 43 (61mg, 0.144μmol), anhydrous THF 
(1.7mL), MeOH (1.7mL) and Pd/C 10%w/w (6mg) was stirred under H2 
atmosphere (1atm) at room temperature. At starting material consumption (2h) 
the mixture was filtered and concentrated in vacuum. The desired product 39 
was obtained as a white solid in 99% yield after trituration with DCM and 
pentane. 
M.p. 175-178°C; Rf 0.01 (EtOAc) 
1
H NMR (400MHz, CDCl3): δ = 2.28 (s, 3H, Me), 2.52 (t, J = 6.4Hz, 2H, CH2CH2COOH), 2.64 (dd, J = 
8.4, 14.8Hz, 1H), 3.05 (t, J = 14.4Hz, 2H), 3.34 (dd, J = 6.0, 14.8Hz, 1H), 3.43 (t, J = 6.4Hz, 2H, 
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CH2CH2COOH), 4.41 (m, 1H), 5.17 (s, 2H, Bn), 7.05 (t, J = 7.6Hz, 1H, Tol), 7.18 (t, J = 7.6Hz, 1H, Tol), 
7.21 (d, J = 8.0Hz, 1H, Tol), 7.81 (d, J = 7.6Hz, 1H, Tol), 8.19 (s, 1H, NH) 8.64 (s, 1H, NH) ppm 
13
C NMR (100MHz, CD3OD): δ = 17.8, 34.6, 36.4, 39.3, 43.1, 49.8, 122.8, 125.8, 127.6, 129.7, 131.5, 
136.6, 150.0, 159.1, 169.0, 172.0 ppm 
IR: ṽ = 3300, 2923, 2854, 1769, 1700, 1638, 1614, 1592, 1309, 1125, 758 cm-1 
HPLC-MS: Rt = 3.87min, m/z = 332 (100) [M-H]
-
, 665 (44) [2M-H]
-
. 
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3. ANTIBIOTICS AND DUAL ACTIVE COMPOUNDS 
3.1 Synthesis of new β-lactam antibiotics 
3.1.1 Antibiotics 
Antimicrobial compounds are defined as molecules capable of suppressing infections caused by 
microorganisms such as fungi and protozoa. Antibiotics, such as β-lactam derivatives, appear to be an 
antimicrobial subgroup. The term antibiotic derives from the Greek anti, against, and bios, life. It was 
introduced in 1942 by Selman Waksman to indicate substances produced by microorganisms and 
characterized by an antagonistic effect against the growth of other bacterial species, thus excluding 
compounds with non-microbial origin, such as the gastric juices, or synthetic molecules.
57
 
Currently, also thanking the progress of pharmaceutical chemistry, the definition includes semi-synthetic 
compounds, such as molecules found in nature and chemically implemented with the aim to enhance the 
desired effects. Moreover, exclusively synthetic molecules are now included. Classified according to their 
chemical structures or referring to  spectra of action, antibiotics are today commonly distinguished in 
relation to the different mechanisms of their antimicrobial activities: 
 - molecules that act on essential bacterial enzymes, such as quinolones and sulfonamides; 
 
- molecules which interfere with protein synthesis, so aminoglycosides, macrolides and tetracyclines. -
They are usually bacteriostatic, since only able to inhibit or limit bacterial replication without really kill 
microorganisms; 
 
60 
- molecules that interfere with the bacterial cell walls construction, as the cases of penicillins, 
cephalosporins and carbapenems, or with that of cell membranes (glycopeptides such as vancomycin and 
polymyxins); 
 
although there is a limited number of examples which outside this division, including daptomycin, natural 
and newly discovered,
58
 and others. However, in most cases antibiotics are small semisynthetic 
compounds characterized by a molecular mass lower than 2000 units,
59
 while first antibiotics entered in 
the pharmacopoeia were exclusively natural. 
In a reverse chronological order, are herein listed the most important antibiotics. Thus, as the most recent 
achievements should be cited daptomycin, a lipopeptide characterized by a working mechanism different 
from those previously studied and exploited. Known since the ‘80 but approved by the FDA (acronym of 
Food & Drug Administration, the US government agency that deals with the regulation of food and 
pharmaceuticals) only in 2003, it seems to act by binding cell membranes causing rapid depolarization 
and subsequent inhibition of protein, RNA and DNA synthesis.
60
 Erythromycin was the founder of 
macrolides: it was isolated in 1953.
61
 Aureomycine (a chlortetracycline), the first tetracycline antibiotic, 
was discovered in 1945,
62
 while Streptomycin, the first aminoglycoside compound, was achieved in 
1943.
63
 
Discovery of penicillin G by Alexander Fleming dates back to 1928. He has the merit of having realized 
the phenomenon, supposing a fungal contamination to produce an antibacterial agent. Due to the time 
needed to identify and isolate the fungus, Penicillum notatum, and to identificate and reproduce the agent, 
clinical evidences on the effectiveness of penicillin came only in 1941. For their penicillin in batch 
production, Chain and Florey earned the Nobel Prize together , with Fleming in 1945.
64
 
However, the first commercially available antibiotic was a sulfonamide named Prontosil. It was 
discovered in 1932 and it was obtained after five years of tests on thousands of compounds structurally 
related to azoic dyes. Prontosil earned to Gerhard Domagk the medicine Nobel Prize of 1939.
65
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Salvarsan is a synthetic antibacterial based on arsenic and used for the treatment of syphilis and 
trypanosomiasis. As it dates back to 1910, it is considerable as the first modern chemotherapeutic agent. It 
is derived from the screening of hundreds of synthetic dyes implemented by Paul Ehrlich. After realizing 
the selectivity in coloring bacterial cells, animals or human, he hypothesized the existence of a species 
able to bind and kill only bacterial cells without damaging the human ones.
66
 
All our actual chemotherapy agents can be considered as originated by the development of this selective 
toxicity concept. 
 
β-Lactam antibiotics  
Starting from the most common and celebrated penicillins and cephalosporins, all their semi-synthetic 
variants have today the 6-aminopenicillanic acid and the 7-aminocephalosporanic acid as precursors. The 
β-lactam ring represent the reference structures of many families of molecules with an antibiotic activity: 
penams, penems, clavams and clavems (Figure 3.1.1), as well as the most modern carbapenams, 
carbapenems and the so-called monobactams, all belong to the β-lactam family.  
 
Figure 3.1.1 Reference structures for β-lactam antibiotics 
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The mechanism by which these molecules exert the antibiotic action is quite specific and related to the 
enzymes responsible for cross-linking of the bacterial cell walls, constituted by the peptidoglycan. It is a 
polymer formed by alternate units of NAG (N-AcetylGlucosamine) and NAM (N-AcetylMuramic acid) 
which is anchored by an (L)-Ala to a (L)Ala-(D)Glu-(L)Cys-(D)Ala-(D)Ala pentapeptide derivatized on 
the cysteine residue with a moiety consists of five (L)-Gly units. The enzyme involved in the crosslinking 
is a transpeptidase and catalyzes the formation of a pentaglycine cross-link through the replacement of the 
(D)Ala-(D)Ala bond with a (D)Ala-(L)Gly bond, where the glycine unit will be the last of one of the 
adjacent pendants (Figure 3.1.2). 
 
Figure 3.1.2 Cross-linked peptidoglycan 
A non-crosslinkage leaves the cell wall not sufficiently resistant and, due to the usually high internal salt 
concentration and to the water permeability, the cell will tend to increase the internal pressure by osmosis, 
until lysis and consequent cell death. 
The transpeptidase enzyme is usually serine-dependent. The mechanism by which β-lactams intervene on 
it passes to their easy opening by attack nucleophilic of serine OH in the transpeptidase active syte. This 
reaction form an irreversible covalent bond. Indeed, because of the different hindrances of antibiotics 
with respect to the natural substrate, the bond formed is no longer divisible. Thus the enzyme resulted 
irreversible inhibitio. Of course, the process is favoured by the how easy azetidin-2-one ring tends to 
undergo opening. 
Although can always occur allergic phenomena, inhibiting an enzyme specific for bacteria these 
molecules do not exhibit toxicity to animal cells, which lack of the transpeptidase. However, even the 
bacterial mature cells, already developed, do not suffer the azetidin-2-one derivatives action. To be an 
efficient therapy and to avoid favoring the occurrence of phenomena of resistance, and therefore the 
development of resistant strains derived from this aspect, is really high the importance of always carrying 
out the entire cycle of each antibiotic treatment, the duration of which depends also on the generations 
replacement time of bacterial species treated. 
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At this point, it should consider the aspect of bacterial resistance, commonly defined as the ability of 
certain bacterial species to survive and multiply in the presence of molecules having antibiotic activity. It 
is then appropriate to distinguish the natural resistance, for example due to the absence of the specific 
target on which an antibiotic is active, from that triggered by prior exposure to the antibiotic. Induced 
resistance phenomena usually occur at the level of drug target changes, or through the development of 
systems to inactivate or even to expel the antibiotic before it exerts its action. In the case of β-lactam 
compounds, enzyme systems known as β-lactamase generally intervene for inactivating the antibiotic 
with a ring opening mechanism.
67
 The phenomenon is typical of antibiotics use, because of natural 
spontaneous mutations that occur every 10
7
-10
8
 replications and which are transmitted, if favorable,  to 
subsequent generations in vertical mode, encouraging their growth and multiplication. Moreover, the 
resistance may also result from genetic horizontal exchange between different strains and also different 
species, which in turn may be selected from others contexts of massive antibiotics presence, such as 
hospital environments. Although this is not the only case, the abuse and the inappropriate use has 
nevertheless contributed to the phenomenon.
68
 Clearly, now “the first rule of antibiotics is to try not to use 
them, and the second is try not to use too many”,69 but in addition to guidelines for rationalizing and 
limingt the administration, where possible, is important as well as developing new drugs with new 
mechanisms of action. In recent years, pharmacology introduced different solutions to solve or at least try 
to stem his problem, starting from marketing preparations containing combinations of the antibiotic and, 
for cases in question, of a β-lactamase inhibitor. Nowadays are known three serine-dependent (A, C, D) 
β-lactamases and one metal-dependent (B) β-lactamase. The actual β-lactamase inhibitors present in 
pharmaceutical preparations are clavulanic acid, sulbactam and tazobactam, active against the A class. 
(Figure 3.1.3).
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Figure 3.1.3 β-Lactamase A inhibitors 
Despite the existence of precautions and tricks, antibiotic resistance is an overall proportion phenomenon, 
soaring and not negligible also because, as already seen, even judicious uses determine a selective 
pressure, which generates resistance. 
The spectrum of the spread of bacterial strains resistant to carbapenems, detected in some hospitalized 
patients, leaves little antibiotic solutions usable. New molecules such as Tigecycline, first of a new class 
of compounds called glycylcyclines, and Colystin, a polymyxin, despite very active are still far from 
being pharmacologically applicable.
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However, some hope is associated to the class of monobactams: Aztreonam is the only commercially 
available member of this family. It is naturally resistant to β-lactamases and it is active against Gram-
negative bacteria, usually the most difficult to be killed. Due to their antibiotic potentialities, a significant 
number of other monobactams exists: they are synthetic and semisynthetic, currently in development and 
in some cases already in clinical phase, such as for Tigemonam.
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3.1.2 Cystic Fibrosis 
Cystic fibrosis (CF) is an autosomal recessive genetic disease, thus a genetic disorder caused by recessive 
allelic form of a defective gene on an autosome (a non-sexual chromosome). It is fully manifested only in 
the homozygotes recessive for that gene, with no clinical symptoms in heterozygotes. Individuals with CF 
present a genotype rr, where “r” is the recessive allele that codes for the disease, while heterozygotes have 
a genotype Rr, where “R” is the dominant allele, resulting in an asymptomatic course of the disease. In 
the case of heterozygotes, the presence of only one recessive allele makes individuals immune to the 
effects of typhoid fever.  
 
Figure 3.1.4 Biochemical processes related to the CFTCR gene mutation 
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This phenomenon takes the name of “advantage in favor of heterozygotes” and makes healthy carriers 
frequency very high (1 in 25) and the disease widespread. In CF, the mutated gene is the CFTCR (Cystic 
Fibrosis Transmembrane Conductance Regulator), which encodes for a protein of 1480 aminoacids 
located on the cell membrane of epithelial cells. These cells are present in lungs and upper airways, 
pancreas, intestines, sweat glands, salivary glands and deferens vases. Their function is to transport 
chlorine ions in the apical membrane, i.e. the membrane exposed on the cavity of the organ in question.
73
 
CF is therefore characterized by a fault in chlorine transport at cellular membrane level, resulting in the 
formation of an ionic imbalance which also causes an increased reabsorption of sodium and water. 
Because of this ionic stress, glands secrete a thick and sticky mucous (Figure 3.1.4). In affected organs, 
these abnormally slimy mucous secretions determine an obstruction of the main ducts causing the most 
typical clinical manifestations of the disease, such as recurrent pulmonary infections, pancreatic 
insufficiency, steatorrhea, malnutrition states, liver cirrhosis, intestinal obstruction and male infertility.
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By focusing on lungs, airways obstruction caused by mucous accumulation generates various issues 
including the onset of inflammations and infections. As a matter of facts, the lung conditions so 
determined, allow bacteria that normally inhabit the mucous membranes to grow out of control. This 
growth can cause pneumonia, and S. aureus, P. aeruginosa and Haemophilus influenzae are the three 
most common organisms in cystic fibrosis patients (Figure 3.1.5). 
 
Figure 3.1.5 Infections incidence related to patients’ ages 
However, less common pathogens can not be easily neglected. For example, bacteria such as B. Cepacia 
often determined drastic living conditions worsening of CF patients. Moreover, since the average life 
expectancy is around 37 years and CF patients are subjects of frequent and long hospitalizations, 
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infections appear to be often by resistant bacterial strains, further complicating the treatment of the 
disease. 
Inflammation phenomena is a physiological response to infections. In CF patients’ lungs, epithelial cells 
release highly reactive molecules (ROS and RNS, Reactive Oxygen and Nitrogen Species) in the 
extracellular space to counteract pathogens. This is the so-called oxidative stress phenomenon.
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However, several studies showed the inefficient these defenses, especially against infections by resistant 
strains. In CF patients, the production of these chemical species increases during years, probably due to a 
progressive dysfunction of cells. Moreover, not only the chlorine transport is affected by the CF, but it is 
also altered the transport of other small molecules, including glutathione, an endogenous antioxidant. All 
these aspects promoted a ROS and RNS accumulation in extracellular spaces, attacking the patient tissues 
and thus increasing symptoms. 
 
3.1.3 New β-lactam antibiotics 
The group with whom I did my Ph.D. is working since a long time on the synthesis and design of 
potential β-lactam leads able to counteract resistant bacterial strains. In particular, a completely new class 
of β-lactams called 4-alkylidene β-lactams was designed and synthesized.76 Their structures were 
designed with the objective of increasing the electrophilicity of the amide carbon, promoting the 
nucleophilic attack of bacterial transpeptidases (Figure 3.1.6). The C-4 double bond allows the 
stabilization of the ring opening product through delocalization by resonance on the unsaturated system. 
Other functionalization evaluated from our group regarded the derivatization of nitrogen atom
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 and the 
introduction of particular functions on the C-3 β-lactam position.78 
 
 
 
Figure 3.1.6 4-Alkylidene β-lactams reactivity towards transpeptidases 
The antibacterial activity of 4-alkylidene β-lactams was assessed by the research group of Prof. Cocuzza, 
University of Milan-Bicocca. The evaluation allows to determine the antibiotic activity in vitro and to 
calculate MICs (Minimum Inhibitory Concentration, expressed as mg/L) on Gram-positive and Gram-
negative bacterial strains, with high resistance and β-lactamase producing strains and not (Streptococcus 
pyogenes and pneumococci, methicillin-sensitive and methicillin-resistant Staphylococcus aureus, 
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Staphylococcus epidermis and Haemophilus influenzae). The best results were obtained from the 
molecules in Table 3.1.1, showed with the relative MIC values, expressed in mg/L. 
Compound S. Pyog. S. Pneum. MRSA MSSA S. Epiderm. H. Infl 
 
32 128 16 8 8 1 
 
16 128 128 32 64 64 
 
128 >128 128 8 4 >128 
 
128 128 32 16 2 64 
 Table 3.1.1 MICs for some 4-alkylidene β-lactams 
The encouraging results obtained led to further modifications on the 4-alkylidene structures, in particular 
synthesizing 4-alkylidene β-lactams characterized by a particular substituent on the nitrogen atom: the 
thiomethyl group (-SMe). This allowed to synthesize a library of 4-alkylidene β-lactams characterized by 
a stronger lipophilicity, induced by that group, and interesting biological activities. 
As a matter of facts, N-thiomethyl β-lactams were already studied for their biological activity against 
resistant bacterial strains such as MRSA and Bacillus species.
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 Moreover, the interest towards this class 
of biomolecules has evolved due to the biological activity shown especially against Staphylococcus 
strains.  
The research group of Professor Turos focused his attention on synthesis and antibacterial properties of 
monobactam N-thiomethylated derivatives,
80
 as well as on bicyclic derivatives. Chemical properties that 
this group gave to β-lactams were also highlighted: 
- the entire substrate resistance against many of the nucleophiles used in organic synthesis (-CN, -N3, 
alcohols) and biomolecules (such as glutathione and penicillanases, proteins responsible for penicillins 
degradation); 
- highly lipophilic character; 
- stability during the processes of chromatographic purification;  
Furthermore, the idea is that the 4-alkylidenic structure favors not only the ring opening reaction, which is 
the typical reactivity for β-lactams antibiotic action, but also the thioalkylation of biological targets 
(nucleophiles with a sulfhydryl -SH, i.e. cysteine of enzyme active sites or other substrates bearing the 
same function). 
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4-Alkylidene β-lactams provide an increased reactivity due to the presence of a good electron-
withdrawing group. We wondered that the same reactivity can be reached if in C-4 position were 
alternately present a good leaving group. An example could be the acetate group already present in some 
commercially available azetidinones commonly used in the synthesis of β-lactam derivatives. These 
substitution could allow an easier synthetic pathway of molecules which can be thought to present 
activities comparable to the ones of 4-alkylidene derivatives. Moreover, potencies could be increased by 
thiomethyl derivatization.  
In every case,  the comparison could allow to understand if on C-4 position an electron-withdrawing 
group able to delocalize an ionic charge is more or less important than the presence of a leaving group, 
thus defining an important structure-activity relationship for β-lactams. 
 
3.1.4 New dual active β-lactams  
As part of an interdisciplinary research project, involving the synthesis of new monocyclic β-lactams 
specifically designed to target resistant Gram-positive bacterial strains, a series of new azetidinones with 
polyphenolic side chains were evaluated for both their antibacterial
81
 and antioxidant activities.
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 As a 
general trend, to activate the antioxidant potency of the tested compounds to a significant extent the 
presence of phenolic OH resulted necessary, with the exception of 4-alkylidene-thiophenol derivative (1) 
which had no phenolic residues but retained a certain antioxidant activity. More recently a series of N-
methylthio-azetidinones were evaluated in vitro against Gram-positive and Gram-negative clinical 
isolates and in particular on MRSA and MSSA strains isolated from patients with cystic fibrosis.
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 The 
combination of an N-SMe group and a benzyl ester on the 4-alkylidene-side chain, or 
electronwithdrawing groups, such as OAc, on the C-4 position of the β-lactam ring, appeared to 
strengthen the potency against Gram-positive bacteria. 
 
Figure 3.1.7 β-Lactam compounds tested for the antioxidant activity 
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This study reports the evaluation of physicochemical parameters, such as the antioxidant activity and 
redox potentials, of some N-methylthio-azetidinones with antibacterial potency. The aim of this ongoing 
project was in fact to develop dual targeting molecules with elements incorporated in their structure that 
would allow dual antibacterial and antioxidant activities in order to contrast unfavorable clinical 
conditions, such as those resulting from bacterial colonization of the lung associated with extensive 
epithelial damage brought about by chronic pulmonary oxidative stress. 
All 15 monocyclic β-lactams investigated here are depicted in Figure 3.1.7. Compounds 1, 2, 3, 4, 5, 7, 8, 
9, and 10 were prepared according to previously reported procedures.
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 N-Methylsulfoxide-4-acetoxy-
azetidin-2-one 6 (Scheme 3.1.1) was prepared starting from commercial 4-acetoxy-azetidin-2-one which 
was treated with LiHMDSA followed by addition of mesylchloride. 
 
Scheme 3.1.1 Synthesis of β-lactams 6 and 11 
Analogously, N-methylthio-azetidin-2-one 11 was obtained treating commercial azetidin-2-one with 
LiHMDSA and then S-methyl methanethiosulfonate (Scheme 3.1.1). 
 
Scheme 3.1.2 Synthesis of β-lactams 13, 14, 15, 16, 17 and 19 
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Compounds 12-15 were prepared starting from the commercial available (3R,4R)-4-acetoxy-3-[(1R)-
tbutyldimethylsilyloxy-ethyl]-azetidin-2-one. The starting compound was N-thiomethylated to afford 
compound 3 using Et3N as a base because LiHMDSA or LDA led to the formation of significant amounts 
of by-products. Compound 3 was then deprotected using BF3·Et2O in MeCN on the 3-O-
(tbutyldimethylsilyl)-ethyl side chain to give the corresponding alcohol 4 (Scheme 3.1.2).  
Treatment of 4 with the appropriate O-protected benzoic acid 19, 21 or 22, DCC or EDC as coupling 
reagents and in the presence of a catalytic amount of DMAP in dichloromethane, gave compounds 12, 16 
and 17. 
 
Scheme 3.1.3 Synthesis of acids 6, 21 and 22 
As regards the benzoic acids, methyl 4-(ethoxymethoxy)-3,5- dimethoxybenzoic acid 19 and (E)-3-(3,4-
bis(ethoxymethoxy)phenyl)acrylic acid 21 were prepared starting from syringic methyl ester or caffeic 
methyl ester, respectively through protection of the phenolic oxygen atoms with chloromethylethylether 
followed  by alkaline hydrolysis of methyl esters 18 and 20 (Scheme 3.1.3). 
Finally, compounds 12 and 17 were treated with trifluoroacetic acid (TFA) to eliminate the phenolic 
protection and to give compounds 13 and 15. The ethoxymethylether as protective group was not 
effective in the synthesis of 3,4-dihydroxybenzoic ester 14 which was successfully obtained using TBS to 
protect the phenolic positions in compound 16. 
 
Antioxidant activity 
Antioxidant activity determination based on different approaches was carried out, in light of the 
importance of a multidimensional evaluation of the antioxidant activity.
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 The β-lactams were then 
subjected to four antioxidant assays: the Briggse Rauscher (BR) oscillating reaction,
86
  the Trolox 
Equivalent Antioxidant Capacity (TEAC) assay,
87
 the DPPH (2,2-diphenyl-1-picrylhydrazyl DPPH· 
stable radical) test
88
 and the Ferric Reducing Antioxidant Power (FRAP) method.
89
  The majority of the 
synthesized β-lactams did not show appreciable antioxidant activity with BR, TEAC, DPPH, or FRAP 
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methods; moreover compounds 2, 3 and 10 were also tested with the Foline Ciocalteu (FC) reagent
90
 to 
check if the N-methylthio-β-lactam skeleton has some reductive properties, but the result was negative. 
N-unsubstituted compounds 8 and 9 gave also negative results to antioxidant tests. Only the N-
methylthio-β-lactams 12-15 with phenolic moieties were active and showed values in Table 3.1.2 (a: S. 
aureus American Type Culture Collection ATCC 29213 and ATCC 43300 were used as control strains. b: 
na = no activity, nd = not determined. c: See reference [84]. d: Result of only one measure at 14.7μM in 
mixture. e: FOT = cefotaxime and CTX = ceftriaxone were used as reference antibiotics). TEAC values 
for compounds 14 and 15 are in line with those of some polyphenolic-β-lactams we previously reported, 
ranging from 0.4 to 2.0mM eq.Trolox. The DPPH and FRAP values are in satisfactory agreement with the 
TEAC ones taking into account the different chemistry of the methods. For comparison, the TEAC values 
for ascorbic acid (vitamin C) and α-tocopherol (vitamin E) are 1.05 and 0.97 respectively, the DPPH 
values are 1.1 and 0.5 respectively, and the FRAP values is 2.0 for the two vitamins. As expected, 
compound 12 doesn’t shows antioxidant activity with these three methods because it does not contain 
phenolic OH groups in the molecule (negative control). Compound 13 is a very low active antioxidant 
than the other two phenolic substituted molecules, a possible interpretation is given in next paragraph. 
The BR values for all compounds are surprisingly higher than those of some polyphenolic-β-lactams 
previously reported, ranging from 0.021 to 0.28μM eq. Re. We suspect that these unusual results are due 
to parallel reaction of oxidation of sulphur in the NSMe group by acidic iodate that compete with the 
HOO· scavenging reaction. On the contrary this parallel reaction doesn’t occur with the usual N-
unsubstituted β-lactams. 
 
Table 3.1.2 Results of antioxidant and antibacterial tests 
 
Structure-activity relationships 
As a general trend, to activate the antioxidant potency of the tested compounds, the presence of two or 
three phenolic OH groups are necessary.
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 A theoretical method to calculate the Bond Dissociation 
Enthalpies (BDE) for molecules belonging to the class of polyphenols and to correlate them with their 
free radical scavenging activities has been reported by Wright et al.;
92
 these authors also proposed 
empirical additivity rules that take into account the electronic, H-bond and conjugation effects of 
substituents in the phenol parent molecule to evaluate the BDE of a given phenolic OH group. In this way 
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a value of BDE or DBDE = (BDEcomp - BDEΦ-OH) can easily be calculated from the data reported in 
reference [93]. It was found that the number of phenolic OH is not so important and that it is the strategic 
placing of these groups with respect to other substituents that determine the strength of the OH group and 
then the antioxidant activity. From the data reported in reference [93], we calculated the DBDE values for 
two model compounds A and B in comparison with the free radical scavenging activity for compounds 13 
and 14 (Figure 3.1.8). 
 
Figure 3.1.8 ΔBDE for and B in comparison with the for 13 and 14 
As can be seen, results for the model match well with the experimental data, thus justifying the very low 
free radical scavenger potency of compound 13 with respect to that of 14. 
 
Voltammetry 
It is well known that thioethers can be oxidized to sulfoxides and further to sulfones by H2O2 or by many 
other oxidizing agents.
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 The negative results of the antioxidant assays gave evidence that in the 
experimental conditions the N-methylthio group was not prone to be oxidized. To interpret these results 
we decided to perform some cyclic voltammetry experiments on the two molecules 9 and 11 chosen as 
models. In the first molecule the bivalent sulphur atom is bonded to C-4 atom of the ring while in the 
second molecule the bivalent sulphur atom is bonded to the nitrogen atom of the β-lactam ring. Aim of 
the investigation was to measure the ability of such model compounds to undergo oxidation to evaluate 
their antioxidant activity through the measure of the corresponding standard potentials. We also submitted 
to cyclic voltammetry the thioester 1, which has no antibiotic activity and that in a previous work [83] 
showed some antioxidant activity both in the BR or TEAC tests (acidic and neutral pH method, 
respectively), and explained with a possible generation of an intermediate radical cation R2S·
+
. The 
voltammograms are reported in Figure 3.1.9. All species displayed in acetonitrile a very similar CV 
behavior showing, in the positive potential region, a main anodic peak at about 0.9V attributed to the 
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reversible oxidation of the pristine species. Weak-to-strong adsorption effects were observed in the CV 
pattern, leading in most cases to fouling of the electrode surface and thus to a highly irreversible behavior. 
On the basis of such results, and assuming that potentials determined under the aprotic and relatively 
apolar conditions of CV (Figure 3.1.9) may be directly used for comparisons in the aqueous media, all the 
investigated compounds should not show appreciable antioxidant activity towards TEAC, DPPH or 
FRAP antioxidant methods. 
 
Figure 3.1.9 Current potential diagrams for compounds 1, 9 and 11 
The redox potential of the couples ABTS·
+
/ABTS (TEAC); DPPH·/ DPPH, (TPTZ)2Fe
3+
/(TPTZ)2/Fe
2+
 
(FRAP) are in fact 0.68V, 0.28V,
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 and 0.77V,
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 respectively, then ABTS·
+
, DPPH·, (TPTZ)2Fe
3+
 can 
thermodynamically be reduced by compounds with lower reduction potential. This is likely applicable to 
all N-methylthio-β-lactams synthesized here, except for compounds 13, 14 and 15. These compounds in 
fact contain phenolic moiety in the side chain, and many phenolic compounds have lower oxidation 
potential thus reacting with ABTS·
+
, DPPH· and (TPTZ)2Fe
3+
. 
 
Antibacterial activity 
In order to evaluate the potential antibacterial activity of the new β-lactam derivatives with anti-oxidant 
properties, the minimum inhibitory concentrations (MICs) of compounds 13-15 were determined in vitro 
against 45 clinical strains of MRSA isolated from CF patients. Preliminary results (see Table 3.1.2) on the 
antibacterial activity demonstrated compounds 13 and 15 to be the most active with MIC values ranging 
from 16 to 128 mg/L against the tested isolates; in particular compound 15 showed MIC50 and MIC90 
values equal to 64mg/L. Table 3.1.2 summarizes the antioxidant and antibacterial data of exemplificative 
new β-lactams. Compounds 4, 5, 8, 9 and 10 notwithstanding the potency against resistant S. aureus 
strains and the presence of a sulphur atom in the structure did not present a sufficient antioxidant activity. 
The dual activity is present in case of compounds 13, 14, 15 in which the presence of phenolic residues on 
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the hydroxyethyl-side chain switched on the antioxidant potency thus conjugated with an encouraging 
result of antibacterial activity. 
 
3.1.5 Other β-lactam antibiotics and dual active compounds 
To further investigate the potentialities of this interesting family of antioxidant and antibacterial β-
lactams, more easy to synthesize if compared to the previous developed 4-alkylidenes, we designed two 
other β-lactam molecules in which the antioxidant moiety is the same of BHT. We reached the two 
desired targets by final deprotection of the phenolic moieties as well as described before (Scheme 3.1.4). 
 
Scheme 3.1.4 Synthesis of dual active β-lactam derivatives 23 and 24 
As shown in the previous paragraph, the synthetic pathway to obtain the new lactams was maintained, 
only the benzoic acid used for the esterification step was changed. The carboxylic acid was prepared 
following the previously reported  procedure with a methyl esterification followed by phenolic group 
protection and finally saponification of the acid function to reach intermediate 28, as reported in Scheme 
3.1.4. 
Compound 24 was synthesized by hydrogenolysis from 23 A direct comparison between antibacterial 
potencies of 23 and 24 should account for the efficacy of N-thiomethyl group to the specific activity.. 
Synthesis of these N-thiomethylated derivatives, as shown in Scheme 3.1.4, requires alcohol 25 as β-
lactam starting material. It corresponds to compound 4 unless for thiomethyl functionalization, and it was 
directly obtainable from the same commercially available substrate. 
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Unfortunately, the yield of all the esterification processes wereunsatisfactory,  in particular, in this case it 
was not possible to get  the -lactam 27. 
However, we found an interesting reaction which was able to give the free NH converting an N-
thiomethylated β-lactam by hydrogen treatment in the presence of Pd/C (Scheme 3.1.5). This observation 
was particularly interesting because it opens the route to NH derivatives poorly obtained  
fromesterification reactions.  
 
 
Scheme 3.1.5 Synthesis of β-lactam 24 by de-thiomethylation of 23 
As will shown in the next paragraph, this couple of molecules already confirmed what we thought about 
the thiomethylation: it improves antibacterial activities of β-lactams, particularly bring a bacteriostatic 
effect and not properly an antibiotic action (Table 3.1.4). 
To further investigate this effect, we designed other compounds in which acetoxy group was not present 
(Figure 3.1.10). In this way we tried to demonstrate both the importance of this leaving group in the 
position C-4 of the β-lactam ring and the value of antibacterial action bring by the thiomethyl moiety. 
 
Figure 3.1.10 New β-lactams synthesized to demonstrate SAR hypothesis 
Fortunately, we observed that treating our 4-acetoxy-β-lactam derivatives with a reducing agent such as 
sodium borohydride was possible to selectively remove the acetoxy group, thus obtaining a methylene 
group on the C-4 position (Scheme 3.1.6). 
Thus, β-lactam intermediate 38 way directly obtained. The corresponding thiomethylated compound 40 
was reached by the same thiomethylation reaction conditions mentioned above. The two intermediate 
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were both deprotected, with an acid treatment by HCl to reach 39, and using BF3 as Lewis acid to 
obtained 41. 
 
Scheme 3.1.6 Synthesis of β-lactams precursors 39 and 41 
Using the appropriate protecting groups strategy we prepared alibrary of new molecules showed in Figure 
3.1.7, tested for both  antibiotic and antioxidant activities. 
As well as for compounds 23 and 24, the -lactam 33 was prepared by hydrogenolysis treatment to 
remove the thiomethyl moiety from compound 37 (Scheme 3.1.7).  
 
Scheme 3.1.7 Synthesis of compounds 33 and 37 
For compounds 30 and 34 we were able to maintain the synthetic pathway equal to what shown in the 
previous paragraph, modifying the esterification process just changing the β-lactam substrate (Scheme 
3.1.8).  
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Scheme 3.1.8 Synthesis of compounds 30 and 34 
In case of compounds 31 and 35 it was necessary to differentiate the protecting group strategy due to the 
inefficiency of esterification processes or difficulties in deprotection steps (Scheme 3.1.9).  
 
Scheme 3.1.9 Synthesis of compounds 31 and 35, and of acids 48 and 49 
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The preparation of compounds 32 and 36 required a different protecting group strategy. 
 
Scheme 3.1.10 Synthesis of compounds 32 and 36, and of acid 51 
In this case, we found in the tbutyldimethylsilyl ether (OTBS)the best choice for protecting phenolic 
groups inthe esterification. The TBS  could be removed by Lewis acid treatment, such as  boron 
trifluoride (Scheme 3.1.10). 
 
Antibacterial and antioxidant activities 
All the new  compounds showed an interesting antioxidant activity, as shown in Table 3.1.3 for the more 
antioxidant molecules however only  N-thiomethylated derivatives  had a certain  antibacterial activity 
and, in particular, it was established that they were bacteriostatic agents. 
 
BR, µM eq. 
Resorcinol 
TEAC, mM eq. 
Trolox 
DPPH, mM eq. 
Trolox 
FRAP, mM eq. 
FeSO4 
23 only > 37.2 in mix 0.10 ± 0.01 negligible negligible 
24 0.99 ± 0.04 1.26 ± 0.02 0.8  ± 0.2 2.05 ± 0.03 
30 only > 46.5 in mix negligible negligible negligible 
34 only > 41.9 in mix negligible negligible negligible 
Table 3.1.3 Antioxidant activities evaluation for β-lactams 23, 24, 30 and 34 
This demonstrated that an electron-withdrawing or a  leaving group, on the C-4 position, was fundamental 
for this kind of biological activity (Table 3.1.4, with activities evaluated over more than twenty different 
clinical bacterial strains isolated from CF patients and compared with of Linezolid, Ciprofloxacin, and 
Cefuroxime as reference antibiotics). Only selected antibiotic activities are herein reported, but it clearly 
appered that the best MIC value belongs to compound 23, which has both Nthiomethyl- and the acetoxy 
group on the C-4 position of the β-lactam ring. 
Due to the interesting enhancement of antibacterial activity brought from introduction of the thiomethyl 
group, we took some C-3 halogenated β-lactams already known from our group and we prepared their 
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corresponding N-thiomethyl derivatives (Scheme 3.1.11). Being the synthesis of the chlorinated 
molecules not stereoselective, the two diastereoisomeric precursors were separated by flash 
chromatography and derivatized. 
 S. aureus 
strains 
S. faecalis 
strains 
S. hominis 
strains 
S. epidermidis 
strains 
23 4 - 128 
24 > 128 > 128 > 128 > 128 
30 > 128 > 128 > 128 > 128 
34 > 128 > 128 > 128 > 128 
36 32 - 128 128 128 32 - 64 
Linezolid 0.5 - 2 1 32 8 - 16 
Ciprofloxacin 1 - 128 4 > 128 > 128 
Cefuroxime 2 - > 128 > 128 8 16 - > 128 
Table 3.1.4 Antibiotic activities for β-lactams 23, 24, 30, 34 and 36 
Unfortunately, as for their precursors, the new β-lactam 53 and 55 showed a certain cytotoxicity when 
tested in vitro and were therefore left apart. 
To conclude the behavior analysis of N-thiomethyl-β-lactam compounds, we found MIC ranges of 0.5-
32mg/L for 54 and of 2-32mg/L for 52, to be compared with very variable and worse range for 
compounds 53 and 55 (8->128mg/L). 
 
Scheme 3.1.11 Synthesis of compounds 53 and 55 
The antibacterial data obtained let us to conjectured that this group maybe determines a different 
mechanism of action which need to be associated with other structure features for a giving a lead 
antibiotic drug. 
 
3.1.6 Thio-methylation reaction improvements 
Because of the interest in the N-thiomethylation reaction, some efforts were dedicated to its optimization. 
We worked on the two commercially available starting materials depicted in Figure 3.1.11 as model 
substrate. 
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Figure 3.1.11 Compounds used for optimizing thiomethylation reaction 
As reported in the Table 3.1.5, despite the variation of a lot of parameters, such as the base used and its 
equivalents, the amount of the thiomethylating agent and the reaction medium, it was never possible to 
reach high yields. obtained after flash chromatography  purification and in other cases evaluated from 
1
H-
NMR  
 
SM, 
[mmol] 
base, 
eq. 
MeSSO2R’, 
eq. 
solvent y% 
B, 1.0 LDA, 1.0 Me, 2.5 THF 35 
B, 0.25 LDA, 1.0 MeC6H4, 2.5 THF 38 
B, 0.25 
TEA, 2.7; 
DMAP, 0.1 
Me, 2.5 DCM 20 
B, 0.25 
TEA, 2.0; 
DMAP, 0.1 
Me, 1.5 DCM 38 
B, 0.25 
TEA, 2.0; 
DMAP, 0.1 
MeC6H4, 1.5 DCM 11 
B, 0.25 
TEA, 2.0; 
DMAP, 0.1 
Me, 1.5 THF ~0 
B, 0.25 TEA, 0.2 Me, 2.5 DCM 10 
B, 0.25 
DiPEA, 2.0; 
DMAP, 0.1 
Me, 1.5 DCM 4 
A, 0.25 DBU, 2.0 Me, 1.5 DCM 
not 
determined 
B, 0.25 NaH, 1.1 Me, 2.5 THF 8 
B, 0.25 K2CO3, 2.0 Me, 1.5 acetone 18 
B, 0.25 Imidazole, 2.0 Me, 1.5 DMF ~0 
B, 0.25 Pyridine, ~123.6 Me, 1.5 pyr ~0 
B, 0.25 tBuOK, 1.1 MeC6H4, 1.5 THF ~0 
B, 0.25 TEA, 2.0 Me, 1.5 DCM <20 
Table 3.1.5 Base, solvent and thiomethylating agent optimization 
It appeared that the best conditions were obtained with LDA as base in THF as solvent, or with the couple 
TEA and DMAP in DCM, but the temperature of -78°C and the general conditions necessary for using 
LDA prompt us to prefer the second procedure. 
The introduction of a more reactive thiomethylating agent appeared to be fundamental for improving the 
process yield. Thus, we tried to produce in situ and immediately use a form of chlorinated thiomethyl 
group. Using sulfuryl chloride, a chlorine source, and dimethyl disulfide, we were able to generate this 
reactant. Thus, we studied the conditions for its preparation and use, optimizing this promising procedure 
(Table 3.1.6). 
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SM, 
[mmol] 
base, 
eq. 
Me2S2/SO2Cl2 eq. solvent [h] T [°C] TM/SM 
B, 0.5 TEA, 1.1 0.5/0.55 DCM 1 r.t. 10/4 
B, 0.5 - 0.5/0.55 DCM 1 r.t. 1,5/10 
B, 0.5 TEA, 1.1 1.0/1.1 DCM 1 r.t. 8,4/10 
B, 0.5 TEA, 2.2 1.5/1.65 DCM 1 r.t. 10/6 
B, 0.5 TEA, 1.1 0.5/0.55 DCM 1 r.t. 10/4,5 
B, 0.5 TEA, 2.2 1.0/1.1. DCM 1 r.t. 10/4,5 
B, 0.5 TEA, 1.1 0.5+0.5/0.55+0.55 DCM 1+1 r.t. 10/5 
B, 0.5 TEA, 1.1 0.5/0.55 DCM 1 reflux 10/2,5 
A, 0.5 TEA, 1.1 0.5/0.55 DCM 1 r.t. 10/6 
B, 0.5 TEA, 1.1 0.5/0.55 DCM 1 reflux 10/5 
B, 0.5 TEA, 1.1 0.5/0.55 DCM 4 30-35 10/13 
B, 0.5 TEA, 1.1 0.5/0.75 DCM 1 r.t. 10/13,5 
B, 0.5 TEA, 1.1 0.75/0.5 DCM 1 r.t. 10/5,5 
B, 0.5 TEA, 2.0 0.5/0.55 DCM 1 r.t. 10/8 
B, 0.5 TEA, 1.1 0.5/0.55 DCM 16 r.t. 10/5,5 
B, 0.5 TEA, 1.1 0.5/0.55 MeCN 1 r.t. 3,5/10 
B, 0.5 TEA, 1.1 0.5/0.55 THF 1 r.t. 0/10 
B, 2.0 TEA, 1.1 0.5/0.55 DCM 1 r.t. 10/6,5 
B, 0.5 DiPEA, 1.1 0.5/0.55 DCM 1 r.t. 10/7,5 
B, 0.5 TEA, 2.2 0.5/0.55 DCM 1 r.t. 10/13 
Table 3.1.6 Cl-SMe thiomethylation reaction conditions evaluation 
In this way, we reached yields up to 80% with reagent very less expensive of the others previously used. 
Moreover, yields can be seen as conversions, thus SM could be recovered untouched and re-used. 
 
 
3.2 A new lead dual active β-lactam 
3.2.1 Lead β-lactam synthesis optimization 
From the library of new -lactam compounds developed one derivative emerged as a possible lead 
compound to testin vivo the bioavailability. The molecule identified for the treatment of CF patients as 
the optimal one, due to its entire set of features, had been already synthesized by our group and was 
previously treated in Table 4.1.1 . Lead drug 56 is herein depicted in Figure 3.2.1. 
 
Figure 3.2.1 Lead dual active β-lactam 56 chosen for in vivo evaluation 
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At first, was necessary to optimize its synthesis up to the gram-scale. Of course, for doing that we came 
back to its original synthesis (Scheme 3.2.1, as previously reported from our research group): there was 
two main crucial steps: i.the formation of two diastereoisomers in the 4-alkylidene synthesis with a yield 
never exceeding 50%; Ii. the esterification, always critical for this kind of molecules. 
The synthesis of 4-alkylidene had already been studied in the past: although it was proved to be possible 
an almost completely selective formation of E isomer, it has never been possible to reach the opposite. 
However only the product with the Z configuration has the higherantibacterial activity. 
 
Scheme 3.2.1 Synthetic pathway for 56, to be optimized 
For this reason it was decided to study and develop an isomerization reaction, to convert the not useful E-
isomer into the Z one. Then, we worked on the esterification  reaction itself: it was made in peptide 
coupling condition without good yields. However, other more classical conditions for esterification were 
unsuccessfully tried, such as both Lewis and Brönsted bases and acids catalyzed processes, Mitsunobu 
reaction, Yamaguchi protocols ,and various activation methodologies. 
 
E to Z isomerization 
Previous studies have shown that the Z isomer is more thermodynamically stable than the E, due the 
formation of an hydrogen bond between the NH and the carbonyl group of the C-4 side chain. Despite 
this, it was never observed a spontaneous isomerization of the pure solid  compound, even after long 
times at r.t. and exposed to air. 
Then, it was evaluated the possibility to thermal driven isomerization. Moreover, we studied the 
opportunity of making the isomerization with a catalyst such as Amberlyst 15 (an acid resin), DMAP (an 
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organic base) and CsCO3 (an inorganic base), as shown in Table 3.2.1, E/Z ratios were evaluated by 
1
H-
NMR analysis. 
 
SM, 
[mmol] 
Catalyst Solvent T [°C], t E/Z ratio 
0.05 - MeCN 50°C, 4h 1/0.12  
0.05 Amberlyst H-15 MeCN r.t., 12h 1/0.19  
0.05 DMAP MeCN r.t., 12h 1/0.93  
0.05 CsCO3 MeCN 50°C, 12h - 
0.05 DMAP MeCN 50°C, 4h 1/ 9  
Table 3.2.1 E/Z isomerization conditions optimization 
As previously indicated , E/Z ratio were evaluated referring to CHCONH signals of ethyl side chain on 
the C-3s. In Figure 3.2.2 are clarified the signals used for data presented just now. Given the positive 
results obtained with DMAP as catalyst, the last test was performed maintaining the same conditions of 
the third entry (in Table 3.2.1) a part of temperature, increased to 50°C. It allowed a 90% formation of the 
desired Z isomer. 
Thus, for isomerization we identified as optimal reaction conditions the use of MeCN as solvent, DMAP 
as catalyst in 10% loading, and 4h stirring at 50°C as best time and temperature setting. 
To deeper analyze this conversion process, we set on a kinetic isomerization study. Working in MeCN, 
with a boiling point of 81.6°C (354.6K), we designed a set of experiments at different temperatures: 
258K, 273K, 303K, 323K and 343K. 
 
Figure 3.2.2 
1
H-NMR zoomed spectra for a ~1/1 E/Z mixture 
CHCONH 
(E) 
CHCONH 
(Z) 
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Being aware that after about 4h the reaction equilibrium is completely unbalanced toward the Z isomer, 
and wanting to avoid this, reactions were carried out only for 1h (for further experimental details see the 
Experimental section). 
Evaluating E/Z ratio (Table 3.2.2) at the end, we could construct a curve from which evaluate an estimate 
value for the ΔG‡ between E and Z isomers, starting from the Boltzmann distribution equation: 
 ln (Z/E) = 1/T·(ΔG‡/kB·NA) 
As a matter of facts, from the curve was necessary to cut out the warmer data, maybe due to experimental 
difficulties in keeping constant the inside reagents concentration at a temperature so near to MeCN 
boiling point, so herein related will not reported at all. 
Z E Z/E ln (Z/E) T [K] 
1/T 
[K
-1
] 
0,13 1 0,13 -2,040220829 258 0,003876 
0,18 1 0,18 -1,714798428 273 0,003663 
0,30 1 0,30 -1,203972804 303 0,003300 
0,46 1 0,46 -0,776528789 323 0,003096 
Table 3.2.2 Data evaluated and calculated for E-Z ΔG‡ determination 
With reference to the Boltzmann equation, we made the curve of the logarithm of Z/E ratio as a function 
of the temperature inverse. 
 
Figure 3.2.3 Curve obtained from the varying temperature experiments 
The slope, reported on the graph showed in Figure 3.2.3, will be so directly related to ΔG‡ between the 
two isomers. Thus, we were able to determine the value of ΔG‡ between the two species in 3.14kcal/mol. 
 
optimization of the Esterification reaction. 
To optimize this step, we conducted different experiments varying a lot of parameters such as adding 
order of reagents, solvent, anhydricity of the system, base and activator, base and activator equivalents 
employed, scale of the process, temperature and MW irradiation. Every tentative exploited is reported in 
Table 3.2.3, with yield always obtained after FC purification. 
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SM, 
[mmol] 
Acid DMAP DCC Solvent T or MW Time [min] y [%] 
0.2 1.58 0.2 1.58 PhCl, 2mL 100W 10 (x4) 36 
0.2 1.58 0.2 1.58 PhCl, 2mL 40W 10 36 
0.2 1.58 0.2 1.58 PhCl, 2mL 40W 30 37 
0.5 1.58 0.2 1.58 DMF, 2mL 40W 10 - 
0.2 1.1 0.2 1.1 PhCl, 2mL 40W 10 5 
0.2 1.58 0.2 1.58 PhCl, 2mL r.t. 240 29 
0.3 1.58 0.2 1.58 PhCl, 2mL 40W 10 18 
0.2 1.58 0.2 1.58 PhCl, 2mL 400W 1 8 
0.2 1.58 0.2 1.58 PhCl, 2mL r.t. 240 10 
0.2 1.58 0.2 1.58 PhCl, 2mL r.t. 240 nd 
0.2 1.58 0.2 1.58 PhCl, 2mL r.t. 240 < 3 
0.2 1.58 0.2 1.58 PhCl, 2mL r.t. 240 < 3 
0.2 1.58 0.5 1.58 PhCl, 2mL r.t. 240 3 
0.2 2.0 0.2 2.0 PhCl, 2mL r.t. 240 < 3 
0.3 1.58 0.2 1.58 PhCl, 2mL 50°C 120+120 34 
0.2 1.58 1.0 1.58 PhCl, 2mL r.t. 240 12 
0.2 1.0 1.0 
1.0, 
EDC 
PhCl, 2mL 40W 10 < 22 
0.31 1.58 0.2 1.58 PhCl, 2mL 40W 10 (x3) 63 
Table 3.2.3 Esterification reaction optimization 
Summarizing what we obtained, reactants introduction order must be β-lactam SM at first, followed by 
the solvent, then acid 19, DMAP and DCC. 
The reaction should be conducted using MW irradiation as a heat source, with a power of 40W for 10 
minutes. Alternatively, the best results were obtained at r.t. for 4h stirring. Chlorobenzene was shown to 
be the best solvent, while as the activator was optimal the use of DCC, although it is more difficult to 
remove during work-up and FC purification. An increase of DCC and acid equivalents was excluded: 
1.58 equivalents were sufficient in both cases, while for DMAP 0.2 equivalents seemed to be enough. 
Working in solvents saturated with water and without a protecting atmosphere, comparing to the use of 
commercial anhydrous solvents and an inert atmosphere and anhydrous reaction conditions, appeared to 
furnish similar results. This allows to reduce the operating costs and to simplify the experimental 
procedure. 
Increasing the scale up to 0.3mmol seemed to furnish an increase of the yield, but the use of non-
protected syringic acid (data not reported) was shown to be impossible in these optimized conditions. 
 
3.2.2 thermostability, lipophilicity and cytotoxicity of the Lead β-lactam 
Wanting to support 56 on a nano-carrier (i.e. Solid Lipid Nanoparticles, in collaboration with Nanovector 
s.r.l., Turin) for its delivery, have been initially assessed its thermal stability. As a matter of facts, the 
conveying process necessary for the formulation requires to withstand for ten minutes at a temperatures of 
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about 50°C. For this reason, compound was placed in water and stirred at 60°C for 1h: HPLC-MS and 
600MHz 
1
H-NMR analysis showed no decomposition. As further confirmation, the same sample was 
brought to 70°C for 30min, checking again the complete absence of signals associated to degradation, 
either by HPLC-MS and by 600MHz 
1
H-NMR (for further details, see Experimental section). 
Lipophilicity in terms of logP and water solubility of our compound were both evaluated, in order to 
better set out the conveying conditions and to optimize their formulation (always in collaboration with 
Nanovector s.r.l.): 
 56: 1.58 (logP, ChemBiodraw est.), 23.044 mg/L (Wat. Sol., v1.01 est.) 
In collaboration with Prof. C.E.A. Cocuzza group, University of Milan-Bicocca, potential non selective 
toxicities of the new antimicrobial agents (56 and 57, the internal standard designed and synthesized for 
the biodistribution analytical evaluation, as below described) were evaluated by cell viability assays 
performed in adenocarcinoma alveolar basal epithelial cells (A549). A549 cell line was chosen as suitable 
model of respiratory system for drug toxicity and targeting studies because of its high degree of 
morphological and functional differentiation in vitro. For each experiment cells were seeded as 
30000cells/cm
2
 onto 24-well plates, and after two days treated with increasing concentrations of different 
antimicrobial compounds: 
 56: 18-70µg/mL 
 57: 80-120µg/mL 
As lead, 56 showed an increasing cytotoxic effect only reaching the LC50 at 70µg/mL, when 
administrated alone or encapsulated (Figure 3.2.4). About 20-25% mortality was observed in cells treated 
with SLNs alone, independently to the lipid concentrations administrated. The cytotoxic effects observed 
by might be due to a partial interference with the viability assay employed, indeed a different cell 
morphology can be observed. Thus, compound 56 by itself and as SLN formulation was completely ready 
for biodistribution and safety in vivo studies on mice. 
 
Figure 3.2.4 MTT assay results for cytotoxicity evaluation 
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Thus, we did the intratracheal DiR-SLN administration and the whole in vivo study in collaboration with 
Prof. C.E.A. Cocuzza, University of Milan-Bicocca. 
 
3.2.3 Analytical evaluation of lead β-lactam for in vivo biodistribution  
The analysis of biological samples derived from in vivo tests of compound 56, administered by itself and 
conveyed on Solid Lipid Nanoparticles (SLN formulation), required the use a particularly specific and 
sensitive technique because the amount to be analyzed was in the order of nanomolar or less. 
We chose HPLC/MS-MS instrumentation, working with a triple quadrupole. Moreover, given the 
biological origin of the samples and the consequent presence of complex matrixes, it was necessary to 
identify and introduce an appropriate pre-treatment method. As below specified, we optimized an SPE 
system using a sample of dry extract from mouse lungs, evaluating as biological matrix influenced the 
determination of lead compound and internal standard (matrix effect), and optimizing sample preparation 
and chromatographic run. Indeed, the need of a quantitative analysis required the design, the synthesis 
and the use of an internal standard (depicted in Figure 3.2.5), to be introduced in biological samples 
before the pretreatment step.  
 
Figure 3.2.5 Designed internal standard 57 
In this way, referring to the known amount of introduced standard, it was possible to relate the signals 
obtained for the lead 56 to those of the standard, obtaining quantitatively reliable data. We designed the 
internal standard as similar as possible to compound 56 (Figure 3.2.5), in order to have the most close 
chemical properties from every points of view. In fact, working in MS-MS it was only fundamental a 
significative difference in the molecular weights. For the synthesis, we followed the reliable procedure 
reported for the lead 56, substituting to the syringic acid moiety the vanillic one, as in Scheme 3.2.2. 
 
Scheme 3.2.2 Acid 59 preparation 
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Using this intermediate we applied the known procedure to the preparation of the internal standard 57, as 
herein reported in Scheme 3.2.3. 
 
Scheme 3.2.3 Synthesis of the designed internal standard 57 
Then, we set out an SPE pre-treatment method and we demonstrated that was possible to recover only one 
fraction (f7, see Experimental section for details) for collecting all the 56 and 57 amounts, that during 
HPLC run will be completely separated from matrixes residues (Figure 3.2.5, on the left). Moreover, we 
analyzed the matrix effect on the 56 MS-MS signal, found that it became present in the terms of a signal 
enhancement only after 56 and 57 elution with the adopted HPLC conditions (Figure 3.2.5, on the right). 
This method was validated for only the lung matrix. Thus, to analyze other samples the conditions herein 
found must be demonstrated in their validity. However, we verified that 56 and 57 could be 
simultaneously MS-MS analyzed using a negative ionization in the conditions optimized for 56 (see 
Experimental section for further details), furnishing significative signals for nM to also tens of pM 
analyte amounts. 
 
Figure 3.2.5 Matrix effect removal evaluation 
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From the preliminary analysis (Table 3.2.4, although the whole study still be in progress), we found no 56 
in plasma samples (or amounts lower that the technique limit of detection), while the biggest amounts 
were recognized in brains. Moreover, in brains of mice treated with 56 without SLN formulation was 
found a little excess of the detected drug amounts. Livers of mice treated with the SLN formulation 
resulted more loaded as well. On the contrary, higher concentrations were found in lungs for the 
administration of the lead compound 56 by itself. Thus, it could be hazardously correlated to the use or 
not of the SLN nanoconveying system. To further confirm the obtained data, very close to the detection 
limit of the already developed technique, we also pre-treated and analyzed samples from double and triple 
amounts of biological samples (respectively, in Table 3.2.5 and 3.2.6). 
 56 area 57 area 56/57 56 correct area 
56 
[nM] 
Brain6 10 23358 0,00042812 26,0 0,05565 
Brain7 5,07 11940 0,00042462 13,2 0,05520 
Brain8 9 27164 0,00003500 23,4 0,04307 
Brain9 7 13793 0,00050750 18,2 0,06597 
Brain10 10 29978 0,00033358 26,0 0,04336 
Liver2 20 1070 0,01869159 52,0 2,42991 
Liver3 19 1599 0,01188243 49,4 1,54471 
LUng8 19 4085 0,00465116 49,4 0,60465 
LUng9 50 5336 0,00937031 130,0 1,21814 
Table 3.2.4 Preliminary data from mice biological samples 
Compared to what obtained from the first tissues amounts, no significative difference in the recorded data 
could be noticed analyzing doubled quantities of lungs.  
 56 area 57 area 56/57 56 correct area 
56 
[nM] 
LUng3 D 23 5789 0,00397305 59,8 0,516497 
LUng6 D 43 6093 0,00705728 111,8 0,917446 
LUng7 D 11 1490 0,00738255 28,6 0,959732 
LUng8 D 570 1134 0,50264550 1482 65,34392 
LUng9 D 160 3611 0,04430906 416 5,760177 
LUng10 D 22 3966 0,00554715 57,2 0,72113 
Table 3.2.5 Preliminary data from mice biological double samples 
The same observation could be made while triple amounts of all the tissue analyzed. 
 56 area 57 area 56/57 56 correct area 
56 
[nM] 
Plasma3 T  814    
Brain3 T 10 19630 0,00050942 26 0,089702 
Liver3 T 16 516 0,03100775 41,6 5,459989 
LUng3 T 12 3511 0,00341783 31,2 0,601827 
Plasma8 T  1554    
Brain8 T 6 18331 0,00032731 15,6 0,057635 
Liver8 T  737    
LUng8 T 50 3782 0,01322052 130 2,32793 
Table 3.2.6 Preliminary data from mice biological triple samples 
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The developed method is therefore confirmed in its validity for quantitative determination of 56, 
compared to 57, in biological samples at least for lung matrixes. The applicability to other matrixes 
samples must deepened. 
 
 
3.3 Experimental section 
3.3.1 General informations 
As previously reported (Paragraph 2.3.1). 
 
3.3.2 Synthesis of new β-lactam dual active compounds 
Azetidinones 1,
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 2, 3, 4, 5, 7, 8, 9 and 10 were prepared as previously reported [79]. 
 
1-Methylsulfonyl-4-oxoazetidin-2-yl acetate (6) 
A 1M solution of LiHMDSA (1.1mL, 1.1mmol) was added to a solution of 4-acetoxy-2-
azetidinone (129mg, 1.0mmol) in THF (10mL) at -78°C under inert atmosphere, followed by 
methanesulfonyl chloride (194μL, 2.5mmol). The solution was allowed to warm to room 
temperature and was monitored by TLC. After 3h the reaction was quenched with aqueous 
NH4Cl (15mL) and extracted with EtOAc (3x10mL). The organic extracts were dried over Na2SO4 and 
the residue was purified by flash-chromatography (cyclohexane/EtOAc: 60/40) to afford product 6 (42 
mg, 20%) as a pale yellow oil. 
1
H (400MHz, CDCl3): 2.17 (s, 3H, CH3CO2), 3.10 (dd, J = 2.0, 16.4Hz, 1H, CHCHH), 3.23 (s, 3H, 
SO2CH3), 3.54 (dd, J = 4.8, 16.4Hz, 1H, CHCHH), 6.47 (dd, J = 2.0, 4.8Hz, 1H, CHCHH) ppm 
13
C (100MHz, CDCl3): 20.7, 42.5, 45.7, 75.6, 161.0, 169.3 ppm 
IR: ṽ = 2917,1757, 1161 cm-1 
HPLC-MS: Rt = 2.47min, m/z = 225 [M+H2O]
+
, 230 [M+Na]
+
, 246 [M+K]
+
, 437 [2M+Na]
+
 
Found C, 34.92; H, 4.51; N, 6.90; S, 15.32%; C6H9NO5S requires C, 34.78; H, 4.38; N, 6.76; S, 15.48% 
 
1-(Methylthio)azetidin-2-one (11) 
LiHMDSA (2.2mL, 1M solution in THF, 2.2mmol) was added to a solution of 2-azetidinone 
(142mg, 2mmol) in THF (14mL) at -78°C under inert atmosphere, followed shortly by S-
methyl methanethiosulfonate (514µL, 5mmol). The solution was allowed to warm to room temperature 
and was monitored by TLC. After 3h, the reaction was quenched with aqueous NH4Cl (15mL) and 
extracted with EtOAc (3x10 mL). The organic extracts were dried over Na2SO4 and the residue was 
purified by flash-chromatography (cyclohexane/EtOAc: 75/25) to afford product 11 (187 mg, 80%) as a 
pale yellow oil. 
1
H NMR (200MHz, CDCl3): δ 2.41 (s, 3H, SMe), 3.04 (t, J = 4.8Hz, 2H, CH2), 3.40 (t, J = 4.8Hz, 2H, 
CH2) ppm 
13
C NMR (100MHz, CDCl3): δ 21.9, 38.7, 43.0, 170.9 ppm 
IR: ṽ = 2970, 2917, 1757,1161 cm-1 
HPLC-MS: Rt = 1.97min, m/z: 118 [M+H]
+
, 135 [M+H2O]
+
, 140 [M+Na]
+
, 257 [2M+Na]
+
 
GC-MS: Rt = 8.04min, m/z: 117 (M), 75 (M-COCH2), 60 (M-COCH2-Me) 
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Found C, 40.83; H, 5.98; N, 11.87; S, 27.15 %; C4H7NOS requires C, 41.00; H, 6.02; N, 11.95; S, 27.37% 
 
(R)-1-((2R,3R)-2-acetoxy-1-(methylthio)-4-oxoazetidin-3-yl)ethyl-4-(ethoxymethoxy)-3,5-
dimethoxybenzoate (12) 
To a solution of 4 (117mg, 0.53mmol), in DCM (20mL) at 0°C under inert 
atmosphere, the acid 19 (216mg, 0.84mmol), DMAP (13mg, 0.11mmol) and 
DCC (174mg, 0.84mmol) were added). After 10 minutes the mixture was 
allowed to warm to room temperature. After 70 hours the reaction was 
washed with cool water and extracted with DCM (3x15mL). The collected 
organic phases were dried on Na2SO4 and evaporated. The residue was treated with EtOAc and filtered. 
The solid was discarted whereas the solvent was evaporated and purified by flash-cromatography 
(cyclohexane/EtOAc: 70/30) obtaining product 12 (177mg, 73%) as a white syrup. 
[α]D = -3.25° (c = 1.6, CHCl3) 
1
H NMR (400MHz, CDCl3): δ 1.17 (t, J = 7.2Hz, 3H, CH3CH2), 1.48 (d, J = 6.4Hz, 3H, CH3CHOCO), 
2.14 (s, 3H, CH3CO2), 2.47 (s, 3H, SCH3), 3.46 (dd, J = 1.2, 6.4Hz, 1H, CHCHO), 3.84 (q, J = 7.2Hz, 2H, 
CH3CH2), 3.87 (s, 6H, 2OCH3), 5.20 (s, 2H, OCH2O), 5.43 (quintet, J = 6.4 Hz, 1H, CH3CHO), 6.21 (d, J 
= 1.2Hz, 1H, CHOAc), 7.22 (s, 2H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ 14.8, 18.2, 20.8, 22.8, 56.1, 64.1, 64.9, 66.9, 81.5, 96.4, 106.7, 125.1, 
138.9, 153.0, 164.9, 167.3, 169.6 ppm 
IR: ṽ = 3323, 2926, 2850, 1789, 1755, 1716, 1126 m-1 
HPLC-MS: Rt = 8.62min, m/z: 475 [M+H2O]
+
 
Found C, 52.58; H, 5.94; N, 3.11; S, 6.89%; C20H27NO9S requires C, 52.51; H, 5.95; N, 3.06; S, 7.01% 
 
(R)-1-((2R,3R)-2-acetoxy-1-(methylthio)-4-oxoazetidin-3-yl)ethyl-4-hydroxy-3,5-dimethoxy 
benzoate (13) 
A stirred solution of 12 (76mg, 0.17mmol) in DCM under inert atmosphere 
was treated with aliquots of trifluoroacetic acid (12µL, 0.17mmol) every 15 
minutes until the disappearing of the starting material. After the completion of 
the reaction, the solvent and the trifluoroacetic acid were evaporated to obtain 
13 (55mg, 81%) as a yellow oil. 
[α]D = -36.3° (c = 0.52, CHCl3) 
1
H NMR (400MHz, CDCl3): δ 1.50 (d, J = 6.4Hz, 3H, CH3CHOCO), 2.16 (s, 3H, CH3CO2), 2.49 (s, 3H, 
SCH3), 3.48 (dd, J = 1.2, 6.0Hz, 1H, CHCHOCO), 3.94 (s, 6H, 2OCH3), 5.44 (quintet, J = 6.4Hz, 1H, 
CH3CHO), 5.97 (s, 1H, OH), 6.23 (d, J = 1.2Hz, 1H, CHOAc), 7.26 (s, 2H, Ar) ppm 
13
C NMR (100MHz, CDCl3): δ 18.3, 20.8, 22.9, 56.4, 64.2, 66.7, 81.5, 106.7, 120.6, 139.5, 146.6, 165.2, 
167.5, 169.7 ppm 
IR: ṽ = 3412, 2938, 2850, 1783, 1756, 1711, 1116 cm-1 
HPLC-MS: Rt = 5.68min, m/z: 417 [M+H2O]
+
, 422 [M+Na]
+
, 821 [2M+Na]
+
 
 
(R)-1-((2R,3R)-2-acetoxy-1-(methylthio)-4-oxoazetidin-3-yl)ethyl-3,4-
bis(tbutyldimethylsilyloxy)benzoate (16)  
To a solution of 4 (121mg, 0.55mmol) in DCM (8.2mL), compound 22 
(210mg, 0.55mmol) and DMAP (67mg, 0.55mmol) were added. The mixture 
was then cooled to 0°C, EDC (105mg, 0.55mmol) was added and the system 
was allowed to reach rt in 10 minutes. After 30h, the reaction was quenched 
with water and some drops of HCl (1M), extracted with DCM, dried on 
Na2SO4 and evaporated. The sylilated intermediate 16 was obtained after FC (DCM/Et2O 99/1) in 23% 
yield (73mg) as an oil. 
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[α]D = -13.8° (c = 0.5, DCM) 
1
H NMR (400MHz, CDCl3): δ 0.22 (s, 6H, SitBuMe2), 0.23 (s, 6H, SitBuMe2), 0.99 (s, 9H, SitBuMe2), 
1.00 (s, 9H, SitBuMe2), 1.47 (d, J = 6.0Hz, 3H, CH3CHOCO), 2.17 (s, 3H, CH3CO2), 2.47 (s, 3H, SCH3), 
3.47 (dd, J = 1.6, 6.0Hz, 1H, CHCHO), 5.45 (quintet, J = 6.0Hz, 1H, CH3CHO), 6.26 (d, J = 1.2Hz, 1H, 
CHOAc), 6.82-6.84 (m, 1H, Ar), 7.46-7.49 (m, 2H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ -4.2, -4.1, -4.1, -4.0, 18.3, 18.4, 18.5, 20.9, 22.8, 25.8, 25.9, 64.1, 66.3, 
81.0, 120.4, 122.3, 122.9, 123.6, 146.8, 152.0, 165.0, 167.5, 169.8 ppm 
IR: ṽ = 3427, 2930, 2858, 1793, 1758, 1719, 1120 cm-1 
HPLC-MS: Rt = 26.60min, m/z: 601 [M+H2O]
+
, 606 [M+Na]
+
, 1190 [2M+Na]
+
 
 
(R)-1-((2R,3R)-2-acetoxy-1-(methylthio)-4-oxoazetidin-3-yl)ethyl3,4-dihydroxy benzoate (14) 
To a solution of 16 (47mg, 0.08mmol) in anhydrous MeCN (1.64mL) under 
inert atmosphere and at 0°C BF3·Et2O (23µL, 0.182mmol) was added dropwise. 
After 30 minutes the ice-bath was removed, and after 45 minutes at rt the 
reaction was quenched with a pH = 6 phosphate buffer solution 0.1M, extracted 
with DCM, dried on Na2SO4 and evaporated. The crude was finally triturated to 
afford the desired product 14 in 46%yield (13mg) as a light yellow oil. 
[α]D = -13.7° (c = 0.25, DCM) 
1
H NMR (400MHz, CDCl3): δ 1.73 (d, J = 6.0Hz, 3H, CH3CHOCO), 2.18 (s, 3H, CH3CO2), 2.47 (s, 3H, 
SCH3), 3.49 (dd, J = 1.2, 4.8Hz, 1H, CHCHO), 5.46 (quintet, J = 6.0Hz, 1H, CH3CHO), 6.28 (d, J = 
1.2Hz, 1H, CHOAc), 6.86 (d, J = 1.2Hz, 1H, Ar), 7.44 (dd, J = 2.0, 8.4Hz, 1H, Ar), 7.50 (d, J = 2.0Hz, 
1H, Ar)  ppm 
13
C NMR (50MHz, CDCl3): δ 18.3, 20.9, 22.7, 64.0, 66.3, 80.8, 114.8, 116.5, 121.8, 123.5, 143.4, 149.2, 
165.3, 168.2, 170.1 ppm 
IR: ṽ = 3371, 2983, 2929, 1781, 1761, 1713, 1602, 1294 cm-1 
HPLC-MS: Rt = 5.00min, m/z: 373 [M+H2O]
+
, 378 [M+Na]
+
, 733 [2M+Na]
+ 
Found C, 50.96; H, 4.91; N, 3.96; S, 8.95 %. C15H17NO7S requires C, 50.70; H, 4.82; N, 3.94; S, 9.02% 
 
(E)-(R)-1-((2R,3R)-2-acetoxy-1-(methylthio)-4-oxoazetidin-3-yl)ethyl-3-(3,4-
bis(ethoxymethoxy)phenyl)acrylate (17) 
To a solution of 4 (68mg, 0.31mmol) in DCM (11.6mL), compound 
21 (145mg, 0.49mmol) and DMAP (7.6mg, 0.06mmol) were added. 
The mixture was then cooled to 0°C, DCC (101mg, 0.49mmol) was 
added and the system was allowed to reach r.t. in 15 minutes. After 
65h, the reaction was quenched with water, extracted with DCM, 
dried on Na2SO4, evaporated and triturated with EtOAc to separate dicycloexylurea precipitate. The 
solution was then evaporated and purified by FC (cyclohexane/EtOAc 90/10 to 80/20) to afford the 
product in 61% yield (94mg) as an oil. 
[α]D = -7.4° (c = 0.84, DCM) 
1
H NMR (400MHz, CDCl3): δ 1.21-1.28 (m, 6H, 2OCH2CH3), 1.44 (d, J = 6.4Hz, 3H, CH3CHO), 2.17 (s, 
3H, CH3CO2), 2.51 (s, 3H, SCH3), 3.42 (dd, J = 1.6, 6.0Hz, 1H, CHCHO), 3.74-3.81 (m, 4H, 
2OCH2CH3), 5.30 (s, 2H, OCH2O), 5.31 (s, 2H, OCH2O), 5.37 (quintet, J = 6.0Hz, 1H, CH3CHO), 6.22 
(d, J = 1.6Hz, 1H, CHOAc), 6.25 (d, J = 16.0Hz, 1H, CH=CHCO), 7.13 (dd, J = 2.0, 8.0Hz, 1H, arom), 
7.19 (d, J = 8.0Hz, 1H, Ar), 7.37 (d, J = 2.0Hz, 1H, Ar), 7.53 (d, J = 16.0Hz, 1H, CH=CHCO) ppm 
13
C NMR (50MHz, CDCl3): δ 15.0, 15.1, 18.3, 20.9, 22.7, 64.1, 64.5, 64.6, 66.1, 80.9, 93.8, 94.1, 115.5, 
115.7, 116.0, 123.4, 128.4, 145.3, 147.5, 149.5, 165.9, 167.5, 169.8 ppm 
IR: ṽ = 3327, 2977, 2930, 1789, 1757, 1711, 1635, 1599, 1510, 1437, 1251, 1159 cm-1 
HPLC-MS: Rt = 9.90min, m/z: 515 [M+H2O]
+
, 520 [M+Na]
+
, 1017 [2M+Na]
+ 
Found C, 55.78; H, 6.32; N, 2.68; S, 6.30 %; C23H31NO9S requires C, 55.52; H, 6.28; N, 2.82; S, 6.44% 
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(E)-(R)-1-((2R,3R)-2-acetoxy-1-(methylthio)-4-oxoazetidin-3-yl)ethyl-3-(3,4-dihydroxyphenyl) 
acrylate (15) 
To a solution of 17 (94mg, 0.19mmol) in DCM (23mL) under inert 
atmosphere aliquots of TFA (64.5µL, 0.869mmol) were added every 15 
minutes until the disappearing of the starting material (TLC monitoring). 
The solution was evaporated and the crude was purified by flash-
chromatography (cyclohexane/EtOAc 40/60). The product obtained from 
the collected fractions was finally triturated with pentane to afford the 
desired product 15 as a white solid in 90% yield (65mg). 
[α]D = -19.3° (c = 1.11, DCM) 
1
H NMR (400MHz, CDCl3): δ 1.44 (d, J = 6.0Hz, 3H, CH3CHOCO), 2.19 (s, 3H, CH3CO2), 2.52 (s, 3H, 
SCH3), 3.44 (dd, J = 1.2, 5.2Hz, 1H, CHCHO), 5.38 (quintet, J = 6.0Hz, 1H, CH3CHO), 6.18 (d, J = 
16.0Hz, 1H, CH=CHCO), 6.23 (d, J = 1.2Hz, 1H, CHOAc), 6.87 (d, J = 8.0Hz, 1H, Ar), 6.97 (dd, J = 2.0, 
8.4Hz, 1H, Ar), 7.06 (d, J = 1.6Hz, 1H, Ar), 7.54 (d, J = 16.0Hz, 1H, CH=CHCO) ppm 
13
C NMR (50MHz, CDCl3): δ 18.2, 20.9, 22.7, 63.8, 65.9, 80.8, 114.1, 114.3, 115.4, 122.4, 126.9, 144.2, 
146.1, 147.0, 166.5, 168.5, 170.1 ppm 
IR: ṽ = 3391, 2933, 1755, 1716, 1605, 1515, 1445, 1397, 1260, 1056 cm-1 
HPLC-MS: Rt = 5.60min, m/z: 399 [M+H2O]
+
, 404 [M+Na]
+
, 785 [2M+Na]
+ 
Found C, 53.89; H, 5.13, N 3.55; S, 8.37 %; C17H19NO7S requires C, 53.53; H, 5.02; N, 3.67; S, 8.41% 
 
Methyl 4-(ethoxymethoxy)-3,5-dimethoxybenzoate (18) 
A solution of methyl 4-hydroxy-3,5-dimethoxybenzoate (1.24g, 5.9mmol) in 
THF (10mL) was added dropwise to a suspension of NaH (60%  in mineral oil, 
306mg, 7.6mmol) in THF (20mL) at 0°C under inert atmosphere. After 10 
minutes a solution of chloromethylethylether (1.1mL, 11.75mmol) in THF 
(7mL) was added dropwise and the reaction was allowed to warm to room temperature and monitored by 
TLC. After 2h the reaction was quenched with aqueous NH4Cl (30mL) and extracted with EtOAc 
(3x20mL). The organic extracts were dried over Na2SO4 and concentrated to obtain product 18 (1.46g, 
92%) as pale yellow solid. 
M.p. 53-56°C 
[α]D = -19.3° (c = 1.11, DCM) 
1
H NMR (200MHz, CDCl3): δ 1.21 (t, J = 7.0Hz, 3H, CH3CH2), 3.88 (q, J = 7.0Hz, 2H, CH3CH2), 3.90 
(s, 6H, 2OCH3), 3.92 (s, 3H, CO2CH3), 5.23 (s, 2H, OCH2O), 7.31 (s, 2H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ 14.6, 51.8, 55.8, 64.6, 96.2, 106.4, 125.3, 138.4, 152.8, 166.3 ppm 
IR: ṽ = 2926, 1720, 1592, 1128 cm-1 
HPLC-MS: Rt = 7.81min, m/z: 271 [M+H]
+
, 293 [M+Na]
+
, 309 [M+K]
+ 
Found C, 57.62; H, 6.80 %; C13H18O6 requires C, 57.77; H, 6.71% 
 
Methyl 4-(ethoxymethoxy)-3,5-dimethoxy benzoic acid (19) 
A stirred solution of 18 (730mg, 2.7mmol) in 10mL of a mixture of THF/MeOH: 
90/10 was treated with 5M NaOH (2.7mL). The reaction was heated at 40°C for 
4 hours and monitored by TLC. At completion, EtOAc (10mL) was added and 
the organic phase was separated and discarded. The aqueous phase was then 
cooled to 0°C and adjusted to pH = 6 with aqueous NH4Cl. The mixture was extracted with EtOAc 
(3x15mL), dried on Na2SO4 and concentrated to afford 19 (432mg, 63%) as a white solid. 
M.p. 108-109°C 
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1
H NMR (400MHz, CDCl3): δ 1.22 (t, J = 7.2Hz, 3H, CH3CH2), 3.89 (q, J = 7.2Hz, 2H, CH3CH2), 3.92 
(s, 6H, 2OCH3), 5.26 (s, 2H, OCH2O), 7.37 (s, 2H, Ar) ppm 
13
C NMR (75MHz, CDCl3): δ 14.8, 56.0, 64.9, 96.3, 107.1, 124.5, 139.3, 153.0, 171.5 ppm 
IR: ṽ = 3398, 2924, 1716, 1589, 1120 cm-1 
HPLC-MS: Rt = 1.53min, m/z: 279 [M+Na]
+
, 535 [2M+Na]
+ 
Found C, 56.18; H, 6.34 %; C12H16O6 requires C, 56.24; H, 6.29% 
 
(E)-methyl 3-(3,4-bis(ethoxymethoxy)phenyl)acrylate (20) 
A solution of caffeic acid methyl ester  (540mg, 2.78mmol) in THF (6mL) 
was added dropwise into a solution of NaH (60% dispersion in oil, 289mg, 
7.2mmol) in THF (15mL) under inert atmosphere and at 0°C. After 10 
minutes a solution of chloromethyl ethyl ether (1.01mL, 11.1mmol) in THF 
(7mL) was added dropwise. After 2h the solution was allowed to rt and quenched by adding a saturated 
NH4Cl solution, extracted with DCM, dried over Na2SO4 and evaporated. The product 20 was obtained in 
90% yield (776mg) after flash-chromatography (cyclohexane/EtOAc 90/10) as a colorless oil. 
M.p. 108-109°C 
[α]D = -19.3° (c = 1.11, DCM) 
1
H NMR (400MHz, CDCl3): δ 1.21-1.27 (m, 6H, 2OCH2CH3), 3.74-3.81 (m, 4H, 2OCH2CH3), 3.81 (s, 
3H, OCH3), 5.30 (s, 1H, OCH2O), 5.31 (s, 1H, OCH2O), 6.33 (d, J = 16.0Hz, 1H, CH=CHCO), 7.15 (dd, 
J = 2.0, 8.0Hz, 1H, Ar), 7.19 (d, J = 8.4Hz, 1H, Ar), 7.39 (d, J = 1.6Hz, 1H, Ar), 7.63 (d, J = 16.0Hz, 1H, 
CH=CHCO) ppm 
13
C NMR (100MHz, CDCl3): δ 14.9, 15.0, 51.4, 64.3, 64.4, 93.6, 94.0, 115.5, 115.9, 116.0, 123.1, 128.5, 
144.4, 147.4, 149.2, 167.4 ppm 
IR: ṽ = 2977, 2900, 1717, 1634, 1600, 1582, 1511, 1436, 1393, 1105 cm-1 
HPLC-MS: Rt = 9.20min, m/z: 311 [M+H]
+
, 333 [M+Na]
+
, 349 [M+K]
+ 
Found C, 62.12; H, 7.38 %; C16H22O6 requires C, 61.92; H, 7.15% 
 
(E)-3-(3,4-bis(ethoxymethoxy)phenyl)acrylic acid (21) 
A stirred solution of 20 (310mg, 1mmol) in 3.8mL of a mixture of 
THF/MeOH 90/10 was treated with 1mL NaOH 5M, warmed at 40°C and 
stirred for 4h. After completion, EtOAc (6mL) was added and discharged. 
The aqueous phase was treated with HCl (1M), extracted with EtOAc, the 
organic phase was dried over Na2SO4 and evaporated to afford the desired product in 96% yield (284mg) 
as a white solid. 
M.p. 101-103°C 
1
H NMR (400MHz, CDCl3): δ 1.22-1.29 (m, 6H, 2OCH2CH3), 3.75-3.85 (m, 4H, 2CH3CH2O), 5.31 (1H, 
s, OCH2O), 5.33 (s, 1H, OCH2O), 6.35 (d, J = 16.0Hz, 1H, CH=CHCO), 7.18 (dd, J = 1.6, 8.8Hz, 1H, 
Ar), 7.22 (d, J = 8.8Hz, 1H, Ar), 7.42 (d, J = 1.6Hz, 1H, Ar), 7.73 (d, J = 16.0Hz, 1H, CH=CHCO) ppm 
13
C NMR (100MHz, CDCl3): δ 15.0, 15.1, 64.5, 64.6, 93.8, 94.2, 115.5, 115.8, 116.0, 123.7, 128.3, 146.8, 
147.5, 149.7, 172.1 ppm 
IR: ṽ = 2976, 1683, 1626, 1596, 1514, 1418, 1244, 1114 cm-1 
HPLC-MS: Rt = 1.90min, m/z: 297 [M+H]
+
, 319 [M+Na]
+
, 335 [M+K]
+
, 
Found C, 60.52; H, 6.95 %; C15H20O6 requires C, 60.80; H, 6.80% 
 
3,4-bis(tbutyldimethylsilyloxy)benzoic acid (22) 
To a solution of 3,4-dihydroxy-benzoic acid (500mg, 3.24mmol) in DMF (5.8mL) 
under inert atmosphere, imidazole (1.983g, 29.16mmol) and then TBSCl (2.2g, 
14.6mmol) were added. After 66h the reaction was quenched at 0°C by adding water, 
and then extracted with Et2O (10x4mL). The organic phases were washed twice with 
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water and brine, dried over Na2SO4 and evaporated. To the persilylated intermediate (2.049g, 4.12mmol) 
in a 6mL MeOH/THF 40/60, a solution of K2CO3 (231mg, 1.67mmol) in water (2.2mL) was added. After 
12h the mixture was quenched a 0°C by adding a saturated solution of citric acid and extracted with Et2O. 
The organic phases were washed with water and brine, dried over Na2SO4 and evaporated. The product 
was finally obtained by flash-chromatography (DCM/MeCN: 90/10) purification in 75% yield (930mg) as 
a white solid. 
M.p. 152-154°C 
1
H NMR (400MHz, CDCl3): δ 0.24 (s, 6H, SitBuMe2), 0.25 (s, 6H, SitBuMe2), 1.00 (s, 9H, SitBuMe2), 
1.01 (s, 9H, SitBuMe2), 6.88 (d, J = 8.0Hz, 1H, Ar), 7.60 (d, J = 2.0Hz, 1H, Ar), 7.63 (dd, J = 1.6, 8.8Hz, 
1H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ -4.1, -4.0, 18.4, 18.5, 25.8, 25.9, 120.5, 122.4, 122.7, 124.4, 146.8, 152.5, 
171.2 ppm 
IR: ṽ = 2970, 2917, 1757,1161 cm-1 
HPLC-MS: Rt = 1.97min, m/z: 118 [M+H]
+
, 135 [M+H2O]
+
, 140 [M+Na]
+
, 257 [2M+Na]
+
 
GC-MS: Rt = 8.04min, m/z: 117 (M), 75 (M-COCH2), 60 (M-COCH2-Me) 
Found C, 59.64; H, 8.96 %. C19H34OSi2 requires C, 60.80; H, 6.80%. 
 
3.3.3 Antioxidant potencies, voltammetry and antibacterial activities 
Antioxidant activity evaluation methods, electrochemical experiment conditions, bacterial strains 
selection and antibacterial activities evaluation method follow. 
 
BR assay 
Relative antioxidant activity (r.a.c.) with respect to a substance chosen as standard, resorcinol (Re) in our 
case, is determined on the basis of concentrations of sample and resorcinol that give the same tinhib; r.a.c. 
is expressed as mM resorcinol equivalents. 
Oscillatory behaviors’ V(Pt) were followed potentiometrically by using the couple bright platinum 
electrode (Hamilton 238945)-Ag/AgCl double junction electrode (Ingold 373-90-WTE-ISE-S7) 
connected to a multimeter (WTW pH 540 GLP), controlled by a PC. Reacting mixtures were 
thermostated at 25.0±0.1°C. The straight line of the standard was checked before each series of 
measurements. 
 
TEAC assay 
The radical cation is preformed by reaction between ABTS and K2S2O8 in PBS medium, pH = 7.4; the 
mixture was kept in the dark until the reaction was complete and absorbance at 734nm stable. 
Spectroscopic measurements were performed in triplicate at four concentrations of the β-lactams in 
DMSO. Suitably diluted solutions of the standard (Trolox) were treated in the same way. In brief, 3.0mL 
of diluted ABTS·
+
 solution and 30mL of sample were mixed in a photometric cuvette and absorbance was 
measured at 734nm at exactly 6min after the mixing of the reagents (T = 30.0±0.1°C). A blank with 
DMSO was measured in the same way. The difference between the absorbance of the blank and the 
sample gave ΔE6 (E6blank - E6sample = ΔE6). Data (ΔE6 vs conc. in mM) are well fitted by straight 
96 
lines through the origin (following the Lambert&Beer law). Then, the relative antioxidant activity with 
respect to Trolox (TEAC) was obtained by the ratio: 
 TEAC = m(smp)/m(Trolox) 
where m(smp) and m(Trolox) are the slopes of the straight lines of the sample and the standard 
respectively. Standard error of this ratio is calculated in the usual way. Here also the straight line of the 
standard was always checked before each series of measurements. 
 
DPPH assay 
The principle of this method is the decolorization of the stable radical 2,2-diphenyl-1-picrylhydrazyl 
(DPPH·) by antioxidants. The DPPH· is intensely purple colored (λmax = 512-530nm) due to the presence 
of the picric group (1,3,5-nitrobenzene) and is stabilized by either the steric hindrance of the aromatic 
substituents and the delocalization of the unpaired electron on the whole structure. The disappearance of 
this radical due to the addition of an antioxidant H-donor, may be evaluated spectrophotometrically, at its 
absorption maximum in methanol (515nm). The measured decrease in absorbance at 515nm is an 
expression of the antioxidant capacity of a sample.
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The extent of the decolorization is a function of concentration and time. Trolox was used as the standard. 
In practice 2.9mL of DPPH· methanolic solution was placed in a cuvette and the initial absorbance, A0, 
was measured. Then 100mL was added and mixed; after 15min the final absorbance, Af, was measured. 
The percentage of inhibition was calculated according to the following equation (%): 
 Inhibition = (1-Af/A0)x100. 
The same procedure was repeated with the standard. Data (%inhib vs conc. in mM) are well fitted by 
straight lines through the origin (following the Lambert&Beer law). 
Then, the relative antioxidant activity with respect to Trolox was obtained by the ratio: 
 DPPH = m(smp)/m(Trolox). 
 
FRAP assay 
2,4,6-Tris(2-pyridyl)-s-triazine-Fe
3+
 (FRAP reagent) was prepared by mixing suitable amounts of TPTZ 
and FeCl3 solutions in aqueous acetate buffer. In brief, 3.0mL of FRAP reagent and 100mL of suitably 
diluted sample were mixed in a photometric cuvette and absorbance was measured after exactly 4min 
after the mixing(T = 25.0±0.1°C). 
The absorbance of the blue Fe
2+
 complex is measured at 593nm (Shimadzu UV-1601 PC 
spectrophotometer). Four or five different sample concentrations were tested and the straight line Abs vs. 
conc. was then compared with that of the standard (FeSO4). The Lambert&Beer law is followed, then the 
ratio: 
 FRAP = m(smp)/m(Fe
2+
) 
gives the relative ferric reducing activity (mmol equiv Fe
2+
). 
 
97 
Cyclic voltammetry 
All electrochemical experiments were conducted in acetonitrile from Sigma-Aldrich (>99.5% over 
molecular sieves) after careful de-aeration of the reaction mixture with argon; in all instances a silver wire 
was used as a pseudo-reference electrode, while a platinum coil was used as a counter electrode. 
Voltammetric analysis was performed with platinum, gold and glassy carbon working electrodes (Ø = 
2mm) using a function generator AMEL mod 568 equipped with a digital oscilloscope. 
 
Bacterial isolates 
A collection of 45 recently isolated and well characterized for the antimicrobial susceptibility phenotype 
MRSA strains recovered from CF patients was tested. All the strains were isolated at the Department of 
Pediatrics, CF Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of 
Milan. 
The in vitro susceptibility of methicillin-resistant isolates of S. aureus to new antimicrobial compounds 
was evaluated by means of the broth microdilution method for the determination of the minimum 
inhibitory concentrations (MIC), in accordance with the Clinical and Laboratory Standards Institute 
(CLSI; formerly National Committee for Clinical Laboratory Standards) guidelines.
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 Briefly, serial two-
fold dilutions were made of the compounds in 96-well plates in order to obtain concentrations ranging 
from of 0.06-128mg/L in cation-adjusted MullereHinton broth (DIFCO). An equal volume of 
1·10
6
CFU/mL (Colony Forming Unit/mL) bacterial inoculum was added to each well of the microtitre 
plate containing 0.05 mL of the serial antibiotic concentrations. The microtitre plate was then incubated 
overnight at 37°C and subsequently analyzed for the presence of visible bacterial growth. MIC was 
defined as the lowest concentration of the tested compound able to inhibit visible growth of the 
microorganism after overnight incubation. 
All the tested compounds were solubilized in 100% DMSO and appropriate dilutions were set up to 
prevent its toxicity. 
Positive strain controls without antimicrobial compounds, controls with DMSO and uninoculated media 
were run parallel to the tested compounds under the same conditions. 
S. aureus American Type Culture Collection (ATCC) 29213 (MSSA) and ATCC 43300 (MRSA) were 
used as control strains. Cefotaxime sodium salt was used as the reference antibiotic for MIC experiments 
validation. Breakpoints for resistance were those recommended by the CLSI.
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3.3.4 Synthesis of other antibiotic and dual active β-lactam compounds 
Azetidinone 25, 52, 54 and 56, and all the intermediate for its preparation from not optimized procedures, 
were prepared as previously reported [19, 79]. 
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Methyl 3,5-di-tbutyl-4-(ethoxymethoxy) benzoate (29) 
In a 50mL three-necks flask were suspended under nitrogen atmosphere 177mg 
of NaH (95%, 7.38mmol) in THF (11.0mL) and, at 0°C,  a THF solution (6mL) 
of methyl 3,5-di-tbutyl benzoate (650mg, 2.46mmol)was dropped, followed by 
1 hour stirring at room temperature. Were then added, at 0°C, 450L of 
ethoxymethyl chloride dissolved in 6mL of THF, and after 12h stirring at r.t. 
the reaction was quenched with a NH4Cl saturated solution, then extracted with EtOAc (3x10mL), dried 
over Na2SO4 and concentrated in vacuum. After FC purification 29 was obtained in 95% yield (760mg) as 
a colorless oil. 
Rf 0.60 (cyclohexane/Et2O, 90/10) 
1
H NMR (400MHz, CDCl3): δ 1.32 (t, J = 7.2Hz, 3H, EtO) 1.47 (s, 18H, tBu), 3.89 (s, 3H, OMe), 3.87(q, 
J = 6.8Hz, 2H, EtO), 4.95 (s, 2H, OCH2O), 7.90 (s, 2H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ 15.2, 31.8, 35.8, 51.9, 65.6, 99.6, 124.7, 128.1, 144.7, 158.9, 167.4 ppm 
IR: ṽ = 3427, 2961, 1721, 1597, 1430, 1389, 1363, 1302, 1237, 1134, 1026, 996, 952, 885, 770 cm-1 
HPLC-MS: Rt = 15.40min, m/z: 60 (100) [M-EOM-2tBu-Ph]
+
, 323 (40) [M+H]
+
 
 
3,5-di-tbutyl-4-(ethoxymethoxy)benzoic acid (28) 
In a one-neck flask 2.3mL of 5.6M NaOH aqueous solution were added to 
760mg of 29 dissolved in a THF/MeOH mixture (8.3mL/0.96mL) and the 
temperature was then increased to 40°C. After 3 days stirring EtOAc was added 
and water used for washing 3 times; the aqueous phases were then acidified to 
pH = 6 with HCl and extracted with EtOAc (3x3mL). The organics were dried 
Na2SO4 and concentrated in vacuum affording 533mg of 28 (y = 95%) as a white solid. 
M.p. (170-172)°C; Rf 0.71 (cyclohexane/EtOAc 90/10) 
1
H NMR (400MHz, CDCl3): δ 1.33 (t, J = 7.2Hz, 3H, EtO), 1.48 (s, 18H, tBu), 3.90 (q, J = 6.8Hz, 2H, 
EtO), 4.95 (s, 2H, OCH2O), 7.90 (s, 2H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ 15.2, 31.8, 35.8, 65.7, 99.7, 123.7, 128.9, 144.9, 159.9, 172.2 ppm 
IR: ṽ = 3415, 2956, 1683, 1414, 1385, 1303, 1253, 1158, 1141, 1114, 942 cm-1 
HPLC-MS: Rt = 13.61min, m/z: 307 (100) [M-H]
+
, 634 (10) [2M-2H+Na]
+
 
 
(R)-((2R,3R)-2-acetoxy-methylthio-4-oxoazetidin-3-yl)ethyl-3,5-di-tbutyl-4-(ethoxymethoxy) 
benzoate (26) 
In a 25mL two-necks flask were dissolved under nitrogen atmosphere 
75mg of 4 (0.34mmol) in 5.0mL of anhydrous DCM, followed by 
addition of 28 (105mg, 0.34mmol), DMAP (124mg, 0.34mmol) and, at 
0°C,  EDC (192mg, 0.34mmol). The solution was stirred at r.t. 3 days, 
following by TLC monitoring, and was finally quenched at 0°C with 
water, extracted with EtOAc (3x5mL), dried over Na2SO4 and concentrated in vacuum. After treatment 
by flash-chromatography (cyclohexane/EtOAc 85/15) 26 was obtained in 36% yield (63mg) as a colorless 
oil. 
Rf 0.33 (cyclohexane/EtOAc 60/40) 
[α]D = -37.2° 
1
H NMR (400MHz, CDCl3): δ 1.33 (t, J = 7.2Hz, 3H, EtO), 1.45 (s, 18H, tBu), 1.50 (d, J = 6.0Hz, 3H, 
Me) 2.18 (s, 3H, OAc), 2.49 (s, 3H, SMe), 3.50 (dd, H, J = 1.6 Hz), 3.90 (quartet, J = 6.8 Hz, 2H, EtO), 
4.96 (s, 2H, OCH2O), 5.44 (quintet, J = 6.4Hz, 1H,), 6.26 (d, J = 1.6Hz, 1H) 7.91 (s, 2H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ 15.2, 18.4, 20.87, 22.9, 31.8, 35.8, 64.1, 65.6, 66.5, 81.3, 99.6, 124.2 , 
128.1, 144.8, 159.3, 165.6, 169.7 ppm 
IR: ṽ = 3427, 2962, 1789, 1760, 1717, 1597, 1363, 1233, 945, 888, 736 cm-1 
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HPLC-MS: Rt = 15.19min, m/z: 142 (100) [M-RCOOH-OAc]
+
, 532 (90) [M+Na]
+
, 1041 (85) [2M+Na]
+
 
 
(R)-((2R,3R)-2-acetoxy-methylthio-4-oxoazetidin-3-yl)ethyl 3,5-di-tbutyl-4-hydroxybenzoate (23) 
In a 25mL two-necks flask were dissolved under nitrogen atmosphere 44mg of 
26 (0.086mmol) in 10.7mL of anhydrous DCM, followed by TFA addition at 
0°C (27L) and TLC monitoring. At SM disappearance the reaction was 
directly concentrated to afford 23 in 97% yield (38mg) as a white solid.  
M.p. (144-147)°C; Rf 0.48 (cyclohexane/EtOAc 60/40) 
[α]D = -15.6° 
1
H NMR (400MHz, CDCl3): δ 1.46 (s, 9H, tBu), 1.47 (s, 9H, tBu), 1.50 (d, J = 6.4Hz, 3H, Me), 2.18 (s, 
3H, OAc), 2.48 (s, 3H, SMe), 3.50 (dd, J = 1.2, 4.4Hz, 1H,), 5.43 (quintet, J = 6.0, 6.4Hz, 1H,), 5.70 (bs, 
OH), 6.28 (d, 1H), 7.85 (s, 2H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ 18.5, 20.9, 22,9, 30.1, 34.3, 64.2, 66.2, 81.3, 120.7, 127.1, 135.7, 158.4, 
165.8, 167.6, 169.7 ppm 
IR: ṽ = 3551, 2961, 2876, 1789, 1711, 1599, 1432, 1359, 1219, 944, 915, 886, 768, 738 cm-1 
HPLC-MS: Rt = 11.98min, m/z: 469 (100) [M+H2O]
+
, 474 (27) [M+Na]
+
, 925 (89) [2M+Na]
+
 
 
(R)-((2R,3R)-2-acetoxy-4-oxoazetidin-3-yl)ethyl 3,5-di-tbutyl-4-hydroxy benzoate (24) 
In a 10mL 2-neck flask a mixture of 27 (10mg, 22μmol), anhydrous THF 
(0.27mL), MeOH (0.27mL) and Pd/C 10%w/w (1.2mg) was stirred under H2 
atmosphere (1atm) at room temperature. At starting material consumption (16h) 
the mixture was filtered and concentrated in vacuum. The desired product 24 
was obtained as a yellow waxy solid in 95% yield (8mg) after purification via 
flash-chromatography (cyclohexane/EtOAc 50/50). 
Rf 0.57 (cyclohexane/EtOAc 50/50) 
[α]D = -29.9° 
1
H NMR (400MHz, CD3CN): δ = 1.43 (s, 9H, tBu), 1.45 (s, 9H, tBu), 1.50 (d, J = 6.8Hz, 3H, Me), 2.10 
(s, 3H, OAc), 3.46 (dd, J = 1.2, 5.2Hz, 1H,), 5.40 (quintet, J = 6.8Hz, 1H,), 5.68 (s, H), 5.87 (d, J = 1.2Hz, 
1H,), 6.53 (bs , NH), 7.85 (s, 2H, Ar) ppm 
13
C NMR (100MHz, CD3OD): δ = 9.9, 18.5, 20.8, 25.7, 29.7, 30.1, 32.2, 34.3, 62.8, 66.6, 76.0, 120.8, 
127.1, 135.8, 158.4, 164.6, 165.9, 171.0 ppm 
IR: ṽ = 3311, 2959, 2874, 1782, 1755, 1709, 1599, 1429, 1369, 1300, 1232, 1131, 1062, 1034, 769 cm-1 
HPLC-MS: Rt = 10.41min, m/z = 346 (95) [M-tBu]
+
, 428 (40) [M+Na]
+
, 833 (100) [2M+Na]
+ 
 
(S)-3-((R)-tbutyldimethylsilyloxyethyl)azetidin-2-one (38) 
In a 100mL two-necks flask under nitrogen atmosphere 1.0g of (2R,3R)-3-((R)-
tbutyldimethylsilyloxyethyl)-4-oxoazetidin-2-yl acetate were dissolved in 30.0mL of 
anhydrous THF before adding, at 0°C, 1.58g of NaBH4 (4eq.) and leaving under agitation at 
room temperature for one day, following by TLC monitoring (cyclohexane/EtOAc 50/50 and 
KMnO4 stain). At SM disappearance the reaction was extracted with DCM, dried over Na2SO4 and 
concentrated in vacuum to reach 38 in 99% yield (796mg) as a white solid. 
 
(S)-3-((R)-1-hydroxyethyl)azetidin-2-one (39) 
In a 50mL two-necks flask under nitrogen atmosphere 796mg (3.74mmol) of 38 were 
dissolved in 18.2mL of MeCN, then 3.74mL of 1M aqueous HCl were added and the reaction 
followed by TLC monitoring (DCM/MeOH 95/5, KMnO4 stain). At SM disappearance the 
reaction was quenched with 1M aqueous NaOH until neutral pH, then evaporated, dissolved 
100 
in a MeCN/MeOH 1/1 solution, filtered and concentrated under vacuum to afford 345mg (y = 80%) of 39 
as white solid. 
 
(S)-3-((R)-tbutyldimethylsilyloxyethyl)-1-(methylthio)azetidin-2-one (40) 
In a 50mL two-necks flask under nitrogen atmosphere 417mg (1.82mmol) of 38 were 
dissolved in 14.3mL of anhydrous THF before slowly adding, at -78°C, 2.18mL of a 1M 
LiHMDSA solution in THF (2.18mmol) and, after some minutes, 0.43mL of MeSSO2Me 
(4.55mmol). After 1h stirring at -78°C and monitoring by TLC (cyclohexane/EtOAc 
70/30), the reaction was quenched with a saturated water solution of NH4Cl, extracted with DCM, dried 
over Na2SO4 and concentrated in vacuum to reach 38 as a yellow oil in 82% yield (411mg) after FC 
purification. 
Rf 0.71 (cyclohexane/EtOAc 70/30) 
1
H NMR (400MHz, CDCl3): δ 0.06 (s, 3H, Me), 0.07 (s, 3H, Me), 0.86 (s, 9H, tBu), 1.61 (d, J = 6.4Hz, 
3H, Me), 2.42 (s, 1H, SMe), 3.26 (dt, J = 4.0, 5.6Hz, 1H, CH), 3.37 (t, J = 5.2Hz, 1H, CH2), 3.52 (dd, J = 
2.0, 2.8Hz, 1H, CH2), 4.27 (dq, J = 2.4, 4.0Hz, 1H, CHMe) ppm 
13
C NMR (100MHz, CDCl3): δ -4.5, -4.9, 17.9, 22.0, 22.6, 25.7, 45.1, 59.3, 64.9, 171.9 ppm 
IR: ṽ = 3518, 2956, 1766, 1471, 1374, 1256, 1172, 1015, 960, 778, 722 cm-1 
HPLC-MS: Rt = 12.5min, m/z: 276 (50) [M+H]
+
, 298 (100) [M+Na]
+
 
 
3-hydroxyethyl-1-methylthioazetidin-2-one (41) 
In a 50mL two-necks flask under nitrogen atmosphere 320mg (1.16mmol) of 40 were 
dissolved in 23.0mL of anhydrous MeCN before slowly adding, at 0°C, 166μL (1.32mmol) 
of BF3·Et2O. After 1h at 0°C (TLC monitoring, cyclohexane/EtOAc 70/30), the reaction 
was quenched with a pH = 6 phosphate buffer solution, then allowed to reach r.t., extracted 
with DCM, dried over Na2SO4 and concentrated to reach 41 as a yellow oil in 71% yield (137mg). 
Rf 0.35 (cyclohexane/EtOAc 50/50) 
1
H NMR (400MHz, CDCl3): δ 1.28 (d, J = 6.4Hz, 3H), 1.80 (bs, 1H), 2.45 (s, 1H), 3.34 (dt, J = 2.0, 
3.6Hz, 1H), 3.47 (t, J = 5.6Hz, 1H), 3.50 (dd, J = 2.4, 3.2Hz, 1H), 4.21 (dq, J = 6.0, 6.4Hz, 1H) ppm 
13
C NMR (100MHz, CDCl3): δ 21.2, 21.5, 45.5, 58.5, 64.4, 172.3 ppm 
IR: ṽ = 3423, 2969, 2920, 1740, 1418, 1309, 1185, 1058, 962, 903 cm-1 
HPLC-MS: Rt = 0.38min, m/z: 162 (100) [M+H]
+
, 184 (100) [M+Na]
+
, 345 (35) [2M+Na]
+ 
 
(R)-1-((S)-methylthio-2-oxoazetidin-3-yl)ethyl 3,5-di-tbutyl-4-(ethoxymethoxy) benzoate (42) 
In a 50mL two-necks flask under nitrogen atmosphere 161mg (1.0mmol) 
of 41 were dissolved in 23.0mL of anhydrous DCM before adding 
308mg (1.0mmol) of acid 28, 124mg (1.0mmol) of DMAP and, at 0°C, 
192mg (1.0mmol) of EDC. The reaction was monitored by TLC and 
quenched at 0°C with HCl until neutrality, then extracted with EtOAc, 
dried over Na2SO4 and concentrated in vacuum to reach 42 as a white solid in 17% yield (77mg) after 
purification via FC (cyclohexane/EtOAc 85/15). 
M.p. (137-140)°C; Rf 0.54 (cyclohexane/EtOAc 60/40) 
[α]D = -50.9° 
1
H NMR (400MHz, CDCl3): δ 1.30 (t, J = 6.8 Hz, 3H, EtO), 1.44 (s, 18H, tBu), 1.46 (d, J = 6.8Hz, 3H, 
Me), 2.42 (s, 3H, SMe), 3.49 (t, J = 1.6Hz, 1H), 3.54 (dd, J = 1.6 Hz, 1H), 3.86 (quartet, J = 6.8Hz, 2H, 
EtO), 4.93(s, 2H, OCH2O), 5.44 (quintet, J = 6.4Hz, 1H), 7.90 (s, 2H, Ar) ppm 
13
C NMR (100MHz, CDCl3): δ 15.2, 18.7, 21.9, 29.6, 31.8, 35.8, 46.9, 56.9, 65.6, 68.3, 99.6, 124.4 , 
128.1, 144.8, 159.3, 165.8, 169.9 ppm 
IR: ṽ = 3419, 2964, 1761, 1718, 1597, 1431, 1387, 1365, 1333, 1293, 1236, 1135, 1181, 1113, 1083, 
1058, 942, 767 cm
-1
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HPLC-MS: Rt = 14.48min, m/z: 452 (100) [M+H]
+
, 469 (14) [M+H2O]
+
, 925 (13) [2M+Na]
+
 
 
(R)-1-((S)-methylthio-2-oxoazetidin-3-yl)ethyl 3,5-di-tbutyl-4-hydroxybenzoate (37) 
In a 50mL two-necks flask were dissolved under nitrogen atmosphere 92mg of 
42 (0.17mmol) in 22.0mL of anhydrous DCM, followed by TFA addition at 
0°C (54L) and TLC monitoring. At SM disappearance the reaction was 
directly concentrated to afford 37 in 95% yield (67mg) as a white solid after 
pentane titration.  
M.p. (138-140)°C; Rf 0.49 (cyclohexane/EtOAc 50/50) 
[α]D = -58.8° 
1
H NMR (400MHz, CDCl3): δ 1.44 (s, 18H, tBu), 1.45 (d, J = 6.0Hz, 3H, Me), 2.42 (s, 3H, SMe), 3.51 (t, 
J = 6.4Hz, 1H), 3.57 (dd, J = 2.4, 5.6Hz, 1H), J = 6.8Hz), 5.43 (quintet, J = 6.4Hz, 1H), 5.70 (bs, OH), 
7.83 (s, 2H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ 18.6, 21.9, 30.1, 34.3, 47.1, 56.7, 68.1, 120.6 , 127.1, 135.8, 158.5, 166.3, 
171.1 ppm 
IR: ṽ = 3563, 2960. 1758, 1709, 1600, 1428, 1361, 1300, 1233, 1188, 1124, 1083, 1054, 1030, 890, 768, 
737 cm
-1
 
HPLC-MS: Rt = 11.47min, m/z: 394 (100) [M+H]
+
, 416 (10) [M+Na]
+
, 809 (30) [2M+Na]
+
 
 
(R)-1-((2R,3R)-2-acetoxy-4-oxoazetidin-3-yl)ethyl 3,5-di-tbutyl-4-hydroxybenzoate (33) 
In a 10mL 2-neck flask a mixture of 37 (55mg, 0.14mmol), anhydrous THF 
(1.7mL), MeOH (1.7mL) and Pd/C 10%w/w (8.0mg) was stirred under H2 
atmosphere (1atm) at rt overnight. At starting material consumption (16h) the 
mixture was filtered and concentrated in vacuum. The desired product 33 was 
obtained as a white solid in 41% yield (20mg) after purification via FC 
(cyclohexane/EtOAc 50/50). 
Rf 0.31 (cyclohexane/EtOAc 50/50) 
[α]D = -28.1° 
1
H NMR (400MHz, CD3CN): δ = 1.43 (s, 18H, tBu), 1.46 (d, J = 6.0Hz, 3H, Me), 3.36 (dd, J = 2.8, 
3.2Hz, 1H), 3.44 (t, J = 5.2Hz, 1H), 3.50 (dd, J = 1.2Hz, 1H), 5.43 (quintet, J = 6.4Hz, 1H), 5.83 (bs, 
OH), 7.86 (s, 2H, Ar) ppm 
13
C NMR (100MHz, CD3OD): δ = 18.7, 30.1, 34.3, 39.4, 56.9, 68.5, 121.1 , 127.1, 135.7, 158.3, 166.1, 
167.7 ppm 
IR: ṽ = 3311, 2959, 2873, 1756, 1705, 1599, 1428, 1361, 1301, 1234, 1192, 1131, 1067, 1030 cm-1 
HPLC-MS: Rt = 9.77min, m/z = 348 (100) [M+H]
+
, 717 (40) [2M+Na]
+
, 
 
 
(S)-((R)-2-oxoazetidin-3-yl)ethyl 4-(ethoxymethoxy)-3,5-dimethoxybenzoate (43) 
In a 50mL two-necks flask under nitrogen atmosphere 47mg (0.41mmol) of 
39 were dissolved in 8.76mL of anhydrous DCM before adding 150mg 
(0.58mmol) of acid 19, 72mg (0.58mmol) of DMAP and, at 0°C, 111mg 
(0.58mmol) of EDC. The reaction was monitored by TLC and quenched at 
0°C with HCl until neutrality, then extracted with EtOAc, dried over 
Na2SO4 and concentrated in vacuum to reach 43 as a colorless oil in 29% yield (41mg) after purification 
via FC (cyclohexane/EtOAc 80/20 to 30/70). 
Rf 0.42 (EtOAc) 
[α]D = -29.0° 
1
H NMR (400MHz, CDCl3): δ 1.19 (m, 3H), 1.49 (d, J = 8.0Hz, 3H), 3.33 (dd, J = 4.0, 8.0Hz, 1H), 3.46 
(dd, J = 4.0, 8.0Hz, 1H), 3.54 (m, 1H), 3.85 (m, 2H), 3.88 (s, 6H), 5.21 (s, 2H), 5.95 (bs, 1H, NH) 7.25 (s, 
2H) ppm 
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13
C NMR (100MHz, CDCl3): δ 14.9, 18.5, 39.5, 56.2, 56.4, 65.0, 69.4, 96.5, 106.8, 125.5, 138.9, 153.1, 
165.2, 167.4 ppm 
IR (KBr): ṽ = 3416, 2976, 2938, 1747, 1591, 1338, 1128 cm-1 
HPLC-MS: Rt = 6.25min, m/z: 354 (100) [M+H]
+
, 371 (15) [M+H2O]
+
, 729 (30) [2M+Na]
+ 
 
(R)-1-((S)-2-oxoazetidin-3-yl)ethyl 4-hydroxy-3,5-dimethoxybenzoate (30)  
In a 25mL two-necks flask were dissolved under nitrogen atmosphere 27mg of 43 
(0.17mmol) in 9.27mL of anhydrous DCM, followed by TFA addition at 0°C 
(28L) and TLC monitoring (cyclohexane/EtOAc 10/90). At SM disappearance 
the reaction was directly concentrated to afford 30 in 22% yield (5mg) as a white 
solid after FC purification (DCM/acetone 98/2 to 90/10).  
Rf 0.40 (DCM/acetone 70/30) 
[α]D = -58.8° 
1
H NMR (400MHz, CDCl3): δ 1.28 (d, J = 16.0Hz, 3H), 3.35 (dd, J = 4.0, 8.0Hz, 1H), 3.39 (dd, J = 4.0, 
8.0Hz, 1H), 3.55 (m, 1H), 3.95 (s, 6H), 5.58 (m, 1H), 5.72 (bs, 1H, NH), 5.93 (s, 1H, OH), 7.25 (s, 2H) 
ppm 
13
C NMR (100MHz, CDCl3): δ 18.2, 47.1,56.5, 56.6, 68.7, 106.8, 119.1, 139.8, 146.5, 165.8, 168.1 ppm 
IR (KBr): ṽ = 3399, 2922, 2849, 1740, 1607, 1515, 1462, 1338, 1230, 1116 cm-1 
HPLC-MS: Rt = 2.49min, m/z: 296 (100) [M+H]
+
 
 
(R)-1-((S)-1-(methylthio)-2-oxoazetidin-3-yl)ethyl 4-(ethoxymethoxy)-3,5-dimethoxybenzoate (44) 
In a 50mL two-necks flask under nitrogen atmosphere 66mg (0.41mmol) 
of 41 were dissolved in 8.76mL of anhydrous DCM before adding 
150mg (0.58mmol) of acid 19, 72mg (0.58mmol) of DMAP and, at 0°C, 
111mg (0.58mmol) of EDC. The reaction was monitored by TLC and 
quenched at 0°C with a saturated NH4Cl solution and 1M HCl until 
neutrality, then extracted with DCM, dried over Na2SO4 and concentrated in vacuum to reach 44 as a 
colorless oil in 27% yield (44mg) after purification via FC (cyclohexane/EtOAc 85/15 to 70/30). 
Rf 0.45 (cyclohexane/EtOAc 50/50) 
[α]D = -53.5° 
1
H NMR (400MHz, CDCl3): δ 1.2 (dd, J = 4.0, 12.0Hz, 3H), 1.49 (d, J = 4.0Hz, 3H), 2.45 (s, 3H), 3.47 
(dd, J = 4.0, 8.0Hz, 1H), 3.57 (dd, J = 4.0, 8.0Hz, 2H), 3.85 (m, 2H), 3.87 (s, 6H), 5.22 (s, 2H), 5.44 (m, 
1H), 7.25 (s, 2H) ppm 
13
C NMR (100MHz, CDCl3): δ 14.9, 18.5, 22.0, 46.9, 56.1, 56.8, 65.0, 68.9, 96.5, 106.7, 125.3, 139.0, 
153.1, 165.1, 169.8 ppm 
IR (KBr): ṽ = 2976, 2934, 1767, 1592, 1416, 1330, 1127 cm-1 
HPLC-MS: Rt = 8.54, m/z: 400 (100) [M+H]
+
, 417 (75) [M+H2O]
+
, 821 (35) [2M+Na]
+ 
 
(R)-1-((S)-1-(methylthio)-2-oxoazetidin-3-yl)ethyl 4-hydroxy-3,5-dimethoxybenzoate (34) 
In a 25mL two-necks flask were dissolved under nitrogen atmosphere 42mg of 
44 (0.1mmol) in 12.2mL of anhydrous DCM, followed by TFA addition at 0°C 
(37L, 0.5mmol) and TLC monitoring (cyclohexane/EtOAc 40/60). At SM 
disappearance the reaction was directly concentrated to afford 34 in 32% yield 
(11mg) as a white solid after pentane titration.  
Rf 0.35 (cyclohexane/EtOAc 40/60) 
[α]D = -12.7° 
1
H NMR (400MHz, CDCl3): δ 1.28 1.46 (d, J = 8.0Hz, 3H), 2.42 (s, 3H), 3.46 (dd, J = 8.0, 12.0Hz, 1H), 
3.55 (dd, J = 8.0, 12.0Hz, 2H), 3.88 (s, 6H), 5.41 (m, 1H), 5.92  (bs, 1H, OH), 7.24 (s, 2H) ppm 
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13
C NMR (100MHz, CDCl3): δ 18.5, 22.0, 47.0,56.5, 56.7, 68.7, 106.7, 120.3, 139.5, 146.6, 165.3, 169.9 
ppm 
IR (KBr): ṽ = 3423, 2923, 1749, 1638, 1458, 1116 cm-1 
HPLC-MS: Rt = 5.34min, m/z: 342 (100) [M+H]
+
, 359 (10) [M+H2O]
+
, 705 (10) [2M+Na]
+
 
 
methyl 3,4-bis(benzyloxy) benzoate (47) 
In a 25mL two-necks flask under nitrogen atmosphere 500mg (3.24mmol) of 3,4-
dihydroxy benzoic acid were dissolved in 6.5mL of anhydrous DMF before adding 
2.76g (20.0mmol) of K2CO3 and 1.8mL (15.0mmol) of BnBr. The reaction was 
monitored by TLC (cyclohexane/EtOAc 90/10) and quenched with ice, extracted with 
EtOAc, washed with a saturated aqueous NH4Cl solution (2 times) and brine (1 time), then dried over 
Na2SO4 and concentrated in vacuum to reach 47 as a white solid in 97% yield (1.332g) after purification 
via FC (cyclohexane/EtOAc 95/5). 
 
3,4-bis(benzyloxy)benzoic acid (48) 
In a 50mL flask 1.125g (2.65mmol) of 47 were dissolved in 25.0mL of MeOH and 
4.9mL of 5M aqueous NaOH (24.6mmol)were added. After three day stirring at reflux 
and following by TLC monitoring (Et2O/EtOAc 90/10) half of the solvent was 
evaporate under vacuum, water was added and the crude treated with petroleum ether 
before acidifying the aqueous phase with 1M HCl and extracting with EtOAc. The organic phase was 
then dried over Na2SO4, filtered and concentrated to reach 48 as a white solid in 99% yield (0.879g). 
 
(R)-1-((S)-1-(methylthio)-2-oxoazetidin-3-yl)ethyl 3,4-bis(benzyloxy) benzoate (46) 
In a 100mL two-necks flask under nitrogen atmosphere 150mg (0.93mmol) of 
41 were dissolved in 21.0mL of anhydrous DCM before adding 311mg 
(0.93mmol) of acid 48, 115mg (0.93mmol) of DMAP and, at 0°C, 178mg 
(0.93mmol) of EDC. The reaction was monitored by TLC and quenched at 0°C 
with HCl until neutrality, then extracted with EtOAc, dried over Na2SO4 and 
concentrated in vacuum to reach 46 as a yellow oil in 18% yield (81mg) after purification via FC 
(cyclohexane/EtOAc 85/15). 
Rf 0.49 (cyclohexane/EtOAc 60/40) 
1
H NMR (400MHz, CDCl3): δ 1.45 (d, J = 6.0Hz, 3H, Me), 2.43 (s, 3H, SMe), 3.45 (dt, J = 2.4, 4.0Hz, 
1H, CH), 3.52 (t, J = 5.6Hz, 1H, CH2), 3.54 (m, 1H, CH2), 5.22 (m, 2H, CH2Bn), 5.40 (dq, J = 3.2, 3.6Hz, 
1H, CHMe), 6.92 (d, J = 8.0Hz, 1H, Ar), 7.41 (m, 5H, Bn), 7.49 (m, 5H, Bn), 7.59 (m, 2H, Ar) ppm 
13
C NMR (100MHz, CDCl3): δ 18.5, 21.8, 46.8, 56.8, 68.5, 70.7, 71.2,113.1, 115.6, 122.7, 123.9, 127.0, 
127.3, 127.8, 127.9, 128.4, 128.5, 136.4, 136.7, 148.3, 153.1, 165.1, 169.8 ppm 
IR: ṽ = 3064, 3032, 2928, 1766, 1709, 1599, 1510, 1454, 1427, 1380, 1270, 1206, 1130, 1024, 875,735, 
697 cm
-1
 
HPLC-MS: Rt = 11.50min, m/z: 478 (60) [M+H]
+
, 495 (100) [M+H2O]
+
, 500 (40) [M+Na]
+
, 979 (70) 
[2M+Na]
+ 
 
(R)-1-((S)-2-oxoazetidin-3-yl)ethyl 3,4-bis(benzyloxy)benzoate (45) 
In a 10mL 2-neck flask a mixture of 46 (106mg, 0.22mmol), anhydrous THF 
(1.5mL), MeOH (1.5mL) and Pd/C 10%w/w (14mg) was stirred under H2 
atmosphere (1atm) at room temperature. At starting material consumption (16h) 
the mixture was filtered and concentrated in vacuum. The desired product 24 was 
obtained as a white waxy solid in 27% yield (26mg) after purification via flash-
chromatography (cyclohexane/EtOAc 40/60). 
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Rf 0.60 (cyclohexane/EtOAc 40/60) 
[α]D = -39.9° 
1
H NMR (400MHz, CD3CN): δ = 1.44 (d, J = 6.4Hz, 3H, Me), 3.26 (dd, J = 1.6, 4.0Hz, 1H), 3.39 (t, J = 
5.6Hz, 1H ), 3.57 (dd, J = 7.2, 6 .0Hz, 1H), 5.40 (quintet, J = 6.4Hz, 1H), 5.71 (bs, NH), 6.90 (d, J = 
9.2Hz, 2H, Ar), 7.35 (m, 10H, Bn), 7.57 (d, J = 6.8Hz, 1H, Ar) ppm 
13
C NMR (100MHz, CD3OD): δ = 18.6, 22.3, 25.8, 29.7, 35.1, 39.3, 40.3, 46.0, 51.9, 55.9, 56.7, 61.1, 
63.9, 68.9, 70.8, 71.3, 76.6, 101.4, 113.2, 115.7, 123.0, 127.1, 127.3, 127.9, 128.0, 128.5, 128.6, 136.4, 
136.8, 148.3, 152.9, 153.2, 165.2, 167.4 ppm 
IR: ṽ = 3332, 2974, 2930, 2872, 1755, 1710, 1600, 1510, 1454, 1427, 1380, 1343, 1270, 1206, 1130, 
1064, 1023, 763, 738, 697 cm
-1 
HPLC-MS: Rt = 10.01min, m/z = 449 (100) [M+H2O]
+
, 454 (10) [M+Na]
+
, 885 (45) [2M+Na]
+ 
 
(R)-1-((S)-2-oxoazetidin-3-yl)ethyl 3,4-dihydroxybenzoate  (31) 
In a 10mL 2-neck flask a mixture of 45 (26mg, 61μmol), anhydrous THF 
(0.43mL), MeOH (0.43mL) and Pd/C 10%w/w (4mg) was stirred under H2 
atmosphere (1atm) at room temperature. At starting material consumption (16h) the 
mixture was filtered and concentrated in vacuum. The desired product 31 was 
obtained as a white waxy solid in 59% yield (9mg) after purification via flash-
chromatography (cyclohexane/EtOAc 50/50). 
Rf 0.33 (cyclohexane/EtOAc 50/50) 
[α]D = -22.6° 
1
H NMR (400MHz, CD3CN): δ = 1.39 (d, J = 6.0Hz, 3H, Me), 3.31 (dd, J = 2.8Hz, 1H), 3.41 (t, J = 
5.6Hz, 1H), 3.50 (dd, J = 2.4, 2.8Hz, 1H), 5.31 (quintet, J = 6.4Hz, 1H), 7.01 (bs, NH), 7.44 (m, 2H, Ar,), 
7.48 (s, 1H, Ar), 8.27 (bs, OH), 8.62 (bs, OH) ppm 
13
C NMR (100MHz, CD3OD): δ = 18.7, 30.1, 34.3, 39.4, 56.9, 68.5, 121.1 , 127.1, 135.7, 158.3, 166.1, 
167.7 ppm 
IR: ṽ = 3380, 2925, 1734, 1701, 1603, 1522, 1443, 1363, 1295, 1228, 1114, 1092, 1064,  952, 766 cm-1 
HPLC-MS: Rt = 1.95min, m/z = 252 (85) [M+H]
+
, 274 (50) [M+Na]
+
, 525 (100) [2M+Na]
+ 
 
3,4-bis(ethoxymethoxy)benzoic acid (49) 
A solution of methyl 3,4-dihydroxybenzoate (495g, 2.95mmol) in THF (5.9mL) 
was added dropwise to a suspension of NaH (60% in mineral oil, 354mg, 
8.85mmol) in THF (17.7mL) at 0°C under inert atmosphere. After 10 minutes a 
solution of chloromethylethylether (808μL, 8.85mmol) in THF (6.4mL) was 
added dropwise and the reaction was allowed to warm to room temperature and monitored by TLC. After 
2h the reaction was quenched with aqueous NH4Cl (30mL) and extracted with EtOAc (3x20mL). The 
organic extracts were dried over Na2SO4 and concentrated to obtain methyl 3,4-bis(ethoxymethoxy) 
benzoate (733mg, 87%) as pale yellow oil after flash-chromatography purification (cyclohexane/EtOAc 
50/50). It was directly dissolved in a mixture of THF/MeOH (7.25/0.87mL) and treated with 5M NaOH 
(2.14mL). The reaction was heated at 40°C for 4 hours and monitored by TLC. At completion, EtOAc 
(2x10mL) was added and the organic phase was separated and discarded. The aqueous phase was then 
cooled to 0°C and adjusted to pH = 6 with aqueous 1M HCl. The mixture was extracted with EtOAc 
(3x15mL), dried on Na2SO4 and concentrated to afford 49 (571mg, 99%) as a white solid. 
 
(R)-1-((S)-1-(methylthio)-2-oxoazetidin-3-yl)ethyl 3,4-bis(ethoxymethoxy)benzoate (50) 
In a 100mL two-necks flask under nitrogen atmosphere 95mg (0.59mmol) of 
41 were dissolved in 13.6mL of anhydrous DCM before adding 224mg 
(0.83mmol) of acid 49, 101mg (0.83mmol) of DMAP and, at 0°C, 159mg 
(0.83mmol) of EDC. The reaction was monitored by TLC and quenched at 
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0°C with HCl until neutrality, then extracted with DCM, dried over Na2SO4, filtered and concentrated in 
vacuum to reach 50 as a colorless oil in 32% yield (78mg) after purification via FC (cyclohexane/EtOAc 
80/20). 
Rf 0.73 (cyclohexane/EtOAc 40/40) 
[α]D = -36.1° 
1
H NMR (400MHz, CDCl3): δ 1.15-1.27 (m, 6H, EtO), 1.45 (d, J = 6.0Hz, 3H, Me), 2.43 (s, 3H, SMe), 
3.37-3.38 (m, 1H), 3.47-3.48 (m, 1H), 3.52-3.54 (m, 1H), 3.70-3.80 (m, 4H, EtO), 5.28 (s, 2H, OCH2O), , 
5.32 (s, 2H, OCH2O), 5.41 (quintet, J = 6.4Hz, 1H, CHO), 7.18 (d, J = 8.4Hz, 1H, Ar), 7.62 (d, J = 8.4Hz, 
1H, Ar) 7.77 (s, 1H, Ar) ppm 
13
C NMR (100MHz, CDCl3): δ 15.0, 18.3, 18.7, 21.9, 46.9, 56.9, 64.6, 68.0, 68.6, 93.5, 94.2, 115.0, 
118.0, 123.6, 124.6, 146.7, 151.2, 165.0, 169.9 ppm 
IR: ṽ = 3503, 2977, 2922, 1768, 1715, 1601, 1510, 1434, 1263, 1170, 1112, 981, 765 cm-1 
HPLC-MS: Rt = 9.13min, m/z: 414 (100) [M+H]
+
, 431 (85) [M+H2O]
+
, 436 (25) [M+Na]
+
, 849 (37) 
[2M+Na]
+ 
 
(R)-1-((S)-1-methylthio-2-oxoazetidin-3-yl)ethyl 3,4-dihydroxybenzoate (35) 
In a 25mL two-necks flask were dissolved under nitrogen atmosphere 78mg of 
50 (0.19mmol) in 23.0mL of anhydrous DCM, followed by TFA repeated 
addition, every 30min, at 0°C (139L, 0.5mmol, repeated for 7 times) and with 
TLC monitoring (cyclohexane/EtOAc 40/60). At SM disappearance the reaction 
was directly concentrated to afford 35 in 41% yield (23mg) as a yellow oil after 
FC purification (DCM/acetone 90/10). 
Rf 0.34 (cyclohexane/EtOAc 40/60), 0.33 (DCM/acetone 80/20) 
[α]D = -164.4° 
1
H NMR (400MHz, CDCl3): δ 1.40 (d, J = 6.4Hz, 3H, Me), 2.41 (s, 3H, SMe), 
3.55-3.59 (m, 3H), 5.43 (quintet, J = 5.6Hz, 1H, CHO), 6.84 (d, J = 8.4Hz, 1H, Ar), 7.39 (dd, J = 1.2, 
8.4Hz, 1H, Ar), 7.50 (d, J = 1.2Hz, 1H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ 18.3, 21.9, 46.6, 56.5, 67.7, 114.7, 116.5, 121.7, 123.3, 143.7, 149.4, 165.7, 
171.5 ppm 
IR (KBr): ṽ = 3441, 1701, 1685, 1637, 625 cm-1 
HPLC-MS: Rt = 4.02min, m/z: 298 (100) [M+H]
+
, 315 (35) [M+H2O]
+
, 617 (13) [2M+Na]
+
 
 
(E)-3-(3,4-bis(tbutyldimethylsilyloxy)phenyl)acrylic acid (51) 
To a solution of caffeic acid (450mg, 2.5mmol) in DMF (4.5mL) under inert 
atmosphere, imidazole (1.53g, 22.5mmol) and then TBSCl (11.25mmol) were 
added. After 40h the reaction was quenched at 0°C by a citric acid saturated 
solution and then extracted with Et2O. The organic phases were washed twice 
with water and brine, dried over Na2SO4 and evaporated. To the persilylated intermediate (1.798g) in 
1.86mL MeOH and 3.10mL of THF, a solution of K2CO3 (187mg, 1.35mmol) in water (1.86mL) was 
added. After 24h the mixture was quenched a 0°C by adding a saturated solution of citric acid and 
extracting with Et2O. The organic phases were washed with water and brine, dried over Na2SO4 and 
evaporated. The product was finally obtained by FC purification (DCM/MeCN 95/5) in 70% yield 
(984mg) as a white solid.  
 
(E)-(R)-1-((S)-2-oxoazetidin-3-yl)ethyl3-(3,4-bis((tbutyldimethylsilyl)oxy) phenyl)acrylate (52) 
In a 50mL two-necks flask under nitrogen atmosphere 127mg (1.1mmol) of 
39 were dissolved in 25.0mL of anhydrous DCM before adding 629mg 
(1.54mmol) of acid 51, 191mg (1.54mmol) of DMAP and, at 0°C, 296mg 
(1.54mmol) of EDC. The reaction was monitored by TLC and quenched at 
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0°C with 1M HCl until neutrality, then extracted with DCM, dried over Na2SO4 and concentrated in 
vacuum to reach 52 as a colorless oil in 36% yield (215mg) after purification via two FCs (DCM/Et2O 
80/20, then cyclohexane/EtOAc 90/10). 
 
(E)-(R)-1-((S)-2-oxoazetidin-3-yl)ethyl 3-(3,4-dihydroxyphenyl)acrylate (32) 
In a 50mL three-necks flask under nitrogen atmosphere 101mg (0.2mmol) of 
52 were dissolved in 4.1mL of anhydrous MeCN before slowly adding, at 0°C, 
58μL of BF3·Et2O. After 30 minutes stirring at 0°C the reaction was allowed to 
reach room temperature and was then quenched at 0°C with a pH = 7.5 
aqueous phosphate buffer solution at starting material disappearance, extracted 
with EtOAc, dried over Na2SO4, filtered and concentrated in vacuum to reach 
32 as a yellow oil in 14% yield (8mg) after pentane titration. 
Rf 0.27 (cyclohexane/EtOAc 40/60) 
1
H NMR (400MHz, CD3OD): δ 1.69 (d, J = 6.4Hz, 3H, Me), 3.00 (dd, J = 7.2, 13.2Hz, 1H), 3.82 (dd, J = 
8.0, 14.8Hz, 1H), 3.88 (dd, J = 5.6, 14.8Hz, 1H), 5.03 (quintet, J = 7.2Hz, 1H, CHO), 6.46 (d, J = 15.6Hz, 
1H, Csp2H), 6.87 (d, J = 8.4Hz, 1H, Ar), 7.09 (dd, J = 2.0, 8.4Hz, 1H, Ar), 7.16 (d, J = 2.0, 1H, Ar), 7.76 
(d, J = 15.6, 1H, Csp2H) ppm 
HPLC-MS: Rt = 1.502min, m/z: 278 (100) [M+H]
+
 
 
 
(E)-(R)-((S)-methylthio-2-oxoazetidin-3-yl)ethyl 3-(3,4-bis(tbutyldimethylsilyloxy)phenyl)acrylate 
(53) 
In a 100mL two-necks flask under nitrogen atmosphere 150mg 
(0.93mmol) of 41 were dissolved in 21.0mL of anhydrous DCM before 
adding 380mg (0.93mmol) of acid 51, 115mg (0.93mmol) of DMAP and, 
at 0°C, 178mg (0.93mmol) of EDC. The reaction was monitored by TLC 
and quenched at 0°C with HCl until neutrality, then extracted with 
EtOAc, dried over Na2SO4, filtered and concentrated in vacuum to reach 53 as a yellow oil in 55% yield 
(280mg) after purification via flash-chromatography (cyclohexane/EtOAc 85/15). 
Rf 0.37 (cyclohexane/EtOAc 60/40) 
[α]D = -41.5° 
1
H NMR (400MHz, CDCl3): δ 0.22 (s, 2H, Me2Si of TBS), 0.23 (s, 2H, Me2Si of TBS), 0.99 (s, 9H, 
Me3C of TBS), 1.01 (s, 9H, 3Me), 1.45 (d, J = 6.4Hz, 3H, Me), 2.47 (s, 3H, SMe), 3.45 (dt, J = 2.4, 
4.0Hz, 1H, CH), 3.53 (t, J = 5.6Hz, 1H, CH2), 3.54 (dd, J = 2.4, 4.0Hz, 1H, CH2), 5.35 (dq, J = 6.0, 6.4Hz 
, 1H, CHMe), 6.19 (d, J = 16.0Hz, 1H, =CH), 6.82 (d, J = 8.8Hz, 2H, Ar), 7.01 (m, 1H, Ar), 7.57 (d, J = 
16.0Hz, 1H, =CH) ppm 
13
C NMR (100MHz, CDCl3): δ -4.2, -4.1, 18.3, 18.4, 18.5, 21.8, 25.7, 25.8, 46.8, 56.7, 68.0, 115.1, 120.3, 
121.0, 122,3 127.6, 145.2, 147.1, 149.5, 166.1, 169.9 ppm 
IR: ṽ = 3411, 2930, 2858, 1770, 1709, 1633, 1595, 1567, 1508, 1423, 1289, 1163, 1029, 906, 840, 782, 
735, 696 cm
-1
 
HPLC-MS: Rt = 32.94min, m/z: 574 (100) [M+Na]
+
, 1125 (15) [2M+Na]
+
 
 
(E)-(R)-1-((S)-1-(methylthio)-2-oxoazetidin-3-yl)ethyl 3-(3,4-dihydroxyphenyl)acrylate (36) 
In a 50mL three-necks flask under nitrogen atmosphere 115mg (0.21mmol) 
of 53 were dissolved in 4.3mL of anhydrous MeCN before slowly adding, 
at 0°C, 60μL of BF3·Et2O. After 30 minutes stirring at 0°C the reaction was 
allowed to reach room temperature and was quenched at 0°C with a pH = 6 
phosphate buffer aqueous solution at starting material disappearance, then 
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allowed to r.t., extracted with EtOAc, dried over Na2SO4, filtered and concentrated in vacuum to reach 36 
as a yellow waxy solid in 95% yield (64mg) after purification via flash-chromatography 
(cyclohexane/EtOAc 80/20). 
Rf 0.45 (cyclohexane/EtOAc 60/40) 
[α]D = -44.8° 
1
H NMR (400MHz, CDCl3): δ 1.33 (d, J = 6.4Hz, 3H, Me), 2.44 (s, 3H, SMe), 3.52 (dt, J = 2.4, 4.0Hz, 
1H, CH), 3.54 (t, J = 5.6Hz, 1H, CH2), 3.58 (dd, J = 2.0, 2.4Hz, 1H ,CH2), 5.35 (dq, J = 6.0, 6.4Hz, 1H, 
CHMe), 6.22 (d, J = 16.0Hz, 1H, =CH), 6.85 (d, J = 8Hz, 1H, Ar), 7.08 (d, J = 8Hz, 1H, Ar), 7.13 (s, 1H, 
Ar), 7.52 (d, J = 16.0Hz, 1H, =CH), 8.16 (bs, OH), 8.45 (bs, OH) ppm 
13
C NMR (100MHz, CDCl3): δ 17.8, 20.8, 45.9, 56.6, 67.4, 114.3, 114.5, 115.5, 121.7, 126.6, 145.2, 
145.4, 147.9, 165.6, 169.5, 205.4 ppm 
IR: ṽ = 3365, 2926, 1735, 1601, 1515, 1445, 1363, 1263, 1179, 1055, 983, 856,  816 cm-1 
HPLC-MS: Rt = 5.33min, m/z: 324 (100) [M+H]
+
, 346 (15) [M+Na]
+
, 669 (80) [2M+Na]
+ 
 
(2S,3R)-3-chloro-1-(methylthio)-4-oxoazetidin-2-yl acetate (53) 
A 1M solution of LiHMDSA (605μL, 0.605mmol) was added to a solution of 52 (70mg, 
0.55mmol) in THF (5.5mL) at -78°C under inert atmosphere, followed by methanesulfonyl 
chloride (130μL, 2.5mmol) added drop by drop. The solution was allowed to warm at room 
temperature and was monitored by TLC (cyclohexane/EtOAc 50/50). After 3h the reaction 
was quenched with aqueous NH4Cl and extracted with EtOAc (x2) and DCM (x3). The organic extracts 
were dried over Na2SO4, filtered and concentrated in vacuum. The residue was then recovered and 
purified by flash-chromatography (cyclohexane/EtOAc 70/30) to afford product 53 in an overall 16.5% 
yield. 
Rf 0.64 (cyclohexane/EtOAc 50/50) 
[α]D 25 = +226.0° (c = 3.1, DCM) 
1
H (400MHz, CDCl3): 2.24 (s, 3H, MeCO), 2.57 (s, 3H, SMe), 5.09 (d, J = 4.0Hz, 1H, ClCHACHB), 6.12 
(d, J = 3.2Hz, ClCHACHB) ppm 
13
C (100MHz, CDCl3): 20.7, 22.9, 61.0, 76.7, 77.0, 77.3, 165.4, 169.6 ppm 
IR: ṽ = 2923, 2359, 1791, 1756, 1699, 1221, 1162, 1090 cm-1 
HPLC-MS: Rt = 4.91min, m/z = 168 [M-AcO+H2O]
+
, 210 [M+H]
+
, 227 [M+H2O]
+
, 229 [M(
37
Cl)+H2O]
+
, 
232 [M+Na]
+
 
 
(2R,3R)-3-chloro-1-(methylthio)-4-oxoazetidin-2-yl acetate (55) 
A 1M solution of LiHMDSA (605μL, 0.605mmol) was added to a solution of 52 (70mg, 
0.55mmol) in THF (5.5mL) at -78°C under inert atmosphere, followed by methanesulfonyl 
chloride (130μL, 2.5mmol). The solution was allowed to warm to room temperature and was 
monitored by TLC (cyclohexane/EtOAc 50/50). After 3h the reaction was quenched with 
aqueous NH4Cl and extracted with EtOAc and DCM. The organic extracts were dried over Na2SO4 and 
the residue was purified by flash-chromatography (cyclohexane/EtOAc 70/30) to afford product 55 in 5% 
yield. 
Rf 0.78 (cyclohexane/EtOAc 50/50) 
[α]D = +13.0° (c = 0.9, DCM) 
1
H (400MHz, CDCl3): 2.21 (s, 3H, MeCO), 2.55 (s, 3H, SMe), 4.74 (d, J = 0.8Hz, 1H, ClCHACHB), 6.03 
(d, J = 0.4Hz, ClCHACHB) ppm 
13
C (100MHz, CDCl3): 20.7, 22.6, 61.5, 76.7, 77.0, 77.3, 164.1, 169.4 ppm 
IR: ṽ = 2924, 2853, 1799, 1759, 1216, 1156, 1048cm-1 
HPLC-MS: Rt = 4.77min, m/z = 168 [M-AcO+H2O]
+
, 227 [M+H2O]
+
, 229 [M(
37
Cl)+H2O]
+
, 232 
[M+Na]
+ 
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Thiomethylation optimized general procedure 
In a 10mL two-necks flask under nitrogen atmosphere 22.5μL (0.25mmol) of dimethyl disulfide were 
dissolved in 0.45mL of anhydrous THF before slowly adding, at 0°C, 22.3μL (0.275mmol)of sulfuryl 
chloride dissolved in 0.55mL of THF. After 5-10 minutes stirring at 0°C β-lactam substrate (0.55mmol, 
143mg for B) were added, followed by slowly dropped TEA (77μL, 0.55mmol). The reaction was 
allowed to reach r.t. after 15min and quenched with saturated aqueous NH4Cl solution after 1h stirring, 
then extracted with DCM, dried over Na2SO4 and concentrated in vacuum to reach the desired product 
after FC purification (cyclohexane/EtOAc 80/20 for B). 
 
3.3.5 Lead β-lactam synthesis optimization 
For the isomerization step, we identified as optimal reaction conditions the use of MeCN as solvent, 
DMAP as catalyst in 10% loading, and 4h stirring at 50°C as best time and temperature conditions. 
For the kinetic study of isomerization process, 0.4mL of an E-isomer MeCN mother solution (0.125M, 
0.05mmol) were put in five different reaction vessels already brought at the working temperature. Were 
then added a 0.1mL of a 0.05M DMAP solution in MeCN (0.005mmol). After 1h stirring the reactions 
were directly evaporated, dissolved in CDCl3 and analyzed at 
1
H-NMR for E/Z ratio determination. For 
the esterification process, in a 10mL flask 132mg (0.3mmol) of (Z)-benzyl 2-((S)-3-(R)-1-hydroxyethyl-
4-oxoazetidin-2-ylidene) acetate (the β-lactam intermediate) were dissolved in 2.0mL of chlorobenzene 
before adding 121mg (0.474mmol) of acid 19, 7mg (0.06mmol) of DMAP and 98mg (0.474) of DCC. 
The reaction was then treated for 10 minutes with MW irradiation at 40W, monitored by TLC 
(cyclohexane/EtOAc 50/50) and finally purified by FC (DCM/MeCN 97/3) to reach the target compound 
in a 67% yield (100mg), in the best case. 
 
3.3.6 Thermostability 
For thermostability evaluation, in 0.6mL of milliq. water were suspended and  sonicated 0,63mg of 56. 
First HPLC-MS analysis were made after one week in these conditions, then after 30min stirring at 60°C, 
and finally after 60min stirring at 70°C. After both the thermal treatments, water was evaporated and 
0.6mL of CDCl3 were added to record 600MHz
 1
H-NMR spectra. The same thermostability analysis was 
performed on 0.64mg of compound 57, chose as internal standard, (see below) in 0.6mL of milliq. water. 
 
3.3.7 Analysis method development 
(Z)-Benzyl 2-((S)-3-(R)-1-hydroxyethyl-4-oxoazetidin-2-ylidene) acetate (the free alcohol β-lactam 
intermediate) was prepared as previously reported [19]. 
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Methyl 4-(ethoxymethoxy)-3-methoxybenzoate (58) 
In a 100mL 3-necks flask with an addition funnel, to a suspension of NaH (60% 
in oil, 256mg, 6.4mmol) in 1.05mL of anhydrous THF was added dropwise at 
0°C a solution of methyl 4-hydroxy-3-methoxybenzoate (898mg, 4.93mmol) in 
THF (8.0mL) and, after 10min, a solution of EOM-chloride in 7.0mL of THF. 
The reaction was allowed to stir at r.t. and was followed by TLC monitoring (cyclohexane/EtOAc 50/50). 
At the disappearance of SM (2h) it was quenched with a saturated NH4Cl solution until pH = 6, then 
extracted with EtOAc (3x15mL) and evaporated to afford only 58 as a yellow oil (1.183g, y = 99%). 
Rf 0.75 (cyclohexane/EtOAc 50/50) 
1
H (400MHz, CDCl3): 1.23 (t, J = 14.4Hz, 3H, Et), 3.78 (quartet, J = 14.0Hz, 2H, Et), 3.90 (s, 3H, 
COOMe), 3.94 (s, 3H, OMe), 5.35 (s, 2H, OCH2O), 7.21 (d, J = 17.2Hz, 1H, Ar) ), 7.57 (d, J = 4.0Hz, 
1H, Ar) ), 7.65 (dd, J = 3.6, 16.8Hz, 1H, Ar) ppm 
13
C (100MHz, CDCl3): 14.7, 51.5, 55.6, 64.2, 93.3, 112.2, 114.4, 123.0, 123.5, 148.8, 150.4, 166.3 ppm 
IR: ṽ = 3409, 2952, 1712, 1598, 1513, 1435, 1293, 1112, 765 cm-1 
HPLC-MS: Rt = 7.37min, m/z = 241 (100) [M+H]
+
, 263 (14) [M+Na]
+
 
 
4-(ethoxymethoxy)-3-methoxybenzoic acid (59) 
In a 100mL flask 58 (1.183g, 4.93mmol) was dissolved in 9.86mL of THF and 
4.93mL of MeOH, then a solution of NaOH (986mg, 24.64mmol) in water 
(4.93mL) was added and the reaction left stirring at r.t. until SM disappearance 
(18h). EtOAc was then added (2x10mL), the aqueous phases recovered and 
treated at 0°C with an aqueous HCl solution (1M) to reach pH = 7-8, then extracted again with EtOAc 
(1x10mL), and finally was added HCl (1M) until pH = 5 to allow EtOAc (3x10mL) extraction, Na2SO4 
anhydrification, filtration and in vacuum concentration of the desired product. 59 was obtained as white 
solid (568mg) in 51% yield, eventually recrystallizing from MeCN. 
M.p. (133-135)°C; Rf 0.21 (cyclohexane/EtOAc 50/50) 
1
H NMR (400MHz, CD3OD): δ 1.24 (t, J = 7.2Hz, 3H, Et), 3.79 (quartet, J = 6.8Hz, 2H, Et), 3.96 (s, 3H, 
OMe), 5.38 (s, 2H, OCH2O), 7.25 (d, J = 8.4Hz, 1H, Ar), 7.63 (d, J = 1.6Hz, 1H, Ar), 7.75 (dd, J = 1.6, 
8.4Hz, 1H, Ar) ppm 
13
C NMR (50MHz, CDCl3): δ 15.0, 56.0, 64.7, 93.7, 112.8, 114.6, 122.9, 124.3, 149.1, 151.4, 171.9 ppm 
IR: ṽ = 3396, 3048, 2962, 2901, 1681, 1590, 1458, 1426, 1279, 1116, 737 cm-1 
HPLC-MS: Rt = 11.07min, m/z: 225 (100) [M-H]
-
 
 
(R)-1-((S,Z)-2-(2-(benzyloxy)-2-oxoethylidene)-4-oxoazetidin-3-yl)ethyl 
4-(ethoxymethoxy)-3-methoxybenzoate (60) 
In a 50mL 2-neck flask, to a solution of (Z)-benzyl 2-((S)-3-(R)-1-
hydroxyethyl-4-oxoazetidin-2-ylidene) acetate (the 4-alkylidene β-
lactam intermediate, 83mg, 0.32mmol) in DCM (12.0mL) was 
added 59 (115mg, 0.51mmol), DMAP (8mg, 0.064mmol) and, at 
0°C, DCC (105mg, 0.51mmol), allowing to reach r.t. after 15 
minutes and then to stir 40 hours before quenching the reaction with water, extracting with DCM 
(3x10mL), evaporating and recovering five times with EtOAc to remove the insoluble DC-Urea. The 
mixture was concentrated in vacuum and the crude was finally purified by flash-chromatography 
(DCM/MeCN 98/2 to 95/5) to afford 60 in 16% yield (24mg) as a colorless oil. 
Rf 0.81 (cyclohexane/EtOAc 30/70), 0.58 (cyclohexane/EtOAc 50/50) 
[α]D = +13.6° (c = 4.36mg/mL, DCM) 
1
H NMR (400MHz, CD3OD): δ 1.22 (t, J = 7.2Hz, 3H, Et), 1.52 (d, J = 6.4Hz, 2H, Me), 3.77 (quartet, J = 
7.2Hz, 2H, Et), 3.90 (s, 3H, OMe), 4.02 (d, J = 6.4Hz, 1H, MeCHCH), 5.15 (d, JAB = 12.4Hz, 1H, Bn), 
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5.19 (d, JAB = 12.0Hz, 1H, Bn), 5.28 (s, 1H, CHCOOBn), 5.34 (s, 2H, OCH2O), 5.48 (quintet, J = 6.4Hz, 
1H, MeCHCH) 7.20 (d, J = 8.0Hz, 1H, Ar), 7.32-7.37 (m, 5H, Bn), 7.54 (d, J = 2.0Hz, 1H, Ar), 7.61 (dd, 
J = 2.0, 8.8Hz, 1H, Ar), 8.70 (bs, 1H, NH) ppm 
13
C NMR (100MHz, CDCl3): δ 15.0, 18.1, 55.9, 61.6, 64.6, 66.1, 67.1, 90.6, 93.6, 112.4, 114.7, 123.2, 
123.4, 128.3, 128.5, 135.7, 149.2, 151.0, 152.2, 164.6, 165.0, 166.6 ppm 
IR: ṽ = 3295, 2980, 1822, 1704, 1658, 1601, 1511, 1268, 1217, 1139, 1109, 736 cm-1 
HPLC-MS: Rt = 9.99min, m/z: 487 (100) [M+H2O]
+
, 961 (13) [2M+Na]
+
 
 
(R)-1-((S,Z)-2-(2-(benzyloxy)-2-oxoethylidene)-4-oxoazetidin-3-yl) 
ethyl-4-hydroxy-3-methoxybenzoate (57) 
In a 25mL two-necks flask were dissolved under nitrogen 
atmosphere 22mg of 60 (46.9μmol) in 5.8mL of anhydrous DCM, 
followed by 23.1 TFA equivalents distributed, every 30min, in 5 
hours and always added at 0°C. At starting material disappearance 
the reaction was directly concentrated to afford 57 in 99% yield 
(19mg) as a sticky-waxy solid after pentane titration. 
Rf 0.01 (cyclohexane/EtOAc 40/60) 
[α]D = +11.3°(c = 3.45mg/mL, DCM) 
1
H NMR (400MHz, CDCl3): δ 1.52 (d, J = 6.4Hz, 2H, Me), 3.91 (s, 3H, OMe), 4.02 (d, J = 6.0Hz, 1H, 
MeCHCH), 5.15 (d, JAB = 12.0Hz, 1H, Bn), 5.19 (d, JAB = 12.0Hz, 1H, Bn), 5.28 (s, 1H, CHCOOBn), 
5.48 (quintet, J = 6.0Hz, 1H, MeCHCH) 6.94 (d, J = 8.4Hz, 1H, Ar), 7.33-7.37 (m, 5H, Bn), 7.51 (s, 1H, 
Ar), 7.60 (d, J = 8.4Hz, 1H, Ar) 8.73 (bs, 1H, NH) ppm 
13
C NMR (50MHz, CDCl3): δ 18.1, 56.0, 61.7, 66.2, 67.1, 90.6, 111.8, 114.2, 121.7, 124.3, 128.2, 128.3, 
128.6, 135.7, 146.4, 150.4, 152.2, 164.7, 165.0, 166.7 ppm 
IR: ṽ = 3379, 2933, 2852, 1819, 1699, 1659, 1597, 1514, 1282, 1220, 1144, 1029 cm-1 
HPLC-MS: Rt = 8.32min, m/z: 409 (100) [M-H]
-
; 429 (100) [M+H2O]
+
, 845 (36) [2M+Na]
+ 
 
SPE pre-treatment and HPLC/MS-MS analysis 
All solvents employed were LC-MS grade and were used with 0,1% of LC-MS grade HCOOH when 
specified. 
Was used an SPE Waters Oasis HLB 3cc column, preconditioned with 3mL MeCN + 0,1% HCOOH 
followed by 3mL H20 + 0,1% HCOOH and then loaded with the dried sample recovered in 150μL of a 
95/5 mixture of H20 + 0,1% HCOOH and MeCN + 0,1% HCOOH: the first fraction (f1) was so collected. 
Three 1mL H20 + 0,1% HCOOH fractions were then eluted, followed by a sequence of 1mL 80/20 of H20 
+ 0,1% HCOOH and MeCN + 0,1% HCOOH (f5), 1mL of a 60/40 mixture (f6), 1mL of 40/60 (f7) and 
1mL of 20/80 (f8). 
The HPLC column Waters XSelect HSS T3 3.5µm (2.1x150mm) was conditioned at 0.3mL/min with two 
cycles  H2O/MeCN 80/20 → 20/80 (10min), then 5min → 80/20 (10min), then 5min → 40/60. 
Were always injected 20μL of samples via a 250μL Hamilton syringe, washed every time with a 1/1 
mixture of H20 + 0,1% HCOOH and MeCN + 0,1% HCOOH. 
The analysis was performed at 0.3mL/min, with H2O/MeCN 90/10 → 10/90 (10min), then 5min → 90/10 
(5min), for a 20min overall running time. 
Rt (56, 57): 12.3-12.6min (due to manual injection and analysis starts) 
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The  MS-MS analysis was made on a WatersMicromassQuattroPremier XE, with parameters optimized 
for 56 (440.16 [M-H]
-
 → 196.77 [Syringic-H]-). To monitoring 57 were employed the same conditions, 
but working on different ions (410.06 [M-H]
-
 → 166.84 [Vanillic-H]-). 
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4. NUCLEOPHILIC SUBSTITUTIONS IN WATER 
4.1 Green synthesis of new antioxidant β-lactams 
4.1.1 Water as solvent 
Unlike what occurs today, water was used as reaction solvent in the development of the first organic 
chemistry industrial processes. In 1828, F.Wohler developed urea synthesis by heating an aqueous 
solution of ammonium isocyanate. During years, water has been substituted by hydrocarbon solvents and 
its use decreased to very few processes. This was due to the improvement of petrol industries and 
organometallic chemistry, which employs reagents extremely sensitive to moisture and air.
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Recently, the re-discovery of water as a solvent was linked to the growth of an environmental awareness 
in the community. Therefore, chemical transformations started to be designed with more sustainable 
approaches. The use of the so-called green solvents is one of the already mentioned “Green Chemistry” 
principles, and water is of course included in environmentally friendly solvents. 
The advantages of using water are extremely interesting in terms of safety, toxicity, costs (no organic 
solvent is so cheap as water) and eco-compatibility. However, its use in organic reactions is not so easy to 
implement. A solvent must allow the dissolution of reagents without reacting with them, and it needs to 
be easy eliminated at the end, allowing product isolation. Many organic reagents and compounds are 
poorly soluble in water, and various functional groups are reactivity towards water. 
It is impossible to modify intrinsic reactivity of water, but the low solubility of organic compounds could 
be bypassed. In this regard, some interesting strategies were developed: 
- ionic derivatization, which consists in varying pH of aqueous solutions to increase the solubility of 
ionizable substances. For example, it was exploited the use of buffer solutions that maintain constant the 
pH.
101
 It is often possible to recover products by precipitation, varying back the solution pH; 
- use of surfactants, amphiphilic molecules characterized by a hydrophilic and a hydrophobic portion. At 
specific concentrations (called critical micellar concentrations CMCs), surfactants can form aggregates in 
water. These micelles are spheroidal structures characterized by a hydrophobic core and a hydrophilic 
outer surface. Thus, hydrophobic molecules can be incorporated, allowing their solubilization in water. 
The reaction efficiency is in some cases also increased, because of a contact promotion between reactive 
species inside micelles; 
- use of cyclodextrins (CD), oligosaccharides formed by 6, 7 or 8 monomers of D-(+)-glucopyranose α-
linked through 1-4 glucosidic bonds. CDs are characterized by a truncated conical structure with all 
hydroxyl groups placed in the outer region, hence resulting water-soluble. The internal cavity is 
hydrophobic, allowing complexes formation with suitable dimensioned hydrophobic molecules and 
“increasing” their water-solubility;102 
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functionalization with hydrophilic molecules, a method borrowed from medicinal chemistry to allow the 
transport of drugs into body. It consists in covalently binding small hydrophilic molecules to hydrophobic 
substances, increasing their solubility in aqueous environments; 
- use of an organic cosolvent miscible with water: polar protic solvents such as low MW alcohols, and 
aprotic compounds such as dimethylformamide, dimethylsulfoxide, acetonitrile or acetone are commonly 
employed. Formation of hydrogen bonds, which usually determine the insolubility of many apolar species 
in water, .results decreased. 
The last method is the most applied and constitutes a good compromise for many chemical 
transformations commonly carried out in organic solvents. The use of water as solvent in organic 
synthesis still be a poorly explored field, albeit highly challenging and interesting especially for large-
scale processes. 
 
4.1.2 nucleophilic substitution in water on β-Lactam compounds. 
As a part of a project aimed to introduce polyphenolic antioxidant moieties on antibiotic β-lactams, we 
tried to exploit the reactivity of two commercially available β-lactams (Figure 4.1.1) in water. We 
developed and optimized a nucleophilic substitution reaction of the C-4 acetate group that can be carried 
out in water under mild conditions.  
 
Figure 4.1.1 Commercially available β-lactams 
We conducted a preliminary screening on β-lactams 1 and 2 for choosing the best combination of solvent, 
basic catalysts and reaction conditions, We used resorcinol as nucleophile, as in Scheme 4.1.1. 
 
Scheme 4.1.1 Reaction of 4-acetoxy β-lactams and resorcinol 
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Solvent importance in nucleophilic substitutions is well known. On one hand, protic solvent such as water 
strongly increased monomolecular substitutions, like this process seems to be, but on the other hand 
organic reactions are always hard to proceed in water. Above solubility, β-lactams can undergo ring 
opening reactions with water as nucleophile. 
Hence, the base used became very relevant. Morover, its importance is also related to the discrimination 
of the two possible products derived from a mono- or a di-substitution of resorcinol alcoholic functions 
(Scheme 4.1.1). For our purposes, at least one phenolic group must be kept free in order to achieve an 
antioxidant action on the synthesized molecules. 
Therefore, conditions screening was directed to yield increasing and to the optimization of the processes 
selectivity. 
 
Co-solvent screening 
At first, we worked with triethylamine as base and we varied reaction mediums and stirring times (as 
summeryzed inTable 4.1.1, *: yield for flash-chromatography or Prep HPLC isolated products; **: yield 
calculated from
 1
H-NMR crude spectra; ***: conversion for the two starting materials). 
entry β-Lactam Solvent T t conv
***
 % y (a) % y (b) % 
1 1 H2O r.t. 24h 40% 5%** 20%** 
2 1 H2O 70°C 24h 35% 4% ** 13%** 
3 1 MeCN r.t. 5d 75% 7%** 15%** 
4 1 H2O/MeCN(30%) r.t. 8h 100% 14%* 25%* 
5 2 H2O r.t. 4h 100% 13%** 16%** 
6 2 H2O/MeCN(30%) r.t. 4h 100% 15%* 25%* 
Table 4.1.1 Optimization of reaction conditions 
The use of water as reaction solvent in the presence of a completely miscible organic co-solvent (MeCN 
at 30%) appears to be the preferred choice in terms of yields and conversions (entries 4 and 6). In water, 1 
is not soluble: this lowered the conversion even conducting the reaction at higher temperatures (entries 1 
and 2). For the water soluble substrate 2, although a complete conversion was reached, yields were lower 
than those obtained in the presence of organic co-solvents. In only organic solvents, the reaction showed  
a slow kinetic, and after 5 days the reaction was not yet complete. 
These observations suggested that water plays a key role in the nucleophilic substitution mechanism of 
the reaction. As a matter of facts, a polar protic solvent can stabilize intermediate carbocation of the 
monomolecular substitution mechanism, with a leaving group solvation. Moreover, the activation energy 
for the rate determining step was lowered, speeding up the reaction kinetic (Scheme 4.1.2). 
 
Scheme 4.1.2 Monomolecular nucleophilic substitution mechanism 
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The monomolecular mechanism hypothesis was further corroborated by the obtainment of a 3,4-trans 
azetidinone diastereoisomer starting from enantiomerically pure 1, with a complete configuration 
retention at C-4, as shown by NMR analysis of coupling constants. 
As last observation, reaction times resulted shorter for 2, which disappeared in 3-4 hours, than for  1 (total 
conversion in 8-10h). 
 
Regioselectivity and base screening 
The possibility of a double etherification on both the phenolic groups is related to the different acidity of 
resorcinol itself, which pka is 9.15, and a derivatives, which can be assimilated to m-methoxyphenol, with 
a slightly higher pka of 9.6544. 
To try optimizing this aspect and the whole process, mainly in terms of yield, different organic and 
inorganic bases were tried (as summarized Table 4.1.2 and Table 4.1.3, respectively for substrate 1 and 2; 
*: yields evaluated on products isolated from FC or Prep HPLC; **: yields calculated from
 1
H-NMR 
crude spectra). 
Stoichiometric amounts of the base resulted necessary. Moreover, for both substrates NaOH gave the best 
results in term of conversion and a/b ratio. NaOH, a strong inorganic base, was therefore chosen as 
reference base for all the subsequent studies and synthesis of these derivatives. 
entry Base Base eq. Conv** % y (a) % y (b) % t 
1 none - 0% - - 24h 
2a 
2b 
Et3N 
1 
0.1 (10%) 
100% 
17% 
24%* 
9%** 
20%* 
- 
8h 
8h 
3 Et2NH 1 85% 17%** <2%** 10h 
4 NaOH 1 100% 38%* 18%* 8h 
5 NaHCO3 1 100% 15%** 23%** 10h 
6 AcONa 1 0% - - 48h 
Table 4.1.2 Base screening on 1 
entry Base Base eq. Conv** % y (a) % y (b) % t 
1 none - 0% - - 8h 
2 Et3N 1 90% 12%** 19%** 3h 
3 Et2NH 1 100% 4%* - 4h 
4 NaOH 1 100% 29%** 16%** 3h 
5 NaHCO3 1 70% 7%* 13%* 3h 
Table 4.1.3 Base screening on 2 
 
Conditions  screening 
Reaction conditions screening was made in order to optimize the synthesis of both products a and b. 
For a products, an excess of resorcinol was use (Table 4.1.4, entry 1). It does not lead to the expected 
results. Trying to maintain β-lactam SM always in a low concentration comparing to the one of phenol, 
was evaluated a biphasic system (Table 4.1.4, entry 2): unfortunately a product, when formed, was able to 
be distributed in both phases and react giving b. 
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entry SM 3 Conditions Conv % y (a) % y (b) % 
1 1, 1eq. 2eq. excess of 3 100% 16% 24% 
2 1, 1eq. 1eq. cHex/H2O 50% 7% 13% 
3 1, 1eq. 1eq. 1 dropped in 3 100% 38% 18% 
4 2, 1eq. 1eq. 2 dropped in 3 100% 29% 17% 
5 2, 1eq. 1eq. 3 dropped in 2 100% 25% 13% 
6 1, 1eq. 1eq. 3 dropped in 1 100% - 68% 
7 2, 1eq. 1eq. 3 dropped in 2 100% - 59% 
Table 4.1.4 Optimization of reaction conditions  
The reaction was then conducted slowly dropping a H2O/MeCN solution of SM on a basic solution of 3, 
reaching the best results although without a complete selectivity (Table 4.1.4, entries 3 and 4). 
On the contrary, the obtainment of b products required a slowly addition of the aqueous NaOH solution to 
SM dissolved in H2O/MeCN (Table 4.1.4, entries 6 and 7), allowing yields up to 60-70%. 
 
Nucleophilic substitution with other poly-hydroxylated phenols 
Once setup and optimized the procedure on both the substrates 1 and 2, it was applied to synthesize a 
small library of products working with a series of poly-hydroxylated phenols. Pyrocatechol was the first 
nucleophile employed (Scheme 4.1.2, *: yields after flash-chromatography for 1 and after or Prep HPLC 
for 2). 
Reaction with pyrocatechol and 2 gave product 8a and 6b in relative ratio and yield fully comparable with 
the results obtained using resorcinol. Thus, hindrance resulting from the hydroxyl group in ortho does not 
disfavor the formation of the dimer. 
With substrate 1, ratio of product a and b favors the latter. 
 
Scheme 4.1.2 Substitutions with pyrocatechol 
Considering what stated before, it can be assumed that monomer 7a, once deprotonated and due to a 
mesomeric +m effect of -OR substituent in o position, constitutes a stronger nucleophile of the monomer 
4a, which has instead the substituent -OR in m. 
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As regarding nucleophilic substitution with phloroglucinol on substrate 2, all three possible products were 
isolated (Scheme 4.1.4, *: yields after flash-chromatography). Even in this case, steric hindrance on the 
three positions played no role in favoring less substituted products. 
Moreover, the three products have 
1
H-NMR signals belonging to other minor β-lactam species, which 
could be derived from C-coupling, due to electronic activation of phloroglucinol ring by enolic positions. 
However, eing present in very small amounts and having retention factors almost identical to those of 
majors species, were not isolated. 
 
Scheme 4.1.3 Substitutions with phloroglucinol 
Nucleophilic substitutions with 3,5-dihydroxybenzyl alcohol showed on 2 the same behavior of what 
observed with resorcinol, both in terms of yield and a/b ratio, whereas 1 gave replacement products in 
almost equivalent amounts of a and b (Scheme 4.1.4, *: yields after Prep HPLC for 1, and after flash-
chromatography for 2). 
 
Scheme 4.1.4 Substitutions with 3,5-dihydroxybenzyl alcohol 
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Finally, when reacted with 4-hydroxybenzyl alcohol, 1 gave substitution only on the phenolic hydroxyl 
group (Scheme 4.1.5). 
 
Scheme 4.1.5 Substitution with 4-hydroxybenzyl alcohol 
 
Stereochemistry 
An important aspect in studying the products obtained concerns the stereochemistry. Starting from 
substrate 1, enantiomerically pure with 3 stereogenic centers well defined in absolute configuration R, 
were obtained products existing in single enantiomers. Indeed, all the reactions involved a configuration 
retention at C-4, due to steric effects: substitution could happen only by nucleophile attack from the less 
hindered side of the aciliminium intermediate. 
On the contrary, reactions with 4-acetoxy-azetidinone 2 gave products a as racemic mixtures and b as 
different diastereoisomers, it was used as racemic mixture and there were no stereochemical controls that 
guides the nucleophile attacks. Considering the species 5b obtained in the reaction with resorcinol, it is 
clear that two diastereoisomers can exist: one is a meso form and the other is constituted by the pair of 
two enantiomers (R,R) and (S,S) (Figure 4.1.2). Moreover, same considerations can be extended to every 
b product synthesized with nucleophilic substitution of the acetoxy group on substrate 2. 
We then focused our attention on two of the products obtained from substrate 2: compound 5b resulting 
from coupling with resorcinol (in Figure 4.1.2), and compound 7b derived from reaction with 
phloroglucinol (Figure 4.1.3). 
 
Figure 4.1.2 Analysis of 2b products 
Purification by flash-chromatography on 5b did not allowed any separation. Then, a sample was analyzed 
by chiral HPLC separating three peaks of percentage areas, respectively, of 22%, 50% and 28%. These 
values could be related to the first enantiomer, the meso form and the second enantiomer. For peaks 
related to the two enantiomers would expect areas equal to 25%, given that in the reaction there was no 
enantioselection. Unfortunately, the separation was not optimal due to the close retention times of the two 
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enantiomers and of the meso form. However, it can be deduced that the two diastereoisomers were 
formed in equal amounts (50% - 50%) and therefore the reaction was not diastereoselective or did not 
proceed with a preferential formation of one diastereoisomer over the other. 
 
Figure 4.1.3 Analysis of 10b products 
For 10b the 
13
C-NMR showed two sets of signals which indicates the presence of two species not 
chemically equivalent. This corresponds to the two diastereoisomers represented in Figure 4.1.3. The 
recorded signals had relative percentage of 53% and 47%, suggesting that also in this case the reaction 
did not proceeded with diastereoselectivity. The mixture was then analyzed by chiral HPLC, separating 
two peaks whose areas were 23% and 76%. It can be assumed that the first peak belongs to one 
enantiomer and the second one to the overlap of the not separated meso form and second enantiomer. The 
hypothesis was supported by perfect match between the ratio of diastereoisomers obtained by chiral 
HPLC and those calculated from 
13
C-NMR (53% to 47%). 
 
Chemoselectivity 
Chemoselectivity of reaction between substrates 1 and 2 with p-amino and p-carboxylic acid substituted 
phenols was finally analyzed (Scheme 4.1.6). 
 
Scheme 4.1.6 Substitution with p-amino and p-carboxylic acid phenols 
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As from optimization phase, were used 2eq. of NaOH to promote deprotonation of acid hydrogens and of 
the phenolic OH, but a so hard basic environment was evidently not tolerated by the β-lactam, which 
underwent decomposition (Table 4.1.5, with * for yields evaluated on products isolated from flash-
chromatography, and ** for yields calculated from
 1
H-NMR crude spectra). Therefore, yield in the OH 
coupling product does not exceed 15% and the secondary product of the reaction, identified by 
1
H-NMR, 
was the ester of hydroxy benzoic acid 16 with itself. 
To avoid lactam decomposition, the same reaction was carried out with 1eq. of NaHCO3: conversion 
resulted very low due to the formation of sodium carboxylate, stabilized by resonance and thus slightly 
nucleophilic (Table 4.1.5, entry 2). With 1eq. of TEA the conversion was as well not complete. Moreover, 
next to 17a was identified by 
1
H-NMR of the crude the presence of a compound assumed to result from 
coupling with the carboxylate group, index of a poor selectivity of the process. 
The reaction was then conducted with 2eq. of TEA: TM yield increased, but the kinetics remained very 
slow (20h). It was in contrast with what observed in the previously studied reactions of poly-hydroxy 
phenols with 2, which were faster (2-4h). 
entry Base Conv % y % 
1 NaOH (2eq.) 100% 15%* 
2 NaHCO3 (1eq.) 10% - 
3 Et3N (1eq.) 60% 17%** 
4 Et3N (2eq.) 100% 36%* 
Table 4.1.5 Chemoselectivity with p-hydroxy benzoic acid on 2 
Working with aniline, without an other base was not observed any SMs conversion (Table 4.1.6, entries 1 
and 2). Clearly, aniline itself was not enough reactive to attack the β-lactam and promoting the product 
formation without a catalyst. 
Indeed, in presence of a base and with optimized conditions the reaction proceeded via nucleophilic 
substitution of the phenolic OH (entries 3 and 4). Products were subsequently isolated as acetic amide, 
after reactions with acetic anhydride, and analyzed. 
entry β-lactam SM Base Conv % 
1 1 - 0% 
2 2 - 0% 
3 1 NaOH 100% 
4 2 NaOH 100% 
Table 4.1.6 Chemoselectivity with p-hydroxy aniline 
 
Substitutions on N-SMe β-lactams 
Reactions were conducted on two β-lactam substrates (Figure 4.1.4), using resorcinol and implementing 
the conditions developed in the early stages of the study. 
Initially, NaOH was used as base, but since reactions did not lead to the expected products in appreciable 
yields a weaker base such as NaCO3 was chosen, even so without positive results. 
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Figure 4.1.4 N-SMe β-lactams used as SMs 
Finally, nucleophilic substitutions on the N-thiomethyl azetidinones were unsuccessful, a part from traces 
of the desired products observed by 
1
H-NMR analysis. Therefore, the hydrogen atom bonded to nitrogen 
was critical to the success of the substitution on the C-4 of the cycle. 
However, an effort was made to isolate by flash-chromatography purification an interesting amount of the 
most promising antioxidant and antibacterial compound. Derivative 23a was obtained by reacting the 
substrate 21 with resorcinol (Figure 4.1.6). 
 
Figure 4.1.6 Product 23a obtained in traces, isolated and characterized 
 
4.1.3 Activities 
All shown compounds were tested antibacterial and antioxidant activites. Unfortunately, they seems to be 
completely inactive as antibiotic, while the antioxidant potencies are comparable to the ones already 
shown by dual active β-lactams: this kind of activity seems to be mainly related to only phenolic moieties. 
Although we thought that a phenolic moiety in C-4 position of the ring could act as a leaving group, thus 
making the same task of acetoxy group in active compounds showed in Chapter 3, this was not exact. 
Furthermore, it was possible that recognition by enzyme target sites of these compounds has been missed. 
 
 
4.2 New β-lactam phosphate 
4.2.1 Nucleophilic phosphate buffer substitution on β-lactams 
As a matter of facts, we already observed that a phosphate group could be introduce on β-lactam 
compounds by a nucleophilic substitution on the C-4 acetate. We deepened this reaction on the two 
commercially available β-lactams 1 and 2 showed in Figure 4.1.1, analyzing how it was affected by scale, 
phosphate buffer pH and concentration, cosolvents, temperature and time. 
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The reference reaction was carried out stirring compound 2, more water soluble and reactive due to its 
less sterical hindrance, in 1M phosphate buffer (P buffer, pH = 7.5) for 2h, as shown in Scheme 4.2.1.  
 
Scheme 4.2.1 Nucleophilic phosphate substitution on 2 
Unfortunately, an HPLC analysis was not possible on such a polar compound, thus the structure was 
confirmed only by 
1
H, 
13
C and 
31
P NMR studies (the same also for compound 1, which reaction is shown 
in Scheme 4.2.2). 
 
Scheme 4.2.2 Nucleophilic phosphate substitution on 1 
At first, we observed the influence of scale, pH and reaction time on compound 1, less reactive and thus 
easier be used in optimizations. Data collected, reported in Table 4.2.1, showed that basic pH could 
increase the kinetic, as demonstrated from time needed to reach SM disappearance. 
However, increasing too much the pH led to side reactions and worse reaction crudes. Thus, best value 
identified was 7.5, with a buffer concentration of 1M. At least, the reaction scale seemed to be slightly 
relevant. 
 
SM, 
[mmol] 
pH, 
[Pbuffer] 
T [°C] t [h] 
2, 1.0 7.5, 1M r.t. 2 
2, 2.0 7.5, 1M r.t. 2 
2, 1.0 7.5, 1M r.t. 2 
2, 0.5 6.0, 1M r.t. 65 
2, 0.5 6.5, 1M r.t. 40 
2, 0.5 7.0, 1M r.t. 16 
2, 0.5 7.5, 1M r.t. 1 
2, 0.5 8.0, 1M r.t. 1 
2, 1.0 7.5, 1M r.t. 1 
2, 0.5 7.5, 1M r.t. 1 
2, 0.5 8.0, 1M r.t. 1 
Table 4.2.1 Scale, pH and time influence for 2 
Reaction on substrates 1 required harder conditions, mainly in term of temperature (Table 4.2.2). We 
found that 1-2h of reaction were enough only when temperature was increased up to 70°C. Probably, this 
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characteristic was related both to a lower reactivity, caused by the high steric hindrance, and a lower 
water solubility. However, the use of a cosolvent such as MeCN did not show particularly relevant yield 
increase, but it decreases the reaction selectivity, furnishing more complex crudes. 
 
SM, 
[mmol] 
pH, 
[Pbuffer] 
T [°C] t [h] 
1, 0.5 6.0, 1M 70°C 67 
1, 0.5 7.5, 1M 70°C 4 
1, 0.5 9.0, 1M 70°C 2 
1, 1.0 7.5, 1M 50°C 14 
Table 4.2.2 pH, temperature and time influence for 1 
Finally, we used the TBS-deprotected derivative of compound 1, obtaining from the NMR spectra a 1/4 
ratio between the two possible diastereoisomers. In this case, the less steric hindrance determined by the 
TBS absence determined a partial possibility to obtain a nucleophilic substitution also on the more 
hindered side of the molecule. 
 
3.2.2 New hydroxy-apatite β-lactam bioconjugates 
Hydroxyapatite is a rare mineral with chemical composition Ca5(PO4)3(OH). It belongs to the class of 
apatites and it contains an hydroxyl group. 
Hydroxyapatite is also produced and absorbed by organic tissues. As a matter of facts, it is one of the 
main components of bones, being in form of calcium salts such as CaCO3, Ca3(PO4)2 and CaF2. 
In cases of bones substitution or regeneration necessities, the best solution would be the use of patients’ 
own bones. Of course, this is not always possible, but the use of bones from cadavers or animals involves 
a certain number of risks, including rejection. Furthermore, it is difficult to overcome implications due to 
the use of bones with a remodeling mechanism very different from the human one, and with a lower 
quality because of aggressive treatments needed to minimize risks of disease transmission. For these 
reasons, synthetic bone substitutes are often used. 
However, bone substitutes must reproduce the porosity of cancellous bones, which can vary from 50% to 
about 80%. Furthermore, pores of bone substitutes must have the sufficient size so that cells can migrate 
through them as well as blood vessels can pass. Finally, porosities must be interconnected. 
Obviously, bone substitutes must also offer sufficient mechanical properties and they must satisfy a series 
of biological requirements. Thus, the best match with these necessities can be achieved only using natural 
hydroxyapatites bones. 
Zinc substituted hydroxyapatites are nowadays well known for bioactivities such as an increase in the 
growth of human adipose-derived mesenchymal stem cells, and antimicrobial capabilitie. Indeed, a 
significant decrease in the number of viable S. aureus bacteria was observed after Zn-hydroxyapatites 
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contact.
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 Moreover, it was recently shown that hydroxyapatite alternatives, such as with a certain 
percentage of Strontium atoms, can offer variously and interesting biological activities.
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Our improvement considered to enhance this materials by introducing antibiotic β-lactams via observed 
phosphate reaction on our 4-acetoxy derivatives. Moreover, we thought to introduce different β-lactams 
with specifically designed biological activities. 
For the preliminary studies, we worked with commercially available compounds 1 and 2, adding the most 
powerful antibiotic agent 21 (reported again in Figure 4.2.1). 
 
Figure 4.2.1 β-Lactam substrate 21 
We made different tentatives for introducing this moieties on various hydroxyapatites, prepared in 
collaboration with Professor A. Bigi group, University of Bologna. Ww founded that better conditions 
required no base presence and only water as solvent (see Experimental section for further details). Thus, 
Hydroxyapatites needed to be suspended in water and left stirring in presence of the β-lactams substrate, 
at different temperatures such as r.t. for 2 and 70°C for both 1 and 21. 
The obtained bioconjugates were recovered after centrifugation and drying. Their analysis were 
performed by both FT-ATR-IR and calorimetry, respectively for characterization and β-lactams contents 
quantification. As shown by IR spectroscopy, only β-lactam 2 was demonstrated to be chemically bonded 
with hydroxyapatites, while for 1 and 21 it seemed to be only a supportation. As a matter of facts, IR 
carbonyl signals changed in wavenumber for 2, while the same effect was not recognized for compounds 
1 and 21. Indeed, lowest reactivity of 1 and 21 was well known for our group. By calorimetry, we found 
to be able of introducing β-lactams amounts up to 10% of the hydroxyapatites weights for all the three 
substrates evaluated, depending to the preparative reaction loadings. 
Finally, we rapidly optimized the synthesis of dansyl β-lactam derivative 27 (Scheme 4.2.3). 
 
Scheme 4.2.3 Dansyl derivatization to compound 27 
Luminescent derivative 27 was also supported on hydroxyapatite, thus preparing bioconjugates with 
interesting photochemical properties, adequate for uses as bioprobe or tracer. Moreover, it allowed a 
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visual immediate demonstration of its supportation, thus demonstrating the properties on our β-lactam 
compounds to derivatized or to be carried by hydroxyapatites (Figure 4.2.2). 
  
Figure 4.2.2 Hydroxyapatite-27 bioconjugate 
Biological activities evaluation of these new hydroxyapatites biocojugates, at first in terms of antibiotic 
potencies, are currently under assessment. However, is already possible to wonder about the introduction 
of more active β-lactam antibiotics, such as a dual active compound also able to counteract inflammation 
processes, very common in bones substitutions. Moreover, due to the introduction mechanism, all the 
actually known β-lactam biologically activities can be successfully exploited in the preparation of other 
hydroxyapatites derivatives. 
 
 
4.2 Experimental section 
4.2.1 General informations 
As previously reported (Paragraph 2.3.1). 
 
4.2.2 Nucleophilic substitutions in water 
Azetidinones 1 and  2, and all the used phenols were commercially available, while compounds 21 and 22 
were prepared as previously specified. 
 
Poly-hydroxylated β-lactam ethers synthesis 
In a 50mL flask 0.5mmol of phenols were dissolved in 2mL of freshly prepared 0.25M NaOH aqueous 
solution. Then a H2O/MeCN 1/1 solution of 1 or 2 (0.5mmol in 3mL) were dropped in 30 minutes, 
following the reaction by TLC monitoring until SM disappearance. The reaction was then quenched by 
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NaCl addition to separate MeCN and water, which was acidified using aqueous HCl (1M) before 
extracting with EtOAc (3 times). The organic phases were dried over Na2SO4, then filtered and 
concentrated in vacuum, reaching the desired product/s via flash-chromatography or Pre-HPLC 
purifications. 
 
(3R,4R)-3-((R)-1-(tbutyldimethylsilyloxy)ethyl)-4-(3-hydroxyphenoxy) azetidin-2-one (4a) 
M.p. (119-124)°C, white solid; Rf 0.54 (cyclohexane/EtOAc 60/40) 
[α]D = 71.33° 
1
H NMR (400MHz, CDCl3): δ 0.08 (d, J = 6.8Hz, 6H), 0.88 (s, 9H), 1.276 (d, J = 
6.4 z, 3H), 3.31 (d, J = 3.2, 1H), 4.27 (dq, J = 3.2Hz, 6.4Hz, 1H), 5.68 (s, 1H), 6.37 
(s, 1H), 6.42 (m, 1H), 6.46 (dd, J = 2.0, 8.0Hz, 1H), 6.556 (dd, J = 2.4, 8.0Hz, 1H), 6.83 (s, 1H), 7.16 (t, J 
= 8.0Hz, 1H) ppm 
13
C NMR (100MHz, CDCl3): δ = -5.1, -4.3, 17.9, 22.4, 25.7, 64.0, 65.8, 78.4, 103.7, 108.0, 110.0, 130.6, 
157.3, 157.4, 168.0 ppm 
IR: ṽ = 3276,  2929,  2857,  1762, 1598, 1491, 1148, 940 cm-1 
HPLC-MS: Rt = 10.02min, m/z = 294 (100) [M-NHCO]
+
, 360 (51) [M+Na]
+
 
 
(R,3,3'R,4,4'R)-4,4'-(1,3-phenylenebisoxy)bis(3-((R)-1-tbutyldimethylsilyloxyethyl)azetidin-2-one) 
(4b) 
M.p. (114-116)°C, white solid; Rf 0.42 (cyclohexane/EtOAc 60/40) 
[α]D = 74.98° 
1
H NMR (400MHz, CDCl3): δ 0.09 (d, J = 4.8Hz, 12H), 0.88 (s, 18H), 
1.29 (d, J = 6.0Hz, 6H), 3.32 (dd, J = 0.8, 3.2Hz, 2H), 4.283(dq, J = 3.2, 
6.0Hz, 2H), 5.63 (d, J = 0. Hz, 2H), 6.49 (m, 1H) , 6.65(dd, J = 2.4, 8.4Hz, 2H), 7.29 (t, J 8.4Hz, 1H), 
7.365 (s, 2H) ppm 
13
C NMR (100MHz, CDCl3): δ = -5.1, -4.4, 17.9, 22.4, 25.7, 64.1, 66.1, 79.1, 105.4, 110.9, 130.9, 157.8, 
168.0 ppm 
IR: ṽ = 3250, 2930, 2856, 1772, 1596, 1375, 1112, 811 cm-1 
HPLC-MS: Rt = 16.92min, m/z = 521 (53) [M-NHCO]
+
, 587 (100) [M+Na]
+
 
 
4-(3-hydroxyphenoxy)azetidin-2-one (5a)  
M.p. (153-165)°C, white solid; Rf 0.32 (cyclohexane/EtOAc 20/80) 
1
H NMR (400MHz, CD3COCD3): δ 2.90 (dd, J = 1.2, 14.8Hz, 1H), 3.310(ddd, J = 
2.8, 3.6, 14.8Hz, 1H), 5.70 (dd, J = 1.2, 3.6Hz, 1H), 6.396 (m, 2H), 6.487 (dd, J = 
2.0, 8.0Hz, 1H), 7.08 (m, 1H), 8.15 (s, 1H), 8.70 (s, 1H) ppm 
13
C NMR (100MHz CD3COCD3): δ = 45.7, 76.0, 103.4, 106.3, 109.0,  130.1, 157.9, 158.6, 165.1 ppm 
IR: ṽ = 3410, 1744, 1586, 1260, 1191, 1127, 1063 cm-1 
HPLC-MS: Rt = 2.05min, m/z = 180 (100) [M+H]
+
, 202 (73) [M+Na]
+
, 359 (60) [2M+H]
+
 
 
4,4'-(1,3-phenylenebisoxy)bis(azetidin-2-one) (5b) 
M.p. (155-160)°C, white solid; Rf 0.46 (cyclohexane/EtOAc 20/80) 
1
H NMR (400MHz, CD3COCD3): δ 2.92 (dd, J = 1.2, 14.8Hz, 2H), 3.33 (ddd, J 
= 2.8, 4.0, 14.8Hz, 2H), 5.78 (dd, J = 1.2, 4.0Hz, 2H), 6.52 (m, 1H), 6.61 (dd, J 
= 2.4, 8.0Hz,, 2H), 7.24 (t, J = 8.0Hz, 1H), 8.19 (s, 2H) ppm 
13
C NMR (100MHz CD3COCD3): δ = 45.7, 76.0, 103.1, 109.1, 130.4, 157.8, 165.1.ppm 
IR: ṽ = 3421, 2873, 1751, 1579, 1488, 1260 cm-1 
HPLC-MS: Rt = 2.17min, m/z = 247 (100) [M+H]
+
, 264 (76) [M+H2O]
+
, 269 (71) [M+Na]
+
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(3R,4R)-3-((R)-1-(tbutyldimethylsilyloxy)ethyl)-4-(2-hydroxyphenoxy) azetidin-2-one (7a) 
M.p. (104-106)°C, white solid; Rf 0.68 (cyclohexane/EtOAc 60/40) 
[α]D = 41.00° 
1
H NMR (400MHz, CDCl3): δ 0.09  (s, 3H), 0.11 (s, 3H), 0.90 (s, 9H), 1.25 (d, J = 
6.0Hz, 3H), 3.36 (dd, J = 0.8, 3.2Hz, 1H), 4.25 (dq, J = 3.2, 6.4Hz, 1H), 5.65 (s, 1H),  
6.37(s, 1H), 6.82 (dd, J = 1.2, 2.0, 7.6 Hz, 1H), 6.88 (s, 1H), 6.92 (dd, J = 2.4, 7.6Hz, 1H), 6.96 (m, 2H) 
ppm 
13
C NMR (100MHz, CDCl3): δ = -5.1, -4.4, 17.9, 22.5, 25.7, 64.1, 66.0, 80.4, 116.0, 116.2, 120.4, 124.2, 
143.2, 147.0, 167.4 ppm 
IR: ṽ = 3283, 2929, 2856, 2360, 1766, 1597, 1375, 1143, 1080, 1036 cm-1 
HPLC-MS: Rt = 10.52min, m/z = 294 (61) [M-NHCO]
+
, 338 (100) [M+H]
+
, 360 (72) [M+Na]
+
, 675 (13) 
[2M+H]
+
 
 
(R,3,3'R,4,4'R)-4,4'-(1,2-phenylenebisoxy)bis(3-((R)-1-(tbutyldimethylsilyloxy)ethyl)azetidin-2-one) 
(7b) 
M.p. (151-154)°C, white solid; Rf 0.53 (cyclohexane/EtOAc 60/40) 
[α]D = 33.00° 
1
H NMR (400MHz, CDCl3): δ 0.03 (s, 6H, TBS), 0.05 (s, 6H, TBS), 0.83 (s, 18H, 
TBS), 1.23 (d, J = 6.0Hz, 6H, Me), 3.28 (dd, J = 0.8, 3.2Hz, 2H), 4.20 (dq, J = 
3.2, 6.4Hz, 2H, CHOTBS), 5.61 (s, 2H, CHNH), 6.82 (s, 2H), 6.99 (dd, J =  1.2, 
6.6Hz, 2H), 7.05 (m, 2H) ppm 
13
C NMR (100MHz, CDCl3): δ = -5.1, -4.4, 17.9, 22.5, 25.7, 64.1, 66.1, 80.8, 119.6, 124.4, 124.2, 147.2, 
167.1 ppm 
IR: ṽ = 3256, 2929, 2856, 1771, 1375, 1253, 1141, 1079, 1033 cm-1 
HPLC-MS: Rt = 16.51min, m/z = 521 (100) [M-NHCO]
+
, 582 (60) [M+H2O]
+
, 565 (72) [M+H]
+
 
 
4-(2-hydroxyphenoxy)azetidin-2-one (8a) 
M.p. (128-130)°C, white solid; Rf 0.49 (cyclohexane/EtOAc 20/80) 
1
H NMR (400MHz, CD3COCD3): δ 3.06 (dd, J =0.8Hz, 14.8Hz, 1H, CHHCHNH), 3.31 
(ddd, J = 2.8, 3.6, 14.8Hz, 1H, CHHCHNH), 5.79 (dd, J = 0.8, 3.6Hz, 1H, CHNH), 6.81 
(m, 1H, arom), 6.94 (m, 2H, arom), 7.00 (dd, J = 1.2, 8.2Hz, 1H, arom), 7.96 (bs, 1H, 
OH), 8.10 (bs, 1H, NH) ppm 
13
C NMR (100MHz, CD3COCD3): δ = 46.9, 79.5, 118.3, 118.8, 121.7,  125.5, 148.2, 149.8,170.2 ppm 
IR: ṽ = 3235, 1803, 1596, 1351, 1270, 1212, 1194, 1135, 1049, 969, 743, 657 cm-1 
HPLC-MS: Rt = 2.12min, m/z = 359 (79) [M+H]
+
, 202 (45) [M+Na]
+
, 376 (10) [2M+H2O]
+
 
 
4,4'-(1,2-phenylenebis(oxy))bis(azetidin-2-one) (8b) 
M.p. (129-131)°C, white solid; Rf 0.34 (cyclohexane/EtOAc 20/80) 
1
H NMR (400MHz, CD3COCD3): δ 3.02 (d, J = 14.8Hz, 2H, CHHCHNH), 3.36 
(ddd, J = 1.2, 2.8, 14.8Hz, 2H, CHHCHNH), 5.79 (dd, J = 1.2, 3.6 Hz, 2H, CHNH), 
7.06 (m, 4H, arom), 8.08 (s, 2H, NH) ppm 
13
C NMR (100MHz, CD3COCD3): δ = 47.2, 79.6, 79.7, 119.5, 125.4, 125.4,  148.8, 
148.9, 170.2 ppm 
IR: ṽ = 3424, 2955, 1751, 1722, 1652, 1500, 1405, 1349,1246, 1214, 1134, 1018, 954, 746 cm-1 
HPLC-MS: Rt = 1.90min, m/z = 266 (100) [M+H2O]
+
, 519 (13) [2M+Na]
+
 
 
 
129 
4-(3,5-dihydroxyphenoxy)azetidin-2-one (10a) 
M.p. (153-165)°C, white solid; Rf 0.38 (cyclohexane/EtOAc 20/80) 
1
H NMR (400MHz, CD3OD): δ 2.93 (dd, J = 0.8, 14.8Hz, 1H), 3.32 (ddd, J = 2.8, 
3.6, 14.8 Hz, 1H), 5.63 (dd, J = 0.8, 3.6Hz, 1H), 5.90 (d, J = 1.2Hz, 2H), 6.00 (d, J = 
1.2 Hz , 1H) ppm 
13
C NMR (100MHz, CD3OD): δ = 45.9, 76.0, 94.8, 96.9, 158.6, 159.5, 165.9 ppm 
IR: ṽ = 3286, 1740, 1607, 1508, 1491, 1408, 1364, 1148, 1065 cm-1 
HPLC-MS: Rt = 1.92min, m/z = 196 (100) [M+H]
+
, 218 (50) [M+Na]
+
, 413 (35) [2M+Na]
+
 
 
4,4'-((5-hydroxy-1,3-phenylene)bis(oxy))bis(azetidin-2-one) (10b) 
M.p. (155-160)°C, yellow solid; Rf 0.54 (cyclohexane/EtOAc 20/80) 
1
H NMR (400MHz, CD3OD): δ 2.92 (dd, J = 0.8, 14.8Hz, 2H, CHHCHNH), 3.34 
(m, 2H, CHHCHNH), 5.68 (dd, J = 0.8, 3.6Hz, 2H, CHNH), 6.05 (d, J = 1.2Hz, 1H, 
arom), 6.12 (d, J = 1.2Hz, 2H, arom) ppm 
13
C NMR (100MHz, CD3OD): δ = 47.3, 77.50-77.52, 95.85-96.10, 98.56-98.60, 
160.1, 161.1, 166.9 ppm 
HPLC-MS: Rt = 1.70min, m/z = 265 (91) [M+H]
+
, 282 (100) [M+H2O]
+
, 287 (83) [M+Na]
+
 
 
4,4',4''-(benzene-1,3,5-triyltris(oxy))tris(azetidin-2-one) (10c) 
M.p. (160-167)°C, yellow solid; Rf 0. (cyclohexane/EtOAc 20/80) 
1
H NMR (400MHz, CD3OD): δ 2.98 (dd, J = 0.8, 14.8Hz, 3H), 3.37 (m, 3H), 
5.77 (dd, J = 0.8, 3.6Hz, 3H), 6.14 (s, 3H) ppm 
13
C NMR (100MHz, CD3OD): δ = 46.3, 76.6, 97.3, 159.2, 165.8, ppm 
HPLC-MS: Rt = 1.78min, m/z = 334 (19) [M+H]
+
, 351 (100) [M+H2O]
+
, 356 (40) [M+Na]
+
 
 
(3R,4R)-3-((R)-1-((tbutyldimethylsilyl)oxy)ethyl)-4-(3-hydroxy-5-hydroxymethylphenoxy) 
azetidin-2-one (12a) 
Colorless oil; Rf = 0.32 (DCM/EtOAc 20/80); 
[α]D = 80.00° 
1
H NMR (400MHz, CD3OD): δ 0.11 (s, 3H), 0.14 (s, 3H), 0.93 (s, 9H), 1.30 (d, J = 
6.0Hz, 3H), 3.27 (dd, J = 0.8, 3.6 Hz, 1H), 4.29 (dq, J = 3.2, 6.0Hz, 1H), 4.54 (s, 
2H),  5.65 (s, 1H), 6.82 (t, J = 1.2Hz, 1H), 6.90 (dd, J =  1.2, 1.6Hz, 1H), 6.96 (dd, 
J = 1.2, 1.6Hz,1H) ppm 
13
C NMR (100MHz, CD3OD): δ = -4.1, -3.2, 19.7, 23.6, 27.1, 65.8, 66.3, 67.5, 80.3, 104.2, 107.1, 109.9, 
146.5, 160.0, 160.8, 171.4 ppm 
IR: ṽ = 3274, 2930, 285, 1759, 1601, 1461, 1254, 1147, 1085, 1036 cm-1 
HPLC-MS: Rt = 8.65min, m/z = 324 (81) [M-NHCO]
+
, 390 (100) [M+Na]
+
 
 
(R,3,3'R,4,4'R)-4,4'-((5-hydroxymethyl-1,3-phenylene)bisoxy) 
bis(3-((R)-1-(tbutyldimethylsilyloxy)ethyl)azetidin-2-one) (12b) 
M.p. (94-98)°C, white solid; Rf = 0.58 (DCM/EtOAc 20/80); 
[α]D = 103.00° 
1
H NMR (400MHz, CD3OD): δ 0.11 (s, 6H), 0.14 (s, 6H), 0.93 (s, 18H), 
1.31 (d, J = 6.0Hz, 6H), 3.31 (dd, J = 1.2, 3.6Hz, 2H), 4.29 (dq, J = 3.6, 
6.0Hz, 2H), 4.62 (s, 2H),  5.68 (d, J = 1.2,Hz, 2H), 6.49 (d, J = 2.4Hz, 
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1H), 6.68 (d, J = 2.4Hz, 2H) ppm 
13
C NMR (100MHz, CD3OD): δ = -4.0, -3.2, 19.7, 23.6, 27.2, 65.6, 66.4, 67.6, 80.5, 105.4, 109.8, 109.9, 
147.2, 160.1, 171.2 ppm 
IR: ṽ = 3204, 2926, 2853, 1758, 1598, 1374, 1138, 1082, 1085, 1032 cm-1 
HPLC-MS: Rt = 14.45min, m/z = 551 (100) [M-NHCO]
+
, 612 (58) [M+H2O]
+
 
 
4-(3-hydroxy-5-(hydroxymethyl)phenoxy)azetidin-2-one (13a) 
Colorless oil; Rf = 0.47 (cyclohexane/EtOAc 40/60); 
1
H NMR (400MHz, CD3OD): δ 2.98 (dd, J = 0.8, 14.8Hz, 1H), 3.36 (m, 1H), 4.54 (s, 
2H) 5.65 (dd, J = 0.8, 3.6Hz, 1H), 6.31 (d, J = 1.2Hz, 1H), 6.40 (d, J = 1.2Hz , 1H), 
6.54 (d, J = 1.2Hz , 1H) ppm 
13
C NMR (100MHz, CD3OD): δ = 47.0, 65.8, 80.0, 103.9, 106.7, 109.6, 246.5, 159.8, 160.8, 170.4 ppm 
HPLC-MS: Rt = 1.64min, m/z = 210 (40) [M+H]
+
, 227 (100) [M+H2O]
+
, 232 (40) [M+Na]
+
 
 
4,4'-((5-(hydroxymethyl)-1,3-phenylene)bis(oxy))bis(azetidin-2-one) (13b) 
Colorless oil; Rf = 0.60 (cyclohexane/EtOAc 40/60); 
1
H NMR (400MHz, CD3OD): δ 3.01 (dd, J = 0.8, 14.8Hz, 2H), 3.98 (ddd, J = 
2.4, 3.6, 14.8Hz, 2H), 4.60 (s, 2H), 5.76 (dd, J = 0.8, 3.6Hz, 2H), 6.44 (d, J = 
1.2Hz, 1H), 6.63 (d, J = 1.2Hz , 2H) ppm 
13
C NMR (100MHz, CD3OD): δ = 47.1, 65.6, 78.0, 104.3, 109.4, 147.1, 159.87, 170.2 ppm 
HPLC-MS: Rt = 1.21min, m/z = 279 (36) [M+H]
+
, 296 (80) [M+H2O]
+
, 301 (100) [M+Na]
+
 
 
(3R,4R)-3-((R)-1-(tbutyldimethylsilyloxy)ethyl)-4-(4-(hydroxymethyl) phenoxy)azetidin-2-one (15) 
M.p. (138-140)°C, white solid; Rf 0.65 (cyclohexane/EtOAc 50/50) 
[α]D = 66.00° 
1
H NMR (400MHz, CDCl3): δ 0.06 (s, 3H), 0.08 (s, 3H), 0.87 (s, 9H), 1.25 (d, J = 
6.4Hz, 3H), 3.10 (s, 1H), 3.23 (d,  J = 3.2Hz, 1H), 4.21 (dq, J = 3.2, 6.4Hz, 1H), 
4.54 (s, 2H),  5.61 (s, 1H), 6.85 (d, J = 8.4Hz,  2H), 7.25 (d, J = 8.4Hz, 2H), 7.40 (s, 1H) ppm 
13
C NMR (100MHz, CDCl3): δ = -5.1, -4.4, 17.9, 22.4, 25.7, 64.1, 64.6, 65.9, 78.8, 116.8, 128.8, 135.3, 
155.7, 167.6 ppm 
IR: ṽ = 3094, 2928, 2856, 1770, 1511, 1228, 1173, 1136, 1087, 1034 cm-1 
HPLC-MS: Rt = 9.79min, m/z = 308 (74) [M-NHCO]
+
, 374 (100) [M+Na]
+
 
 
4-hydroxybenzoic acid β-lactam derivatives synthesis 
In a 50mL flask 0.5mmol of 4-hydroxybenzoic acid 16 were dissolved in 3mL of a H2O/MeCN 1/1 
solution, then TEA (1mmol, 139μL) and 2 (0.5mmol in 2mL of water, dropped in 30min) were added, 
following the reaction by TLC monitoring until SM disappearance. The reaction was then quenched by 
NaCl addition to separate MeCN and water, which was acidified using HCl (1M) before extracting with 
EtOAc (3 times). The organic phases were dried over Na2SO4, then filtered and concentrated in vacuum, 
reaching the desired product 17a via flash-chromatography with EtOAc. 
 
4-(4-oxoazetidin-2-yloxy)benzoic acid (17a) 
M.p. (123-140)°C, white solid; Rf 0.22 (cyclohexane/EtOAc 10/90) 
1
H NMR (400MHz, CD3OD): δ 3.03 (dd, J = 15.2Hz, 1H), 3.41 (dd, J = 3.6, 
15.2Hz, 1H), 5.83 (d , J = 3.6Hz, 1H), 7.02 (d, J = 8.4Hz, 2H), 8.01 (d, J = 8.0Hz, 
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2H) ppm 
13
C NMR (100MHz, CD3OD): δ = 47.2, 78.1, 117.0, 126.8, 133.8, 162.3, 170.0, 170.4 ppm 
IR: ṽ = 3410, 1744, 1586, 1260, 1191, 1127, 1063 cm-1 
HPLC-MS: Rt = 2.11min, m/z = 208 (100) [M+H]
+
 
 
4-hydroxyaniline β-lactam derivatives synthesis 
In a 50mL flask 0.5mmol of 4-hydroxyaniline 18 were dissolved in 2mL of a freshly prepared 0.25M 
NaOH aqueous solution, then 1 or  2 (0.5mmol in 3mL of H2O/MeCN 1/1 solution) were dropped in 
30min, following the reaction by TLC monitoring until SM disappearance. The reaction was then 
quenched by NaCl addition to separate MeCN and water, which was acidified using HCl (1M) before 
extracting with EtOAc (3 times). The organic phases were dried over Na2SO4, then filtered and 
concentrated in vacuum, reaching the desired 19a and 20a products via FC with EtOAc. 
Directly on the crudes obtained, the corresponding acetic amides were obtained for further analysis 
dissolving them in 2mL of MeCN and 4mL of 0.125M HCl aqueous solution (0.5mmol), then adding 
acetic anhydride (0.6mmol) and 0.5M AcONa in water (0.5mmol). Reaction s were stirred for 2 hours 
following the progresses by TLC and then quenched at SM disappearance by NaCl addition to separate 
MeCN and water, which was acidified using HCl (1M) before extracting with EtOAc (3 times). The 
organic phases were dried over Na2SO4, then filtered and concentrated in vacuum, reaching the desired 
acetamides of 19a and 20a , via flash-chromatography with EtOAc, used for evaluating the yields. 
 
(3R,4R)-3-((R)-1-(tbutyldimethylsilyloxy)ethyl)-4-(3-hydroxyphenoxy)-1-methylthioazetidin-2-one 
(23a) 
Colorless oil; Rf 0.80 (cyclohexane/EtOAc 80/20) 
1H NMR (400MHz, CD3OD): δ 0.08 (d, J = 6.8Hz, 6H), 0.88 (s, 9H), 1.36 (d, J = 
6.4Hz, 3H), 2.40 (s, 3H), 3.34 (d, J = 3.2Hz, 1H), 4.26 (dq, J = 3.2Hz, 6.4Hz, 1H), 
5.13 (s, 1H),   5.75 (s, 1H),  6.58 (d, J = 8.0Hz, 1H), 6.71 (s, 1H), 6.81 (d, J = 
8.0Hz, 1H), 7.21 (t, J =  8.0Hz, 1H) ppm 
13C NMR (100MHz, CD3OD): δ = 47.2, 78.1, 117.0, 126.8, 133.8, 162.3, 170.0, 170.4 ppm 
IR: ṽ = 3410, 1744, 1586, 1260, 1191, 1127, 1063 cm-1 
HPLC-MS: Rt = 11.48min, m/z = 406 (100) [M+Na]
+ 
 
4.2.3 Hydroxy-apatite derivatives 
The optimized conditions required the use of 1M phosphate buffer aqueous solution (10mL every 1mmol 
of substrate). Substrate 2 was directly added, while for 1 the temperature was first increased to 70°c, 
adding 1 at 40°C to better solubilize it. At SM disappearance (TLC monitoring), the crude was evaporated 
using cyclohexane to form the corresponding minimum azeotrope. The resulting solid was recovered with 
a 1/1 MeOH/MeCN mixture, then filtered and concentrated to afford both the products as white solids. 
Azetidinone 26 was prepared as previously specified. 
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4-oxoazetidin-2-yl phosphate (24) 
In a 50mL one-neck flask 2 (129mg, 1mmol) was dissolved in 10mL of 1M phosphate 
buffer (pH = 7.5) and the reaction was followed by TLC (cyclohexane/EtOAc 20/80). At 
SM disappearance, water was evaporated with cyclohexane and the crude extracted with 
10mL of a 1/1 MeOH/MeCN mixture, filtered and concentrated to afford 24 as a white solid in 60% yield 
(101mg). 
Rf 0.01 (cyclohexane/EtOAc 80/20) 
1
H NMR (400MHz, D2O): δ 3.00 (d, J = 15.6Hz, 1H), 3.31 (dd, J = 3.6Hz, 15.2Hz, 1H), 5.65 (t, J = 
3.6Hz, 1H) ppm 
IR (ATR): ṽ = 3275, 1767, 1741, 1375, 1232, 1122, 1043, 962 cm-1 
13
C NMR (400MHz, D2O): δ 45.6, 73.1, 170.7 ppm 
31
P NMR (400MHz, CD3OD): δ 0.71 ppm (while buffer is at 2.5-2.7 ppm, depending on counter ions) 
 
(2R,3R)-3-((R)-1-(tbutyldimethylsilyloxy)ethyl)-4-oxoazetidin-2-yl phosphate (25) 
In a 50mL one-neck flask 1 (287mg, 1mmol) was added to 10mL of 1M phosphate 
buffer (pH = 7.5) already warmed at 70°C. The reaction was followed by TLC 
monitoring (cyclohexane/EtOAc 80/20) and at SM disappearance, water was evaporated 
with cyclohexane and the resulting crude extracted with 10mL of a 1/1 MeOH/MeCN 
mixture, filtered and concentrated to afford 25 as a white solid in 62% yield (201mg). 
Rf 0.01 (cyclohexane/EtOAc 60/40) 
1
H NMR (400MHz, D2O): δ 0.11 (s, 3H, MeSi), 0.13 (s, 3H, MeSi), 0.89 (s, 9H, tBuSi), 1.33 (d, J = 
6.4Hz, 3H, Me), 3.28 (d, J = 3.2Hz, 1H, CHCONH), 4.30 (m, 1H, CHOTBS), 5.70 (d, J = 5.2Hz, 1H, 
CHNH) ppm 
IR (ATR): ṽ = 3190, 2957, 2930, 2856, 1779, 1742, 1376, 1341,1229, 1163, 1077, 1039, 946, 837, 776 
cm
-1
 
13
C NMR (400MHz, D2O): δ -6.3, -5.3, 16.9, 20.9, 21.7, 48.5, 65.2, 75.1, 170.6 ppm 
31
P NMR (400MHz, CD3OD): δ 0.29 ppm (while buffer is at 2.5-2.7 ppm, depending on counter ions) 
 
General procedure for hydroxy-apatite derivatizations 
In a 10mL one-neck flask, to 200mg of hydroxyapatite suspended in 2mL of milliq. H2O were added 
50mg of the β-lactam substrates; after 4h stirring (at r.t. for 2, or at 70°C for 1, 21 and 27) was 
highlighted by TLC that it still be present, but the mixture was however centrifuged (60s at 7.0rpm). Was 
performed a first extraction with H2O (2x2mL) recovering the supernatant after each centrifugation and, 
over the water extracts combined, a subsequent extraction with DCM (3x2mL), which furnished after 
evaporation some mg of the employed lactam. The solid phase was dried at temperatures lower than 40°C 
to usually furnish 2̴20mg of the desired bioconjugate. 
To prepare 5% biconjugate hydroxyapatites, initial β-lactam substrates loading must be of 20mg. 
 
(2R,3R)-3-((R)-(((5-(dimethylamino)naphthalenyl)sulfonyl)oxy)ethyl)-4-oxoazetidin-2-yl acetate 
(27) 
In a 10mL 2-necks flask, to a solution of 26 (87mg, 0.5mmol) in 5mL of 
anhydrous DCM were added dansyl chloride (148mg, 0.55mmol) and DMAP 
(32mg, 0.75mmol). The reaction was followed by TLC (cyclohexane/EtOAc 
50/50) and after 24hours stirring was directly concentrated in vacuum. The 
crude product was purified by flash chromatography (cyclohexane/EtOAc 
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70/30) to afford TM in 36% yield (73mg) as a yellow-green oil. 
Rf 0.32 (cyclohexane/EtOAc 50/50) 
[α]D 25 = -17.83° (c = 13.27, DCM) 
1
H NMR (400MHz, CDCl3): δ  1.38 (d, J = 6.0Hz, 3H, MeCHOSO2),  2.00 (s, 3H, Ac), 2.93 (s, 6H, 
NMe2), 3.32 (d, J = 8.8Hz, 1H, CHCHOAc), 4.81 (dquartet, J = 6.4, 8.4Hz, 1H, CHOSO2), 5.25 (s, 1H, 
CHCHOAc), 6.34 (s, 1H, NH), 7.23 (d, J = 8.0Hz, 1H, Ar), 7.56-7.62 (m, 2H, Ar), 8.26 (d, J = 8.8Hz, 1H, 
Ar), 8.30 (d, J = 7.6Hz, 1H, Ar), 8.67 (d, J = 8.0Hz, 1H, Ar) ppm 
13
C NMR (50.3MHz, CDCl3): δ 19.4, 20.5, 45.3 (2C), 62.0, 75.6, 75.7, 115.5, 119.3, 123.0, 128.5, 129.6, 
129.7, 130.2, 131.7, 131.8, 151.7, 163.3, 170.5 ppm 
IR: ṽ = 3331, 2937, 1785, 1753, 1359, 1232, 1177, 1140 cm-1 
HPLC-MS: Rt = 8.74min; m/z = 407 (100) [M+H]
+
, 813 [2M+H]
+
, 435 (25) [2M+Na]
+
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5. AZETIDINONE-RETINOID HYBRIDS 
5.1 4-Alkylidene β-lactam retinoid hybrids 
5.1.1 Design, synthesis and differentiative effects 
Besides an interesting number of β-lactams in the last decades shown to be able to targeting a wide range 
of biological targets, usually enzymes, some bicyclic β-lactams were recently reported as inhibitors of 
Histone Deacetylases (HDACs), a family of proteins involved in the pattern of acetylation of chromatin 
proteins and thus in the regulation of gene expression.
105
 We recently reported the synthesis of some 
azetidinone derivatives which showed good affinity and specificity towards histone deacetylases HDAC8 
and HDAC6.
106
 
Histone deacetylases are epigenetic regulators playing an important role in modulating gene transcription 
as well as protein function. Eighteen classical HDAC isoforms, divided into IV classes based on yeast 
deacetilases homology, are identified to date. HDAC inhibitors constitute a new class of promising 
anticancer drugs targeting one or more HDAC isoform. HDAC6 overexpression was found in carcinoma 
of oral squamous tissue,
107
 although in breast cancer it correlates with better survival.
108
 In lung, colon, 
and cervical cancer cell line the knockout of HDAC8 gene reduces cell proliferation;
109
 in leukemia cell 
HDAC8 inhibitors leads to apoptosis.
110
 The expression of HDAC8 (class I member) has been correlated 
with poor outcome in neuroblastoma, and in such cell line selective HDAC8 inhibitors induces 
differentiation and proliferation arrest.
111
 Nowadays, there is great interest in the development of small 
molecules that regulate or modulate protein function and chemical genetic offers a valuable approach in 
this field.
112
 Retinoids, as derivatives of Vitamin A, regulate key developmental pathways throughout life, 
by modulating the expression of many genes involved in cell proliferation, migration, differentiation and 
apoptosis, though the molecular mechanisms are not completely understood.
113
 The effects of Retinoic 
Acid (RA) are mediated by the heterodimerization of nuclear RAR (Retinoic Acid Receptor), a family of 
ligand-dependent transcription factors, and RXR (Retinoid X Receptors), the 9-cis RA binding receptor. 
To date, retinoids are known to activate or inhibit MAPK cascade, which is involved in both proliferation 
and growth arrest.
114
 Some synthetic RA-derived molecules exert differentiative effect rather than 
apoptosis, blocking tumor progression in cancer cell lines.
115
 In fact, retinoids are currently used as 
potential chemotherapeutic drugs in the treatment of several cancer types (neuroblastoma, breast cancer, 
lung cancer, rhabdomyosarcoma, and many others).
116
 For this reason, there is great interest in developing 
new synthetic molecules targeting retinoic acid receptors. 
As part of an interdisciplinary project on the development of new β-lactam derivatives with a modular 
structure designed for specific biological activities, the effect of the azetidinone 1 (Figure 5.1.1), 
previously evaluated by us as specific HDAC8 inhibitor, was investigated on the proliferative activity of a 
neuron-like cell line. 
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Figure 5.1.1 β-Lactam derivatives 
Moreover, we developed the synthesis of new β-lactams 2 with a hybrid retinoid-azetidinone structure 
and we investigated the retinoic acid-dependent differentiation of a neuron-like cell line. To our 
knowledge, only two example of β-lactams were reported in the literature with a differentiation-inducing 
activity on leukemia cells.
117
 We report here the synthesis of the new hybrid retinoid β-lactams and 
preliminary results in biological evaluation of the three molecules on neuroblastoma cell line SH-SY5Y. 
 
Design and synthesis 
As mentioned above, we have previously reported an efficient synthesis of β-lactam 1. Its design was 
based on the pharmacophore model of HDAC inhibitors which consists in a modular structure with a cap-
group that interacts with residues in the active site of the receptor and a linker group that sits in a 
hydrophobic channel and positions a metal-binding group which coordinates to the zinc ion in the active 
site. We demonstrated that the azetidinone ring can efficiently work as the zinc-binding group. Moreover, 
the substituent on the nitrogen atom allowed for the specificity against HDAC8 or HDAC6 inhibition. 
Azetidinone 1 was therefore chosen in the present study for its specific HDAC8 activity. 
Once the β-lactam ring was confirmed as an effective zinc binding group for HDAC, we developed a new 
hybrid structure retaining the β-lactam scaffold to target HDACs and functionalized with a retinoic side 
chain which could activate differentiative processes to mimic the action of Retinoic Acid (RA). The 
design of β-lactam 2 was based on a 4-alkylidene-β-lactam scaffold with demonstrated enhanced 
reactivity in protein inhibition,
118
 and functionalized with a retinoid-amide side chain.  
 
Scheme 5.1.1 Retro-synthetic route to retinoid β-lactam 2 
The strategy is outlined in Scheme 5.1.1 and consists of a convergent synthesis with the coupling between 
the 4-alkylidene-azetidinone carboxyl acid 3 and the retinoid amine 4 as the key step. 4-Alkyliden-
azetidin-2-ones can be obtained using an original and well established protocol developed in our 
laboratory starting from 4-acetoxy-azetidinones and diazoesters in the presence of Lewis acids.
119
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Given that 4-acetoxy-azetidinone is commercially available, β-lactam 3 was obtained with TiCl4 and 
benzyldiazoacetate as outlined in Scheme 5.1.2. 
 
Scheme 5.1.2 Synthesis of 4-alkyliden-azetidinone 3 
The 4-alkyliden-β-lactams 5 were obtained in 43% yields and in a E/Z diastereoisomeric ratio of 41/59. 
The diastereoisomeric mixture 5Z/5E was easily separated by flash chromatography. 
Hydrogenolysis of the isolated pure 5Z with Pd on carbon in THF-methanol 1/1 mixture gave 3 in 
quantitative yield. 
Retinoid amine 4 was obtained starting from the easily available β-ionone in a three step reaction 
(Scheme 5.1.3). Addition of lithium acetonitrile to β-ionone in THF at low temperature gave 6, which 
underwent water elimination under ptoluenesulfonic acid catalysis.
120
 
 
Scheme 5.1.3 Synthesis of retinoid amine 4 and retinoid β-lactams 2E and 2Z 
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The nitrile 7 obtained as a E/Z mixture was then reduced to give the amine 4EZ in 79% yield. Finally, 
with a carbodiimide coupling method, amides 2E and 2Z were obtained as a mixture and easily separated 
by flash chromatography. 
The 2E, 4E and 2Z,4E configurations were assigned in the two isomers by NOE 1D analysis on the 
separated products 2E and 2Z (Scheme 5.1.4).  
 
Scheme 5.1.4 NOE 1D correlations in new hybrids for configuration assignments 
In isomer 2E, the methyl group in the chain, chosen as the irradiated site, showed two NOE correlations 
with methylene and methine, respectively, indicating a close spatial relationship whereas for β-lactam 2Z 
NOE enhancements of the two vinyl CH were observed. The 2E, 4E configuration for 2E, and the 2Z, 4E 
configuration for 2Z were thus attributed. 
 
5.1.2 Biological effects 
As said before, HDAC inhibitors are emerging as anti-cancer drugs. In particular, HDAC8 inhibitors have 
shown to regulate proliferation in neuroblastoma cells. As potential HDAC inhibitors, we evaluated the 
antiproliferative effect of azetidinones 1, 2E, and 2Z on undifferentiated SH-SY5Y. Moreover, as β-
lactams 2E and 2Z have hybrid retinoid-azetidinone structures, we performed a set of experiments aiming 
to evaluate differentiative action of β-lactams 2E and 2Z compared to azetidinone 1 and retinoic acid 
treated cells. 
In fact, retinoids are currently used as potential chemotherapeutic drugs in the treatment of several cancer 
types including neuroblastoma due to their differentiative action. In order to assess azetidinone 1, 2E and 
2Z cytotoxicity, we calculated first the IC50 (50% inhibiting concentration) using MTT assay (Figure 
5.1.2, on undifferentiated SH-SY5Y; IC50 ranges are reported above the curves depicted. Data are shown 
as mean). The MTT assay is a colorimetric assay for measuring the activity of cytosolic enzymes that 
reduce tetrazolium dye (MTT) in formazan salt in living cells. IC50 values were calculated and are 
reported above the curves in Figure 5.1.2. 
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Figure 5.1.2 Cytotoxic evaluation of 1, 2E and 2Z 
The concentration used for subsequent experiments was chosen accordingly in order to obtain cytostatic 
effects rather than apoptosis or necrosis (Figure 5.1.2). 
 
Effect on proliferation 
In a preliminary analysis of biological effect on proliferation, undifferentiated SH-SY5Y cells were 
exposed to 7.5μM of azetidinone 1, 10μM of β-lactams 2E and 2Z for 24, 48, 72 and 96h, the number of 
cells was counted daily and compared to control (vehicle treated). Figure 5.1.3 [The rate of cells 
proliferation was determined as total cell number. Cells were incubated in the presence of 7.5μM of 
azetidinone 1, 10μM of 2E and 2Z and counted at 24, 48, 72, 96 h. Significant differences between 
groups were observed after 48h of treatment. Statistical analysis was performed with two-way ANOVA, 
Dunnet’s multiple comparisons test (a: ctrl vs β-lactam 2E, p < 0.05; b: ctrl vs β-lactam 2Z, p < 0.01; c: 
ctrl vs azetidinone 1 and β-lactam 2E p < 0.001, d: ctrl vs β-lactam 2Z p < 0.0001, e: ctrl vs azetidinone 1 
and β-lactam 2E p < 0.0001, f: ctrl vs β-lactam 2Z p < 0.001)] shows the proliferation curve of control 
cells (ctrl, open circle), azetidinone 1 (black square), β- lactam 2E (black triangle) and 2Z treated cell 
(black rhombus). 
Significant differences were observed between the groups (twoway ANOVA, Dunnet’s multiple 
comparisons test). β-lactams 2E and 2Z determine a significative reduction in cell proliferation after 48 h 
of treatment (a: ctrl vs β-lactam 2E; b: ctrl vs β-lactam 2Z). All the compounds tested show an 
antiproliferative effect compared to control from 72 to 96 h (c: ctrl vs azetidinone 1 and β-lactam 2E, d: 
ctrl vs β-lactam 2Z, e: ctrl vs azetidinone 1 and β-lactam 2E p < 0.0001, f: ctrl vs β-lactam 2Z). Although 
the reduction is stable, doubling time calculated in 24-72h range (Td) is affected exclusively in cells 
treated with β-lactam 2Z (TdCTRL = 34.9h; Td1 = 39h, Td2 = 39.78, Td8 = 51.25), whereas doubling time 
calculated in 24-96h range is not affected 
These results indicated a slight effect of azetidinone 1, 2E and 2Z on SH-SY5Y proliferation. 
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Figure 5.1.3 Effect of azetidinones 1, 2E and 2Z on SH-SY5Y proliferation 
 
Differentiation effects 
As they are derived from neuroblastoma, SH-SY5Y may be differentiated toward neural-like lineage. 
Retinoic acid is a powerful differentiating molecule inducing growth inhibition, neurites lengthening and 
branching. A six-days RA treatment induces neural-like differentiation as shown by neurites outgrowth 
[Figure 5.1.4, βIII-tubulin (A-C) and neurofilament (D-F) were used to investigate a possible microtubule 
and intermediate filaments rearrangement. Panels A and F refer to vehicle treated cells; B and G to cells 
treated for 6 days with RA; C and F correspond to cells treated for 6 days with 7.5μM of azetidinone 1, D 
and I correspond to cells treated for 6 days with 10μM of β-lactam 2E; E and J correspond to cells treated 
for 6 days with 10μM of β-lactam 2Z (Scale bar = 10micron). Graphs K and L refer to βIII-tubulin and 
neurofilament immunoreactive area, respectively, normalized for number of cells. Statistical analysis was 
performed with one-way ANOVA, Tukey post test, **p < 0.01, ***p < 0.001, ****p < 0.0001] visualized 
by βIII-tubulin and NF200. Quantitative analysis was performed measuring the βIII-tubulin and NF200 
network normalized according to the cells number. As hybrids retinoid-azetidinones, we investigated a 
possible differentiative effect of β-lactams 2E and 2Z compared to azetidinone 1 and RA treated SH-
SY5Y. βIII-Tubulin is an early marker for differentiation toward neuronal lineage and the increase of 
βIII-tubulin area may be related to an early stage of differentiation. Neurofilament play important 
structural roles and influence axonal transport, neurite outgrowth and cell survival. Sample micrographs 
of cell SH-SY5Y exposed to the vehicle (control), RA, azetidinone 1, and β-lactams 2E and 2Z are shown 
in Figure 5.1.4, where panels A-E refers to β-tubulin-IR, and panels F-J refers to neurofilament-IR, graph 
K and L to respective quantification of IR area/number of cells. While a differentiative effect of RA is 
evident in both βIII-tubulin and NF200 immunostaining (panels A vs panel B and panel F vs panel G, 
respectively) and azetidinone 1 does not display any differentiative effect (panels A vs panel C and panel 
F vs panel H), β-lactams 2E (panels A vs panel D and panel F vs panel I) and 2Z (panels A vs panel E 
and panel F vs panel J) induce a moderate differentiation, which is statistically significant in βIIItubulin 
staining (panels K and L, statistical analysis was performed with one-way ANOVA, Tukey post test).  
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Figure 5.1.4 Effect of azetidinone 1, 2E and 2Z on SH-SY5Y differentiation 
This effect could be possibly related to moderate structural analogies among RA and β-lactams 2E and 
2Z. The data indicate a differentiative effect of β-lactams 2E and 2Z on SH-SY5Y, even though smaller 
when compared to RA. The absence in the β-lactams 2E and 2Z of an ionizable function, as like the 
carboxylic acid in RA, can explain the observed lower activity, as reported for some non-ionizable RA 
derivatives such as RA-esters or amides.
121
 To bind effectively to the retinoic acid receptor (RAR), the 
polar terminus of the retinoid must be capable of efficient interactions, as observed in the crystal structure 
of RA-RAR complex.
122
 The β-lactam scaffold, while it would not be considered a strong “polar 
terminus” in anchoring RAR, shows a positive effect on SH-SY5Y cell differentiation (β-lactams 2E and 
2Z), and it deserves further investigation. 
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5.2 Experimental section 
5.2.1 General informations 
As previously reported (Paragraph 2.3.1). 
 
5.2.2 Synthesis 
Azetidinone 5Z was prepared as previously reported.
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(Z)-2-(4-Oxoazetidin-2-ylidene)acetic acid (3) 
To a solution of 5Z (220mg, 1.01mmol) in a 10 mL mixture of THF/MeOH 1/1 was 
added Pd/C 10% (44mg). The solution was treated with H2 (1atm) and after 2h was 
filtered on celite and concentrated to give 3 (100mg, 78%) as a yellow solid. 
M.p. 162-163°C 
1
H NMR (400MHz, DMSO): δ = 3.57 (s, 2H), 4.98 (s, 1H), 10.47 (bs, 1H), 11.94 (bs, 1H) ppm 
13
C NMR (100MHz, CD3OD): δ = 46.0, 92.2, 153.3, 169.7, 171.0 ppm 
IR: ṽ = 3289, 2919, 1828, 1185 cm-1 
HPLC-MS: Rt = 1.66min, m/z (%) = 128 [M+H]
+
, 150 [M+Na]
+
, 679 [2M+Na]
+
  
C5H5NO3: calc C 47.25, H 3.97, N 11.02%; found C 47.42, H 3.92, N 10.87% 
 
(E)-3-Hydroxy-3-methyl-5-(2,6,6-trimethylcyclohexen-1-yl)pent-4-enenitrile (6) 
To a stirred solution of acetonitrile (330mL, 6.24mmol) in anhydrous THF (5mL) at -
78°C under inert atmosphere were added dropwise nButyllithium 2.5M in THF 
(6.86mmol, 2.74mL) and thereupon a solution of β-ionone (1g, 5.2mmol) in dry THF 
(4mL) were added over a period of 10min. The solution was allowed to warm at room temperature and 
after 3h the reaction was quenched with aqueous NH4Cl (10mL) and extracted with EtOAc (3x10mL). 
The organic extracts were dried over Na2SO4, filtered and concentrated in vacuum. Flash chromatography 
(cyclohexane/EtOAc: 80/20) of the extracts gave 6 (1.031g, y = 85%) as a pale yellow oil. 
1
H NMR (400MHz, CDCl3): δ = 0.92 (s, 6H, CMe2), 1.35-1.38 (m, 2H, CMe2CH2), 1.41 (s, 3H, 
MeCOH), 1.49-1.55 (m, 2H, CMe2CH2CH2), 1.58 (s, 3H, MeC=C), 1.88-1.91 (m, 2H, 
CMe2CH2CH2CH2), 2.56 (s, 2H, CH2CN), 3.34 (bs, 1H, OH), 5.45 (d, 1H, J = 16.0 Hz, CH=CHCOH), 
6.11 (d, 1H, J = 16.0 Hz, CH=CHCOH) ppm 
13
C NMR (100MHz, CD3OD): δ = 18.8, 20.9, 27.4, 28.3 (2C), 31.6, 32.3, 33.6, 38.9, 70.8, 117.3, 
127.1,128.5,136.0,136.6 ppm 
IR: ṽ = 3444, 3023, 2925, 2256,1722, 1651, 1644, 1114 cm-1 
GC-MS: Rt = 16.81min, m/z (%) = 193 [M-CH2CN]
+
, 218 [M-Me]
+
, 233 [M]
+
 
C15H23NO: calc C 77.21, H 9.93, N 6.00%; found C 77.01, H 9.98, N 5.92% 
 
(2ZE,4E)-3-Methyl-5-(2,6,6-trimethylcyclohex-1-enyl)penta-2,4-dienenitrile (7EZ) 
A solution of 6 (400mg, 1.72mmol) and ptoluenesulfonic acid (33mg, 0.172mmol) in 
toluene (17mL) was refluxed and the reaction was followed by TLC. After the 
completion of the reaction the solution was cooled at 0°C and washed with a solution 
of NaHCO3 5% and after with water. The organic extracts were dried over Na2SO4, filtered and 
concentrated in vacuum obtaining 352mg (95%) of 7 as a E/Z: 54/46 mixture. Characterization resulted in 
agreement with the reported data.
124
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(2EZ,4E)-3-Methyl-5-(2,6,6-trimethylcyclohexen-1-yl) penta-2,4-dienamine (4EZ) 
Amine 4 was prepared as reported.
125
 E/Z: 59/41, pale yellow oil 
1
H NMR (400MHz, CDCl3): δ = 0.97 (s, 6H, CMe2 trans), 0.98 (s, 6H, CMe2 
cis),1.41-1.48 (m, 2H, CMe2CH2), 1.48-1.64 (m, 2H, CMe2CH2CH2), 1.68 (s, 3H, 
CH2MeC=C trans), 1.72 (s, 3H, CH2CH2MeC=C cis), 1.81 (s, 3H, MeC=CH trans), 1.88 (s, 3H, 
MeC=CH cis),  1.95-1.97 (m, 2H, CH2CH2MeC=C), 2.47 (bs, 2H, NH2), 3.40 (d, J =6.8Hz, 1H, 
CH2NH2), 5.37 (dd, 1H, J = 6.4, 7.6Hz, CH=CHCH2NH2 cis), 5.45 (dd, 1H, J = 6.4, 7.2Hz, 
CH=CHCH2NH2 trans),5.94-6.01 (m, 2H, CH=CH trans) 6.12 (d, J = 15.6Hz, 2H, CH=CH cis) 6.30 (d, J 
= 15.6Hz, 2H, CH=CH cis) ppm 
13
C NMR (100MHz, CDCl3): δ = 12.2, 19.1, 21.6, 28.4 (2C), 32.7, 34.1, 38.4, 39.3, 126.0, 128.5, 128.6, 
129.0, 129.3, 130.1,133.7,135.0,137.1,137.5,137.8 ppm 
IR: ṽ = 3373, 2928, 2866, 1454, 1266 cm-1 
GC-MS: Rt = 16.09min (cis), 16.57min (trans), m/z (%) = 187 [M-CH2CN]
+
, 204 [M-Me]
+
, 219 [M]
+
 
 
(2Z)-N-(2EZ,4E-3-Methyl-5-(2,6,6-trimethylcyclohexenyl)penta-2,4-dienyl) 
2-(4-oxoazetidin-2-ylidene)acetamide (2E, 2Z) 
To a solution of β-lactam 3 (55mg, 
0.43mmol) in dry DCM (4.5mL) under inert 
atmosphere at 0°C were added amine 4EZ 
(94mg, 0.43mmol), DMAP (53mg, 
0.43mmol) and after 10min EDC (82.5mg, 
0.43mmol). The solution was stirred at 0°C 
for 45min and after was allowed to warm at room temperature. The reaction was followed by TLC and 
after the disappearing of the starting materials was quenched with aqueous NH4Cl (10mL) and extracted 
with DCM (3x5mL). The organics were dried over Na2SO4, filtered and concentrated in vacuum. The E/Z 
mixture was separated by flash chromatography (cyclohexane/EtOAc 70/30) affording 2E (62mg) and 2Z 
(44mg) in an overall yield of 75%. 
Configurations of the two diastereoisomers was assigned by NOE 1D studies. 
2E: white syrup: Rf = 0.4 (cyclohexane/EtOAc, 50/50) 
1
H NMR (400MHz, CDCl3): δ = 1.00 (s, 6H),1.46 (m, 2H),1.62 (m, 2H),1.68 (s, 3H), 1.86 (s, 3H), 2.01 
(m, 2H), 3.51 (s, 2H), 4.06 (m, 2H), 5.02 (s, 1H), 5.30 (bs, 1H, NH), 5.43 (m, 1H), 6.01 (d, J = 16.0Hz, 
1H), 6.13 (d, J = 16.0Hz, 1H), 8.75 (bs, 1H, NH) ppm 
13
C NMR (100 MHz, CDCl3): δ = 12.5, 19.2, 21.6, 28.8, 29.7, 32.9, 34.2, 37.3, 39.5, 44.9, 92.2, 124.9, 
127.0, 129.0, 136.6, 137.5, 137.6, 146.6, 165.3, 166.3 ppm 
IR: ṽ = 3367, 3250, 2958, 2922, 2853, 1815, 1692 cm-1 
HPLC-MS: Rt = 12.72min, m/z (%): 329 [M+H]
+
 
C20H22N2O2: calc C 73.14, H 8.59, N 8.53%; found C 72.98, H 8.65, N 8.41% 
2Z: pale yellow syrup: Rf = 0.5 (cyclohexane/EtOAc, 50/50) 
1
H NMR (400MHz, CDCl3): δ = 1.26 (s, 6H), 1.47 (m, 2H), 1.63 (m, 2H), 1.70 (s, 3H), 1.91 (s, 3H), 2.02 
(m, 2H), 3.51 (m, 2H), 4.04 (m, 2H), 4.99 (s, 1H), 5.25 (bs, 1H, NH), 5.36 (m, 1H), 6.22 (d, J = 16.0Hz, 
1H), 6.38 (d, J = 16.0Hz, 1H), 8.72 (bs, 1H, NH) 
13
C NMR (100MHz, CDCl3): δ = 19.2, 20.3, 21.7, 28.9, 29.7, 32.9, 34.1, 36.4, 39.5, 44.9, 92.3, 123.1, 
129.0, 129.6, 129.7, 136.7, 137.7, 146.4, 165.3, 166.3 ppm 
IR: ṽ = 3327, 2954, 2923, 2853, 1810, 1683 cm-1 
HPLC-MS: Rt = 11.21min, m/z (%): 329 (65) [M+H]
+
, 351 (100) [M+Na]
+
, 679 (70) [2M+Na]
+
 
C20H22N2O2: calc C 73.14, H 8.59, N 8.53%; found C 72.88, H 8.65, N 8.38% 
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6. NEW Pt(II) BIOCONJUGATES 
6.1 New luminescent β-lactam Pt(II) bioconjugates 
6.1.1 β-Lactam Pt (II) bioconjugates 
Transition metal-bioconjugates is an active field of research which have been found to be potential 
therapeutics and can play a role as tracers in immunological analysis based on several analytical 
methods.
126
 Furthermore, the possibility to combine the therapeutic properties with diagnostics tools 
making compounds with dual functionality, i.e. theranostic agents, recently blossomed the possibility to 
simultaneously use powerful imaging tool in order to unveil real-time biochemical process, compound 
accumulation, drug activity and interaction, and to gather information about the fate of the compounds, 
just to cite some.
127
 
In this respect, much effort is currently devoted to the preparation of luminescent complexes based on 
second and third row transition metals such as Ir (III), Rh (I), Ru (II) and Pt (II), for applications in bio-
imaging in vitro, in cellulo and in vivo.
128
 Such increasing scientific interest is driven by the fact that 
judicious choice of coordinating ligands together with the presence of the heavy metal might provide 
enhanced physicochemical properties, such as photostability, large Stokes shifts, tunable emission colors, 
and high photoluminescence quantum yield.
129
 Furthermore, as consequence of the formally spin-
forbidden nature of the radiative processes, such Transition Metal Complexes (TMCs) possess long-lived 
excited states with lifetime that spans over greater orders of magnitude when compared to widely used 
organic fluorophores
130
 (i.e., from ns to ms and from ps to ns for the formers and the latters, respectively), 
allowing the successful employment of time-gated microscopy techniques for imaging purposes.
131
 
However, TMCs typically show excitation bands in the deep-blue and ultraviolet region that severely 
hampers their use in real applications for in cellulo and in vivo experiments. 
Among all the investigated complexes, luminescent platinum (II) derivatives possess the tendency to 
aggregate into self-assembled nanostructures by means of weak μ-μ and closed-shell metallophilic 
(dz2•••dz2) interactions. The establishment of such intermolecular interactions yields to the formation of 
lower-lying excited states, namely Metal-Metal-to-Ligand Charge Transfer (MMLCT). We have very 
recently demonstrated that is possible to take advantage from the formation of such aggregates to obtain 
luminescent TMCs based labels able to self-assemble in cellular compartments forming highly emitting 
aggregates as consequence of the protection from quenchers (e.g., dioxygen) in biological relevant 
environments. Even more interestingly, the formation of the MMLCT bands yielded sizeable 
bathochromic shift of both excitation and emission allowing easy excitation of the probe with visible 
light. 
The β-lactams have been scarcely studied as ligands for metal-complexes,132 and most of the examples 
deal with metallocene derivatives. Recently examples of Pd and Pt complexes with azetidinones
133
 and 
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bio-organometallic Ir and Rh with β-lactam ligands134 were reported. However, specifically designed 
metal complexes-bioconjugates should allow the possibility to couple the multifacet biological activities 
of β-lactams with photoactive metal complexes. This could represent an interesting combination since 
amongst the new strategies to combat antibiotic-resistant infections, antimicrobial photodynamic therapy 
appears promising for the treatment of local infections caused by both Gram-positive and Gram-negative 
bacteria.
135
 
We did the first step towards the development of bio-conjugates between azetidinones and luminescent 
platinum complexes. We have chosen platinum compounds because of their interesting photophysics that 
can be tuned upon the formation of aggregates.
136
 Furthermore, platinum complexes are widely used in 
biomedical application due to their anticancer activity, and their ability to recognize proteins. We report 
on the synthesis and photophysical properties of neutral luminescent platinum complexes coupled through 
a coordinated pyridine on the C4 side chain of the (3R,4R)-3-((R)-1-tbutyldimethylsilyloxyethyl)-
azetidin-2-one as a β-lactam model. The complexes, which bear a trifluoromethyl-substituted tridentate 
chromophoric ligand, are able to show high tendency towards aggregation in biological relevant 
environments. Furthermore, it is known in medicinal chemistry that the presence of the highly 
hydrophobic trifluorometyl groups would allow a certain degree of lipophilicity and cellular permeability. 
Many trifluoromethyl-substituted derivatives are indeed known to cross cellular and nuclear 
membranes.
137
 We can envisage that the here reported and characterized molecules could therefore be 
parent compounds of a novel set of bio-imaging probes with self-assembling properties for particular 
biological targets, such as bacteria, proteins, or receptors. 
 
6.1.2 Synthesis and photophysical characterization 
In 1974, Clauss et al. reported that the 4-acetoxyazetidin-2-one undergoes a nucleophilic displacement of 
the acetoxy group with a variety of nucleophiles.
138
 This observation prompted many laboratories to use 
4-acyloxy-azetidinones as substrates for the synthesis of a variety of β-lactams and nowadays they are 
useful industrial intermediates for the synthesis of carbapenem.
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Starting from (3R,4R)-3-((R)-1-tbutyldimethylsilyloxyethyl)-azetidin-2-one (A, Scheme 7.1.1), which is 
commercially available, we took advantage of the aptitude of 4-acetoxy group to undergo nucleophilic 
substitution reactions and we tried to insert on the C-4 position of the β-lactam ring a residue which will 
be a suitable metal ligand. On a first attempt, the 4-OH-pyridine was chosen as nucleophile and the 
corresponding azetidinone 1 was obtained in good yields. On attempting the complexation of 1 with 
Pt(II)Cl2(DMSO)2 as the platinum precursor, 2,6-bis(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)pyridine as 
the tridentate ligand (py-CF3-trzH2) in CHCl3, and in the presence of the Hünig base (iPr2EtN) at 50°C, 
we obtained only the 4-OH-pyridyl-Pt(II) complex 2. A tentative explanation is that the C-4 position of 
the expected β-lactam B could result activated by the direct conjugation of the phenolic moiety with the 
pyridine coordinated to platinum. Thus in the aqueous work-up the displacement of the ligand from the 
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azetidinone intermediate B occurred and only the pyridine complex 2 was isolated (Scheme 6.1.1). 
Compound 2 has been already characterized by De Cola and coworkers and it will not hereafter further 
investigated. 
 
Scheme 6.1.1 Synthetic procedure for compounds 1 and 2 
To avoid the electronic coupling between the pyridine and the azetidinone moiety, a short alkyl chain was 
introduced as a spacer. Thus 3-pyridyl-propanol and the 4-acetoxy-azetidinone A were coupled (Scheme 
7.1.2) to give the azetidinone 3. Compound 3 was then treated with the platinum (II) precursor, the ligand 
2,6-bis(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)pyridine, in the presence of iPr2EtN in CHCl3 at 50°C 
leading to the β-lactam complex 4 (Scheme 6.1.2). The new platinum-based bio-conjugate was purified 
by column chromatography and fully characterized. 
 
Scheme 6.1.2 Synthetic strategy to the new β-lactam platinum conjugate 4 
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Complex 4 is however poorly soluble in organic solvents and completely insoluble in water. To improve 
its solubility we then inserted a short tetraethylene glycol chain as spacer between the pyridine and the β-
lactam moieties. The synthetic pathway is depicted in Scheme 7.1.3 and started from the reaction of 4-
chloromethylpyridine with tetraethylene glycol, to give compound 5. The new tetraethyleneglycol-pyridyl 
ligand 5 was preliminarily evaluated as platinum ligand in reaction with the Pt(II) precursor obtaining 
complex 6 (Scheme 6.1.3) successfully. Treatment of the starting 4-acetoxyazetidinone A with 5 gave the 
β-lactam complex 7, which was treated with the Pt(II) precursor, the py-CF3-trzH2, iPr2EtN in CHCl3 at 
50°C to give the desired β-lactam complex 8. 
 
Scheme 6.1.3 Synthetic route to obtain the azetidinone-Pt(II) complex 8 
The β-lactam conjugate 8 was obtained in 59% yield after flash chromatography purification and fully 
characterized. The complex 8 was very soluble in several organic solvents (DCM, CHCl3, THF, MeOH, 
ethyl acetate and acetone), and in water it rapidly formed a homogeneous colloidal suspension. The 
purified conjugates 4 and 8 were fully characterized by mass spectrometry (ESI), IR, and NMR 
spectroscopy. In Figure 7.1.1 
1
H NMR (400MHz) spectra of compounds 4, 8 and the β-lactam 3 are 
reported in comparison. The successful complexation of the β-lactam 3 to platinum in compounds 4 and 8 
was confirmed by the downfield shift of the ortho-aromatic pyridine protons of the C-4 side chain of the 
β-lactam, which moved from 8.5 ppm in compound 3 to 9.4 ppm for 4 and 8. 
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Figure 6.1.1 
1
H NMR (400MHz) spectra of 3, 4 and 8 (from bottom to top) in CDCl3 
On the contrary, resonance peaks relative to the peculiar hydrogen atoms on the β-lactam ring b, c, and d 
(Figure 6.1.1) were influenced by complexation to a much lesser extent. Therefore, the β-lactam ring 
should not be involved in platinum complexation and it could save its own characteristics and properties. 
This is an important observation in view of a possible application of the conjugation described here on 
biologically active azetidinones. 
 
Photophysical Characterization 
The complexes 4 and 8 were also fully characterized using electronic absorption, steady state and time 
resolved emission spectroscopy and the corresponding data are summarized in Table 6.1.1 (where sh 
denotes a shoulder; [a]: amplitude-weighted lifetimes; [b]: recorded at 450 nm; [c]: recorded at 585 nm). 
 
Table 6.1.1 Photophysical data for compounds 4 and 8 at rt, 77K and in solid state 
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The absorption and emission spectra in dilute (concentration 1·10
-5
M) CHCl3 solution at room 
temperature (solid traces: absorption and normalized emission spectra for samples of compound 4, in 
black, and 8, in red), and at concentration of 5·10
-5
M in 2-MeTHF glassy matrix at 77K (dashed traces) 
are displayed in Figure 6.1.2 (Emission spectra collected upon λexc at = 300nm). 
 
Figure 6.1.2 Absorption and emission spectra for 4 (black) and 8 (red) 
As shown in the electronic absorption spectrum in dilute CHCl3 fluid solution, both compounds 4 and 8 
display absorption features in two main regions. At lower energy in the region 360-400 nm, a weak broad 
and featureless band with molar extinction coefficient, ε, of 0.8 and 1.1·103M–1cm–1 (at λabs = 403nm) for 
compounds 4 and 8, respectively, is attributable to the overlap of energetically lower-lying spin-allowed 
inglet-manifold metal-to-ligand charge transfer, 
1
MLCT, and ligand-centered, 
1
LC, excitation processes 
as typical of similar reported cyclometalated platinum (II) complexes. Such excitation can be mainly 
described as a shift of electron density from the filled d metal-based molecular orbitals to the empty MOs 
of the tridentate ligand with π* character,  π(Pt)π*. On the other hand, the more intense (ε = 0.26-
2.44·10
4
M
–1
cm
–1
) and structured absorption features present at higher energy (λabs = 250-340nm) can be 
attributed to 
1
LC bands. Unfortunately, the low solubility of the complexes in solvents with a wide range 
of polarity hampered studies on solvent dependence. As shown in Figure 6.1.2, upon photoexcitation in 
the range 300-400nm, diluted fluid air-equilibrated solutions in CHCl3 of both complexes display 
moderate (PLQY = 2%) and structured emission in the blue region of the visible spectrum with a 
maximum at 464, and vibrational bands at 492 and 525, and a shoulder at 567nm. The observed emission 
band with vibronic progression is similar to other reported platinum (II) derivatives bearing N^N^N 
tridentate chelating motifs and is attributed to π–π* transitions involving the tridentate ligand. All the 
complexes has bi-exponential radiative deactivation kinetics: τ1 = 278ns and τ2 = 13ns for compound 4 
and τ1 = 239ns and τ2 = 14ns for compound 8 (see Table 6.1.1 for more details). 
The assembling formation for the β-lactam-platinum conjugates 4 and 8 have also been investigated in the 
solid state, and the corresponding normalized excitation (dotted traces) and emission (solid traces) 
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spectra, collected at the λem maximum and upon λexc at 350nm, for solid-state samples of 4 (black) and 8 
(red) are reported in Figure 6.1.5. 
 
Figure 6.1.5 Normalized emission and excitation spectra for 4 and 8 in solid state 
Interestingly, upon photoexcitation between 300 and 400nm, the solid state samples display a very intense 
emission band centered at 596 and 589nm with PLQY as high as 55 and 56% for compound 4 and 8, 
respectively. The excited-state lifetimes decay with monoexponential kinetics and are 321 and 341ns for 
complex 4 and 8, respectively. Similar to the 77K spectra, such bright emission is attributable to the 
3
MMLCT emitting excited-state established upon aggregation of the complex in the solid state. Even 
more interestingly, the excitation spectra recorded at the maximum of emission wavelength display a 
typical 
1
MMLCT band with onset wavelength as long as 580nm for compound 4, allowing the possibility 
to excite such luminescent probes in their aggregated form with visible light with a wavelength that 
approaches the so-called therapeutic window (600-1300nm). Overall, the several nanosecond lifetime 
scale, the very bright emission in air-equilibrated conditions of the aggregated compounds, as well as the 
excellent stability of the compounds, are valuable properties that should facilitate further exploration of 
the behavior of such species for bioapplications and as theranostic agents. 
 
 
6.2 Experimental section 
6.2.1 General informations 
As previously reported (Paragraph 2.3.1). 
 
6.2.2 Synthesis 
Azetidinone A is commercially available and was used without any further purifications. 
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(3R,4R)-3-((R)-1-(tbutyldimethylsilyloxy)ethyl(-4-(pyridin-4-yloxy)azetidin-2-one (1) 
In a 25mL flask, to a stirred solution of A (143mg, 0.5mmol) in acetonitrile 
(1.0mL) were slowly added H2O (4.0mL), then 4-hydroxypyridine (95mg, 
1.0mmol) and finally Et3N (154μL, 1.1mmol). The reaction was followed by 
TLC (EtOAc/cyclohexane 8/2) and after 1h stirring, the mixture was extracted 
with DCM (3x10mL), dried with Na2SO4, and evaporated in vacuum. After flash-
chromatography purification (acetone to acetone/MeOH 95/5), the desired product 1 was obtained in 
quantitative (144mg, 100%) as a white solid. 
[α]D = 29.8° (c = 0.62, DCM) 
1
H NMR (400MHz, CDCl3): δ = 0.10 (s, 3H, MeSi), 0.12 (s, 3H, MeSi), 0.89 (s, 9H, tBuSi), 1.25 (d, J = 
7.4Hz, 3H, Me), 3.20 (dd, J = 1.5, 4.2Hz, 1H, CHCONH), 4.28 (m, 1H, CHOTBS), 5.43 (s, 1H, 
CHOPyr), 6.37 (d, J = 7.6Hz, 2H, Ar), 7.55 (d, J = 7.6 Hz, 2H, Ar), 7.88 (s, 1H, NH) ppm 
13
C NMR (100.6 MHz, CDCl3): δ = -5.0 ,-4.3, 17.9, 22.5, 25.7, 64.4, 68.1, 68.5, 118.9, 136.3, 165.7, 
179.6 ppm 
IR: ṽ = 3391, 2956, 2929, 2857, 1784, 1634, 1549, 1386, 1257, 1174, 1099, 982, 836, 776 cm-1 
HPLC-MS: Rt = 6.70min; m/z = 323 (100) [M+H]
+
, 645 (59) [2M+H]
+
, 667 (23) [2M+Na]
+
 
 
2,6-Bis(3-trifluoromethyl)-1,2,4-triazol-5-yl)pyridine Pt (II) pyridin-4-ol (2) 
Compound 2 is a known compound,
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 and was prepared as follows. In a 
25mL two-neck flask with a Liebig condenser under a nitrogen atmosphere, 
to a stirred solution of 1 (84mg, 0.23mmol) in chloroform (10.0mL) were 
added 80mg (0.23mmol) of 2,6-bis(3-trifluoromethyl-1H-1,2,4-triazol-5-
yl)pyridine, 97mg  (0.23mmol) of PtCl2·(DMSO)2 and N-ethyl-N,N-
diisopropylamine (80μL, 0.46mmol). The mixture was heated at 50°C, 
stirred overnight and then analyzed by TLC (EtOAc/acetone 8/2). Direct evaporation afforded a crude 
reaction mixture that was purified by flash-chromatography (EtOAc/acetone 9/1 to acetone) to give 
complex 2 (102mg, 70%) as a yellow luminescent waxy solid. 
 
(3R,4R)-3-((R)-1-tbutyldimethylsilyloxyethyl)-4-(3-(pyridin-4-yl)propoxy) azetidin-2-one (3) 
In a 25mL two-neck flask dried and under a nitrogen atmosphere, to a stirred 
solution of A (143mg, 0.5mmol) in dioxane (5.0mL), 3-pyridine-propanol 
(274mg, 2.0mmol) and ZnBr2 (450mg, 2.0mmol) were added. The reaction 
was followed by TLC monitoring (EtOAc/cyclohexane 8/2) and after 56h it 
was quenched by stirring with saturated aqueous NaHCO3 (5mL), extracted 
with DCM (3x10mL), dried with Na2SO4, filtered and evaporated in vacuum. The crude was then purified 
by flash-chromatography (EtOAc/cyclohexane 4/6 to 8/2), and compound 3 (111mg, 61%) was so 
obtained as a colorless oil. 
[α]D = -1.9° (c = 0.76, DCM) 
1
H NMR (400MHz, CDCl3): δ = 0.06 (s, 3H, MeSi), 0.08 (s, 3H, MeSi), 0.87 (s, 9H, tBuSi), 1.25 (d, J = 
6.2 Hz, 3H, Me), 1.94 (m, 2H, OCH2CH2), 2.71 (t, J = 7.6 Hz, 2H, OCH2CH2CH2), 3.02 (d, J = 4.2Hz, 
1H, CHCONH), 3.49 (t, J = 6.4Hz, 2H, OCH2), 4.17 (m, 1H, CHOTBS), 5.04 (s, 1H, CHNH), 6.61 (bs, 
1H, NH), 7.12 (d, J = 4.0Hz, 2H, arom), 8.50 (d, J = 4.0Hz, 2H, arom) ppm 
13
C NMR (100.6MHz, CDCl3): δ = -5.1, -4.4, 17.9, 22.5, 25.7, 29.9, 31.5, 64.2, 65.5, 66.6, 80.5, 124.0, 
149.3, 150.9, 167.9 ppm 
IR: ṽ = 3227, 2955, 2929, 2857, 1767, 1605, 1463, 1417, 1361, 1255, 1120, 1098, 836 cm-1 
HPLC-MS: Rt = 9.65min; m/z = 365 [M+H]
+
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2,6-Bis(3-(trifluoromethyl)-1,2,4-triazol-5-yl)pyridine Pt(II)  
(3R,4R)-3-((R)-1-tbutyldimethylsilyloxyethyl)-4-(3-pyridin-4-yl propoxy)azetidin-2-one (4) 
In a 25mL two-neck round-bottom flask with a Liebig 
condenser, anhydrified and put under nitrogen atmosphere, 
to a stirred solution of 3 (60mg, 0.165mmol) in chloroform 
(7.2mL), 2,6-bis[3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl] 
pyridine (58mg, 0.165mmol), PtCl2·(DMSO)2 (67mg, 
0.165mmol) and N-ethyl-N,N-diisopropylamine  (69μL, 
0.396mmol) were added. The mixture was heated at 50°C 
overnight and analyzed by TLC (EtOAc). Direct 
evaporation of the reaction solvent afforded a crude product that was purified by flash-chromatography 
(DCM/EtOAc 3/7), to obtain 4 (58mg, 39%) as a yellow to orange fluorescent waxy solid. 
[α]D = -2.8° (c = 0.87, DCM) 
1
H NMR (400MHz, CDCl3): δ = 0.07 (s, 3H, MeSi), 0.09 (s, 3H, MeSi), 0.87 (s, 9H, tBuSi), 1.29 (d, J = 
6.4Hz, 3H, Me), 2.03-2.12 (m, 2 H, OCH2CH2), 2.75-2.99 (m, 2H, OCH2CH2CH2), 3.06 (d, J = 3.6Hz, 
1H, CHCONH), 3.50-3.55 (m, 1H, OCHAHB), 3.56-3.66 (m, 1H, OCHAHB), 4.12-4.26 (m, 1H, 
CHOTBS), 5.09 (s, 1H, CHNH), 6.94 (s, 1H, NH), 7.34 (d, J = 6.2Hz, 2H, Ar), 7.63 (d, J = 8.0 Hz, 2H, 
Ar), 7.90 (t, J = 8.0Hz, 1H, Ar), 9.33 (d, J = 6.2Hz, 2H, Ar) ppm 
13
C NMR (100.6MHz, CDCl3): δ = -5.1, -4.3, 17.9, 22.5, 25.7, 28.9, 31.7, 64.3, 65.6, 66.0, 80.5, 118.1, 
119.6 (q, 
1
JC-F = 270Hz), 121.0, 126.4, 143.0, 148.4, 152.5, 152.6 (q, 
2
JC-F = 38Hz), 155.4, 163.5, 167.8 
ppm 
19
F NMR (400MHz, CDCl3): δ = -64.1 ppm 
IR: ṽ = 3286, 2958, 2930, 2858, 1767, 1628, 1482, 1202, 1156, 1132, 1098 cm-1 
MS (ESI
+
): m/z = 907 [M+H]
+
, 929 [M+Na]
+
, 1836 [2M+Na]
+
 
C30H35F6N9O3PtSi (906.83): calc C 39.73, H 3.89, N 13.90; found C 39.65, H 4.21, N 12.44 
 
1-(Pyridin-4-yl)-2,5,8,11-tetraoxatridecan-13-ol (5) 
In a 100mL two-neck flask under a nitrogen atmosphere, to a stirred solution of 4-
chloromethyl-pyridine hydrochloride (820mg, 5.0mmol) in acetonitrile (40.0mL) 
were added tetraethylene glycol (949 μL, 6.5mmol) and Et3N (1.4mL, 10.0mmol). 
After 1h stirring, NaH (60% in oil, 400mg, 10.0mmol) was added and the mixture was stirred overnight at 
room temperature. The progress of the reaction was followed by TLC monitoring (EtOAc/cyclohexane 
8/2) and after 20 hours the reaction mixture was concentrated under vacuum. The obtained crude product 
was then purified by flash-chromatography (acetone/MeOH 95/5) to furnish alcohol 5 in good yield 
(217mg, 76%) as a colorless oil. 
1
H NMR (400MHz, CDCl3): δ = 3.60-3.73 (m, 16H, OCH2CH2O), 4.61 (s, 2H, OCH2Ar), 7.36 (d, J = 
5.2Hz, 2H, Ar), 8.60 (d, J = 5.2Hz, 2H, Ar) ppm 
13
C NMR (100.6MHz, CDCl3): δ = 60.8, 69.5, 69.6, 69.7, 69.9, 70.0, 70.8, 72.2, 72.3, 121.3, 147.4, 148.9 
ppm 
IR: ṽ = 3375, 2969, 2925, 2879, 1465, 1419, 1378, 1301, 1127, 1106, 952 cm-1 
HPLC-MS: Rt = 1.28min; m/z = 286 [M+H]
+
 
 
2,6-Bis(3-trifluoromethyl-1,2,4-triazol-5-yl)pyridine Pt(II) 
1-(pyridin-4-yl)-2,5,8,11-tetraoxatridecan-13-ol (6) 
In a 25mL two-neck flask equipped with a Liebig condenser under a 
nitrogen atmosphere, to a stirred solution of 5 (48mg, 0.17mmol) in 
chloroform (7.4mL), 2,6-bis[3-(trifluoromethyl)-1H-1,2,4-triazol-5-
yl]pyridine (59mg, 0.17mmol), PtCl2·(DMSO)2 (72mg, 0.17mmol) and 
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N-ethyl-N,N-diisopropylamine (71μL, 0.408mmol) were added. The mixture was heated at 50°C, stirred 
overnight and then analyzed by TLC (acetone/EtOAc 8/2). Direct solvent evaporation of the reaction 
mixture afforded a crude product that was purified by CombiFlash (DCM/MeOH 98/2) to obtain 6 (45mg, 
32%) as a yellow to orange fluorescent waxy solid. 
1
H NMR (400MHz, CDCl3): δ = 3.56-3.87 (m, 16H, OCH2CH2O), 4.76 (s, 2H, OCH2Ar), 7.68 (d, J = 
6.0Hz, 2H, arom), 7.89 (d, J = 8.0Hz, 2H, arom), 8.08 (t, J = 8.0Hz, 1H, Ar), 9.62 (d, J = 6.0Hz, 2H, Ar) 
ppm 
13
C NMR (100.6 MHz, CDCl3): δ = 61.6, 70.3, 70.4, 70.5, 70.6, 70.6, 70.7, 70.7, 72.5, 117.8, 119.4 (q, 
1
JC-F = 269Hz), 123.5, 142.7, 147.7, 152.0, 152.1 (q, 
2
JC-F = 38Hz), 152.6, 163.0 ppm 
19
F NMR (400MHz, CDCl3): δ = -64.3 ppm 
IR: ṽ = 3423, 3062, 2922, 2363, 1629, 1482, 1463, 1132 cm-1 
MS (ESI
+
): m/z = 850 [M+Na]+, 1677 [2M+Na]
+
 
C25H26F6N8O5Pt (827.61): calc C 36.28, H 3.17, N 13.54; found C 35.99, H 3.52, N 11.90 
 
(3R,4R)-3-((R)-1-(tbutyldimethylsilyloxy)ethyl)-4-((1-pyridin-4-yl-2,5,8,11-tetraoxatridecan-13-
yl)oxy)azetidin-2-one (7) 
In a 25mL two-necked flask equipped with a Liebig condenser, dried and 
under a nitrogen atmosphere, to a stirred solution of A (143mg, 
0.5mmol) in dioxane (4.0mL), 5 (142mg, 0.5mmol) and ZnBr2 (112mg, 
0.5mmol) were added. The reaction was warmed to 50°C and monitored 
by TLC (EtOAc). After 30h stirring, the reaction was quenched with 
saturated aqueous NaHCO3 (5mL) and the solvents were evaporated under vacuum. The solid mixture 
was treated with a mixture of MeCN/MeOH (1/1, 10mL), filtered, and the liquid phase was concentrated 
under vacuum. After flash-chromatography purification (EtOAc to EtOAc/MeOH 95/5), product 7 
(90mg, 35%) was obtained as a colorless oil. 
[α]D = 4.4° (c = 1.00, DCM) 
1
H NMR (400MHz, CDCl3): δ = 0.06 (s, 3H, MeSi), 0.07 (s, 3H, MeSi), 0.88 (s, 9H, tBuSi), 1.25 (d, J = 
6.4Hz, 3H, Me), 2.94 (dd, J = 1.2, 4.0Hz, 1H, CHCONH), 3.44-3.96 (m, 16H, OCH2CH2O), 4.11-4.18 
(m, 1H, CHOTBS), 4.60 (s, 2H, OCH2Ar), 5.00 (d, J = 1.2Hz, 1H, CHNH), 7.29 (d, J = 5.6Hz, 2H, Ar), 
7.51 (s, 1H, NH), 8.57 (d, J = 5.6Hz, 2H, Ar) ppm 
13
C NMR (50.3MHz, CDCl3): δ = -5.1, -4.2, 17.9, 22.4, 25.7, 26.5, 64.5, 65.4, 69.9, 70.2, 70.3, 70.4, 70.5, 
70.7, 71.2, 71.5, 82.8, 122.2, 148.1, 149.9, 167.6 ppm 
IR: ṽ = 3330, 2955, 2928, 2858, 1764, 1462, 1375, 1253, 1103, 949, 778, cm-1 
HPLC-MS: Rt = 1.45min; m/z = 513 [M+H]
+
 
 
2,6-Bis(3-trifluoromethyl-1,2,4-triazol-5-yl)pyridin Pt(II) (3R,4R)-3-((R)-1-tbutyldimethylsilyloxy 
ethyl)-4-((1-pyridin-4-yl-2,5,8,11-tetraoxatridecan-13-yl)oxy)azetidin-2-one (8) 
In a 25mL two-neck flask with a Liebig condenser under a 
nitrogen atmosphere, to a stirred solution of 7 (44mg, 
0.086mmol) in chloroform (7.2mL), 30mg (0.086mmol) of 
2,6-bis[3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl] pyridine, 
36mg (0.086mmol) of PtCl2·(DMSO)2 and N-ethyl-N,N-
diisopropylamine (36μL, 0.206mmol) were added. The 
mixture was heated at 50°C overnight and then analyzed by 
TLC (EtOAc/acetone 8/2). Direct evaporation of the 
reaction solvent afforded a crude product that was purified by flash-chromatography (EtOAc/acetone 
95/5) to obtained 8 in discrete yield (54mg, 59%) as a yellow to orange luminescent waxy solid. 
[α]D = -0.4 (c = 0.91, THF) 
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1
H NMR (400MHz, CDCl3): δ = -0.01 (s, 3H, MeSi), 0.00 (s, 3H, MeSi), 0.80 (s, 9H, tBuSi), 1.17 (d, J = 
6.4Hz, 3H, Me), 2.88 (d, J = 4.4Hz, 1H, CHCONH), 3.46-3.85 (m, 16H, OCH2CH2O), 4.02-4.14 (m, 1H, 
CHOTBS), 4.68 (s, 2H, OCH2Ar), 4.91 (s, 1H, CHNH), 7.46 (s, 1H, NH), 7.53 (d, J = 6.0Hz, 2H, Ar), 
7.72 (d, J = 8.0Hz, 2H, Ar), 7.95 (t, J = 8.0Hz, 1H, Ar), 9.48 (d, J = 6.0Hz, 2H, Ar) ppm 
13
C NMR (50.3 MHz, CDCl3): δ = -3.7, -3.6, 14.0, 22.6, 23.8, 25.6, 61.7, 66.3, 66.9, 67.4, 67.6, 70.4, 
70.7, 70.8, 72.5, 82.5, 118.0, 120.8 (q, 
1
JC-F = 265Hz), 123.7, 142.9, 148.4, 152.6, 152.7 (q, 
2
JC-F = 40Hz), 
152.8, 160.9, 163.5 ppm 
19
F NMR (400MHz, CDCl3): δ = -64.2 ppm 
MS (ESI
+
): m/z = 1077 [M+Na]
+
 
C36H47F6N9O7PtSi (1054.99): calc C 40.99, H 4.49, N 11.95; found C 40.88, H 4.20, N 12.30 
156 
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7. ASYMMETRIC STRECKER REACTION 
7.1 α-aminonitriles Strecker synthesis 
7.1.1 α-aminonitriles Strecker synthesis using acetone-cyanohydrin 
α-Aminonitrile compounds play a significant role in organic chemistry. Because of their bifunctional 
nature, they are versatile intermediates for the synthesis of natural and bioactive compounds, and they can 
be precursors to important building blocks such as naturally and non-naturally occurring α-amino acids.141 
One of the earliest procedures to obtain α-aminonitriles was the Strecker reaction, a three-component 
reaction between a carbonyl compound, an amine, and cyanide ion.
142
 Spurred on by the ever-increasing 
demand for non-natural enantioenriched α-amino acids for proteomic sciences and medicinal chemistry, 
one of the hottest topics in recent years has been the asymmetric Strecker reaction leading to enantiopure 
α-aminonitriles, precursors of enantiopure α- 
amino acids,
143
 amines, and amine derivatives. In general, two approaches have been used to achieve 
successful asymmetric Strecker reactions: the addition of cyanide to chiral non-racemic imines, and the 
catalytic enantioselective cyanation of achiral imines.
144
 As an example, we dealt some years ago with 
diastereoselective Strecker reactions in a study on the addition of trimethylsilyl cyanide (TMSCN) to 
chiral imines, where the source of chirality was the Oprotected (2S)-lactic aldehyde.
 145
 The optimal 
reaction conditions (Lewis acid catalysts and organic solvent)
146
 varied for imines with different N-
protecting groups. Interestingly, we observed that a preformed N-trimethylsilylimine was capable of 
reacting with TMSCN in dichloromethane without any catalyst to give chiral N-unprotected α-
aminonitriles in good yields and with good diastereoselectivity. The first example of a diastereoselective 
Strecker reaction assisted by a chiral auxiliary on the amine component was reported by Harada, who 
used (S)-1-phenyl-ethylamine as the chiral auxiliary to obtain chiral (S)-α-amino acids after acid 
hydrolysis of the nitrile and cleavage and recovery of the N-alkyl group.
147
 As a result of this approach, 
extensive studies involving other chiral amines, including amino acids, amino amides, amino alcohols, 
sulfinamides, glycosylamines, hydrazines, and others, were carried out with good results in terms of 
yields and diastereoselectivity. A diastereoselective Strecker reaction leading to enantiopure α-aryl 
glycines was recently reported by James and coworkers.
148
 Recently, we reported a simple, convenient, 
and practical method for the synthesis of α-aminonitriles through a catalyst-free Strecker reaction of a 
carbonyl compound, amine, and acetone cyanohydrin in water.
149
 We used acetone cyanohydrin as the 
cyanide source, exploiting its “in situ” dissociation into HCN and acetone. In water, the dissociation 
process was quite slow, but the addition of a small amount of basic compounds dramatically increased the 
decomposition rate. The one-pot reactions proceeded very efficiently without any catalyst at room 
temperature and with high chemoselectivity. α-Aminonitriles were generally obtained in good to excellent 
yields and, it is noteworthy that in some cases, the expected pure α-aminonitrile directly separated from 
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water. The next aim of the project is now to extend the protocol to the asymmetric variant. In this paper, 
we report the synthesis of chiral α-aminonitriles obtained by a diastereoselective Strecker reaction in 
water using enantiopure amines. We screened primary and secondary amines derived from L-proline, L-
phenylglycine, L-phenylalanine, and L-tryptophan in a one-pot procedure with aldehydes and acetone 
cyanohydrin in water and obtained α-aminonitriles incorporating the chiral amine skeleton. We 
investigated the diastereoselectivity and the configurational stabilities of the new chiral α-aminonitriles. 
Furthermore, we evaluated the l-proline-derived aminonitriles as chiral precursors of unusual α-amino 
acids and their derivatives. As there are still only a few reports
150
 dealing with the asymmetric Strecker 
reaction with acetone cyanohydrin as the cyanide source, a contribution to this area was highly desirable.  
 
7.1.2 Primary chiral amines 
The study of the asymmetric variant of the one-pot Strecker reaction in water using acetone cyanohydrin 
as the cyanide source started with some enantiopure primary amines in combination with achiral aromatic 
or aliphatic aldehydes (Table 7.1.1, [a]: combined yields for both isomers; [b]: amines used as 
hydrochloride and treated in situ with 1eq. of Et3N). As model aldehydes, benzaldehyde (1), butanal (2), 
isobutyraldehyde (3), and pivaldehyde (4) were evaluated. As chiral amines, we tested the Harada’s 
source of chirality (S)-1-phenylethylamine (5), β-aminols, β-aminoethers, such as (S)-2-amino-2-
phenylethanol (6), (S)-2-methoxy-1-phenylethanamine (7), (S)-2-amino-3-phenylpropan-1-ol (10), (S)-2-
amino-3-(1H-indol-2-yl)propan-1-ol (11), and methyl esters of L-phenylglycine (i.e., 8), of L-
phenylalanine (i.e., 9), and of l-tryptophan (i.e., 12). Free α-amino acids were also tested, but they did not 
give results. The experimental protocol consisted of pre-mixing the aldehyde and the chiral amine in a 
closed vial without any solvent at room temperature, followed by the addition of water and of one 
equivalent of acetone cyanohydrin, consecutively. The reaction mixture was subjected to orbital shaking 
overnight at room temperature. The reactions proceeded smoothly, and gave the products in good to 
excellent yields. 
The best results in terms of yield were obtained with amine 5 and β-aminols 6 and 10, which gave the 
aminonitriles in almost quantitative yields. Using amino acid methyl esters 8, 9, and 12, the yields were 
lower, and we could detect in the crude mixture the presence of by-products such as aldehyde 
cyanohydrins; in these cases the isolation of the aminonitriles required solvent extraction followed by 
chromatographic purification. 
As regards the diastereoisomeric outcome, amine 5 gave 2/1 mixtures of the two diastereoisomers a and b 
(Table 7.1.1, entries 1-4, products 13-16). Aminonitriles 13,
151
 14,
152
 15
153
 and 16
154
 are known 
compounds, and the absolute configuration of the major diastereoisomers 13a-16a were assigned as (S,S; 
i.e., 1,3-“syn”), by comparison with literature 1H NMR spectroscopic data. 
159 
 
Table 7.1.1 One-pot Strecker reaction in water with 1eq. of acetone cyanohydrin 
(S)-Phenylglycinol 6 gave a general enhancement of the diastereoisomeric ratios with all the aldehydes 
(Table 7.1.1, entries 5-7, compounds 17–19) up to a value of 83:17, which was obtained with compounds 
19a-b. The absolute configurations of the major diastereoisomers 17a and 19a were assigned as (S,R) by 
comparison with the 
1
H NMR spectroscopic data for the same compounds reported in the literature.
155
 For 
compounds 18a-b, the configuration was assigned by comparison with 1H NMR spectra of aminonitriles 
17a-b and 19a-b. In particular, we observed a constant and similar trend in the chemical shift of the 
proton on the carbon α to the CN group. The CHCN signal in the major diastereoisomers (i.e., 17a and 
19a) was more shielded than the corresponding signal in the minor diastereoisomers (i.e., 17b and 19b). 
The same trend was observed for 18a and 18b, and this allowed an assignment of the configuration. 
Notwithstanding the difference in stereochemical descriptors of the major diastereoisomers, i.e., (S,S) for 
aminonitriles 13a-16a, and (S,R) for 17a-19a, the stereoinduction exerted by amine 6 was of the same 
sense as for Harada’s amine 5, giving predominantly the 1,3-“syn” stereoisomers in all cases. 
The key role of the OH group in L-phenylalaninol (6) as an enhancer of dr was confirmed by using the 
corresponding O-methyl ether (i.e., 7) as starting amine. In this case, lower dr values for the product 
aminonitriles (i.e., 20a-b and 21a-b) were obtained: 64:36 and 71:29, respectively. The configurations of 
160 
20a and 21a were assigned as (S,R) on the basis of the same trend of CHCN chemical shifts observed for 
compounds 17 and 19, as discussed above. To confirm the assignment, compound 17a was directly 
transformed into 20a through simple O-methylation (see Supporting Information for experimental details 
and NMR spectroscopic data). 
When methyl esters of amino acids were used as sources of chirality (Table 7.1.1, entries 10-13 and 16-
17), the diastereoisomeric ratios were not outstanding, and a highest dr value of 77/23 was seen for 23a-b, 
obtained from l-phenylglycine methyl ester (8) and butanal (2). The configuration of compounds 22a-b 
was established to be (S,R) by chemical transformation of a 2:1 mixture of 22a/22b into 17a/17b by 
reducing the methyl ester with NaBH4. The configurations of aminonitriles 23a-b, 24a-b, 25a-b, 26a-b, 
and 27a-b were assigned on the basis of the 
1
H NMR chemical shift trends of the whole series. 
Aminonitriles 28a-b are known compounds, and their configurations were assigned by comparison with 
NMR literature data.
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 Whenever the chiral amine was more flexible on the β-carbon, as is the case for 
amines 10 and 11, the diastereoselectivity dropped completely (Table 7.1.1, entries 12 and 17). α-
Substituents on the aldehyde seem to have little influence on diastereoisomeric ratio, with a slight 
increase of dr being seen for aliphatic and α-branched aldehydes compared to benzaldehyde (Table 7.1.1, 
entries 2, 7, 9 and 11), with a few exceptions (Table 7.1.1, entries 2 and 13). 
 
7.1.3 Secondary chiral amines 
One major feature of our Strecker protocol is that it works well with secondary amines. Thus, we decided 
to test secondary chiral amines, including L-proline esters 30– 32, L-prolinol derivatives 33-34, the (4R)-
hydroxy-L-proline ester 35, and (4R)-hydroxy-L-prolinol (36), with 1 and 2 as model aldehydes (Table 
8.1.2, [a]: combined yields for both isomers; [b]: amines used as hydrochloride and treated in situ with 
1eq. of Et3N). The reaction of diphenylprolinol (34) with butanal (2) gave the corresponding aminonitriles 
(i.e., 45a-b) in quantitative yield, and in all other cases, variable amounts of aldehyde cyanohydrins and 
starting materials could be detected in the crude reaction mixtures, and the products had to be purified by 
flash chromatography, thus lowering the yields. When L-proline esters 30, 31, and 32 were used as the 
sources of chirality, quite similar diastereoisomeric ratios were observed (average value 75:25), 
irrespective of the nature of the ester group (methyl, tbutyl, or benzyl) or the aldehyde used (Table 8.1.2, 
entries 1-5, 10 and 11). Better diastereoselectivity were obtained with (S)-prolinol (33), which gave 42 
and 43 with a dr of 82:18 using benzaldehyde or butanal (Table 2, entries 6 and 7). (S)-α,α-
Diphenylprolinol 34 gave the best result, generating a single diastereoisomer with either benzaldehyde (1) 
or butanal (2) (Table 7.1.2, entries 8 and 9). Notably, the enantiomerically pure aminonitrile (i.e., 45a) 
was obtained directly from the crude material in quantitative yield without any purification. 
The absolute configuration of major or exclusive diastereoisomers of the proline-derived α-aminonitriles 
were assigned as (S,S) by X-ray single crystal analysis and 
1
H NMR spectroscopy. 
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Table 7.1.2 One-pot Strecker reaction in water with 1eq. of acetone cyanohydrin 
Products 37–43 and 46–49 showed the same trend in the 1H NMR chemical shift of the CHCN proton, 
with the proton of the major diastereoisomer always more deshielded than that of the minor 
diastereoisomer for the whole series of compounds. Compound 45a was analyzed by single-crystal X-ray 
diffraction, and the absolute structure is shown in Figure 7.1.1. To assign the absolute configuration of 
compound 46a, we had to transform it into iodo derivative 50a by a  
 
Figure 7.1.1 X-ray structures for compounds 45a and 50a 
162 
Mitsunobu reaction,
157
 thus obtaining a crystalline product suitable for Xray diffraction analysis (Figure 
7.1.1). The X-ray diffraction data of the two structures unequivocally confirmed the S configurations of 
the newly-formed stereocenters. 
The stereochemical assignment using 1H NMR signal trends was confirmed by several chemical 
transformations. Thus, compound 46a was transformed into 48a by methylester reduction with NaBH4, 
and in the same way, 47a was transformed into 49a, and 37a into 42a. Finally, compound 37a was 
converted into 44a by Grignard addition. 
For the one-pot Strecker reaction, two mechanisms have been proposed: one going via an imine (or 
iminium ion) intermediate, the other via an aminol intermediate.
158
 The imine route is more plausible in 
those cases where the Strecker reaction is carried out in organic solvents and in the presence of a 
dehydrating agent that could force the elimination of water. However, Tanaka et al. demonstrated that 
imines could be efficiently formed also in water by mixing aromatic aldehydes and amines; the Schiff 
bases separated from the aqueous medium as crystalline products in structure of the amine on the 
formation of iminium intermediates with aldehydes in water showed that aminol and iminium species 
were intermediates with high barriers, especially for secondary cyclic amines such as proline methyl ester 
and pyrrolidine.
159
 
In case of L-prolinols, because of the presence of a primary alcohol in the side chain, the formation of 
bicyclic 1,3-oxazolidines, as well as imine/imonium and aminol intermediates, could be possible (Figure 
7.1.2).
160
 
 
Figure 7.1.2 Reaction intermediates and models for the asymmetric induction 
To obtain some evidence about the intermediates involved in our catalyst-free one-pot reaction in water, 
NMR analysis was performed with benzaldehyde (1), butanal (2), L-prolinol (33), and L-diphenylprolinol 
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(34). An equimolar mixture of the aldehyde and the amine was pre-mixed at room temperature, and 
aliquots were diluted in NMR tubes in two solvents, D2O or CDCl3, and quickly analyzed. We obtained 
resolvable spectra that indicated the presence of several species in solution (see Supporting Information 
for details and spectra). When L-prolinol (33) was mixed with benzaldehyde (1) in CDCl3 and D2O, two 
new distinct species with specific signals in the range 5.4-5.5ppm were observed, together with some 
remaining starting materials. The spectra of butanal (2) and prolinol (33) showed similar species with 
signals at 4.0-4.5ppm; in D2O, traces of the aldehyde hydrate and an imonium species appeared. Upon 
addition of acetone cyanohydrin, the resonances of the two new species disappeared, and those of the 
corresponding aminonitriles appeared. The rapid consumption of the intermediate species agreed with our 
previously reported observation that acetone cyanohydrin decomposes quickly in H2O in the presence of 
traces of amine or imine species to give acetone and HCN. Careful analysis of 
1
H and 
13
C NMR spectra 
and comparison with authentic spectra of 1,3-oxazolidines reported in the literature
161
 allowed us to 
assign a bicyclic 1,3-oxazolidine structure to the two diastereoisomeric intermediates. However, the 
diastereoisomeric ratio of the 1,3-oxazolidines (7/3) observed in the NMR analysis did not strictly 
correspond to the dr of the final aminonitrile products (for instance 42a/42b 82:18, see Table 7.1.2), 
because of epimerization phenomena (see below). Interestingly, the 
1
H NMR analysis of the reaction of 
diphenylprolinol (34) with aldehydes 1 or 2 in CDCl3 revealed, as well as large amounts of starting 
materials remaining, the presence of only one isomer of 1,3-oxazolidine,
162
 and this corresponds to the 
fact that a single diastereoisomer of aminonitrile was obtained in the Strecker reaction with both 
aldehydes (Table 7.1.2, entries 8 and 9). The presence of bicyclic intermediates could provide indirect 
evidence for a high reactivity of the iminium species, which presumably have a very short lifetime in 
aqueous solution and undergo a rapid intramolecular cyclization. However, despite the presence of 
several reactive intermediates, upon the addition of acetone cyanohydrin to the aqueous solution, all of 
the productive equilibria shifted to form the aminonitrile products. As a tentative model for the 
asymmetric induction exerted by the l-prolinols, the predominant or exclusive formation of (S,S)-
aminonitriles could derive from addition to the Re face of the iminium, or from bimolecular nucleophilic 
substitution from the bottom face of the 1,3-oxazolidine (Figure 7.1.2).All of the proline-derived α-
aminonitriles were new compounds, and bearing in mind the importance and the utility of proline 
derivatives in organocatalysis and metal catalysis, the preservation of l-proline and (4R)-4-hydroxy-(S)-
proline scaffolds in the target molecules allowed the formation of very interesting bifunctional 
compounds suitable for the design and synthesis of new chiral ligands. Thus, we investigated the 
reactivity of some of the proline-derived aminonitriles in reduction and hydrolysis, just to explore their 
transformation into new chiral aminols and amino acids. We treated aminonitriles 37a and 38a with 
LiAlH4, and obtained chiral 1,5-aminols 51a and 52a, respectively, by concomitant reduction of the ester 
and nitrile groups (Scheme 7.1.1). 
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Scheme 7.1.1 Reduction of some chiral α-aminonitriles 
According to the literature, hydrolysis of the nitrile group should be a routine transformation. We found, 
however, that the hydrolysis of pure aminonitrile 37a occurred under drastic conditions with an excess of 
aqueous HCl (37%) for 24h at reflux, and gave a 75/25 mixture of two diastereoisomers 53a and 53b in 
88% total yield (Scheme 7.1.2). To avoid the epimerization, we tried several milder conditions reported in 
the literature, such as HCl (5% in dioxane),
163
 sulfuric acid in DCM at 0°C, or NaHCO3 (1M aqueous).
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None of these reactions resulted in the formation of dicarboxylic acids, only epimerization of the starting 
aminonitriles and retro-Strecker products were observed. 
 
Scheme 7.1.2 Hydrolysis of some chiral α-aminonitriles 
Even alcoholysis procedures with HCl in methanol designed to transform the cyanide group into a methyl 
ester
165
 did not succeed. On the other hand, good results were obtained in the hydrolysis of the nitrile to 
an amide. Using a stoichiometric amount of TiCl4 in acetic acid and 4eq. of water,
166
 pure 37a was 
converted into amide 54a in quantitative yield without any epimerization. It is interesting that when the 
same procedure was used with 4-hydroxy-prolinol 48a, bicyclic lactone 55a was formed, due to an 
intramolecular cyclization. This result on the epimerization phenomena in the hydrolysis reaction, as well 
as the observation of unexpected spontaneous epimerization in stored samples, prompted us to face the 
problem of configurational stability of α-aminonitriles. For example, we observed that isolated minor 
diastereoisomer 37b partially converted into the major diastereoisomer (i.e., 37a) over time, whereas 
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major diastereoisomer 37a did not epimerize. Also, in a 86/14 mixture of compounds 48a–b, minor 
diastereoisomer 48b completely isomerized into 48a within a month. The epimerization of aryl-α-
aminonitriles has already been reported in the literature. Sakurai, for instance, observed isomerization of 
diastereoisomeric α-aryl aminonitriles when the compounds were dissolved in DMSO, or after heating.167 
We so prepared DMSO-d6 solutions of isolated pure diastereoisomers 37a and 37b and we heated them at 
80°C for 24h. 
1
H NMR spectra of both of the samples showed the formation of traces of benzaldehyde 
and L-proline methyl ester, and also of epimerization products with a final diastereoisomeric ratio of 
68/32 (37a/37b) starting from 37a, and 65/35 (37a/37b) starting from 37b. Moreover, the two separated 
diastereoisomeric aminonitriles, 46a and 46b, after being heated without solvent for 24h at 80°C, gave 
identical 
1
H NMR spectra recorded in CDCl3 that showed epimerization products in both samples with a 
convergent diastereoisomeric ratio 46a/46b of 72/28. Even in those cases, we observed traces of starting 
materials, benzaldehyde and trans 4-hydroxy-(S)-proline methyl ester, together with two further 
diastereoisomers derived from the partial racemization (about 15%) of the carbon α to the ester group. In 
the case of butanal derivatives 47a-b, the same experiment gave a complex product mixture, and the 
spectra were not resolvable. The presence of starting materials, and the observation that final 
diastereoisomeric ratios obtained in the isomerization experiments were consistent with the 
diastereoisomeric ratios obtained in the Strecker protocol (Table 7.1.2, entries 1 and 10), suggest that 
epimerization takes place by a retro-Strecker dehydrocyanation/cyanation mechanism. 
 
 
7.2 Experimental section 
7.2.1 General informations 
As previously reported (Paragraph 2.3.1). 
 
7.2.2 Crystal data 
Single-crystal X-ray diffraction data were collected for 45a and 50a at r.t. with an Oxford Diffraction 
Xcalibur diffractometer equipped with a Mo-Kα radiation source (λ = 0.71073Å) and a Sapphire3 CCD 
detector. The structure was solved using SHELXS-97 (others) or SIR-92 (iodioderiv) programs; 
SHELXL-97 was used for structural refinement.
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7.2.3 Synthesis 
Amines 5, 6, 8, 9, 10, 12, 30, 31, 32, 33, 34 and 35 were purchased from Sigma-Aldrich and used without 
purification, Amines 7,
169
 11
170
 and 36
171
 were synthesized following published procedures. Compounds 
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13, 14, 15, 16, 17, 19 and 28 were known, and after the synthesis gave spectroscopic data consistent with 
the published data. 
 
General Procedure for α-aminonitriles 13-29 and 37-49 
The chosen aldehyde (1mmol) and amine (1mmol) were mixed in an orbital shaker at room temp. in a 
5mL vial equipped with a screw cap. After 10min, water (4mL) and acetone cyanohydrin (1mmol) were 
added, and the cap was closed. If the amine was used as its hydrochloride, triethylamine (1mmol) was 
added prior to the addition of the aldehyde. The mixture was stirred in an orbital shaker for 20h. The 
reaction mixture was poured into brine (5mL) and extracted with DCM (2x10mL), then the combined 
extracts were dried with Na2SO4 and concentrated. If necessary, the products were purified by flash 
chromatography. Diastereoisomeric ratios were determined from 
1
H NMR spectra or HPLC data of the 
crude material. 
 
2-(2-Hydroxy-1-phenylethyl)amino pentanenitrile (18) 
The major diastereoisomer was separated by flash chromatography, the minor isomer 
was characterized in the crude mixture. 
Data for major isomer 18a (2R,2S): yellow syrup 
[α]D = +157.37° (c = 0.64, DCM) 
1
H NMR (400MHz, CDCl3): δ = 0.92 (t, J = 7.2Hz, 3H, Me), 1.48-1.58 (m, 2H, CH3CH2CH2), 1.74-1.79 
(dt, J = 7.2, 7.2Hz, 2H, CH3CH2CH2), 2.34 (bs, 2H, OH and NH), 3.30 (t, J = 7.2 Hz, 1H, CHCN), 3.61 
(dd, J = 9.6, 11.2Hz, 1H, CHHOH), 3.80 (dd, J = 4.0, 11.2 Hz, 1H, CHHOH), 4.13 (dd, J = 4.0, 9.6Hz, 
1H, CHPh), 7.28-7.39 (m, 5H, Arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 13.4, 18.9, 35.6, 47.7, 63.1, 67.2, 120.1, 127.7, 128.3, 128.8, 138.1 ppm 
IR: ṽ = 3415, 3325, 2962, 2932, 2227, 1065 cm-1 
C13H18N2O (218.29): calc C 71.53, H 8.31, N 12.83; found C 71.99, H 8.45, N 12.72 
HPLC-MS: Rt = 7.35min; m/z = 219 [M+H]
+
, 241 [M+Na]
+
. 
Data for minor isomer 18b (2S,2S): yellow syrup 
1
H NMR (400MHz, CDCl3): δ = 0.95 (t, J = 7.2Hz, 3H, Me), 1.48-1.58 (m, 2H, CH3CH2CH2), 1.69-1.78 
(m, 2H, CH3CH2CH2), 2.46 (bs, 2H, OH and NH), 3.55-3.88 (m, 3H, CHCN, CH2OH), 3.99 (dd, J = 4.4, 
7.6Hz, 1H, CHPh), 7.28-7.39 (m, 5H, arom) ppm 
HPLC-MS: Rt = 6.51min; m/z = 219 [M+H]
+
, 241 [M+Na]
+
 
 
2-[(2-Methoxy-1-phenylethyl)amino]-2-phenylacetonitrile (20) 
Characterized as a diastereoisomeric mixture, signals refer to the major 
diastereoisomer, only the main signals of the minor diastereoisomer are reported. 
Data for major isomer 20a (2R,2S) and minor isomer 20b (2S,2S): orange oil.  
1
H NMR (400MHz, CDCl3): δ = 3.33 (s, 3H, OCMe minor), 3.40 (s, 3H, OMe), 
3.46-3.54 (m, 2H, CH2OMe), 3.96 (dd, J = 3.2, 8.8Hz, 1H, PhCHCH2O minor), 4.40 (dd, J = 5.6, 8.0Hz, 
1H, PhCHCH2O), 4.49 (s, 1H, CHCN), 4.71 (s, 1H, CHCN minor), 7.27-7.43 (m, 6H, arom), 7.50-7.54 
(m, 4H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 51.8, 58.6, 60.6, 76.9, 118.6, 127.2, 127.8, 128.4, 128.7, 128.8, 128.9, 
135.1, 138.1 ppm 
IR: ṽ = 3325, 2890, 2228, 1108 cm-1 
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HPLC-MS: Rt = 9.68min, minor isomer, m/z = 240 [M-CN]
+
, 267 [M+H]
+
; Rt = 10.19min, major isomer, 
m/z = 240 [M-CN]
+
, 267 [M+H]
+
 
Compound 20a was also obtained starting from 17a. 
 
2-[(2-Methoxy-1-phenylethyl)amino]pentanenitrile (21) 
Characterized as a diastereoisomeric mixture, signals refer to the major 
diastereoisomer. 
For the minor diastereoisomer only the main signals of are reported. 
Data for major isomer 21a (2R,2S) and minor isomer 21b (2S,2S): orange oil. 
1
H NMR (400MHz, CDCl
3
): δ = 0.91 (t, J = 7.2Hz, 3H, Me), 0.93 (t, J = 7.2Hz, 3H, Me minor), 1.49-1.55 
(m, 2H, CH3CH2CH2), 1.63-1.69 (m, 2H, CH3CH2 CH2, minor), 1.71-1.78 (m, 2 H, CH3CH2CH2), 3.25 (t, 
J = 7.2Hz, 1H, CHCN), 3.36–3.44 (m, 2H, CH2OMe), 3.41 (s, 3H, OMe), 3.76 (t, J = 6.8Hz, 1H, CHCN), 
4.13 (dd, J = 3.6, 7.6Hz, 1H, NHCHPh), 4.25 (dd, J = 5.2, 8.0Hz, 1H, NHCHPh), 7.28-7.39 (m, 5H, Ar) 
ppm 
13
C NMR (100MHz, CDCl3): δ = 13.5, 18.9, 35.8, 47.5, 58.6, 60.2, 77.0, 120.3, 127.7, 128.2, 128.7, 138.4 
ppm 
IR: ṽ = 3326, 2962, 2930, 2225, 1689, 1455, 1118 cm-1 
HPLC-MS: Rt = 9.13min, minor isomer; m/z = 233 [M+H]
+
, 438 [2M-CN]
+
; 
Rt = 9.68min, major isomer; m/z = 233 [M+H]
+
, 438 [2M-CN]
+
 
 
Methyl 2-((Cyano-phenyl-methyl)amino)-2-phenylacetate (22a) 
Characterized as a diastereoisomeric mixture, yellow oil. 
Data for major isomer 22a (2R,S) 
1
H NMR (400MHz, CDCl3): δ = 2.78 (dd, J = 3.6, 10.4Hz, 1 H, NH), 3.71 (s, 3H, 
Me), 4.50 (d, J = 10.4Hz, 1H, PhCHCO2), 4.77 (d, J = 3.6 Hz, 1 H, PhCHCN), 7.35-
7.55 (m, 5H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 51.7, 52.7, 63.2, 118.2, 127.3, 128.1, 128.8, 128.9, 129.0, 129.2, 134.2, 
136.1, 171.7 ppm 
IR: ṽ = 3327, 2252, 1739, 1453 cm-1 
HPLC-MS: Rt = 9.00min; m/z = 254 [M-CN]
+
, 276 [M-HCN+Na]
+
, 281 [M+H]
+
, 303 [M+Na]
+
, 319 
[M+K]
+
 
Data for minor isomer 22b (2S,S) 
1
H NMR (400MHz, CDCl3): δ = 2.54 (dd, J = 6.4, 6.8Hz, 1H, NH), 3.74 (s, 3H, Me), 4.62 (d, J = 6.8Hz, 
1H, PhCHCO2), 4.87 (d, J = 6.8Hz, 1H, CHCN), 7.35-7.55 (m, 5H, arom) ppm 
IR: ṽ = 3327, 2252, 1453 cm-1 
HPLC-MS: Rt = 8.83min; m/z = 254 [M-CN]
+
, 276 [M-HCN+Na]
+
, 281 [M+H]
+
, 303 [M+Na]
+
, 319 
[M+K]
+
 
 
Methyl 2-(1-cyanobutylamino)-2-phenylacetate (23) 
Characterized as a diastereoisomeric mixture, yellow oil. 
Data for major isomer 23a (2R,S) 
1
H NMR (400MHz, CDCl3): δ = 0.91 (t, J = 7.2Hz, 3H, CH3CH2), 1.47-1.62 (m, 2H, 
CH3CH2CH2), 1.74-1.80 (m, 2H, CH3CH2CH2), 2.45 (d, J = 11.6Hz, 1H, NH), 3.25 
(dt, J = 6.8, 11.6Hz, 1H, CHCN), 3.71 (s, 3H, CO2CH3), 4.64 (s, 1H, CHPh), 7.33-7.43 (m, 5H, arom) 
ppm 
13
C NMR (100MHz, CDCl3): δ = 13.3, 18.8, 35.4, 47.4, 52.7, 63.2, 119.7, 128.1, 128.8, 128.9, 137.1, 
171.9 ppm 
IR: ṽ = 3331, 3031, 2960, 2875, 2253, 2226, 1739, 1455, 1436 cm-1 
HPLC-MS: Rt = 8.62min; m/z = 220 [M-CN]+, 247 [M+1]
+
, 269 [M+Na]
+
, 285 [M+K]
+
. 
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Data for minor isomer 23b (2R,S) 
1
H NMR (400MHz, CDCl3): δ = 0.97 (t, J = 7.2Hz, 3H, CH3CH2), 1.47-1.62 (m, 2H, CH3CH2CH2), 1.74-
1.80 (m, 2H, CH3CH2CH2), 2.04 (bs, 1 H, NH minor), 3.72 (s, 3H, CO2CH3), 3.68-3.76 (m, 1H, CHCN), 
4.65 (s, 1H, PhCH), 7.33-7.43 (m, 5H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 13.4, 18.8, 35.5, 48.8, 52.7, 63.3, 119.8, 127.6, 128.6, 128.7, 136.3, 
172.3 ppm 
HPLC-MS: Rt = 8.32min; m/z = 220 [M-CN]
+
, 247 [M+H]
+
, 269 [M+Na]
+
, 285 [M+K]
+
 
 
Methyl 2-((cyano-phenylmethyl)amino)-3-phenylpropanoate (24) 
Characterized as a diastereoisomeric mixture, pale yellow oil. 
HPLC-MS: Rt = 9.40min (major+minor); m/z 268 [M-CN]
+
, 295 [M+H]
+
, 317 
[M+Na]
+
, 333 [M+K]
+
. 
Data for major isomer 24a (2R,S) 
1
H NMR (400MHz, CDCl3): δ = 2.42 (bs, 1H, NH), 2.96 (dd, J = 8.4, 13.6Hz, 1H, PhCHHCH), 3.12 (dd, 
J = 5.2, 13.6Hz, 1H, PhCHHCH), 3.70 (dd, J = 5.2, 8.4Hz, 1H, CHCH2Ph), 3.75 (s, 3H, Me), 4.58 (s, 1H, 
CHCN), 7.19-7.56 (m, 10H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 39.7, 52.2, 52.9, 60.4, 118.6, 126.9, 127.4, 128.5, 128.9, 129.1, 129.3, 
134.3, 136.8, 173.6 ppm 
IR: ṽ = 3328, 2952, 2925, 2293, 2229, 1736 cm-1. 
Data for minor isomer 24b (2S,S) 
1
H NMR (400MHz, CDCl3): δ = 2.10 (br. s, 1H, NH), 2.93-3.00 (m, 1 H, PhCHH), 3.14 (dd, J = 5.6, 
14.0Hz, 1H, PhCHH), 3.79 (s, 3H, Me), 3.88 (dd, J  = 5.6, 8.0Hz, 1 H, CHCH2), 4.88 (s, 1H, CHCN), 
7.19-7.56 (m, 10 H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 39.4, 52.1, 53.3, 59.6, 118.4, 127.1, 127.5, 128.6, 129.0, 129.1, 129.2, 
134.2, 136.2, 173.6 ppm 
 
Methyl 2-(1-cyanobutylamino)-3-phenylpropanoate (25) 
Diastereoisomers separated by flash chromatography. 
Data for major isomer 25a (1R,S): pale yellow oil 
[α]D = 292.6 (c = 1.25, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 0.89 (t, J = 6.8Hz, 1H, CH3CH2CH2), 1.40-1.49 (m, 2H, CH2), 1.57–1.69 
(m, 2H, CH2), 2.03 (dd, J = 7.7, 10.4Hz, 1H, NH), 2.86 (dd, J = 7.6, 13.6Hz, 1H, CHHPh), 3.02 (dd, J = 
5.6, 13.6Hz, 1H, CHHPh), 3.27 (dt, J = 7.2, 10.4Hz, 1H, CHCN), 3.62 (ddd, J = 5.6, 7.6, 7.7Hz, 1H, 
CH2CHNHCO2Me), 3.74 (s, 3H, Me), 7.17-7.31 (m, 5H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 13.3, 18.7, 35.7, 39.8, 49.4, 52.1, 61.2, 119.9, 126.8, 128.4, 129.3, 
136.9, 173.7 ppm 
IR: ṽ = 3328, 3002, 2874, 2225, 1956, 1888, 1737, 1205 cm-1 
C15H20N2O2 (260.33): calc C 69.20, H 7.74, N 10.76; found C 69.25, H 7.81, N 10.68 
HPLC-MS: Rt = 9.16min; m/z = 261 [M+H]
+
, 283 [M+Na]
+
. 
Data for minor isomer 25b (1S,S) 
 1
H NMR (400MHz, CDCl3): δ = 0.91 (t, J = 7.2Hz, 1H, CH3CH2CH2),1.40-1.49 (m, 2H, CH2), 1.57-1.69 
(m, 2H, CH2), 21.81 (bs, 1H, NH), 2.92 (dd, J = 8.0, 14.0Hz, 1H, CHHPh), 3.12 (dd, J = 5.6, 14.0Hz, 1H, 
CHHPh), 3.70-3.76 (m, 1H, CHCN), 3.72 (s, 3H, Me), 3.81-3.86 (m, 1H, CH2CHNHCO2Me), 7.17-7.31 
(m, 5H, arom) ppm 
HPLC-MS: Rt = 8.90min; m/z = 261 [M+H]
+
, 283 [M+Na]
+
 
 
2-(1-Hydroxy-3-phenylpropan-2-yl amino)-3-methylbutanenitrile (26) 
Characterized as a diastereoisomeric mixture enriched in the minor stereoisomer after 
flash chromatography, pale yellow oil. 
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Data for major isomer 26a (2R,1S) 
1
H NMR (400MHz, CDCl3): δ = 0.98-1.03 [m, 6H, CH(Me)2], 1.90-1.96 [m, 1H, CH(Me)2], 2.65 (dd, J 
= 7.2, 13.2Hz, 1H, CHCHHPh), 2.77 (dd, J = 6.0, 13.2Hz, 1H, CHCHHPh), 3.09-3.16 (m, 1H, 
CH2CHCH2), 3.30 (d, J = 5.6 Hz, 1H, CHCHCN), 3.42 (dd, J = 7.2, 11.2Hz, 1H, CHCHHOH), 3.74 (dd, J 
= 4.0, 11.2Hz, 1H, CHCHHOH), 7.24-7.39 (m, 5H, arom) ppm 
HPLC-MS: Rt = 7.22min, m/z = 206 [M-CN]
+
, 233 [M+H]+, 255 [M+Na]
+
. 
Data for minor isomer 26b (2S,1S) 
1
H NMR (400MHz, CDCl3): δ = 1.00 (d, J = 6.8Hz, 3 H, CH3CHCH3), 1.05 (d, J = 6.8Hz, 3H, 
CH3CHCH3), 1.61 (bs, 1H, OH), 1.88-1.99 [m, 1H, CHCH(Me)2], 2.14 (bs, 1 H, NH), 2.80 (dd, J = 8.4, 
13.6Hz, 1H, CHCHHPh), 2.94 (dd, J = 6.0, 13.6Hz, 1H, CHCHHPh), 3.17-3.22 (m, 1H, CH2CHCH2), 
3.43-3.47 (m, 2H, CHCHHOH, CHCHCN), 3.66 (dd, J = 3.2, 11.2 Hz, 1 H, CHCHHOH), 7.24–7.39 (m, 
5 H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 17.9, 19.1, 31.7, 38.0, 54.9, 58.1, 61.9, 119.1, 126.9, 128.8, 129.2, 137.2 
ppm 
IR: ṽ = 3442, 3338.7, 2963, 2929, 2227, 1120 cm-1 
HPLC-MS: Rt = 6.87min; m/z = 206 [M-CN]
+
, 233 [M+H]
+
, 255 [M+Na]
+
 
 
2-((1-Hydroxy-3-(1H-indol-2-yl)propan-2-yl)amino)-3-methylbutanenitrile (27) 
Characterized as a diastereoisomeric mixture, pale yellow oil. 
Data for major isomer 27a (2R,1S) 
1
H NMR (400MHz, CDCl3): δ = 0.98-1.00 [m, 6H, CH(Me)2], 1.68-2.04 (bs, 2H, 
OH, NHCHCN), 1.86-1.97 [m, 1H, CHCH(Me)2], 3.01 (ddd, J = 0.8, 8.0, 
14.4Hz, 1H, IndCHHCH), 3.07 (ddd, J = 0.8, 8.4, 14.4Hz, 1H, IndCHHCH), 3.28-3.34 (m, 1H, 
CH2CHCH2), 3.46-3.53 (m, 2H, CHCHCN, CHCHHOH), 3.70 (dd, J = 3.6, 10.8Hz, 1H, CHCHHOH), 
7.06-7.25 (m, 3H, arom), 7.37-7.40 (m, 1H, arom), 7.62-7.66 (m, 1H, arom), 8.09 (bs, 1H, NHInd, 
minor), 8.14 (bs, 1H, NHInd) ppm 
13
C NMR (100MHz, CDCl3): δ = 17.8, 19.1, 26.8, 31.8, 55.2, 57.6, 62.4, 111.2, 111.4, 118.7, 119.5, 
119.6, 122.2, 122.5, 127.4, 136.2 ppm 
IR: ṽ = 3412, 3057, 2228, 1457, 1031 cm-1 
HPLC-MS: Rt = 7.66min; m/z = 245 [M-CN]
+
, 294 [M+Na]
+
 
Data for minor isomer 27b (2S,1S) 
1
H NMR (400MHz, CDCl3): δ = 0.98-1.00 [m, 6 H, CH(Me)2], 1.68-2.04 (bs, 2H, OH, NHCHCN), 1.86-
1.97 [m, 1H, CHCH(Me)2], 2.81 (ddd, J = 0.8, 3.6, 14.4Hz, 1H, IndCHHCH), 2.96 (ddd, J = 0.8, 6.0, 
14.4Hz, 1H, IndCHHCH), 3.23-3.29 (m, 1H, CH2CHCH2), 3.46-3.53 (m, 2H, CHCHCN, CHCHHOH), 
3.77 (dd, J = 3.6, 10.8Hz, 1H, CHCHHOH), 7.06-7.25 (m, 3H, arom), 7.37-7.40 (m, 1H, arom), 7.62-7.66 
(m, 1H, arom), 8.09 (bs, 1H, NHInd) ppm. 
13
C NMR (100MHz, CDCl3): δ = 17.9, 19.2, 27.4, 31.7, 55.3, 58.4, 64.3, 111.2, 111.8, 118.7, 119.5, 
119.8, 122.3, 122.6, 127.6, 136.3 ppm 
HPLC-MS: Rt = 7.35min; m/z = 245 [M-CN]
+
, 294 [M+Na]
+
 
 
Methyl 2-(1-cyanobutyl)amino-3-(1H-indol-2-yl)propanoate (29) 
Characterized as a diastereoisomeric mixture, pale yellow oil. 
Data for major isomer 29a (1R,S) 
1
H NMR (400MHz, CDCl3): δ = 0.87 (t, J = 7.2 Hz, 3 H, CH3CH2CH2), 1.39-
1.53 (m, 2H, CH3CH2CH2), 1.64-1.70 (m, 2H, CH3CH2CH2CH), 1.74 (bs, 1H, CHNHCHCN), 3.10 (ddd, 
J = 0.8, 7.2, 14.8Hz, 1H, IndCHHCH), 3.21 (ddd, J = 0.8, 5.2, 14.8Hz, 1H, IndCHHCH), 3.41 (t, J = 8.0 
Hz, 1H, CH2CHCN), 3.71-3.76 (m, 1H, CH2CHCOMe), 3.71 (s, 3H, CO2Me), 7.07-7.24 (m, 3H, arom), 
7.35-7.39 (m, 1H, arom), 7.61-7.64 (m, 1H, arom), 8.08 (bs, 1H, NHInd) ppm 
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13
C NMR (100MHz, CDCl3): δ = 13.2, 18.6, 28.9, 35.3, 48.9, 52.1, 60.5, 110.8, 111.1, 118.6, 119.6, 
119.9, 122.1, 122.8, 127.3, 136.0, 174.1 ppm 
IR: ṽ = 3445, 2977, 2227, 1736, 1494, 1155 cm-1 
HPLC-MS: Rt = 8.78 min; m/z = 273 [M-CN]
+
, 300 [M+H]
+
, 322 [M+Na]
+
 
Data for minor isomer 29b (1R,S) 
1
H NMR (400MHz, CDCl3): δ = 0.90 (t, J = 7.2Hz, 3H, CH3CH2CH2), 1.39-1.53 (m, 2H, CH3CH2CH2), 
1.64-1.70 (m, 2H,CH3CH2CH2CH), 2.09 (bs, 1H, CHNHCHCN), 3.15 (ddd, J = 0.8, 8.4, 14.4 Hz, 1 H, 
IndCHHCH), 3.31 (ddd, J = 0.8, 4.8, 14.8 Hz, 1H, IndCHHCH), 3.66 (t, J = 6.8 Hz, 1H, CH2CHCN), 
3.73 (s, 3H, CO2Me) , 3 .96 ( dd , J = 5. 2 , 8. 4Hz, 1H, CH2CHCOMe), 7.07-7.24 (m, 3H, arom), 7.35-
7.39 (m, 1H, arom), 7.61-7.64 (m, 1H, arom), 8.12 (bs, 1H, NHInd) ppm 
13
C NMR (100MHz, CDCl3): δ = 13.3, 18.7, 29.2, 35.7, 49.3, 52.1, 59.4, 110.3, 111.2, 118.6, 119.5, 
119.9, 122.3, 122.7, 127.3, 136.2, 173.8 ppm 
HPLC-MS: Rt = 8.63 min; m/z = 273 [M-CN]
+
, 300 [M+H]
+
, 322 [M+Na]
+
 
 
Methyl 1-(cyanophenylmethyl)pyrrolidine-2-carboxylate (37) 
Diastereoisomers separated by flash chromatography. 
Data for major isomer 37a (S,1S): yellow oil. 
[α]D = -94.06° (c = 0.64, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 1.79-1.87 (m, 2H, CH2CH2CH2), 2.06-2.14 (m, 1H, 
CHHCHCO2Me), 2.21-2.31 (m, 1H, CHHCHCO2Me), 2.55 (dt, J = 8.8, 8.8Hz, 1H, 
CH2CHHN), 2.72-2.76 (m, 1 H, CH2CHHN), 3.61 (dd, J = 7.2, 9.2Hz, 1H, CHHCHCO2Me), 3.80 (s, 3H, 
Me), 5.37 (s, 1H, CHCN), 7.35-7.43 (m, 3H, arom), 7.57-7.60 (m, 2H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 22.8, 28.8, 48.2, 52.1, 58.1, 63.0, 116.0, 127.6, 128.7, 128.8, 133.8, 
173.3 ppm 
IR: ṽ = 2953, 2227, 1743, 1206 cm-1 
C14H16N2O2 (244.29): calc C 68.83, H 6.60, N 11.47; found C 69.02, H 6.71, N 11.57 
HPLC-MS: Rt = 8.37min; m/z = 245 [M+H
]+
, 267 [M+Na]
+
 
Data for minor isomer 37b (S,1R): yellow oil. 
1
H NMR (400MHz, CDCl3): δ = 1.58-1.98 (m, 2H, CH2CH2CH2), 2.00-2.09 (m, 1H, CHHCHCO2Me), 
2.12-2.22 (m, 1H, CHHCHCO2Me), 2.91-2.99 (m, 1H, CHHN), 3.32 (s, 3H, Me), 3.33-3.38 (m, 1H, 
CH2CHHN), 3.48 (dd, J = 4.0, 9.2Hz, 1H,CH2CHCO2Me), 5.17 (s, 1H, CHCN), 7.35-7.41 (m, 3H, arom), 
7.45-7.52 (m, 2H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 23.9, 30.4, 51.6, 53.1, 58.7, 61.0, 116.6, 128.3, 128.6, 129.1, 132.9, 
174.0 ppm 
HPLC-MS: Rt = 7.27min; m/z = 245 [M+H]
+
, 267 [M+Na]
+ 
 
Benzyl 1-(1-cyanobutyl)methylpyrrolidine-2-carboxylate (38) 
The major diastereoisomer was separated by flash chromatography, the minor isomer 
was characterized in the crude mixture. 
Data for major isomer 38a (S,1S): pale yellow oil. 
[α]D = -64.37° (c = 1.4, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 0.97 (t, J = 7.2Hz, 3H, CH3CH2CH2), 1.43-1.60 (m, 2H, CH3CH2), 1.70-
1.82 (m, 2H, CH2CH2CH2), 1.87-1.94 (m, 2H, CH3CH2CH2), 1.99-2.07 (m, 1H, CHHCHCO2Me), 2.12-
2.22 (m, 1H, CHHCHCO2Me), 2.59 (dt, J = 8.8, 8.4Hz, 1 H, CHHN), 3.11 (ddd, J = 4.4, 6.4, 8.8Hz, 1H, 
CHHN), 3.43 (dd, J = 6.4, 8.4Hz, 1H, CHCO2Me), 3.73 (s, 3H, Me), 3.97 (t, J = 7.6Hz, 1H, CHCN) ppm 
13
C NMR (100MHz, CDCl3): δ = 13.3, 19.2, 23.0, 28.6, 34.4, 47.9, 52.0, 54.0, 63.5, 117.8, 173.3 ppm 
IR: ṽ = 2960, 2876, 2223, 1747, 1175 cm-1 
C11H18N2O2 (210.14): calc C 62.83, H 8.63, N 13.32; found C 62.78, H 8.71, N 13.48 
HPLC-MS: Rt = 7.49min; m/z = 130 [M-CH3(CH2)2CHCN+H]
+
, 211 [M+1]
+
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Data for minor isomer 38b (S,1R) 
1
H NMR (400MHz, CDCl3): δ = 0.94 (t, J = 8.0 Hz, 3H, CH3CH2CH2), 1.43-1.60 (m, 2H, CH3CH2), 1.70-
1.82 (m, 2H, CH2CH2CH2), 1.87-1.94 (m, 2H, CH3CH2CH2), 1.99-2.07 (m, 1H, CHHCHCO2Me), 2.12-
2.22 (m, 1H, CHHCHCO2Me), 2.80-2.87 (m, 1H, CHHN), 3.19–3.24 (m, 1H, CHHN), 3.56 (dd, J = 4.0, 
12.0Hz, 1H, CHCO2Me), 3.76-3.81 (m, 1H, CHCN), 3.82 (s, 3H, Me) ppm 
13
C NMR (100MHz, CDCl3): δ = 13.4, 19.3, 24.1, 29.2, 34.7, 47.9, 51.9, 3.7, 63.5, 118.2, 175.0 ppm 
HPLC-MS: Rt = 6.92min; m/z = 211 [M+H]
+
 
 
tButyl 1-(cyanophenylmethyl)pyrrolidine-2-carboxylate (39) 
Diastereoisomers separated by flash chromatography. 
Data for major isomer 39a (S,1S): pale yellow oil. 
[α]D = -54.53° (c = 0.27, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 1.52 [s, 9H, CMe3], 1.78-1.84 (m, 2H, CH2CH2CH2) , 
2.02-2.10 (m, 1H, CHHCHCO2Me), 2.16-2.25 (m, 1H, CHHCHCO2Me), 2.54 (dt, J = 7.6, 9.2 Hz, 1H, 
CH2CHHN), 2.71 (ddd, J = 4.4, 6.0, 9.2Hz, 1H, CHHN), 3.48 (dd, J = 6.8, 8.8Hz, 1H, CHCO2tBu), 5.39 
(s, 1H, CHCN), 7.34-7.43 (m, 3H, arom), 7.58-7.61 (m, 2H, arom) ppm 
13
C NMR (50.3MHz, CDCl3): δ = 22.7, 28.1, 28.8, 48.2, 58.2, 63.6, 81.4, 116.2, 127.6, 128.7 (2 C), 
134.1, 171.9 ppm 
IR: ṽ = 2959, 2874, 2227, 1735, 1010 cm-1 
C17H22N2O2 (286.37): calc C 71.30, H 7.74, N 9.78; found C 71.53, H 7.86, N 9.84. 
HPLC-MS: Rt = 10.88min; m/z = 172 [M-tBu-CN+3H]
+
, 260 [M-CN]
+
, 287 [M+H]
+
, 309 [M+Na]
+
, 325 
[M+K]
+
 
Data for minor isomer 39b (S,1R): pale yellow oil. 
1
H NMR (400MHz, CDCl3): δ = 1.57 (s, 9 H, CMe3), 1.82-1.89 (m, 1H, CH2CHHCH2), 1.92-1.98 (m, 1 
H, CH2CHHCH2), 1.99–2.07 (m, 1 H, CHHCHCO2Me), 2.09-2.18 (m, 1H, CHHCHCO2Me), 2.54 (dt, J 
= 6.4, 9.2Hz, 1H, CH2CHHN), 3.35-3.40 (m, 2H, CHHN, CHCO2tBu), 5.16 (s, 1H, CHCN), 7.35-7.39 
(m, 3H, arom), 7.52–7.54 (m, 2 H, arom) ppm 
HPLC-MS: Rt = 10.09min; m/z = 172 [M-tBu-CN+3H]
+
, 260 [M-CN]
+
, 287 [M+H]
+
, 309 [M+Na]
+
, 325 
[M+K]
+ 
 
tButyl 1-(1-cyanobutyl)pyrrolidine-2-carboxylate (40) 
Characterized as a diastereoisomeric mixture, pale yellow oil. 
IR: ν˜ = 2964, 2933, 2223, 1739, 1150, 1100 cm-1 
Data for major isomer 40a (S,1S) 
1
H NMR (400MHz, CDCl3): δ = 0.98 (t, J = 7.6Hz, 3H, CH3CH2CH), 1.47 [s, 9H, CMe3] , 1.49-1.59 (m, 
4H, CH2CH2CH3), 1.74-1.81 (m, 1H, CHHCH2N), 1.82-1.91 (m, 1H, CHHCH2N), 1.94-2.02 (m, 1H, 
CHHCHCOOCH3), 2.07-2.15 (m, 1H, CHHCHCO2Me), 2.57 (dt, J = 8.0, 8.8Hz, 1H, CHHN), 3.07-3.12 
(m, 1H, CHHN), 3.29 (dd, J = 6.8, 8.8Hz, 1H, CHCO2CH3), 3.99 (t, J = 7.6Hz, 1H, CHCN) ppm 
13
C NMR (100MHz, CDCl3): δ = 13.4, 19.3, 22.9, 28.1, 28.6, 34.5, 47.9, 54.1, 
64.2, 81.2, 118.1, 171.9 ppm 
HPLC-MS: Rt = 10.26min; m/z = 275 [M+Na]
+
 
Data for minor isomer 40b (S,1R) 
1
H NMR (400MHz, CDCl3): δ = 0.94 (t, J = 7.2Hz, 3H, CH3CH2CH), 1.46 (s, 9H, CMe3), 1.49-1.59 (m, 
4H, CH2CH2CH3), 1.74-1.81 (m, 1H, CHHCH2N), 1.82-1.91 (m, 1H, CHHCH2N), 1.94-2.02 (m, 1H, 
CHHCHCOOCH3), 2.07-2.15 (m, 1H, CHHCHCO2CH3), 2.77-2.83 (m, J = 8.8Hz, 1H, CHHN), 3.18-
3.22 (m, 1H, CHHN), 3.39 (dd, J = 3.2, 9.6Hz, 1H, CHCO2CH3), 3.78 (dd, J = 6.4, 9.6Hz, 1H, CHCN) 
ppm 
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13
C NMR (100MHz, CDCl3): δ = 13.4, 19.4, 24.3, 27.9, 29.7, 35.0, 47.9, 55.7, 64.2, 80.8, 118.5, 174.0 
ppm 
HPLC-MS: Rt = 9.68min; m/z = 275 [M+Na]
+
 
 
Benzyl 1-(cyanophenylmethyl)pyrrolidine-2-carboxylate (41) 
Diastereoisomers separated by flash chromatography. 
Data for major isomer 41a (S,1S): pale yellow oil. 
[α]D = -65.20° (c = 1.19, CHCl3) 
1
H NMR (400MHz, CDCl3) : δ = 1.58-1.87 (m, 2H, CH2CH2CH2), 2.09-2.18 (m, 1H, 
CHHCHCO2Bn), 2.21-2.31 (m, 1H, CHHCHCO2Me), 2.59 (dt, J = 8.0, 8.4Hz, 1H, CH2CHHN), 2.70-
2.75 (m, 1H, CH2CHHN), 3.65 (dd, J = 6.8, 8.8Hz, 1H, CHHCHCO2Bn), 5.21 (d, JAB = 12.4Hz, 1H, 
CHHPh), 5.26 (d, JAB = 12.4Hz, 1H, CHHPh), 5.35 (s, 1H, CHCN), 7.35-7.41 (m, 8H, arom), 7.50-7.52 
(m, 2H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 22.8, 28.6, 48.1, 58.0, 62.9, 66.6, 115.9, 127.4, 128.2, 128.3, 128.5, 
128.6, 128.7, 133.7, 135.5, 172.4 ppm 
IR: ṽ = 3064, 3033, 2926, 2850, 2227, 1956, 1888, 1743, 1175 cm-1 
C20H20N2O2 (320.38): calc C 74.98, H 6.29, N 8.74; found C 75.07, H 6.34, N 8.69 
HPLC-MS: Rt = 10.86 min; m/z = 321 [M+H]
+
, 343 [M+Na]
+
 
Data for minor isomer 41b (S,1R): pale yellow oil. 
[α]D = -17.93° (c = 0.99, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 1.88-1.99 (m, 2H, CH2CH2CH2), 2.01-2.08 (m, 1H, CHHCHCO2Bn), 
2.10-2.22 (m, 1H, CHHCHCO2Bn), 2.98 (dt, J = 6.8, 8.8Hz, 1H, CH2CHHN), 3.37 (dt, J = 2.8, 8.8Hz, 
1H, CHHN), 3.52 (dd, J = 4.0, 9.6Hz, 1H, CHHCHCO2Bn), 4.71 (d, JAB = 12.0Hz, 1H, CHHPh), 4.80 (d, 
JAB = 12.4Hz, 1H, CHHPh), 5.17 (s, 1H, CHCN), 7.18-7.20 (m, 2H, arom), 7.31-7.39 (m, 6H, arom), 
7.46-7.51 (m, 2H, arom) ppm 
13
C NMR (50 MHz, CDCl3): δ = 23.8, 30.4, 52.8, 58.4, 60.9, 66.1, 116.7, 128.0, 128.1, 128.2, 128.3, 
128.5, 128.9, 132.9, 135.4, 173.3 ppm 
IR: ṽ = 3064, 3033, 2952, 2828, 2226, 1743, 1166 cm-1 
C20H20N2O2 (320.38): calc C 74.98, H 6.29, N 8.74; found C 75.21, H 6.44, N 8.61. 
HPLC-MS: Rt = 9.98min; m/z = 321 [M+H]
+
, 343 [M+Na]
+
, 359 [M+K]
+
 
 
2-(2-(Hydroxymethyl)pyrrolidin-1-yl)-2-phenylacetonitrile (42) 
Characterized as a diastereoisomeric mixture. 
Signals refer to the major diastereoisomer, only the main signals of the minor 
diastereoisomer are reported, pale yellow oil. 
Data for major isomer 42a (2S,2S) and minor isomer 42b (2R,2S) 
1
H NMR (400MHz, CDCl3): δ = 1.67-1.74 (m, 1H, NCH2CH2CHHCH), 1.76-1.87 (m, 
2H, CH2CHHCH2, NCH2CH2CHHCH), 1.99-2.04 (m, 1H, CH2CHHCH2), 2.15 (bs, 1H, OH), 2.62 (dt, J 
= 8.8, 9.6Hz, 1H, CH2CHHN), 2.68-2.73 (m, 1H, CHHN), 2.88-2.95 (m, 1H, minor) , 3.00-3.04 (m, 1H, 
minor), 3.11-3.16 (m, 1H, CHCH2OH), 3.61 (dd, J = 3.6, 11.2Hz, 1H, CHCHHOH), 3.82 (dd, J = 3.2, 
11.2Hz, 1H, CHCHHOH), 5.11, (s, 1H, CHCN minor), 5.27 (s, 1H, CHCN), 7.37-7.42 (m, 3H, arom), 
7.43-7.52 (m, 2H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 23.1, 27.5, 49.2, 57.9, 62.6, 63.2, 116.3, 127.5, 128.7, 128.8, 134.1 ppm 
IR: ṽ = 3424, 3063, 3033, 2924, 2875, 2227, 1602, 1452, 1077 cm-1 
HPLC-MS: Rt = 5.36min, minor isomer; m/z = 190 [M-CN]
+
; Rt = 6.38min, major isomer; m/z = 217 
[M+H]
+
, 190 [2M-CN]
+
 
Compound 42a was also obtained starting from 37a by reduction of the ester functionality with NaBH4. 
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2-(2-Hydroxymethyl-pyrrolidin-1-yl) pentanenitrile (43) 
Characterized as a diastereoisomeric mixture. 
Signals refer to the major diastereosiomer, only the main signals of the minor 
diastereoisomer are reported, pale yellow oil. 
Data for major isomer 43a (2S,2S) and minor isomer 43b (2R,2S) 
1
H NMR (400MHz, CDCl3): δ = 0.98 (t, J = 7.2 Hz, 3H, CH3CH2CH2), 1.46-1.56 (m, 2H, CH3CH2CH2), 
1.71-1.87 (m, 4H, CH3CH2CH2, CH2CH2CH2), 1.92-1.98 (m, 2H, CH2CH2CH2CH), 2.63 (dt, J = 6.8, 
8.8Hz, 1H, CH2CHHN), 2.7-2.83 (m, 1 H, minor), 2.92-2.97 (m, 1H, CHCH2OH), 3.03-3.08 (m, 1H, 
CH2CHHN), 3.11-3.17 (m, 1H, minor), 3.46 (ddd, J = 3.6, 8.8, 12.0Hz, 1H, CHCHHOH), 3.63 (ddd, J = 
2.8, 2.8, 12.0Hz, 1H, CHCHHOH), 3.72 (dd, J = 6.0, 9.2Hz, 1H, CHCN minor), 3.83 (dd, J = 7.6, 8.0Hz, 
1H, CHCN) ppm 
13
C NMR (100MHz, CDCl3): δ = 13.4, 19.3, 23.4, 27.2, 34.7, 48.7, 53.5, 62.5, 62.8, 118.0 ppm 
IR: ṽ = 3423, 2962, 2960, 2875, 2224, 1640, 1043 cm-1 
 
(S)-2-[(S)-2-Hydroxydiphenylmethylpyrrolidinyl]-2-phenylacetonitrile (44a) 
White solid, M.p. 105-112°C 
[α]D = 21.39° (c = 0.38, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 1.55-1.79 (m, 2H, CH2CH2CH2), 1.84-1.91 [m, 1H, 
CH2CHHCHC(Ph)2OH], 2.04-2.14 [m, 1H, CH2CHHCHC(Ph)2OH], 2.67-2.76 (m, 2H, 
CH2CH2N), 4.03 (s, 1H, CHCN), 4.15 (bs, 1H, OH), 4.33 [dd, J = 4.4, 9.2Hz, 1H, CHHCHC(Ph)2OH], 
7.17-7.23 (m, 3H, arom), 7.29-7.38 (m, 8H, arom), 7.60-7.62 (m, 2H, arom), 7.78-7.80 (m, 2H, arom) 
ppm 
13
C NMR (100MHz, CDCl3): δ = 23.8, 29.4, 50.7, 59.1, 68.9, 78.2, 116.6, 125.2, 125.4, 126.7, 127.1, 
127.4, 128.3, 128.7, 128.8, 128.9, 133.9, 145.5, 147.1 ppm 
IR: ṽ = 3500, 2970, 1682, 1596 cm-1 
C25H24N2O (368.47): calc C 81.49, H 6.57, N 7.60; found C 81.62, H 6.68, N 7.51 
HPLC-MS: Rt = 12.07min; m/z = 342 [M-CN]
+
, 369 [M+H]
+
, 391 [M+Na]
+
 
Compound 44a was also obtained in 41% yield starting from 37a by Grignard addition. 
 
(S)-2-[(S)-2-Hydroxydiphenylmethyl-pyrrolidin-1-yl]pentanenitrile (45a) 
White solid, M.p. 107-114°C 
[α]D = -36.21° (c = 0.62, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 0.66 (t, J = 6.8 Hz, 1H, CH3CH2), 1.06-1.16 (m, 2H, 
CH3CH2CH2), 1.37-1.46 (m, 1H, CH3CH2CHH), 1.48-1.58 (m, 1H, CH3CH2CHH), 1.73-1.84 [m, 3H, 
CHHCHHCHC(CPh2OH)] , 1.93-2.06 [m, 1H, CH2CHHCH(CPh2OH)], 2.71-2.79 (m, 2H, CHCN, 
CH2CHHN), 3.09-3.14 (m, 1H, CH2CHHN), 3.96 (bs, 1H, OH), 4.10 [dd, J = 3.6, 9.2Hz, CH(CPh2OH)], 
7.16-7.21 (m, 2H, arom), 7.27-7.34 (m, 4H, arom), 7.53-7.56 (m, 2 H, arom), 7.61-7.63 (m, 2H, arom) 
ppm 
13
C NMR (100MHz, CDCl3): δ = 13.0, 18.9, 24.0, 28.9, 34.5, 50.1, 54.7, 69.6, 77.9, 118.4, 125.1, 125.4, 
126.5, 126.8, 128.1, 128.5, 145.4, 147.1 ppm 
IR: ṽ = 3411, 3066, 3023, 2923, 2224, 1141 cm-1 
C22H26N2O (334.45): calc C 79.00, H 7.84, N 8.38; found C 79.28, H 7.92, N 8.44 
HPLC-MS: Rt = 11.78min; m/z = 308 [M-CN]+, 335 [M+H]
+
 
 
Methyl 1-(cyanophenylmethyl)-4-hydroxypyrrolidine-2-carboxylate (46) 
Diastereoisomers separated by flash chromatography. 
Data for major isomer 46a (2S,4R,1S): white solid, M.p. 88-92°C 
[α]D = -74.20 (c = 1.5, CHCl3) 
174 
1
H NMR (400MHz, CDCl3): δ = 1.77 (bs, 1H, OH), 2.23-2.27 (m, 2H, CH2CHCO2Me), 2.57 (dd, J = 4.0, 
10.4Hz, 1H, CHCHHN), 3.08 (dd, J = 5.2, 10.4Hz, 1H, CHCHHN), 3.80 (s, 3H, Me), 3.92 (dd, J = 7.6, 
8.8Hz, 1H, CHHCHCO2Me), 4.37-4.42 (m, 1H, CHOH), 5.38 (s, 1H, CHCN), 7.37-7.43 (m, 3H, arom), 
7.57-7.59 (m, 2H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 38.7, 52.2, 56.7, 57.9, 61.6, 69.2, 116.2, 127.5, 128.8, 128.9, 133.5, 
172.8 ppm 
IR: ṽ = 3178, 2227, 1740, 1207 cm-1 
C14H16N2O3 (260.29): calc C 64.60, H 6.20, N 10.76; found C 65.02, H 6.18, N 10.68 
HPLC-MS: Rt = 5.41min; m/z = 234 [M-CN]
+
, 261 [M+H]
+
, 283 [M+Na]
+
 
Data for minor isomer 46b (2S,4R,1R): white solid, M.p. 103-104°C. 
[α]D = -13.10° (c = 1.5, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 1.99 (bs, 1H, OH), 2.11 (dddd, J = 0.8, 4.8, 8.4, 9.2Hz, 1H, 
CHCHHCHCO2Me), 2.18-2.25 (m, 1H, CHCHHCHCO2Me), 2.89 (ddd, J = 0.8, 4.0, 9.6Hz, 1H, 
CHCHHN), 3.38 (s, 3H, Me), 3.55 (dd, J = 4.8, 9.6 Hz, 1H, CHCHHN), 3.75 (dd, J = 6.4, 8.4Hz, 1H, 
CHHCHCO2Me), 4.55-4.60 (m, 1H, CHOH), 5.16 (s, 1H, CHCN), 7.37-7.41 (m, 3H, arom), 7.47-7.50 
(m, 2H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 39.4, 51.7, 57.9, 59.6, 60.6, 69.8, 116.6, 128.3, 128.7, 129.2, 132.4, 
173.2 ppm 
IR: ṽ = 3377, 2943, 2230, 1739, 1207 cm-1 
C14H16N2O3 (260.29): calc C 64.60, H 6.20, N 10.76; found C 64.81, H 6.29, N 10.64 
HPLC-MS: Rt = 3.99min; m/z = 234 [M-CN]
+
, 261 [M+H]
+
, 283 [M+Na]
+
, 543 [2M+Na]
+
 
 
Methyl 1-(1-cyanobutyl)-4-hydroxypyrrolidine-2-carboxylate (47) 
Diastereoisomers separated by flash chromatography. 
Data for major isomer 47a (2S,4R,1S): pale yellow oil. 
[α]D = -103.90° (c = 0.6, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 0.97 (t, J = 7.6 Hz, 3H, CH3CH2CH2), 1.48-1.60 (m, 
2H, CH3CH2CH2), 1.73-1.79 (m, 3H, CH3CH2CH2, OH), 2.12-2.24 (m, 2H, CH2CHCO2Me), 2.63 (dd, J = 
3.6, 10.4Hz, 1H, CHHCHHN), 3.43 (dd, J = 5.2, 10.4Hz, 1H, CHHCHHN), 3.73-3.78 (m, 1H, 
CHHCHCO2Me), 3.75 (s, 3H, CH3), 3.99 (t, J = 7.6Hz, 1H, CHHCHCN), 4.45-4.51 (m, 1H, CHOH) ppm 
13
C NMR (50.3MHz, CDCl3): δ = 12.9, 18.7, 34.0, 38.1, 51.8, 53.5, 56.0, 61.7, 68.6, 117.5, 172.7 ppm 
IR: ṽ = 3450, 2959, 2874, 2226, 1743, 1438, 1090 cm-1 
C11H18N2O3 (226.27): calc C 58.39, H 8.02, N 12.38; found C 58.48, H 8.11, N 12.21 
HPLC-MS: Rt = 3.99min; m/z = 200 [M-CN]
+
, 227 [M+H]
+
, 249 [M+Na]
+
 
Data for minor isomer 47b (2S,4R,1R) 
1
H NMR (400MHz, CDCl3) : δ = 0.94 (t, J = 7.2 Hz, 1H, CH3CH2CH2), 1.42-1.57 (m, 2H, CH3CH2CH2), 
1.59-1.72 (m, 2H, CH3CH2CH2), 1.87 (bs, 1H, OH), 2.14 (dddd, J = 0.8, 5.6, 8.4, 14.0Hz, 1H, 
CHCHHCHCO2Me), 2.22-2.28 (m, 1H, CHCHHCHCO2Me), 2.82 (ddd, J = 0.8, 4.4, 10.0Hz, 1H, 
CHCHHN), 3.42 (dd, J = 5.6, 10.0Hz, 1H, CHCHHN), 3.75 (s, 3H, Me), 3.76-3.82 (m, 2H, CHCO2Me, 
CHCN), 4.52-4.58 (m, 1H, CH2CHOH) 
HPLC-MS: Rt = 3.31min; m/z = 200 [M-CN]
+
, 227 [M+H]
+
, 249 [M+Na]
+
 
 
2-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-phenylacetonitrile (48) 
Compound 48a (2S, 4R, 1S), the major isomer, was obtained pure and characterized 
after spontaneous isomerization of a 48a/48b mixture, pale yellow solid, M.p. 105-
107°C. 
[α]D = -110.91° (c = 0.66, MeOH) 
1
H NMR (400MHz, CDCl3): δ = 1.95 (ddd, J = 4.4, 8.0, 13.0Hz, 1H, CHCHHCH), 
1.92-2.11 (bs, 2H, OH), 2.06 (ddd, J = 6.8, 8.4, 13.0 Hz, 1H, CHCHHCH), 2.59 (dd, J = 4.8, 10.0Hz, 1H, 
175 
CHCHHN), 3.01 (dd, J = 6.0, 10.0Hz, 1H, CHCHHN), 3.39-3.45 (m, 1H, CHHCHCH2OH), 3.62 (dd, J = 
4.0, 12.0Hz, 1H, CHCHHOH), 3.85 (dd, J = 3.2, 12.0Hz, 1H, CHCHHOH), 4.31-4.36 (m, 1H, CHOH), 
5.32 (s, 1H, CHCN), 7.37-7.42 (m, 3H, arom), 7.48-7.51 (m, 2H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 37.1, 57.4, 57.7, 61.5, 62.7, 69.4, 116.4, 127.4, 128.9 (2C), 133.7 ppm 
IR (nujol): ṽ = 3334, 2229 cm-1 
C13H16N2O2 (232.28): calc C 67.22, H 6.94, N 12.06; found C 66.89, H 6.98, N 11.99 
HPLC-MS: Rt = 2.49min (major + minor); m/z = 206 [M-CN]
+
, 233 [M+H]
+
, 255 [M+Na]
+
, 487 
[2M+Na]
+
 
Data for minor isomer 48b (2S,4R,1R): obtained only as a diastereoisomeric mixture, only the main 
signals are reported. 
1
H NMR (400MHz, CDCl3): δ = 3.85 (dd, J = 5.2, 11.6Hz, 1H, CHCHHOH), 4.40-4.50 (m, 1H, CHOH), 
5.16 (s, 1H, CHCN) ppm 
Compound 48a was also obtained starting from 46a by reduction of the ester functionality with NaBH4. 
 
2-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl) pentanenitrile (49) 
Characterized as a diastereoisomeric mixture, signals refer to the major diastereoisomer, 
only the main signals of the minor diastereoisomer are reported. 
Data for major isomer 49a (2S,4R,2S) and minor isomer 49b (2S,4R,2S): pale yellow 
oil. 
1
H NMR (400MHz, CDCl3): δ = 0.97 (t, J = 7.2 Hz, 3H, CH3CH2CH2), 0.98 (t, J = 7.6 
Hz, 3H, CH3CH2CH2, minor), 1.45-1.68 (m, 2H, CH3CH2CH2), 1.66-1.79 (m, 2H, CH3CH2CH2), 1.89 
(ddd, J = 4.0, 7.6, 13.0Hz, 1H, CHCHHCH), 1.96-2.07 (m, 1H, CHCHHCH), 2.63 (dd, J = 4.0, 9.6Hz, 
1H, CHCHHN), 2.77 (dd, J = 5.6, 9.6Hz, 1H, CHCHHN, minor), 3.20-3.26 (m, 1H, CHCHCH2OH), 3.34 
(dd, J = 5.6, 10.0Hz, 1H, CHCHHN), 3.48 (dd, J = 3.2, 12.0Hz, 1H, CHCHHOH), 3.55-3.59 (m, 1H, 
CHCHHOH minor), 3.68 (dd, J = 3.2, 12.0Hz, 1H, CHCHHOH), 3.77 (dd, J = 6.4, 10.0Hz, 1H, CHCN, 
minor), 3.87 (t, J = 8.0Hz, 1H, CHCN), 4.40 (m, 1H, CHOH) ppm 
13
C NMR (100MHz, CDCl3): δ = 13.3, 19.2, 34.6, 36.9, 53.2, 57.0, 61.5, 61.7, 69.7, 118.1 ppm 
IR: ṽ = 3406, 2961, 2874, 2226, 1097 cm-1 
HPLC-MS: Rt = 1.79min (major + minor); m/z = 172 [M-CN]
+
, 199 [M+H]
+
, 221 [M+Na]
+
 
Product 49a was also obtained starting from 42a by reduction of the ester functionality with NaBH4. 
 
Methyl (2S,4S)-1-[(S)-cyanophenylmethyl]-4-iodopyrrolidine-2-carboxylate (50a) 
DEAD (40% solution in toluene, 107mg, 0.61mmol) was added dropwise to a stirred 
solution of 46a (134mg, 0.51mmol) and triphenylphosphine (161mg, 0.61mmol) in 
THF (1.5mL) at 0°C, and then methyl iodide (38μL, 0.61mmol) was added. After 
20min, the solution was warmed to room temperature and stirred for 5h until TLC 
showed that the reaction was complete. The reaction mixture was concentrated to 
dryness under reduced pressure, and the residue was purified by flash chromatography to give 50a 
(153mg, 0.41mmol, 81%) as a white solid, M.p. 80-85°C. 
[α]D =-28.55° (c = 0.20, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 2.66 (ddd, J = 6.0, 6.4, 14.4Hz, 1H, CHICHHCHCO2Me), 2.91 (ddd, J = 
6.8, 9.2, 14.4Hz, 1H, HHCHCO2Me), 2.99 (dd, J = 4. 0, 11.2Hz , 1H, NCHHCHI), 3.05 (dd, J = 6.0, 
11.2Hz, 1H, NCHHCHI), 3.76 (dd, J = 6.8, 8.8Hz, CH2CHCO2Me), 3.84 (s, 3H, Me), 4.32 (m, 1H, CHI), 
5.49 (s, 1H, CHCN), 7.37-7.46 (m, 3H, arom), 7.64-7.66 (m, 2H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 15.3, 41.8, 52.5, 57.8, 59.1, 62.2, 116.4, 127.3, 128.9, 129.0, 133.2, 
171.8 ppm 
IR: ṽ = 3028, 2950, 2230, 1746, 1493, 1130 cm-1 
C14H15IN2O2 (370.19): calc C 45.52, H 4.08, N 7.57; found C 45.62, H 4.11, N 7.42 
HPLC-MS, Rt = 9.93min; m/z 371 [M+H]+, 393 [M+Na]
+
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[(S)-1-((S)-2-amino-1-phenylethyl)pyrrolidin-2-yl]methanol (51a) 
A solution of LiAlH4 (2M in Et2O, 500μL) was added dropwise to a stirred solution of 
cyanoester 37a (0.2mmol) in THF (1.7mL) at 0°C under an inert atmosphere. After 
15min, the solution was warmed to room temperature. The progress of the reaction was 
monitored by TLC, and at completion after 4h tartrate Na-K salt (saturated aqueous) 
was added with vigorous stirring to favor phase separation. The separated organic phase was dried 
(Na2SO4) and concentrated, and the residue was purified by flash chromatography (eluent 
CHCl3/MeOH/NH4OH, 60/30/1) to yield 17mg of product 51a (39%). 
[α]D = 1.68° (c = 0.31, DCM) 
1
H NMR (400MHz, D2O): δ = 1.62-1.71 (m, 2 H, NCH2CH2CH2), 1.78-1.87 (m, 2H, NCH2CH2CH2), 
2.66 (m, 1H, NCHHCH2CH2), 2.91 (m, 1H, NCHHCH2), 3.02 (m, 2H, CH2NH2), 3.15 (m, 2H, CHN, 
CH2OH), 3.35 (dd, J = 4.4, 12.4Hz, 1H, CH2OH), 3.74 (dd, J = 4.8, 10.8Hz, 1H, PhCHN), 7.40-7.53 (m, 
5H, Ph) ppm 
13
C NMR (50.3MHz, D2O): δ = 24.4, 28.7, 43.6, 52.9, 60.6, 64.9, 68.0, 127.7, 127.9, 128.3, 128.6, 128.8, 
139.2 ppm 
IR (neat): ṽ = 3358, 2924, 1599, 1493, 1453, 1379, 1074, 1040, 766, 735, 704 cm-1 
HPLC-MS: Rt = 1.26min; m/z = 221 [M+H]
+
 
 
[(S)-1-((S)-1-aminopentan-2-yl)pyrrolidin-2-yl] methanol (52a) 
Following the same procedure as above, starting from 38a. Yield 36%, orange oil. 
[α]D = +68.0° (c = 1.50, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 0.93 (t, J = 6.4Hz, 3H, CH3CH2CH2), 1.31-1.46 (m, 
4H, CH3CH2CH2), 1.63-1.82 (m, 4H, NCH2CH2CH2), 2.61-2.82 (m, 4H,CHCH2NH2, NCH2CH2CH2), 
2.97-3.13 (m, 5H, OH, NH2, NCHCH2NH2, CH2CHCH2OH), 3.30 (dd, J = 4.8, 10.8Hz, 1H, CHHOH), 
3.48 (dd, J = 3.6, 10.8Hz, 1H, CHHOH) ppm 
13
C NMR (100MHz, CDCl3): δ = 14.3, 20.4, 24.5, 29.0, 31.7, 42.4, 50.0, 58.8, 60.9, 64.4 ppm 
IR: ṽ = 3280, 2957, 2927, 2870, 1660, 1106 cm-1 
C10H22N2O (186.29): calc C 64.47, H 11.90, N 15.04; found C 64.58, H 11.99, N 14.78 
 
2-Carboxy-1-(carboxyphenylmethyl)pyrrolidin-1-ium chloride (53) 
A solution of 37a (2.75mmol, 670mg) in HCl (37%, 12mL) was heated at reflux for 
24h, and after completion of the reaction, the water was removed. The crude material 
was washed with DCM to obtain 692mg of 53 (88%) as a mixture of diastereoisomers 
(de 78:22). Characterized as a diastereoisomeric mixture. Signals refer to the major 
diastereoisomer, only the main signals of the minor diastereoisomer (white solid) are reported. 
Data for major isomer 53a (2S,S) and minor isomer 53b (2S,R) 
1
H NMR (400MHz, CD3OD) : δ = 2.02-2.31 (m, 3H, CH2CH2, CH2CHHCH), 2.39-2.46 (m, 1 H, 
CH2CHHCHCO2H), 2.54-2.64 (m, 1H, CH2CHHCHCO2H, minor), 3.36-3.46 (m, 1H, NCHHCH2, 
minor), 3.56-3.62 (m, 1H, NCHHCH2), 3.59-3.67 (m, 1H, CH2CHHN, minor), 3.95-4.01 (m, 1H, 
NCHHCH2), 4.39-4.43 (m, 1H, CH2CHCO2H, minor), 4.49 (dd, J = 6.4, 9.2 Hz, 1H, CH2CHCO2H), 5.45 
(s, 1H, PhCH), 5.55 (s, 1H, PhCH, minor), 7.51-7.62 (m, 5 H, Ph) ppm 
Data for major diastereoisomer 53a 
13
C NMR (100MHz, CD3OD): δ = 25.2, 31.4, 57.9, 67.7, 2.3, 131.3, 131.5, 132.2, 132.9, 170.7, 171.8 
ppm 
HPLC-MS: Rt = 1.48min; m/z = 250 
 
 
Methyl (2S)-1-((S)-2-amino-2-oxo-1-phenylethyl)pyrrolidine-2-carboxylate (54a) 
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Methyl ester 37a (1.64mmol, 400mg), acetic acid (9.84mmol, 637μL), water 
(6.56mmol, 118μL), TiCl4 (3.28mmol, 360μL), and DCM (1mL) were added in that 
order to a 5mL vial equipped with a screw cap. The solution was stirred overnight on 
an orbital shaker, and the reaction was monitored by TLC. When the reaction was 
complete, DCM was added, and the organic phase was separated and discarded. The aqueous solution 
was treated with saturated NaHCO3 until basic pH was reached, and then it was extracted with DCM. The 
combined organic extracts were dried with Na2SO4 and concentrated in vacuum to give 429mg of 54a in 
quantitative yield, white solid, M.p. 149-154°C. 
[α]D = +2.83° (c = 1.20, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 1.81-1.96 (m, 3H, CH2CH2CH2, CHHCHCO2), 2.00-2.08 (m, 
1H,CH2CHHCHCO2), 2.71-2.77 (m, 1H, CH2CHHN), 3.27-3.32 (m, 1H, CH2CHHN), 3.36 (dd, J = 4.0, 
9.6Hz, 1H, CH2CHCO2), 3.50 (s, 3H, Me), 4.24 (s, 1H, PhCHCONH2), 5.73 (bs, 1H, CONHH), 7.29-7.33 
(m, 5H, arom), 7.66 (bs, 1H, CONHH) ppm 
13
C NMR (100MHz, CDCl3): δ = 24.2, 30.6, 51.7, 54.4, 61.7, 73.2, 128.5, 128.6, 129.2, 136.5, 174.8, 
175.9 ppm 
IR: ṽ = 3397, 2919, 1725, 1667, 1129 cm-1 
C14H18N2O3 (262.30): calc C 64.10, H 6.92, N 10.68; found C 63.99, H 6.94, N 10.72 
HPLC-MS: Rt = 3.41min; m/z = 263 [M+H]
+
, 285 [M+Na]
+
, 547 [2M+Na]
+
 
 
(4S,7R,8aS)-7-Hydroxy-4-phenyltetrahydro-1H-pyrrolo[2,1-c][1,4]-oxazin-3(4H)-one (55a) 
The product was obtained in 40% yield after flash chromatography following the same 
procedure reported for the synthesis of amide 54a from aminol 48a. 
Pale yellow oil. 
[α]D = –2.47° (c = 0.15, CHCl3) 
1
H NMR (400MHz, CDCl3): δ = 1.92 (ddd, J = 4.8, 9.6, 14.0Hz, 1H, CHOHCHHCH), 
2.09-2.17 (m, 1H, CHOHCHHCH), 2.91 (dd, J = 3.6, 10.0Hz, 1H, NCHHCHOH), 3.12-1.15 (d, J = 
10.0Hz, 1H, NCHHCHOH), 3.84-3.92 (m, 1H, CH2CHCH2OCO), 4.14 (dd, J = 4.8, 11.6Hz, 
CHCHHOCO), 4.17 (dd, J = 4.4, 11.6Hz, CHCHHOCO), 4.49-4.51 (m, 1H, CH2CHOHCH2), 4.60 (s, 
1H, CHPh), 7.37-7.40 (m, 3H, arom), 7.64-7.66 (m, 2H, arom) ppm 
13
C NMR (100MHz, CDCl3): δ = 37.6, 52.9, 62.2, 65.8, 68.4, 71.3, 127.1, 128.2, 128.7, 135.5, 170.9 ppm 
IR: ṽ = 3362, 2924, 2853, 1737, 1042 cm-1 
C13H15NO3 (233.26): calc C 66.94, H 6.48, N 6.00; found C 66.88, H 6.53, N 6.09 
HPLC-MS, Rt = 2.44min; m/z = 234 [M+H]
+
, 256 [M+Na]
+
, 272 [M+K]
+
, 489 [2M+Na]
+
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8. LACCASE MEDIATED OXIDATIONS 
8.1 Laccase-Mediator Oxidations Systems (LMS) for alcohols 
8.1.1 Introduction 
Oxidations are pivotal reactions in organic synthesis and are widely used in industrial processes for the 
synthesis of bulk, fine and specialty chemicals.
172
 At the same time, oxidations are among the most 
polluting and hazardous processes, delivering toxic waste, as in the case of traditional stoichiometric 
oxidants based on Cr
VI
 or Mn
VII
 salts. To develop cleaner and eco-efficient catalytic oxidation processes, 
a number of greener catalytic methodologies have been developed by using less toxic metal catalysts and 
molecular oxygen or air as the oxidant.
173
 However, many of these systems still require harsh reaction 
conditions, give metal-containing wastes, and selectivity can be difficult to control. Hence, to develop 
more benign and selective redox processes, biocatalysis is emerging as a valuable tool.
174
 Bio-oxidations 
have the added value of high levels of selectivity (regio-, chemo-, and stereo-) that are reliable even for 
fine chemicals with complex structures and possessing oxidation-sensitive functional groups.
175
 
Considering the oxidation of alcohols, an important transformation in the synthesis of fine chemicals, 
more frequently biocatalysis made use of oxidoreductases (dehydrogenases and oxidases), whereas 
peroxidases and monooxygenases were employed to a lesser extent.
176
 Some biocatalytic methods that 
used whole cells were also reported.
177
 As representative examples, the enantioselective oxidation of 2-
phenylpropanol by Acetobacter aceti
178
 and the oxidation of primary alcohols to aldehyde by 
Gluconobacter oxydans
179
 have been reported. In these cases, intact cells were used as the oxidizing 
agent. Laccases (EC 1.10.3.2) belong to the multi-copper family of oxidases. These enzymes contain four 
copper centers per protein molecule and catalyze the oxidation of electron-rich aromatic substrates, 
usually phenols or aromatic amines, by using oxygen as the electron acceptor.
180
 Because water is the 
only byproduct formed, in principle, they are ideal catalysts for sustainable chemical and technological 
processes. Laccases are widely distributed in nature and perform a multiplicity of functions linked to 
either synthetic or degradation processes.
181
 Fungal laccases, for instance, play a critical role in lignin and 
humus degradation,
182
 and they are of particular interest because such enzymes are secreted 
extracellularly in response to simple inducers; this makes their production and purification relatively 
simple. Laccases have broad industrial applications, for instance, in pulp and paper industry, biosensor 
technology, in the organic synthesis of useful compounds, and offer great interest in environmental 
biotechnology.
183
 
Although the natural substrates of laccases are the phenolic residues of lignin, the inclusion of appropriate 
mediators in the laccase-mediator system (LMS) makes the oxidation of nonphenolic substrates 
accessible.
184
 The application of the LMS in the oxidation of alcohols is well documented in the 
literature.
185
 Commonly, laccases oxidize secondary alcohols to ketones and primary alcohols to the 
180 
corresponding aldehydes, whereas the overextended oxidation of primary alcohols to carboxylic acid was 
less reported.
186
 
Herein, we report developments in chemoenzymatic oxidation by commercial laccase from Trametes 
versicolor (TvL) of some primary alcohols to the carboxylic acids or aldehydes and of selected secondary 
alcohols to ketones with a particular emphasis on stereoselectivity. Moreover, within an interdisciplinary 
project dedicated to improving the sustainable production of active pharmaceutical compounds by the use 
of chemoenzymatic processes,
187
 we report herein an  important application of laccase TvL in the bio-
oxidation of some (S)-profenols to (S)-profens, which are important benchmark drugs in the class of non-
steroidal anti-inflammatory drugs (NSAIDs). To the best of our knowledge, laccase-mediated oxidation 
of this important class of substrate has not yet been reported; the only example reported is the bio-
oxidation of 2-flurbiprofenal by using an engineered alcohol dehydrogenase (ADH). 
 
8.1.2 Laccase alcohol oxydation to carbonyls or carboxylic acids 
The use of isolated laccases for alcohol oxidation to obtain aldehydes was already reported. As a first 
attempt, we used the commercially available fungal laccase from TvL (Sigma-Aldrich) and 2,2,6,6-
tetramethyl-1-piperidinyloxy (TEMPO; free radical) as a mediator. Reactions were conducted on benzyl 
alcohol (1a; 0.5 mmol) as a model compound, in NaOAc buffer (pH 4.5, 0.1m), and TEMPO (20 mol%) 
in open vials to ambient air. As expected, the reaction gave benzaldehyde (2a) and better yields were 
obtained in the absence of acetate buffer (Table 8.1.1, entries 1 and 2). However, for prolonged reaction 
times with closed vials under an oxygen atmosphere, a considerable amount of benzoic acid was obtained 
(Table 9.1.1, entries 3 and 4). Thus, to increase the efficiency of the process leading to carboxylic acids, 
further experiments were conducted and the most effective reaction conditions in terms of enzyme 
amount, solvent and cosolvent, pH, and oxygen source were found (Table 8.1.1). The best experimental 
conditions were found to be as follows: 1) the use of TEMPO in 20% molar ratio, other mediators, such 
as 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS), 1-hydroxybenzotriazole (HOBT), and 
p-OH- and p-amino- TEMPO, were used without positive results; 2) several cosolvents and additives 
were tested, such as THF, acetone, DMSO, MeCN, tBuOMe, DCM, tBuOH, Triton X, two ionic liquids, 
NaCl, and NBu4HSO4, but better results were obtained in pure water or with little amounts of acetone; 3) 
different pH conditions were explored and better results were obtained with buffers at pH 4.5 or no buffer 
(the pH becomes acidic  during the reaction course); and 4) better results were obtained by bubbling 
oxygen into the reaction balloon or vial, then closing it with a cap. As far as the reaction time is 
concerned, reactions were monitored by TLC, HPLC, or NMR spectroscopy generally every 24h and 
stopped at complete alcohol conversion or when substrate conversion did not proceed further. 
Representative results on several primary alcohols are reported in Table 8.1.1 ([a] Procedure A: substrate 
(0.5mmol), enzyme (5mg, 68U), mediator TEMPO (20mol%), solvent (6mL), O2 bubbled through a 
closed vial. [b] Ratio between starting alcohol, aldehyde and acid was evaluated by 
1
H NMR 
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spectroscopy, or 
19
F for entries 24 and 25. [c] Formation of acetal between aldehyde and alcohol was 
observed. [d] Formation of acetophenone, a known by-product of 2-phenylpropanal (2u), was observed. 
[e] Procedure B was used). 
 
Table 8.1.1 Bio-oxidation of primary alcohols with Laccase from TvL 
For benzyl alcohols 1a and 1c-i, the efficiency in the oxidation to acids strongly depends on the nature of 
the substituents on the aromatic ring. Donor-substituted benzyl alcohols 1c-e provided null or modest 
results, whereas acceptor-substituted benzyl alcohols gave the corresponding benzoic acids in modest to 
good yields, as in the case of 1g and 1h (Table 8.1.1, entries 14 and 15). The best results were obtained 
with heteroaromatic primary alcohols, in particular, pyridilmethanols 1j-l gave the corresponding pyridil–
carboxylic acids quantitatively (Table 8.1.1, entries 17-19). Aliphatic alcohols 1o and 1p reacted poorly, 
but activated 1q gave the trifluoroacetic acid, even if extended reaction times were required (Table 8.1.1, 
entry 25); for substrate 1q, a buffered solution (pH 4.5) was necessary because of the incoming strong 
acidity of trifluoroacetic acid, as a matter of fact, in H2O alone the oxidation to acid was poor (Table 
8.1.1, entry 24). 
The oxidation of primary alcohols to the corresponding carboxylic acids can be considered a two-step 
oxidation: first to aldehyde and then to the corresponding carboxylic acid (Scheme 8.1.1). Oxidation in 
water of aldehydes to acids would proceed through a germinal diol intermediate.
188
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Scheme 8.1.1 The two-step oxidation of primary alcohols 
To ascertain effective catalysis on both oxidative steps, we tested some aldehydes as substrates (Table 
9.1.2, [a] Procedure A: substrate (0.5mmol), enzyme (5mg), mediator TEMPO (20mol%), solvent (6mL), 
O2 bubbled through a closed vial. [b] Yields of products isolated after acid-base workup). As a first test, 
we tried 2a as a substrate under standard conditions and benzoic acid was successfully obtained (Table 
9.1.2, entry 2). With no enzyme, the oxidation was poor; thus giving evidence for a low efficiency of 
spontaneous aldehyde oxidation (Table 8.1.2, entry 1). Substituted pyridine-carbaldehyde 2j gave the 
corresponding acid in excellent yield, whereas 2g gave a poorer result probably because of the 
hydrophobicity of the substrate and poor solubility in water (Table 8.1.2, entry 3). 
 
Table 8.1.2 Bio-oxidation of aldehydes with Laccase from TvL 
Concerning the mechanism of the LMS oxidation, Baiocco et al. proposed two possible routes by which 
the mediator could oxidize the substrate: the Electron Transfer (ET) and Hydrogen Abstraction Transfer 
(HAT) routes.
189
 Kinetic studies on TEMPO strongly supported an ionic hydrogen abstraction route
190
 
that has precedents in the efficient oxidation procedures of alcohols by TEMPO with chemical 
oxidants.
191
 The effectiveness of the catalytic activity of TEMPO in alcohol oxidation by O2 is due to the 
intermediate formation of the oxamonium salt, which is the actual oxidant species
192
 and continuously 
restored by laccase. A tentative ionic route for the two-step oxidation of alcohols to carboxylic acids by 
TvL laccase/TEMPO is proposed in Figure 8.1.1. The efficiency of the process could depend on the 
facility of hydrogen abstraction
193
 on the starting alcohol and the gem-diol intermediate, together with the 
hydration equilibrium of the aldehyde. If the hydrogen acidity were too low, oxidation would be difficult. 
183 
Moreover, if the solubility of the aldehyde in H2O were too low and/or its hydration equilibrium 
unfavorable, the reaction could stop at the aldehyde level. From this perspective, the results obtained, for 
instance, with 1o, 1p, or cynnamyl alcohol (1b) could be interpreted.  
 
Figure 9.1.1 The ionic route for the two-step oxidation of alcohols 
Bio-oxidations by laccases are usually conducted in acetate buffer at pH 4.5-4.8. However, we observed 
improved yields with unbuffered solutions in water. This result could derive from a salting-out effect in 
buffered solutions with a lowered solubility of reagents or intermediates. Moreover, it is known that the 
stability of the TEMPO nitroxyl radical in acidic medium, such as in acetate buffer, is low, and for longer 
reaction times the mediator decomposed to a greater extent.
194
 A better result with unbuffered aqueous 
solutions could be thus consistent with the pH-dependent stability of the mediator. However, in the case 
of 1q (Table 8.1.1, entries 24 and 25), acetate buffer was necessary because during the reaction progress, 
the incoming trifluoroacetic acid strongly decreases pH and could decompose the mediator and/or 
denature enzyme over long reaction times. Following our interest in the oxidation of arylpropanols,
195
 we 
then tried the optimized protocol on 1u, which successfully gave the 2-phenylpropanoic acid in good 
yields (Table 8.1.1, entries 29-33). The LMS oxidation worked well: conversion was always complete, 
the selectivity to the carboxylic acid was good, and only traces of the corresponding aldehyde 2u were 
detected in the crude reaction mixture. The efficiency and selectivity strongly depended on the relative 
positions (span) of the aromatic ring with the hydroxy group: 1t and 1u were efficiently converted into 
the carboxylic acids, on the contrary 1r and 1s gave none or only traces of the corresponding acids (Table 
8.1.1, entries 26-29). To rule out the possibility that any racemization of the stereogenic center occurred 
during bio-oxidation, we tested (2S)- or (2R)-phenylpropanol (Table 8.1.1, entries 32 and 33). The 
enantiomeric purity of the starting alcohols was completely retained in the final acids. For a five-day 
reaction in simple water, enantiomerically pure (2R)- or (2S)-phenylpropionic acids were thus 
quantitatively obtained. 
184 
The good result obtained with 1u prompted us to explore the laccase-catalyzed oxidation of a series of 2-
arylpropanols (Table 9.1.3, [a] Procedure B: substrate (1mmol), enzyme (20mg/mmol), mediator TEMPO 
(20mol%), solvent (20mL), O2 bubbled in a closed vial. [b] Yields of products isolated after acid–base 
workup. [c] S refers to the marked stereogenic center. [d] Yield refers to ketoprofen 6e). Our attention 
was addressed to some profenols, 4a-f, as industrially relevant substrates. All profenols could be oxidized 
in good to excellent yields with a total retention of configuration when (S)-2-arylpropanols were used 
(Table 8.1.3, entries 2, 6, 9, 10, 12 and 14). The enantiomerically pure 2-arylpropanols were obtained 
through enzymatic reduction of the corresponding 2-arylpropanals following the Dynamic Kinetic 
Resolution (DKR) protocol we developed. 
The use of a 10% organic cosolvent, such as acetone or DMSO, gave improved results, depending on the 
substrate; for instance, compound 4b gave a better result with acetone 10%, whereas 4c gave a better 
result with DMSO (Table 8.1.3, entries 6 and 9). In case of 4e and 4f, the use of 10% acetone was 
detrimental (Table 8.1.3, entries 13 and 15) and resulted in poor yields of ketoprofen; a significant 
amount of by-products, such as methylarylketones, and partially oxidized products were obtained.  
 
Table 8.1.3 Bio-oxidation of profenols to profens 
To expand the scope, some secondary alcohols were tested under the optimized reaction conditions (Table 
8.1.4, [a] Procedure C: the same as A. [b] Yield calculated from NMR spectroscopic analysis of the crude 
reaction mixture). Cyclohexanol (7a), 1-phenylethanol (7b), and 1-phenylpropanol (7c) gave good results 
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in the production of the corresponding ketones (Table 8.1.4, entries 1-4). 2-Substituted cyclohexanols 7h-
i gave worse yields (Table 8.1.4, entries 10-13), but they showed stringent stereospecific behavior: only 
the 1,2-cis-cyclohexanols were oxidized. This is consistent with previously reported results on 2-
methylcyclohexanols oxidation by cytochrome P-450; it showed higher reactivity for cis-2-
methylcyclohexanol than that of the trans isomer due to steric hindrance.
196
 Interesting and promising 
results were obtained with α-hydroxyacids or α-hydroxyesters. Mandelic acid (7e) gave the corresponding 
oxoacid in satisfactory yields (Table 8.1.4, entries 6 and 7), whereas its methyl ester (7d) gave a better 
result with quantitative yield in a very short reaction time (Table 8.1.4, entry 5).  
 
Table 8.1.4 Bio-oxidation of secondary alcohols 
 
Conclusions 
There is a great need for sustainable oxidation of fine chemicals by employing clean primary oxidants, 
such as oxygen and greener catalysts; thus avoiding the use of harsh organic and inorganic oxidants, even 
in catalytic amounts. From this point of view, the combination of two green and efficient catalysts, such 
as the commercially available enzyme laccase TvL and the stable free radical TEMPO, offers great 
opportunities. We widened the range of applicability by exploring the oxidation, in water, of some 
primary alcohols to the corresponding carboxylic acids or aldehydes and of selected secondary alcohols to 
ketones. Moreover, we succeeded in an important application: the development of the Laccase-Mediator 
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System (LMS) oxidation of 2-arylpropanols (profenols) to the corresponding 2-arylpropionic acids 
(profens), in high yields and with complete retention of configuration.  
 
Figure 8.1.2 Chemoenzymatic route to enantiomerically pure arylpropanoic acids 
Thus, the chemoenzymatic reduction of arylpropanals we already successfully developed through the 
DKR process, coupled with the chemoenzymatic oxidation reported herein, depict a more 
environmentally friendly alternative route to the synthesis of enantiomerically pure profens and 
contributes to improved sustainability in the synthesis of this important class of drugs (Figure 8.1.2, 
where HLADH = Horse Liver Alcohol DeHydrogenase, NADH/NAD
+
 = Nicotinamide Adenine 
Dinucleotide redox couple). 
 
 
8.2 Laccase-Mediator Oxidations Systems (LMS) for amines 
8.2.1 Introduction 
Selective oxidation of amines is an important tool to get functional-group interconversions in organic 
synthesis. Depending on amine, catalytic system, reaction conditions, and oxidizing agent, a panel of 
different products could be obtained, such as, for instance, carbonyl compounds, amides, nitriles, and so 
on (Figure 8.2.1).
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Great progress has been made in recent years in developing catalytic and selective 
methods for amine oxidation.
198
 Focusing on primary amines, some relevant transformations should be 
considered: the oxidation to nitriles or carbonyl compounds, the oxidative self-condensation of the 
starting substrates to give imines, and with a second amine, the oxidative cross-coupling to give cross 
imines (Figure 8.2.1). 
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 oxidation
 
Figure 8.2.1 Functional group diversity generated by amine oxidation 
These oxidative dehydrogenation of amines have often been based on transition metal complexes, as 
catalysts, under aerobic conditions with molecular oxygen as final oxidant
199
 and in water as solvent.
200 
Other approaches utilized Cu salts/N-oxyl radical systems,
201
 metal-organic framework solids,
202
 gold 
catalysis,
203
 metal free aerobic conditions
204 
and, very recently,
 
TiO2 photocatalytic oxidation in water.
205
 
However, many of these systems still require harsh reaction conditions, give metal containing wastes, and 
selectivity can be difficult to achieve and control. 
Biocatalysis is emerging as a valuable tool to develop more benign and selective redox processes.
206 
Bio-
oxidations could have higher selectivity (regio- chemo- or stereo-) suitable even for fine chemicals with 
complex structures and oxidation sensitive functional groups.
207 
In nature, copper amine oxidases (CAOs, 
EC 1.4.3.21-2) couple the oxidation of primary amines to aldehydes with the reduction of molecular 
oxygen to hydrogen peroxide using ortho-quinone cofactors.
208
 
Laccases belong to the multi-copper family of oxidases (EC 1.10.3.2), they contain four copper centers 
per protein molecule and catalyze the oxidation of electron rich aromatic substrates, usually phenols or 
aromatic amines using oxygen as the electron acceptor.
209 
Being water the only by-product, Laccases are 
ideal catalysts for sustainable chemical and technological processes. In fact, they can be used in organic 
synthesis, have industrial applications, and offer great applications in environmental biotechnology.
210
 
Although the natural substrates of laccases are phenolic residues of lignin, the use of mediators in the 
laccase-mediator system (LMS) makes accessible the oxidation of non-phenolic substrates.
211
 
Application of LMS in bio-oxidation of alcohols is well documented in the literature.
212
 Recently, we 
reported an application of LMS in the oxidation of some primary alcohols to the corresponding aldehydes 
and carboxylic acids. Moreover, we succeeded in a relevant application, developing the LMS-oxidation of 
2-arylpropanols (Profenols) to the corresponding 2-arylpropionic acids (Profens), in high yields and with 
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a complete retention of configuration.
213
 Concerning the oxidation of amines, few applications of 
Laccases were reported.
214
 
Herein we describe a selective oxidation of amines employing Laccase from Trametes versicolor 
(Laccase Tv) as the enzyme, TEMPO as mediator and O2 as oxidant, in buffered water as a solvent. We 
found that, depending on the reaction conditions, the bio-oxidation could be selectively driven to give the 
corresponding aldehydes or imines in good yields. 
 
8.2.2 Laccase amine selective oxidation to aldehydes or imines 
Bio-oxidation of amines was initially investigated starting from the reaction conditions optimized for 
alcohol oxidation, as we previously reported:
 
Laccase Tv (Sigma-Aldrich, 5mg, 50units), 2,2,6,6-
tetramethyl-1-piperidinyloxy (TEMPO; free radical) 20mol% in water (6mL) at room temperature with 
O2 bubbled into the reaction vessel for 30s. In a preliminary attempt pOMe-benzylamine (1a, 0.5mmol), 
chosen as a model substrate, did not react (Table 8.2.1, entry 1). The use of unbuffered water as reaction 
medium, which gave good results with alcohols, in this case failed maybe due to inactivation of Laccase 
Tv at the basic pH generated by amine dissolution in H2O.
215
 The use of acetate buffer at pH 4.5 then 
resulted in a successful reaction and 1a was quantitatively converted in the corresponding aldehyde 2a in 
24 hours (Table 8.2.1, entry 2). The product 2a was easily isolated in quantitative yields from the reaction 
mixture by a simple solvent extraction. We extended the reaction time to 7 days to test the possibility of a 
further oxidation of the aldehyde to the corresponding pOMe-benzoic acid (3a), but only the aldehyde 
was recovered (Table 8.2.1, entry 3). Use of a lower amount of the enzyme was evaluated and it was 
observed that the efficiency of the bio-oxidation was maintained until 0.1mg (1U) of Laccase Tv, (Table 
8.2.1, entry 6), even if after 24 hours the reaction was not complete (conversion 83%) and a considerable 
amount of the imine 4a was isolated after work-up (Table 8.2.1, entry 6). On extending the reaction time 
to 7 days aldehyde 2a was quantitatively recovered (Table 8.2.1, entry 7). Our attention was then focused 
on the aqueous reaction medium, and we observed that on lowering the concentration of acetate buffer 
from 0.5M to 0.2M, a complete conversion was reached in a shorter reaction time (Table 8.2.1, entry 8 
versus 2). To stoichiometrically buffer the amine basicity and use the lowest amount of acetate, 
unbuffered H2O with 1eq of acetic acid as additive was tested on 1a, and an efficient oxidation to 
aldehyde 2a was achieved (Table 8.2.1, entry 9). In this condition amine and acetic acid formed the 
corresponding ammonium salt and the amount of free amine in the aqueous solution depends on the 
hydrolysis constant of the salt. On consuming the free-amine by oxidation, the pH of the reaction solution 
lowered by the increasing release of acetic acid from the salt hydrolysis. At neutral pH, phosphate buffer 
pH 7, conversions of 50% and 83% were reached in 24 and 48 hours, respectively. It is interesting to note 
that at this pH a complete selectivity towards the imine 4a was obtained after work-up (Table 8.2.1, 
entries 10-12). 
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TEMPO, the redox mediator in the oxidation with Laccase, is needed in sub-stoichiometric amounts 
because Laccases constantly restore the oxamonium ion responsible of the oxidation of the substrate.
216
 
We then tested the reaction on lowering the amount of TEMPO: from 20 to 10mol% at pH 4.5 the 
reaction proceeded well with complete conversion and total product selectivity towards the aldehyde, 
whereas using 5 and 2.5mol% lower conversion and selectivity were obtained (Table 8.2.1, entries 13, 14 
and 17). On lowering TEMPO mol% at pH 7, the reaction was slowed down and the conversion was poor 
but after the work-up only the imine 4a was recovered (Table 8.2.1, entries 15 and 16). On extending the 
reaction time to 4 days with TEMPO 2.5mol%, the conversion was complete and the imine 4a was 
isolated in 95% yields (Table 8.2.1, entry 18). Under standard conditions in 24 hours (TEMPO 20mol% 
and acetate buffer, Table 8.2.1, entry 19) benzylamine 1b gave quantitatively benzaldehyde 2b, on 
extending the reaction time to 10 days, as well as on lowering the buffer concentration to 0.2M, 
considerable amounts of benzoic acid were detected in the reaction mixture (Table 8.2.1, entries 20 and 
21). To force the obtainment of the carboxylic acid, the reaction was kept at 50°C for long times but only 
the aldehyde was recovered (Table 8.2.1, entry 23).  
 
Table 8.2.1 Optimization of reaction conditions
[a]
 
At pH 7 and TEMPO 2.5 mol%, conversion and selectivity towards the imine 4b was complete, and only 
traces of a further oxidation to benzoic acid were observed after 4 days (entries 24 and 25 in Table 8.2.1, 
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always with: [a] Reaction conditions: substrate (0.5mmol), aqueous buffer (6mL), O2 bubbled in closed 
vial. [b] Conversion determined on the crude reaction mixture after the work-up. [c] Ratio between acid, 
aldehyde and imine has been evaluated by 
1
HNMR. [d] Yields determined on the crude by 
1
H NMR after 
solvent extraction and evaporation). 
From the initial screening, pH and buffer concentration emerged as important parameters on kinetic and 
selectivity of the bio-oxidation. Therefore, we performed time course experiments for the oxidation of 
amine 1a under three different medium conditions: acetate buffer pH 4.5 0.5M and 0.2M, or H2O with 1 
equivalent of acetic acid as additive (Figure 8.2.2, with amine 1a consumption, filled tag, and aldehyde 2a 
formation, empty tag, depending on buffer concentration or additive). The reaction mixture was analysed 
via HPLC by sampling until complete conversions. In acetate buffer 0.5M the reaction required 24 hours 
to give the aldehyde 2a, whereas on decreasing the buffer concentration (0.2M) or in the presence of 
acetic acid in H2O the reaction was faster and complete in 3-4 hours. It is indeed likely that a high buffer 
concentration could be detrimental, at some extent, for TEMPO oxidation by LMS or for solubility of 
reactants in the aqueous medium and resulted in a worsening of the whole process.  
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Figure 8.2.2 Time course of enzymatic oxidation 
The bio-oxidation reaction is quite clean and its progress could be easily monitored by 
1
H NMR 
spectroscopy: as the amine 1a was consumed the aldehyde 2a appeared. Figure 8.2.3 reports a time course 
1
H NMR analysis performed in D2O with 1 equivalent of acetic acid as additive. In detail, in a NMR tube, 
1a (0.05mmol), D2O (0.6mL) and acetic acid (0.05mmol) were mixed, then TEMPO (0.01mmol) and 
Laccase Tv (0.5mg, 5U) were added and finally O2 was bubbled for 30 second, the spectrum was recorded 
(at t = 2min, upper spectrum, Figure 8.2.3), and the NMR tube was then stirred on an orbital shaker at 
150rpm at 30°C. After 60 minutes the tube was re-analyzed and a second spectrum was obtained (Figure 
8.2.3). 
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Figure 8.2.3 
1
H NMR analysis for Laccase Tv/Tempo oxidation of amine 1a to 2a 
The NMR analysis showed that from the very beginning together with 
1
H signals of the starting amine (a-
d), traces of the aldehyde 2a appeared (f-i). After 60 min the aldehyde was as expected much more 
abundant (about 30%) and noteworthy 
1
H NMR analysis showed that during the reaction course no other 
detectable intermediates or by-products were present in the reaction mixture. With a similar NMR 
protocol, we analyzed the reaction under the conditions to selectively get the imine. Amine 1a Laccase 
Tv/TEMPO in buffer phosphate at pH 7 in D2O were mixed, then O2 was bubbled for 30 second. On 
direct sampling and NMR analysis of the reaction mixture, after 2min, only the starting amine 1a was 
detected (Figure 8.2.4), after 4h we found a 1/1 mixture of amine 1a and aldehyde 2a and no imine 
present, while after the work-up, imine 4a was the only product detected (Figure 9.2.4). As a control 
experiment, equimolar amounts of the commercially available aldehyde 2a and the amine 1a were mixed 
in buffer phosphate at pH 7 in D2O but in 24h no traces of the corresponding imine 4a were detected. 
It could be then concluded that the imine is not a reaction intermediate and its quantitative obtainment 
occurred during work-up when the starting amine underwent to condensation with the aldehyde just 
formed in the bio-oxidation. Having explored the reaction conditions for amines 1a and 1b, the optimal 
conditions to selectively obtain aldehydes (2a-b) or imines (4a-b) were then established as follows: buffer 
acetate pH 4.5 at shorter reaction time for obtaining aldehydes, and eventually carboxylic acids at longer 
reaction time, buffer phosphate pH 7 for obtaining imines. 
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Figure 9.2.4 
1
H NMR analysis for Laccase Tv/Tempo oxidation of amine 1a to 2a 
Concerning the mechanism of the amine oxidation by Laccase-TEMPO, a tentative hypothesis could be 
formulated starting from the ionic route proposed for LMS oxidation of alcohols (Figure 8.2.5). The 
effectiveness of the process could depend on the facility of hydrogen abstraction on the starting amine 
supported by observation of an easier oxidation of benzylamines than alkyl amines, together with 
ammonia elimination to give the aldehyde. If the medium conditions slow down the reaction rate at a 50% 
conversion in the work-up procedure condensation of the residual starting amine with the aldehyde gave 
the imine. Noteworthy, the aerobic oxidative homo-coupling of amines to imines is going to take great 
attention as a valuable alternative to the traditional amine–carbonyl condensation,217 and this is the first 
result on such an oxidation obtained with enzymatic catalysis.  
 
Figure 8.2.5 Proposed mechanism for the bio-oxidation of benzylamines 
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To study the applicability of the amine bio-oxidation, the scope of the reaction was extended to a series of 
primary amines (Table 8.2.2, [a] Reaction conditions: substrate (0.5mmol), aqueous buffer (6mL), 
enzyme (5mg), O2 bubbled in closed vial. [b] Conversions were evaluated on crude after work-up. [c] 
Ratio between acid, aldehyde and imine has been evaluated by 
1
H NMR. [d] Yields determined on 
isolated products. [e] Polymerization products), under the optimized conditions for a controlled product 
selectivity. Octylamine 1c, as a model of aliphatic amines, did not react (Table 8.2.2, entry 1) . 
 
Table 8.2.2 Bio-oxidation of primary amines
[a]
 
This result is indeed consistent with the proposed mechanism of a Laccase-Mediator System (LMS), 
which supported an ionic hydrogen abstraction route for oxidation with TEMPO
218
 (Figure 9.2.5): in this 
case the α-proton of 1c acidity was not adequate for an efficient hydrogen abstraction. On the other hand 
dihydroxybenzylamine 1d and pyridine-3-yl-methanamine 1e were completely converted but in a 
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complex mixture of by-products (Table 8.2.2, entries 2 and 3). Actually, Laccases are well known to 
oxidize phenolic compounds which are their natural substrates in lignin and to polymerize aniline.
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Most of the benzyl amines 1f-1l were selectively converted in the corresponding aldehydes or imines in 
good yields depending on the selected reaction conditions. Electronic effects associated with electron 
donating and electron withdrawing substituents on the phenyl ring have little effect on the efficiency of 
the oxidation reaction. The amines 3,5-bis(trifluoromethyl)-benzylamine (1i) and pnitrobenzylamine (1l) 
at pH 4.5 gave a 1/1 mixture of the corresponding aldehydes and imines (Table 9.2.2, entries 17 and 28), 
whereas at pH 7 the selectivity for the imines 4i and 4l was successfully obtained, albeit with lower yields 
(Table 9.2.2, entries 18 and 29). Product selectivity towards the carboxylic acids was obtained with buffer 
acetate 0.2M and a significant amount of acid was obtained with most benzylamines and, remarkably, 
ochlorobenzylamine 1j in 10 days was converted in the corresponding acid 3j in 88% yield (Table 9.2.2, 
entry 21). 
We also applied the Laccase/TEMPO system in the oxidation of α-substituted benzylamine such as 1-
arylethylamines 5a-b (Scheme 9.2.2): in both cases the corresponding acetophenones 6a-b were obtained 
in good conversions and yields. 
 
 
Scheme 8.2.2 Oxidation of α-substituted benzylamines to give ketones 
The bio-oxidation was successful also with secondary benzylamines 7 and 8, as reported in Scheme 9.2.3. 
Both symmetrical or unsymmetrical substituted benzylamines were readily oxidized to the corresponding 
aldehydes. 
 
 
Scheme 8.2.3 Oxidation of secondary dibenzylamines to give aldehydes 
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The easy bio-oxidation of benzylamines suggested a tentative exploration in selective oxidation of 
unsymmetrical secondary amines such as N-benzylaminoesters in which the oxidation resulted in the 
elimination of the benzyl groups as in deprotection steps (as depicted in Scheme 8.2.4). Two substrates 
were tested, the N-benzylvaline methylester 9 and the N-benzyl β-alanine ethylester 10. 
Notwithstanding a total conversion of the starting material, products were difficulty recovered as 
ammonium salt (9a) or after derivatization as their corresponding tbutyloxycarbonylamino derivative 
(10a). 
 
 
Scheme 8.2.4 Oxidation of N-benzyl-aminoesters 
Finally, two heterocyclic amine 2,3-dihydro-isoindole (11) and tetrahydro-isoquinoline (13) were tested 
(Scheme 8.2.5).  
 
 
Scheme 8.2.5 Oxidation of isoindoline and isoquinoline 
Oxidation of dihydro-isoindole 11 was not efficient, giving poor conversion and yields after 7 reaction 
days, but selective: dihydro-isoindolone 12 was the only product obtained. In the case of tetrahydro-
isoquinoline 13, conversion was complete in 7 days, but in the reaction mixture, after the work-up, three 
oxidation products were detected: among them 3,4-dihydro-isoquinoline 14 was the main component, 
detected by NMR on crude. 
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8.3 Experimental section 
8.3.1 General informations 
As previously reported (Paragraph 2.3.1). 
 
8.3.2 Laccase alcohol oxidation to carbonyls or carboxylic acids 
Starting materials: alcohols and aldehydes used as starting materials in Tables 8.1.1, 8.1.2 and 8.1.4 were 
commercially available or known compounds. 
Primary alcohols 1c, 1d, 1f, 1j, 1k, 1l and 1p were obtained by reduction of the corresponding 
commercial aldehyde with NaBH4 in MeOH;  compound 1g  was obtained by reduction of the 
corresponding aldehyde with BH3·THF (5eq) in THF; 1h and 1p were obtained from the corresponding 
carboxylic acids by reduction with borane-dimethylsulfide (BH3·Me2S) in Et2O; 1s was obtained by 
reduction from 1b with H2 on Pd/C. 
Racemic 2-arylpropanols 4a-f in Table 8.1.3 were obtained by BH3·Me2S reduction of racemic 
commercial acids, enantiomerically pure (S)-4a-f were obtained by enantioselective biocatalysis starting 
from the corresponding racemic aldehydes. 
Secondary alcohols 7a, 7b, 7f, 7i, and 7j were obtained by LiAlH4 reduction from the corresponding 
ketone in Et2O; 7d was obtained by acid-catalyzed esterification of 7e and MeOH. 
 
Procedure A 
Experimental oxidation procedure for compounds reported in Tables 8.1.1 and 8.1.2: TEMPO (0.1mmol) 
and the enzyme (5mg) were added to a stirred solution of the alcohol or aldehyde (0. mmol) in the 
appropriate solvent (6mL) in a 10mL vial with a screw cap, then O2 was bubbled for 30s. The solution 
was stirred on an orbital shaker at 150rpm, retained, and the reaction was monitored by TLC. When the 
reaction was complete, the aqueous solution was kept at 0°C and adjusted to pH 2 by slow addition of 
aqueous HCl (1M). The acid aqueous phase was then extracted with DCM (3x5mL). The collected 
organic phases were dried over Na2SO4, filtered, concentrated in vacuum, and analyzed by HPLC and 
1
H 
and 
19
F NMR for alcohols 1h and 1i; 
19
F NMR for 1q. In the case of compounds 1j, 1k, 1l, 2j and 2k the 
crude aqueous phase was directly lyophilized and analyzed by 
1
H NMR spectroscopy. Spectroscopic data 
were consistent with those reported in the literature and in the NMR spectroscopy database (Reaxys and 
AIST SDBS). 
 
Procedure B 
Experimental procedure for the synthesis of 2-arylpropionic acids (profens; Table 9.1.3): TEMPO 
(0.2mmol) and the enzyme (20mg) were added to a stirred solution of the alcohol 4a-f (1mmol) in the 
appropriate solvent (20mL) in a 50mL balloon. O2 was bubbled for 30s and then the balloon was closed 
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with a cap. The solution was stirred on an orbital shaker at 15rpm and kept at room temperature. The 
reaction course was monitored by TLC. When the starting material disappeared, an aqueous saturated 
solution of NaHCO3 at 0°C was added to the flask followed by DCM (2mL). The organic layer was 
separated and discharged, then the aqueous solution was kept at 0°C and adjusted to pH 2 by slow 
addition of aqueous HCl (1M). The acid aqueous phase was then extracted with DCM (3x15mL). The 
collected organic phases were dried over Na2SO4, filtered, and concentrated in vacuum to afford 2-
arylpropionic acids. NMR spectroscopy and HPLC data of obtained products were consistent with those 
previously reported. Enantiomeric excess values were obtained on HPLC chiral columns. 
 
Procedure C 
Experimental oxidation procedure for compounds reported in Table 9.1.4: TEMPO (0.1mmol) and the 
enzyme (5mg) were added to a stirred solution of the alcohol (0.5mmol) in the appropriate solvent (6mL) 
in a 10mL vial with a screw cap, and then O2 was bubbled for 30s. The solution was stirred on an orbital 
shaker at 150rpm, maintained at room temperature, and the reaction was 
monitored by TLC. In case of compounds 7b, 7c, 7d, and 7f, when the reaction was complete, the 
aqueous solution was extracted with EtOAc (3x5mL). The collected organic phases were dried over 
Na2SO4, filtered, concentrated in vacuum, and analyzed by HPLC and 
1
H and 
13
C NMR spectroscopy. In 
case of compound 7e, when the reaction was complete, the aqueous solution was kept 
at 0°C and adjusted to pH 2 by slow addition of aqueous HCl (1M). The acid aqueous phase was then 
extracted with DCM (3x5mL). The collected organic phases were dried over Na2SO4, filtered, 
concentrated in vacuum, and analyzed by HPLC and 
1
H and 
13
C NMR spectroscopy. In the case of 
compounds 7a, 7g, 7h, 7i, and 7j, when the reaction was complete, the aqueous solution was extracted 
with Et2O (3x5mL). The collected organic phases were dried over Na2SO4, filtered, concentrated in 
vacuum, and analyzed by HPLC and 
1
H and 
13
C NMR spectroscopy. Spectroscopic data were consistent 
with those reported in the literature and in the NMR spectroscopy database. 
 
8.3.3 Laccase amine selective oxidation to aldehydes or imines 
Starting amines 1a-l, 5a-b, 7, 11, 13, Laccase from Trametes versicolor and TEMPO were purchased 
from Sigma-Aldrich (Sigma 51639, 10U/mg), Benzylamines  8, 9 and 10 were prepared by alkylation 
with benzylbromide. All the obtained products were known and their spectroscopic data were consistent 
with those reported in the literature and in NMR database (Reaxys and AIST SDBS). 
 
General procedure for aldehydes 
To a stirred solution of the amine (0.5mmol) in the appropriate solvent, (acetate buffer pH 4.5 0.5M or 
1eq. of acetic acid in H2O) (6mL) in a 10mL vial with a screw cap, TEMPO (0.1mmol) and the enzyme 
(5mg, 50U) were added. O2 was bubbled for 30 seconds and the vial was closed. The solution was stirred 
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on an orbital shaker at 150rpm and kept at 30°C in thermostat. After completion (TLC monitoring), the 
aqueous solution was extracted with EtOAc (3x5mL). The aqueous phase was then adjusted to pH 2 by 
slow addition of aqueous HCl (1M) and then extracted with EtOAc (3x5mL). The collected organic 
phases were dried over Na2SO4, filtered, concentrated in vacuum and analyzed by 
1
H NMR and 
13
C 
NMR. 
 
General procedure for imines 
To a stirred solution of the amine (0.5mmol) in buffer phosphate pH 7.5 0.5M (6mL) in a 10mL vial with 
a screw cap TEMPO (0.025mmol) and the enzyme (5mg) were added and then O2 was bubbled for 30 
seconds. The solution was stirred on an orbital shaker at 150rpm and kept at 30°C in thermostat. When 
the reaction was complete or after 7 days the aqueous solution was extracted with DCM (3x5mL) and 
EtOAc (3x5mL). The aqueous phase was then adjusted to pH 9 by slow addition of aqueous NaOH (1M) 
and then extracted with DCM (3x5mL). The collected organic phases were dried over Na2SO4, filtered, 
concentrated in vacuum, and analyzed by 
1
H NMR and 
13
C NMR. 
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